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Randomised trials are viewed as the gold standard for evaluating interventions. De-
pending on the intervention as well as other logistical factors, individuals or group
of individuals may be randomised. The former is known as individual randomised
controlled trials (RCTs) and the latter as cluster randomised trials (CRTs). CRTs
offer advantages such as administrative convenience and reduction of contamination
between trial groups but analysis is more complex than that for RCTs, because of
the correlations between participants in the same cluster. When non-adherence to
treatment occurs in the sense that some participants do not receive the randomly
assigned treatment, confounding may exist as there may be common factors influenc-
ing treatment received and outcome. Consequently, the intention-to-treat approach,
which compares outcomes between the groups as randomised, assesses the effect of
being randomised to treatment rather than the causal treatment effect (effect of
receiving the treatment).
Ad-hoc methods often used to attempt to estimate the causal effect of treatment
received such as per-protocol (PP) and as-treated (AT) approaches are likely to pro-
vide biased estimates because the assumptions necessary for those approaches to be
unbiased are in general implausible. There exists extensive literature on estimating
causal treatment effects from RCTs with non-adherence, but not as much for CRTs.
Instrumental variables (IV) methods have the advantage, over other causal methods,
of accommodating settings where there are unmeasured confounders when making
causal inference.
This thesis contributes to the literature on the estimation of causal treatment ef-
fects in CRTs where there is non-adherence to treatment and focuses on IV-based
methods. I first ascertained the current practice of reporting and addressing non-
adherence when causal treatment effects are of interest in CRTs via a systematic
review of 123 CRT reports. Non-adherence was reported in about half of the CRTs,
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of which a third were interested in the causal treatment effect. All of the reviewed
CRTs that reported adherence-adjusted estimates performed either PP or AT, with-
out discussing the plausibility of the very strong assumptions necessary for such
analyses to result in unbiased causal treatment estimates. No study estimated the
local average treatment effect (LATE), that is the average treatment effect on those
that would comply with the random allocated treatment, or any other appropriate
statistical methods for unbiased causal estimation.
In many clinical settings, the relevant causal question is whether treatment has an
effect among those who are willing to take it, which would be quantified by the
LATE. Hence the thesis focuses on this estimand, starting with an introduction and
assessment of the performance of IV-based methods for estimating LATE at either
cluster level (CL) or individual level (IL) through simulations under the required
identification assumptions for LATE. I also perform sensitivity analyses for IL-LATE
estimation and illustrate those methods using two real CRTs. The methods include
two-stage least squares (TSLS) based on CL outcome summaries and the Wald
estimator with the Schochet-Chiang standard error to estimate CL-LATE, and the
Wald estimator, TSLS with robust cluster standard errors, TSLS with Moulton’s
standard errors and the Bayesian multilevel mixture modelling for estimating IL-
LATE. I conduct extensive simulations and illustrate the methods using real CRTs
data. I demonstrate that TSLS is attractive for the estimation of CL-LATE and
IL-LATE but is inefficient. This inefficiency may be reduced through covariate
adjustment. The Bayesian multilevel mixture modelling is also attractive due to its
flexibility and performs well particularly when non-adherence is at the individual
level and the intracluster correlation coefficient for outcome is large. Stata and R
codes are provided to facilitate implementation by trial investigators. I conclude
by making some recommendations about how to estimate CL-LATE and IL-LATE
to improve the quality of analysis when estimating causal treatment effects in the
presence of non-adherence in CRTs.
4
Acknowledgements
I am deeply grateful to my supervisor Dr Karla Diaz-Ordaz and associate supervisor
Prof Bianca DeStavola for their commitment all these years. I was very fortunate to
have them involved in my PhD and to receive their guidance and critical insights.
I would like to thank Dr Elizabeth Williamson aka Fizz for giving me access to the
TXT4FLUJAB trial data used as a motivating example and also thank the UK Eco-
nomic and Social Research Council (ESRC) via the Bloomsbury Doctoral Training
Centre for providing the financial support. I cannot forget Jenny Fleming and Lau-
ren Dalton, who have been extremely awesome in dealing with the administrative
issues and have made my years at the school so pleasant to the point that I could
carry on with my PhD forever. Unfortunately, I have to move to a next step in my
academic life. Jenny and Lauren, thank you!
My sincere gratitude also is towards my family and friends at and outside LSHTM
for their continuous support and encouragement. I prefer not to name them to avoid
omitting any of them as the list is extremely long and may double the number of
pages of this document. However, with no intention to offend the rest, I would like
to thank my officemates Anower (“our daddy”), Kleio (“the crazy superwoman”),
Simon (“the robot”), Tom (“Tom Cruise’s body double”) and Ollie (“my little geek
brother”) with whom I shared the same heat, cold and water drip noise throughout
my PhD.
Finally, I thank God Almighty for taking care of me and strengthening me from the
day I was born until today.
5
Contents
List of Tables 12
List of Figures 15
1 Introduction 22
1.1 Rationale for randomised trials . . . . . . . . . . . . . . . . . . . . . 22
1.2 Individual and cluster randomised trials . . . . . . . . . . . . . . . . 23
1.2.1 Intracluster correlation coefficient . . . . . . . . . . . . . . . . 23
1.2.2 Levels of analysis . . . . . . . . . . . . . . . . . . . . . . . . . 24
1.3 Non-adherence in randomised trials . . . . . . . . . . . . . . . . . . . 25
1.4 Brief review of causal estimands . . . . . . . . . . . . . . . . . . . . . 26
1.4.1 Intention-to-treat . . . . . . . . . . . . . . . . . . . . . . . . . 26
1.4.2 Per-protocol and as-treated approaches . . . . . . . . . . . . . 27
1.4.3 Formal causal estimands . . . . . . . . . . . . . . . . . . . . . 28
1.4.4 Methods for estimating LATE . . . . . . . . . . . . . . . . . . 30
1.5 Illustrative examples . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
1.5.1 The TXT4FLUJAB trial . . . . . . . . . . . . . . . . . . . . . 31
1.5.2 The OPERA trial . . . . . . . . . . . . . . . . . . . . . . . . . 32
1.6 Thesis scope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
1.7 Thesis structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2 Systematic review on the reporting and addressing of non-adherence
in CRTs 37
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2.2.1 Search strategy and inclusion criteria . . . . . . . . . . . . . . 38
2.2.2 Piloting and validation . . . . . . . . . . . . . . . . . . . . . . 39
2.2.3 Data extraction . . . . . . . . . . . . . . . . . . . . . . . . . . 40
6
2.2.4 Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
2.3.1 Trial characteristics . . . . . . . . . . . . . . . . . . . . . . . . 41
2.3.2 The reporting and handling of non-adherence . . . . . . . . . 44
2.3.2.1 Adherence by allocated groups . . . . . . . . . . . . 45
2.3.2.2 Adherence-adjusted analyses . . . . . . . . . . . . . . 45
2.4 Summary of findings . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
2.5 Comparison with previous studies . . . . . . . . . . . . . . . . . . . . 50
3 Introduction to cluster-level summary approaches in CRTs 52
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.2 Overview of random effects linear regression . . . . . . . . . . . . . . 53
3.3 ITT analysis on CL summaries . . . . . . . . . . . . . . . . . . . . . 55
3.3.1 Unadjusted CL summaries . . . . . . . . . . . . . . . . . . . . 55
3.3.2 Adjusted CL summaries . . . . . . . . . . . . . . . . . . . . . 59
3.3.2.1 Continuous outcome . . . . . . . . . . . . . . . . . . 60
3.3.2.2 Binary outcome . . . . . . . . . . . . . . . . . . . . . 61
3.3.3 Obtaining valid inferences . . . . . . . . . . . . . . . . . . . . 62
3.3.3.1 Heteroscedasticity-robust standard errors . . . . . . . 63
3.3.3.2 Weighting strategies . . . . . . . . . . . . . . . . . . 63
3.3.3.3 Weighted least squares estimation . . . . . . . . . . . 64
3.4 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
4 Estimation of local average treatment effect at the cluster level in
CRTs 66
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
4.2 Identification assumptions of CL-LATE . . . . . . . . . . . . . . . . . 67
4.2.1 Notation and technical assumptions . . . . . . . . . . . . . . . 67
4.2.2 Identification assumptions . . . . . . . . . . . . . . . . . . . . 68
4.2.3 Cluster and individual-level non-adherence . . . . . . . . . . . 69
4.3 TSLS estimation of CL-LATE . . . . . . . . . . . . . . . . . . . . . . 71
7
4.3.1 TSLS on CL summaries . . . . . . . . . . . . . . . . . . . . . 71
4.3.1.1 Unadjusted CL-LATE . . . . . . . . . . . . . . . . . 71
4.3.1.2 Covariate-adjusted CL-LATE . . . . . . . . . . . . . 74
4.4 Schochet-Chiang approach . . . . . . . . . . . . . . . . . . . . . . . . 76
4.4.1 Wald estimator . . . . . . . . . . . . . . . . . . . . . . . . . . 76
4.4.2 Traditional standard errors . . . . . . . . . . . . . . . . . . . . 77
4.4.3 Schochet-Chiang standard errors . . . . . . . . . . . . . . . . 78
4.5 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
5 Simulation study of cluster-level LATE estimation in CRTs 81
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
5.2 Data generating process . . . . . . . . . . . . . . . . . . . . . . . . . 81
5.3 Analysis and performance criteria . . . . . . . . . . . . . . . . . . . . 85
5.3.1 TSLS and Wald estimator with Schochet-Chiang SEs . . . . . 85
5.3.2 Performance criteria . . . . . . . . . . . . . . . . . . . . . . . 86
5.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
5.4.1 TSLS estimation . . . . . . . . . . . . . . . . . . . . . . . . . 87
5.4.2 Schochet-Chiang approach . . . . . . . . . . . . . . . . . . . . 93
5.5 Additional simulations . . . . . . . . . . . . . . . . . . . . . . . . . . 97
5.5.1 Results from TSLS estimation . . . . . . . . . . . . . . . . . . 97
5.5.2 Results from Schochet-Chiang approach . . . . . . . . . . . . 101
5.6 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
6 Estimation of local average treatment effect at individual level in
CRTs 107
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
6.2 Identification of IL-LATE . . . . . . . . . . . . . . . . . . . . . . . . 108
6.2.1 Notation and technical assumptions . . . . . . . . . . . . . . . 108
6.2.2 IL-LATE estimand . . . . . . . . . . . . . . . . . . . . . . . . 108
6.3 Estimation of IL-LATE . . . . . . . . . . . . . . . . . . . . . . . . . . 109
6.3.1 TSLS estimation . . . . . . . . . . . . . . . . . . . . . . . . . 109
8
6.3.1.1 Huber-White-Rogers standard error . . . . . . . . . . 110
6.3.1.2 Moulton standard error correction . . . . . . . . . . 110
6.3.2 Wald estimator . . . . . . . . . . . . . . . . . . . . . . . . . . 111
6.3.3 Multilevel mixture model . . . . . . . . . . . . . . . . . . . . . 112
6.3.3.1 Bayesian multilevel mixture model . . . . . . . . . . 113
6.3.3.2 Multilevel mixture model via expectation-maximization115
7 Simulation study of individual-level LATE estimation in CRTs 116
7.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
7.2 Inclusion criteria, analysis and performance criteria . . . . . . . . . . 117
7.2.1 Estimation methods . . . . . . . . . . . . . . . . . . . . . . . 118
7.2.2 Performance criteria . . . . . . . . . . . . . . . . . . . . . . . 118
7.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
7.3.1 Adherence at cluster level . . . . . . . . . . . . . . . . . . . . 119
7.3.2 Adherence at individual level . . . . . . . . . . . . . . . . . . 120
7.4 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
8 Illustration of LATE estimation at the cluster and individual level
using the OPERA and TXT4FLUJAB trial data 125
8.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
8.2 Re-analysis of the OPERA trial . . . . . . . . . . . . . . . . . . . . . 127
8.2.1 Descriptive analysis . . . . . . . . . . . . . . . . . . . . . . . . 127
8.2.2 Cluster-level summary analyses . . . . . . . . . . . . . . . . . 129
8.2.3 Cluster-level LATE . . . . . . . . . . . . . . . . . . . . . . . . 134
8.2.3.1 Plausibility of LATE identification assumptions . . . 134
8.2.3.2 CL-LATE estimates . . . . . . . . . . . . . . . . . . 135
8.2.4 Individual-level analysis . . . . . . . . . . . . . . . . . . . . . 138
8.2.4.1 ITT effect . . . . . . . . . . . . . . . . . . . . . . . . 138
8.2.4.2 Individual-level LATE . . . . . . . . . . . . . . . . . 139
8.3 Re-analysis of the TX4FLUJAB trial . . . . . . . . . . . . . . . . . . 143
8.3.1 Descriptive analysis . . . . . . . . . . . . . . . . . . . . . . . . 143
9
8.3.2 Cluster-level analyses . . . . . . . . . . . . . . . . . . . . . . . 144
8.3.2.1 Plausibility of LATE identification assumptions . . . 144
8.3.2.2 CL-LATE estimation . . . . . . . . . . . . . . . . . . 145
8.3.3 Individual-level analyses . . . . . . . . . . . . . . . . . . . . . 148
8.4 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
9 Illustration of sensitivity analyses using the OPERA trial data 151
9.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151
9.2 Sensitivity analysis approaches . . . . . . . . . . . . . . . . . . . . . . 152
9.2.1 TSLS estimation . . . . . . . . . . . . . . . . . . . . . . . . . 152
9.2.2 Bayesian multilevel mixture model . . . . . . . . . . . . . . . 153
9.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
9.4 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
10 Discussion 160
10.1 Summary of findings . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
10.2 Strengths and limitations . . . . . . . . . . . . . . . . . . . . . . . . . 168
10.3 Practical implications . . . . . . . . . . . . . . . . . . . . . . . . . . . 172
10.4 Further work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172
10.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175
Bibliography 176
Appendices 190
A.1 Systematic Review Protocol . . . . . . . . . . . . . . . . . . . . . . . 191
A.2 List of papers included in the systematic review . . . . . . . . . . . . 193
A.3 Published paper on systematic review . . . . . . . . . . . . . . . . . . 202
A.4 Published paper on CL-LATE estimation . . . . . . . . . . . . . . . . 216
A.5 Choice of parameters value . . . . . . . . . . . . . . . . . . . . . . . . 242
A.6 Proof of “regression anatomy” formula for OLS estimation . . . . . . 243
A.7 Proof of “regression anatomy” formula for WLS estimation . . . . . . 244
A.8 R code for simulated CRT datasets . . . . . . . . . . . . . . . . . . . 245
10
A.8.1 Generating CRTs with cluster-level adherence . . . . . . . . . 245
A.8.2 Generating CRTs with individual-level adherence . . . . . . . 246
A.9 Stata code for CL-TSLS and Schochet-Chiang method . . . . . . . . 248
A.9.1 CL-TSLS with covariate adjustment, using unadjusted CL
summaries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248
A.9.2 CL-TSLS with covariate adjustment, using adjusted CL sum-
maries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248
A.9.3 Schochet-Chiang method . . . . . . . . . . . . . . . . . . . . . 249
A.10 Code for TSLS, Wald and Bayesian estimations . . . . . . . . . . . . 250
A.10.1 Wald estimation with covariate adjustment for cluster-level
adherence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 250
A.10.2 Wald estimation with covariate adjustment for individual-level
adherence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251
A.10.3 TSLS with HWR SEs and covariate adjustment . . . . . . . . 251
A.10.4 TSLS with Moulton’s SEs and covariate adjustment . . . . . . 251
A.10.5 Bayesian multilevel mixture model with covariate adjustment . 253
A.11 Two-level multiple imputation codes using the “jomo” package in R . 253
A.12 Sensitivity analyses code for the OPERA trial . . . . . . . . . . . . . 255
A.12.1 TSLS with Huber-White-Rogers and Moulton’s SEs . . . . . . 255
A.12.2 Bayesian multilevel mixture with local-to-0 prior . . . . . . . . 255
11
List of Tables
2.1 Characteristics of the CRTs included in this review . . . . . . . . . . 43
2.2 Analysis methods stratified by unit of analysis . . . . . . . . . . . . . 44
2.3 Reporting of non-adherence by length of intervention, randomised
arm and level of adherence. . . . . . . . . . . . . . . . . . . . . . . . 46
2.4 Details of the adherence-adjusted analyses performed . . . . . . . . . 49
5.1 Factorial design of the data generating processes and values taken by
the parameters in the simulations . . . . . . . . . . . . . . . . . . . . 83
5.2 Overview of TSLS and Wald estimator with Schochet-Chiang SEs of
CL-LATE and inference strategies used in the simulation study . . . 86
7.1 Overview of TSLS, Wald and Bayesian multilevel mixture estimations
of IL-LATE in the simulation study . . . . . . . . . . . . . . . . . . . 117
8.1 Baseline characteristics and percentages of treatment received by trial
group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
8.2 Residuals variance of SPPB at the individual level, unadjusted and
adjusted CL-summaries (means) SPPB at 12 months by trial group
and overall, using complete records analyses without weighting . . . . 131
8.3 Care home-level ITT effect estimates (as mean difference) on SPPB
at 12 months, using unadjusted CL-summaries on complete records
and multiple imputed data . . . . . . . . . . . . . . . . . . . . . . . . 133
8.4 Care home-level ITT effect estimates (as mean difference) on SPPB
at 12 months, using adjusted CL-summaries on complete records and
multiple imputed data . . . . . . . . . . . . . . . . . . . . . . . . . . 133
12
8.5 CL-LATE estimates (as mean difference) at care home level, of resi-
dents’ attendance to at least one group exercise session on SPPB at
12 months, using unadjusted CL-summaries on complete records and
multiple imputed data . . . . . . . . . . . . . . . . . . . . . . . . . . 136
8.6 CL-LATE estimates (as mean difference) at care home level, of resi-
dents’ attendance to at least one group exercise session on SPPB at
12 months, using adjusted CL-summaries on complete records and
multiple imputed data . . . . . . . . . . . . . . . . . . . . . . . . . . 137
8.7 IL-ITT effect estimates (as mean difference) at resident level, on
SPPB at 12 months, assuming and relaxing variance homogeneity
assumption . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
8.8 IL-LATE estimates (as mean difference) at resident level, of attending
at least one group exercise session on SPPB at 12 months, assuming
ER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142
8.9 Baseline characteristics and percentages of non-adherence for the TXT4FLUJAB
trial . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
8.10 Schochet-Chiang and TSLS estimation of practice-level LATE of re-
minder text messaging to receive flu vaccine on the percentage up-
take of flu vaccine in the TXT4FLUJAB trial using unadjusted CL
outcomes, adjusting for individual-level covariates gender, age and
presence of disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
8.11 TSLS estimation of practice-level LATE of reminder text messag-
ing to receive flu vaccine on the percentage uptake of flu vaccine in
the TXT4FLUJAB trial using adjusted CL outcomes, adjusting for
individual-level covariates gender, age and presence of disease . . . . 147
8.12 IL-LATE estimates (as mean difference) at patient level, of text mes-
sage reminders to receive flu vaccination on the uptake of flu vaccine in
the TXT4FLUJAB trial, assuming and relaxing variance homogene-
ity assumption and adjusting/not adjusting for gender, age, presence
of disease and whether clinic is opened during weekends . . . . . . . . 148
13
9.1 Individual-level LATE estimates expressed as a mean difference on
SPPB at 12 months with/without the exclusion-restriction assump-
tion and assuming variance homogeneity, adjusting and not adjusting
for covariates and obtained on complete records and multiple imputed
data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
9.2 Individual-level LATE estimates expressed as a mean difference on
SPPB at 12 months with/without the exclusion-restriction assump-
tion and assuming level-2 variance heterogeneity across trial groups
or adherence classes, adjusting and not adjusting for covariates . . . . 158
10.1 Summary of how to perform CL-TSLS . . . . . . . . . . . . . . . . . 164
10.2 Recommendations about the estimation of LATE at individual level . 168
14
List of Figures
1.1 Diagram summarising the relationship between random treatment as-
signment (Z), treatment received (D), measured covariates (A and
L), unmeasured covariate (U) and outcome (Y ) . . . . . . . . . . . . 29
2.1 Flow diagram of the identification process for the sample of 123 CRTs
included in this review . . . . . . . . . . . . . . . . . . . . . . . . . . 42
4.1 Diagram summarising the relationship between random treatment as-
signment (Z), treatment received (D), measured CL covariate (W ),
unmeasured covariate (U) and outcome (Y ), assuming Z met assump-
tions (A1) to (A3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.1 Bias (top row) and 95% CI coverage (rows 2–5) of CL-LATE with cluster-
level non-adherence and modest true LATE. Data generation scenarios
represented by ∗,+,×, and ◦. Estimates are obtained via unadjusted
or W -adjusted TSLS with different weights (none, cluster size (CS) and
minimum-variance (MV)) (by column) using CL unadjusted or adjusted
for X outcomes (“unCL” or “adCL”). Small (J = 10) and large (J = 50)
number of clusters results are shown in Panel A and B. . . . . . . . . . . 90
5.2 Bias (top row) and 95% CI coverage (rows 2–5) of CL-LATE with individual-
level non-adherence and modest true LATE. Data generation scenarios
represented by ∗,+,×, and ◦. Estimates are obtained via unadjusted
or W -adjusted TSLS with different weights (none, cluster size (CS) and
minimum-variance (MV)) (by column) using CL unadjusted or adjusted
for X outcomes (“unCL” or “adCL”). Small (J = 10) and large (J = 50)
number of clusters results are shown in Panel A and B. . . . . . . . . . . 91
15
5.3 Bias (top row) and 95% CI coverage (rows 2–5) of CL-LATE with cluster-
level non-adherence and small true LATE. Data generation scenarios rep-
resented by ∗,+,×, and ◦. Estimates are obtained via unadjusted or W -
adjusted TSLS with different weights (none, cluster size (CS) and minimum-
variance (MV)) (by column) using CL unadjusted or adjusted for X out-
comes (“unCL” or “adCL”). Small (J = 10) and large (J = 50) number
of clusters results are shown in Panel A and B. . . . . . . . . . . . . . . 92
5.4 Bias (top row) and 95% CI coverage (rows 2–5) of CL-LATE with individual-
level non-adherence and small true LATE. Data generation scenarios rep-
resented by ∗,+,×, and ◦. Estimates are obtained via unadjusted or W -
adjusted TSLS with different weights (none, cluster size (CS) and minimum-
variance (MV)) (by column) using CL unadjusted or adjusted for X out-
comes (“unCL” or “adCL”). Small (J = 10) and large (J = 50) number
of clusters results are shown in Panel A and B. . . . . . . . . . . . . . . 93
5.5 Bias (top row) and 95% CI coverage of CL-LATE with cluster-level non-
adherence. The true LATE size and the ICC for outcome vary by columns.
Data generation scenarios represented by ∗,+,×, and ◦. Estimates are
obtained using the Wald estimator with Schochet-Chiang SEs without
weighting and unadjusted or adjusted for W . Small (J = 10) and large
(J = 50) number of clusters results are shown in Panel A and B. The
long-dashed black parallel lines are the acceptable 95% coverage range in
the second panel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
5.6 Bias (top row) and 95% CI coverage of CL-LATE with individual-level
non-adherence. The true LATE size and the ICC for outcome vary by
columns. Data generation scenarios represented by ∗,+,×, and ◦. Esti-
mates are obtained using the Wald estimator with Schochet-Chiang SEs
without weighting and unadjusted or adjusted for W . Small (J = 10) and
large (J = 50) number of clusters results are shown in Panel A and B. The
long-dashed black parallel lines are the acceptable 95% coverage range in
the second panel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
16
5.7 Bias of the CL-LATE for the extra simulation where non-adherence
is at the cluster level and a modest true LATE, with high ICCs and
varying numbers of clusters. Estimates are obtained via unadjusted
or adjusted TSLS with different weights (none, cluster size (CS) and
minimum-variance (MV)). Number of clusters varies by rows and ICC
by column. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
5.8 Bias of the CL-LATE for the extra simulation where non-adherence is
at the individual level and a modest true LATE, with high ICCs and
varying numbers of clusters. Estimates are obtained via unadjusted
or adjusted TSLS with different weights (none, cluster size (CS) and
minimum-variance (MV)). Number of clusters varies by rows and ICC
by column. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
5.9 Extra simulation for very imbalanced cluster size settings. Bias (top
row) and 95% CI coverage (Huber-White SEs (or not) and SSDF
corrections (or not)) of the CL-LATE where non-adherence is at the
cluster level, and a modest true LATE. Estimates are obtained via
unadjusted or adjusted TSLS with different weights (none, cluster
size (CS) and minimum-variance (MV)). Small and large number of
clusters results appear in Panels A and B respectively. . . . . . . . . 100
5.10 Extra simulation for very imbalanced cluster size settings. Bias (top
row) and 95% CI coverage (Huber-White SEs (or not) and SSDF
corrections (or not)) of the CL-LATE where non-adherence is at the
individual level, and a modest true LATE. Estimates are obtained
via unadjusted or adjusted TSLS with different weights (none, cluster
size (CS) and minimum-variance (MV)). Small and large number of
clusters results appear in Panels A and B respectively. . . . . . . . . 101
17
5.11 Bias of the CL-LATE for the extra simulation where non-adherence
is at the cluster level (Panel A) and at the individual level (Panel B).
The true LATE size is modest, with high ICCs and varying numbers of
clusters. Estimates are obtained via unadjusted or adjusted Schochet-
Chiang method without weighting. Number of clusters varies by rows
and ICC by column. . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
5.12 Extra simulation for very imbalanced cluster size settings. Bias (top
row) and 95% CI coverage of the CL-LATE using Schochet-Chiang
method without weighting, where non-adherence is at the cluster level
(Panels A and B) and at the individual level (Panels C and D). Small
number of clusters results appear in Panels A and C and large number
of clusters results in Panel B and D. The true LATE size is modest.
The long-dashed black parallel lines are the acceptable 95% coverage
range in the second panel. . . . . . . . . . . . . . . . . . . . . . . . . 104
7.1 Performance of Wald, TSLS and Bayesian multilevel mixture methods
to estimate individual-level LATE in the presence of one-sided non-
adherence at cluster level for CRT with 25 clusters per group where
ICC for outcome is 0.05 (A) and 0.20 (B). The true LATE is 0.4
standard deviation. The long-dashed black parallel lines in the last
panel are the acceptable 95% coverage range. . . . . . . . . . . . . . . 123
7.2 Performance of Wald, TSLS and Bayesian multilevel mixture methods
to estimate individual-level LATE in the presence of one-sided non-
adherence at individual level for CRT with 25 clusters per group
where ICC for outcome is 0.05 (A) and 0.20 (B). The true LATE
is 0.4 standard deviation. The long-dashed black parallel lines in the





ATE Average treatment effect
ATT Average treatment effect on the treated
Bern Bernoulli distribution
Bin Binomial distribution
BMM Bayesian multilevel mixture
CACE Complier average causal effect
CL Cluster level
Cov Covariance
CRA Complete records analysis
CRT Cluster randomised trial
CS Cluster size










LATE Local average treatment effect
MCE Monte Carlo Error
MCMC Markov Chain Monte Carlo
MV Minimum variance






RCT Randomised controlled trial
RSS Residual sum of squares
SD Standard deviation
SE Standard error
SSDF Small sample degrees of freedom
TSLS Two-stage least squares




WLS Weighted least square




 Agbla, S.C. and DiazOrdaz, K., 2018. Reporting non-adherence in cluster
randomised trials: A systematic review. Clinical Trials, 15(3), pp.294-304.
 Agbla, S.C., De Stavola, B. and DiazOrdaz, K., 2019. Estimating cluster-level
local average treatment effects in cluster randomised trials with non-adherence.
Statistical Methods in Medical Research, p.0962280219849613.
Oral presentations
 Causal treatment effects in cluster randomised trials: estimation by cluster-
level instrumental variable methods. Presented at the Current development
in cluster randomised trials and stepped wedge designs Conference in London,
Queen Mary University. 30 November 2017.
 Addressing non-adherence in cluster randomised trials: estimation by cluster-
level instrumental variable methods. Presented at the 44th Young Statisti-
cians’ Meeting in Oxford, Department of Statistics. 30-31 July 2018.
 Estimation of LATE in cluster randomised trials. Presented at the Symposium
of the 50 years of the Masters in Medical Statistics, London School of Hygiene
& Tropical Medicine. 12 April 2019.
Poster presentation
 Estimation of causal treatment effect at cluster level in cluster randomised
trials with non-adherence. Presented at the Research Degrees Poster Day at




This chapter describes randomised trials in general and introduces cluster ran-
domised trials. I clarify what is meant by non-adherence to treatment and highlight
its implications when investigators are interested in causal treatment effects. I use
the terms “treatment” and “intervention” interchangeably. Without formal nota-
tion, I provide a brief review of the causal estimands often used in the biostatistics
literature. Finally, I introduce the trials motivating this work and delineate the
scope of the thesis.
1.1 Rationale for randomised trials
Randomised trials are studies where experimental units are randomly assigned to
either control treatments (referred to as control groups) or active treatments (re-
ferred to as active groups). Here, I focus on two-arm randomised controlled trials.
The random allocation of experimental units to the control or active group, referred
to as randomisation, aims to prevent possible biases such as confounding bias that
may cause systematic differences between trial groups [1, 2]. Randomisation allows
experimental units to have a known probability, equal or unequal, of being assigned
to either treatment while the treatment assigned to each experimental unit cannot
be predicted [2]. Thus, the treatment assignment mechanism is unconfounded, that
is, there are no measured or unmeasured variables that may influence the treatment
allocation and are independently associated with the outcomes of interest. The un-
confoundedness of treatment assignment is a key feature of randomised trials as it
allows us to attribute any observed average difference in the outcome variable across
trial groups to the assignment of the active treatment.
Randomised trials are viewed as the gold standard for testing new interventions in
many disciplines such as public health, epidemiology and social sciences. Through
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randomisation, we aim to balance the distribution of measured and unmeasured
variables across trial groups, making individuals belonging to the control and active
treatment group exchangeable in the sense that they would experience the same
outcome probability to those in the other group, if assigned to it.
1.2 Individual and cluster randomised trials
There exists two types of randomised controlled trials in terms of the nature of the
experimental units involved, that is, individual randomised controlled trials (RCTs)
and cluster randomised trials (CRTs). RCTs are trials where the units of randomi-
sation are individuals such as patients and pupils. CRTs, however, are experiments
where groups of individual units such as those belonging to the same hospital, school
and community, or batches of rats are allocated to either the control or active treat-
ment. CRTs have been increasingly used to assess complex public health, education
or economic interventions that target groups of individuals. CRTs offer some practi-
cal advantages over RCTs such as administrative convenience, reduction of contam-
ination between trial groups and improved adherence to treatment [3–5]. Despite
its practical advantages, there are statistical complexities that may arise in CRTs
because of the dependence of the data that has to be accounted for.
However, selection bias may potentially occur in some CRTs where individual units
are recruited after the clusters have been randomly allocated to a treatment group
or when consent is needed prior to treatment [6,7]. This selection bias can be atten-
uated by either identifying participants and obtaining their consent prior to clusters’
randomisation or allowing a third-party to blindly identify and select participants
into randomised clusters [6].
1.2.1 Intracluster correlation coefficient
The intracluster correlation coefficient (ICC) is a measure of how much of the total
variance is accounted for by the between-cluster variation. The ICC represents the
degree of similarity across individuals within the same cluster than those from other








where σ2B is the between-cluster variance, σ
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W the within-cluster variance and σ
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total variance.
1.2.2 Levels of analysis
Depending on the aims of the trial, data from CRTs can be analysed at the cluster
or individual level. For example, cluster-level analyses may be suitable for CRTs
where investigators are interested in assessing the effect, of general practices (GPs)
sending reminder text messages to their patients, on the proportion of vaccinated
patients rather than the effect on the probability of a patient getting vaccinated.
The latter requires the analysis to be done at the individual level.
The analysis at the cluster level consists of first computing cluster-level summary
statistics of the outcome variable (for instance, means for continuous variables and
proportions for binary variables) and then performing the planned statistical com-
parisons on the cluster-level summaries such as t−test and linear regression [8].
Allowance for differential cluster sizes or varying within-cluster heterogeneity can
be made by weighing the contributions of the various clusters to the group compar-
isons. For instance, this can be achieved with weighted regression. In the cluster-
level summaries analysis, the number of units contributing to the analysis is equal
to the number of clusters.
On the other hand, the analysis at the individual level uses data as collected (i.e.
preserving its hierarchical structure). Therefore, the within-cluster correlations need
to be accounted for to ensure valid inference. This can be achieved through mixed
effects regression (linear, Poisson or logistic for instance, depending on the type of
outcome variable) or generalised estimating equations (GEE) [8].
The level of analysis is determined by the unit of inference [9] and should be clarified
in the protocol at the trial design stage [10]. Analysis at the cluster level may be
preferable when there is small number of clusters. In such settings, inference at
the individual level may not be as reliable as the between-cluster variance may be
poorly estimated [8].
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1.3 Non-adherence in randomised trials
By non-adherence to treatment (also referred to as non-compliance), I mean de-
viations from the assigned treatment such that some participants randomised to
the control group receive the active treatment and/or some of those allocated to
the active treatment receive the control treatment. Note that loss of follow up is
viewed as a missing data problem rather than as non-adherence to treatment. I
use “non-adherence to treatment” or simply “non-adherence” or “non-compliance”,
interchangeably.
Non-adherence often occurs in both RCTs and CRTs. A systematic review of RCTs
published in 2008 in BMJ, New England Journal of Medicine, the Journal of the
American Medical Association and The Lancet found that 98 out of 100 RCTs
were reportedly affected by non-adherence [11]. Regarding CRTs, non-adherence
was reported in about 24% and 13% out of 152 published CRTs (searched from
the Cochrane Controlled Trials Register) and 47 unpublished CRTs (searched fron
relevant conference proceedings and the UK National Research Register) between
1997-2000, respectively [12].
Interventions in RCTs are administered directly to individuals and therefore, non-
adherence is related only to the individuals. In CRTs, however, because of the
hierarchical nature of the design, interventions can be implemented either at the
cluster level, or individual level, or even at both cluster and individual levels [13].
Therefore, non-adherence may occur at least at one of cluster and individual level,
depending on the nature of the intervention. Non-adherence is considered to be at
the cluster level if the treatment received was different from that assigned for all
the participants within clusters, and to be at the individual level if the treatment
received differed from the allocated treatment on an individual basis within the same
cluster. Schochet et al. [13] introduced settings where non-adherence occurs at both
cluster and individual levels and interact, adding complexity to the analysis. I only
consider setting where non-adherence does not interact at both levels.
When the control group is not allowed to have access to the active treatment, we
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have “one-sided non-adherence”, whereas there is “two-sided non-adherence” when
both control and active groups are subject to non-adherence.
The recommended approach for analysing randomised trial data is the so-called
intention-to-treat (ITT) analysis [14], that is, the comparison of experimental units’
outcomes between trial groups, regardless the treatment actually received [15, 16].
However, non-adherence in randomised trials has some implications regarding the
interpretation of the ITT results. This is covered in the next section.
1.4 Brief review of causal estimands
This section presents a brief review of causal estimands (quantities of interest in
a population that we want to estimate using a sample from that population) and
some approaches often used in the causal inference literature to measure the effect
of a treatment in the presence of non-adherence.
1.4.1 Intention-to-treat
Two general causal questions can be asked in randomised trials when there is non-
adherence. The first and most common question addressed is: “what is the causal
effect on the outcome of offering this treatment versus an alternative one?”. The
second is “what is the causal effect on the outcome of actually receiving versus
not-receiving the treatment?”. The first question is answered via an ITT analysis
whereas addressing the second one generally requires a more elaborate approach.
In randomised trials where all experimental units receive their allocated treatment,
the two causal questions are equivalent and the ITT approach is appropriate.
In settings where non-adherence occurs without using treatments outside those in
the trial (rescue medication for example), the ITT effect is closer to the null than
the causal effect [17]. Thus, when considering negative outcomes such as side effects,
adverse events or mortality, ITT effect may make a treatment appear less harmful
[17,18]. When there is non-adherence, the ITT effect assesses the benefit of offering
the treatment compared to an alternative treatment (so-called “effectiveness”) in-
stead of the benefit of actually receiving the offered treatment or intervention (also
known as “efficacy”).
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1.4.2 Per-protocol and as-treated approaches
There are two popular approaches attempting to estimate the effect of actually
receiving the treatment in the presence of non-adherence: the per-protocol (PP)
and as-treated (AT) analyses [11]. PP seeks to estimate the causal treatment effect
by restricting the analysis only to experimental units who received their assigned
treatment. If there exist pre-treatment factors that influence both the treatment
received and the outcome, the subgroup of experimental units who received their
assigned treatment is not guaranteed to have similar baseline characteristics in the
control and active groups. Thus, PP may be subject to selection bias and also leads
to a reduction of statistical power because of the exclusion of those who did not
receive the allocated treatment [18,19].
The AT analysis is done by comparing experimental units according to the treatment
received regardless of their treatment assignment [20]. The AT approach also suffers
from potential bias because the random allocation of treatment is substituted with
the actual treatment received which may depend on some factors that also affect the
outcome in those who do not comply. The key feature of random assignment which
is to guard against confounding and ensure groups’ comparability may be altered,
making the interpretation of the results difficult [21].
PP and AT analyses lead to valid causal estimates of treatment effect if the sub-
groups being compared are exchangeable or conditionally (i.e. all the variables
associated with the treatment received and the outcome are adjusted for) exchange-
able [17]. It is very unlikely that the exchangeability assumption is met in practice.
Treatment received after randomisation may likely not be random but may be influ-
enced by factors affecting both treatment received and outcome. These confounding
factors may also not be trivial to measure for a subsequent adjustment. However,
some design such as double-blinding may make the unbiasedness of PP and AT
estimates of causal treatment effect more plausible [18].
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1.4.3 Formal causal estimands
It is helpful to introduce some formality in order to deal with the potential bias
affecting PP and AT analyses. Statistical methods relying on more realistic as-
sumptions than that of exchangeability or exchangeability conditional on observed
pre-treatment variables have been developed and target estimands such as the aver-
age causal or treatment effect (ATE) and the average treatment effect among treated
(ATT) have been proposed [17,22,23].
Another estimand is the local average treatment effect (LATE), that is the average
treatment effect among the subgroup of participants that would receive the random
treatment they would have been assigned to. LATE is sometimes referred to as
complier average causal effect (CACE) in a setting of binary treatment assignment
and binary treatment received [24].
These estimands are formally defined in terms of potential outcomes [25, 26] which
are presented in chapters 4 and 6. However, their identification (ability to estimate
those estimands from the data) like any causal estimands involves assumptions that
are often untestable [26]. The choice of causal estimands is partly driven by the
assumptions that one is willing to make and partly driven by the scientific question
and the data available.
The random treatment assignment can be used as an instrumental variable (IV),
that is a variable fulfilling the following criteria: – (i) independent of measured
and unmeasured confounders of the treatment received-outcome relationship, – (ii)
associated with treatment received, and – (iii) does not directly affect outcome,
except through the treatment received (known as exclusion-restriction (ER)). Let A
be any measured pre-randomisation covariate, L any post-randomisation covariate,
U any unmeasured covariate, Z the random treatment assignment, D the treatment
received and Y the outcome variable of interest. The relationship between A, L, U ,





Figure 1.1: Diagram summarising the relationship between random treatment assign-
ment (Z), treatment received (D), measured covariates (A and L), unmeasured covariate
(U) and outcome (Y )
The bounds (minimum and maximum values) of LATE are identifiable when an IV is
available. The LATE is point-identified with the additional assumption that the Z–
D relationship is monotonic i.e. all experimental units if assigned to the active group
would all either be encouraged or all discouraged to receive the active treatment
(known as monotonicity) [24, 27, 28]. An IV analysis accounts for measured and
unmeasured confounding, without the need to adjust for extra confounders [23].
In many clinical settings, the relevant causal question is whether treatment has an
effect among those who are willing to take it, which would be quantified by the
LATE. Moreover, the required identification assumptions for LATE are easily met
in randomised trials. Hence the causal estimand of interest throughout this thesis is
the LATE. A summary of the assumptions for the identification LATE is shown in
Box 1.4.3. Chapters 4 and 6 formally present in detail the identification assumptions
for LATE.
Box 1.4.3: Identification assumptions for LATE
A key idea is that of potential outcomes, i.e. the outcome that would have been
observed had the randomised allocation been different. Estimands are then defined
in terms of these potential outcomes, with their definitions varying according to the
populations to which they refer. Likewise, the potential treatment received is the
treatment that individuals/clusters would have received had their randomised alloca-
tion been different. Assuming all-or-nothing adherence i.e. setting where adherence
is defined as a binary variable [29], the most common assumptions are:
i. Stable Unit Treatment Value Assumption (SUTVA): the potential outcomes
of the i-th individual are unrelated to the treatment status of all other individuals
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(known as no interference). In addition, consistency is assumed i.e. for those
who actually received treatment level z, the observed outcome is the potential
outcome corresponding to that level of treatment. In CRTs, SUTVA is unlikely
to hold. Instead, we may assume that no interference holds at the cluster level,
i.e. the potential outcome of an individual is unrelated to the treatment status of
individuals in different clusters, but may depend on those within the same cluster
[13,30].
ii. Ignorability of the treatment assignment: Randomised allocation is inde-
pendent of unmeasured confounders (conditional on measured covariates) and the
potential outcomes.
iii. Instrument relevance: The random allocation predicts treatment received.
iv. Exclusion restriction (ER): The random allocation cannot affect the outcomes
directly.
v. Monotonicity: There are no defiers, i.e. individuals who receive treatment only
if they are not randomised to it. Generalisations of these assumptions to CRTs
settings as in Schochet and Chiang [13] have been presented in Chapter 4.
1.4.4 Methods for estimating LATE
Methods such as the Wald estimator (ratio of the effect of the IV on the outcome
to the effect of the IV on the treatment received) [13,31], the two-stage least square
(TSLS) estimation [28] and mixture modelling [32,33] can be used to estimate LATE,
assuming that the IV assumptions and monotonicity hold in addition to the tech-
nical assumptions of SUTVA (consistency and no interference). Multilevel mixture
modelling can be implemented within both a frequentist and Bayesian framework.
These methods are detailed in Chapters 4, 6 and 9.
The use of mixture modelling involves principal stratification [34] which I briefly
present in Box 1.4.4 below.
Box 1.4.4: Principal stratification
1. Instrumental variables (IV): Under assumptions (i)-(v), Angrist et al. [24]
showed that LATE is the ITT effect among those that would receive the active
treatment if they are assigned to it and can be estimated using IV-based method.
LATE is usually estimated using TSLS but the Wald estimator can also be used
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[13, 31]. To account for the clustering, it has been suggested for instance to use
TSLS estimation using Huber-White variance estimator [35].
2. Principal stratification [34]: Under assumptions (i)-(v), each individual may
be grouped into a compliance (or adherence) principal stratum, which is a latent
class, and can be thought of as a baseline covariate defined based on two potential
outcomes for treatment received.
(a) Never-takers receive no active treatment, regardless of their randomised treat-
ment;
(b) Compliers receive the active treatment only if they are randomised to it;
(c) Always-takers receive the active treatment, regardless of their randomised
treatment.
The principal stratification is based on a mixture of distributions across adherence
classes, hence the use of mixture modelling to find out the adherence classes from the
observed data and then estimate LATE. Extensions to CRTs are possible, by using
multilevel mixture models, in either a Bayesian [34] or likelihood approaches [30].
1.5 Illustrative examples
I now briefly introduce the TXT4FLUJAB and the OPERA CRTs that I use to
illustrate some of the analysis approaches. Those examples are complementary to a
simulation study carried out in this thesis. The simulations do not particularly follow
the non-adherence patterns nor the CRT sizes (number of clusters and individual
units within clusters) in either illustrative examples.
1.5.1 The TXT4FLUJAB trial
The TXT4FLUJAB trial was a non-blinded and two-sided non-adherence CRT im-
plemented in the United Kingdom, aiming at estimating the effect of text messages
reminding patients at risk of chronic conditions to get the influenza vaccination dur-
ing the 2013 influenza season [36]. General practices (GPs) were stratified by the
type of software used for text messaging. There were three strata, each of which
characterized by either of the following messaging software: – (i) “CPRD”, – (ii)
“ResearchOne and SystmOne”, and – (iii) “EMIS”, “Vision”, or “Immform”. GPs
were randomised to either standard care (control group, 79 GPs and 51 136 pa-
tients) or a text messaging campaign (active group, 77 GPs and 51 121 patients).
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GPs represent the clusters and patients were the individual units.
Adherence was binary and measured at the patient level. Patients whose GPs were
allocated to the active group are said to adhere if they received the reminder text
messages; whereas, those whose GPs were allocated to the control group are said to
adhere if they did not receive any reminder text message.
GPs were the unit of analysis and the outcome of interest was the proportions of
influenza vaccine uptake at the GPs level. The trial investigators were interested
in the following causal questions: – (i) a question motivating the ITT analysis:
“what is the causal effect on influenza vaccine uptake at the GPs level, of sending
reminder text messages to patients at risk of chronic conditions to get the influenza
vaccination compared to not sending any reminder text message?”, and – (ii) a
question motivating the LATE estimation: “what is the causal effect on influenza
vaccine uptake at the GPs level, of patients at risk of chronic conditions actually
receiving reminder text messages to get the influenza vaccination compared to not
receiving any reminder text message?”. These causal treatment effects at the GPs
level were expressed as a mean risk percentage difference.
1.5.2 The OPERA trial
The OPERA trial was a non-blinded CRT conducted in Warwick and London be-
tween 2008-2010. It was carried out in 78 care-homes (35 allocated to the active
group and 43 to the control group). The intervention was a complex programme
which involved training on depression awareness for care home staff, 45 minutes
physiotherapist-led group exercise sessions for residents (delivered twice a week)
and a whole home component designed to motivate residents to do more daily phys-
ical activity. Staff of care-homes in the control group only received the training on
depression awareness [37]. In total, 900 residents were enrolled (498 in the control
group and 402 in the active group).
No assessment of causal treatment effects was planned by the investigators and
therefore, there was no definition of adherence. However, for illustration purposes,
we used a working definition of adherence as follows: residents in the active group
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are considered to have adhered if they attended at least one group exercise session,
whereas those in the control group adhered if they did not attend any group exercise
sessions. On that basis, adherence was 100% in the control group, whereas 89% of
residents in the active group adhered. Hence, the OPERA trial had one-sided non-
adherence.
The outcome of interest is a secondary outcome defined by the trial protocol, that is,
the Short Physical Performance Battery (SPPB) at 12 months since trial initiation
[37]. SPPB is a score varying from 0 (worst performance) to 12 (best performance)
and measures functional mobility. SPPB consists of three components of physical
function: walking speed, standing balance and sit-to-stand performance [38]. SPPB
was analysed as a continuous variable by the trial investigators [37].
The trial investigators were only interested in the ITT causal question that is: “what
is the causal effect on SPPB at 12 months at the resident level, of offering the in-
tervention as opposed to standard care?”. The ITT analysis showed weak evidence
of ITT effect [37]. I further investigate whether there may be a causal effect of the
intervention and formulate the following question motivating the LATE estimation
presented in chapter 8, that is “what is the causal effect at the cluster and individ-
ual level of receiving the intervention compared to standard care, on SPPB at 12
months?”.
1.6 Thesis scope
Estimation of causal treatment effects in RCTs where there is non-adherence has
been addressed extensively. However, for CRTs, extensions to accommodate cluster-
ing and non-adherence are available but the literature and applications are limited.
For instance, methods listed in section 1.4.4 (Wald estimator, TSLS and Bayesian
mixture modelling) are potential approaches for estimating LATE in CRTs where
there is non-adherence but their performance has not been explored. This thesis
aims to fill this gap by investigating the finite-sample performance of those meth-
ods where the analysis is at either the cluster or the individual level, allowing for
covariate-adjustment and missing data and different approaches for estimating confi-
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dence intervals, and thus contributing to improving good statistical analysis practice
when estimating the causal treatment effects in CRTs where there is non-adherence.
In addition, I extend existing sensitivity analysis strategies to CRT settings and
illustrate their use in practical applications (see Chapter 9).
The focus is on IV-based methods and their applications because of reasons pro-
vided in section 1.4. The scientific question in clinical investigation is often one
involving compliers. Thus, the estimand of interest is the LATE. The objectives of
this research are as follows.
1. To provide a description of the current practice of reporting and
addressing non-adherence in CRTs: The review by Eldridge et al. [12]
gave an insight about the presence of non-adherence in CRTs and pointed out
the lack of adequate statistical methods to account for clustering. However,
this review included CRTs reports from 1997 to 2000. I investigate the current
practice on the reporting of non-adherence and how non-adherence is addressed
when the causal treatment effect is of interest. This is necessary to understand
the extent of the problem and identify the gaps needed to be filled. I therefore
conducted a systematic review reported in chapter 2.
2. To assess the performance of different methods estimating LATE at
the cluster level: From the systematic review in chapter 2 emerged a need for
appropriate statistical methods for estimating causal treatment effects in CRTs
where there is non-adherence at the cluster and individual level. Therefore,
I dedicate chapter 4 to examining the performance of TSLS estimation on
cluster-level summaries to estimate cluster-level LATE through simulations in
the presence of cluster-level or individual-level non-adherence. Application of
TSLS and Wald estimations on the TXT4FLUJAB and the OPERA trials
data are described in chapters 8.
3. To assess the performance of different methods estimating LATE at
the individual level: This complements the previous objective in addressing
the need for appropriate estimation methods for individual-level effects, in the
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presence of cluster-level or individual-level non-adherence. I compare the re-
sults obtained from applying IV-based methods for estimating the individual-
level LATE, using data from the TXT4FLUJAB and the OPERA trials in
chapters 8. Sensitivity analyses using the OPERA trial are also conducted in
chapter 9, to assess the robustness of individual-level LATE estimates when
relaxing the ER assumption.
1.7 Thesis structure
The rest of the thesis is organised as follows. Chapter 2 presents a systematic review
conducted to ascertain the extent of non-adherence in CRTs and the current practice
in terms of addressing non-adherence when estimating causal treatment effects is of
interest.
Chapter 3 introduces cluster-level summary approaches in CRTs. Chapter 4 fo-
cuses on cluster-level summary-based analyses, lays the assumptions required for
the identification and estimation of LATE at the cluster level, and presents alter-
native statistical approaches to estimate cluster-level LATE. Chapter 5 presents a
simulation study assessing the performance of estimation methods of cluster-level
LATE presented in Chapter 4 and lessons about when and how these statistical ap-
proaches should be used, assuming all required assumptions for LATE identification
and estimation hold.
Chapter 6 addresses the estimation of LATE at the individual level, introduces the
required assumptions and a range of statistical methods that can be used at that
end. Chapter 7 assesses, via simulation, the performance of individual-level LATE
estimation.
Chapter 8 illustrates methods introduced in chapters 4 and 6 using the TXT4FLUJAB
and the OPERA trials. Chapter 9 investigates sensitivity analyses, through applica-
tions using the OPERA trial only, the robustness of LATE estimates at the cluster
and individual levels, when there is a departure from the ER assumption.
Finally, Chapter 10 summarises the findings, discusses the strengths and limitations
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of IV-based methods covered in this thesis and proposes some recommendations for
estimating LATE in CRTs, whether at the cluster level or at the individual level.
This chapter also presents avenues of future work.
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Chapter 2.
Systematic review on the reporting and
addressing of non-adherence in CRTs
2.1 Introduction
Consolidated Standards of Reporting Trials (CONSORT) guidelines for RCTs and
CRTs have been proposed to improve the reporting of trials [14, 39]. Investigators
are encouraged to follow those guidelines when conducting and reporting trials.
However, despite the CONSORT check-list [14, 39] requesting explicitly to report
numbers assigned, on treatment and analysed, previous systematic reviews found
that adherence to treatment is often under-reported, and when reported, sufficient
detail on how adherence was defined is often not included [5, 11]. CRTs are more
complex to run, analyse and report than RCTs, and appropriate statistical methods
accounting for the clustering in the data need to be used [3,40]. This applies also to
methods used to estimate causal treatment effects. Systematic review studies have
been conducted to investigate the reporting and analysis practices in addressing
non-adherence in RCTs [11, 41] but no similar study on our knowledge had been
done for CRTs.
The current chapter establishes the prevalence of non-adherence and describes the
methods used to obtain causal treatment effects. For this, I perform a secondary
analysis of data originally extracted for a systematic review investigating the re-
porting and adjustment of missing data in CRTs [42]. I also propose guidelines for
reporting adherence and conducting causal analysis of CRTs. The chapter is or-
ganised as follows. Section 2.2 describes the methods including the search, piloting,
data extraction and analysis. Section 2.3 presents the results. Section 2.4 provides a
summary of the findings and section 2.5 contrasts the results with previous studies.
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This systematic review is published in Clinical Trials and a copy can be found in
appendix A.3.
2.2 Methods
This includes the search strategy, inclusion criteria, piloting and validation, the data
extraction and analysis of the data generated by the systematic review.
2.2.1 Search strategy and inclusion criteria
DiazOrdaz et al. [42] previously identified 526 CRT reports using a published elec-
tronic search strategy shown in Box 2.2.1, of which 188 were excluded because those
reports did not meet the inclusion criteria based on the titles and abstracts. From
the remaining 338 reports, they randomly excluded approximately a fifth (62 re-
ports) and carried out the assessment of the full text on the remaining 276 reports.
The random exclusion of a fifth of the reports eligible for full-text assessment was
to reduce the workload without undermining the validity of the systematic review
process. Out of the 276 reports assessed, 132 met the inclusion criteria for analysis.
The present review uses those 132 CRTs previously identified. The review protocol
except the electronic search strategy is reported in Appendix A.1. Reports were eligi-
ble for inclusion if they were full reports of cluster randomised controlled trials, pub-
lished in English in 2011. They were excluded if they were quasi-experimental, self-
identified as pilot, feasibility, or preliminary studies; only reported cost-effectiveness
or where no data at the individual level were collected. We also excluded crossover
trials, where deviations from randomised treatment may include failure to follow
the randomised sequence of treatments, and studies reporting only sub-samples of
previously published CRTs data.
While the systematic review includes CRT reports published in 2011, it is impor-
tant to note that the pre-print version of the updated CONSORT statement for
CRTs [39] was available a year earlier and there were no new guidelines concerning
the reporting and handling of non-adherence as compared to the previous version
of the CONSORT statement [14]. Having said this, it is arguable that although
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methods for estimating causal treatment effects in both RCTs and CRTs have been
published prior to 2011 [24,25,27,30,43,44], these methods were not well known or
accepted in the clinical trials community. It is plausible that my findings no longer
reflect current practices, as the recent focus on causal inference methodology within
clinical trials, especially the addendum to the International Council for Harmonisa-
tion of Technical Requirements for Registration of Pharmaceuticals for Human Use
(ICH) E9 guidelines [45], published in 2017, highlighting the importance of LATE
estimands, may have had a positive impact in the current reporting and analysis
practices.
Box 2.2.1: Electronic search strategy used by DiazOrdaz et al. [42]
#1 (randomized trial) AND (clinical trial) [All Fields]
#2 ((cluster randomization) OR (cluster randomisation) OR (cluster) OR
(clustered) OR (clustering) OR (clusters) OR (group-randomized) OR
(group-randomised) OR (randomisation unit) OR (randomization unit)) [All Fields]
#3 animal [All Fields]
4#1 AND #2
5#4 NOT #3
6 Feasibility [All Fields]
7 Pilot [All Fields]
8 Protocol [All Fields]
9 Review [All Fields]
#10 : #6 OR #7 OR #8 OR #9
#11 : #5 NOT #10
#12 : year [2011] (for scoping)
#11 : AND #12
(searched performed in PubMed on 18 June 2012)
(”2011”[Date - Publication] : ”2011”[Date - Publication])
2.2.2 Piloting and validation
Two researchers independently piloted a data extraction form using five randomly
selected reports. This helped to identify extra relevant information to extract and
to improve the study protocol. After updating the study protocol and the data
extraction form, a random sample of fifteen reports was used for validation of the
extraction procedures. In case of discrepancy, a final decision was made by consensus
39
and the appropriate information was recorded in the data extraction form. Once the
team was satisfied with the extraction procedure, I performed the data extraction
in the whole sample. When there was doubt or ambiguity, this was reviewed by the
second extractor and a consensus was reached.
2.2.3 Data extraction
Data were extracted on one primary outcome per report, defined as that specified
by the authors or, if not specified, the outcome used in sample size calculations. If
no primary outcome was specified and no sample size calculation was reported, the
first outcome presented in the abstract or manuscript was considered as primary.
Information was collected on the type of cluster, the type of primary outcome (bi-
nary, continuous, categorical), whether a harm outcome was investigated [46], and
the type of intervention given in the control arm (placebo, standard care or active).
Information on the level of adherence (cluster-level or individual-level) was also
recorded. Non-adherence was considered to be at the cluster level if the treatment
received was different from that assigned for all the participants within clusters, and
it was considered to be at the individual level if the treatment received differed from
the allocated treatment on an individual basis within the same cluster.
Additionally, data on total number of clusters and individuals randomised and anal-
ysed were extracted as well as numbers of clusters and individuals receiving the al-
located treatment. We defined treatment non-adherence as discrepancy between the
allocated course of treatment and the actual treatment received [11]. Descriptions
of treatment adherence, including intra-cluster correlation coefficient for treatment
adherence [30], were also recorded, when reported. I also recorded information on
adherence-adjusted analyses and whether clustering was accounted for.
I adapted the definitions by Dodd et al. [11] and extracted data about the duration
of the intervention. A “one-off” intervention is defined as that which is received at
a single time point, e.g. a surgery. A “short-term” intervention is defined as an
intervention implemented at different time points over a short period; for example,
five training sessions on the importance of breastfeeding over one week. Any other
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recurrent intervention over an extended period of time was classified as a “long-term”
intervention.
2.2.4 Analysis
Simple analyses were performed to describe the frequency of adherence-reporting
and the reported methods used to adjust for non-adherence. I provide the median
(and the first and third quartiles) of the number of clusters and individuals that are
randomised, the number of clusters and individuals on treatment and the number
of clusters and individuals included in the analysis.
For the percentage of non-adherence, I used the author-reported non-adherence when
this was reported numerically. If not, I calculated the percentage of non-adherence
for each study, from the data provided in the manuscript (the ratio between “off
allocated treatment” participants to the total number randomised).
2.3 Results
After excluding 7 reports that used only sub-samples of CRTs data and 2 crossover
trials, our final sample included 123 CRTs. See the Flow Chart, Figure 2.1. During
the validation phase, the two extractors had an initial agreement of 93%, ultimately
achieving consensus by discussion.
2.3.1 Trial characteristics
Trial characteristics are shown in Table 2.1. Interventions were mainly concerned
with changing healthcare practices (63 trials, 51%), educational practices (27 trials,
22%) or lifestyle (25 trials, 20%). In most trials, standard care was used as the
control intervention (96 trials, 76%). The primary outcome was either continuous
(65 trials, 53%) or binary (57 trials, 46%), with one exception (multi-category).
Adverse events were investigated in 12 trials (10%).
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Records identified through 
electronic database searching 
(n=526)
Full-text reports assessed for 
inclusion (n=276)
Reports eligible for full text 
screening (n=338)
Records screened (n=526)








All data at cluster level=2
Full-text not available=2
Pilot study=1
Studies previously included in
DiazOrdaz et al.
(n=132)
Records excluded at random (n=62)
Records excluded on the basis of title or 
abstract (n=188)
Studies included in review 
(n=123)
Reports not included in this review
(n=9)
Sub-sample analysis of CRT=7
Crossover trial=2
Figure 2.1: Flow diagram of the identification process for the sample of 123 CRTs
included in this review
The intervention was implemented exclusively at the cluster level in 65 trials (53%)
and at the individual level in 58 trials (47%). Long-term interventions were the most
common (83 trials, 68%), followed by short-term interventions (35 trials, 28%). The
majority of the studies were two-arm trials (106 trials, 86%). The median (1st–3rd
quartiles) number of clusters randomised in each trial arm was 12 (7–24) and the
number of clusters per trial arm ranged from 2 to 199. The number of individuals
per cluster had a median (1st–3rd quartiles) of 27 (10–65) with a range of 2 to 14350.
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Table 2.1: Characteristics of the CRTs included in this review
Characteristics Included trials (123 CRTs)
Type of intervention, n (%)
Healthcare practice 63 (51.2)
Lifestyle changes 25 (20.3)
Educational 27 (22.0)
New drug 5 (4.1)
Vaccination/screening 3 (2.4)
Type of control intervention, n (%)
Standard practice 94 (76.4)
Active control 27 (22.0)
Placebo 2 (1.6)




Investigation of adverse events, n (%) 12 (9.8)
Number of trial arms, n (%)
2 106 (86.2)
3-4 17 (13.8)
Level of intervention, n (%)
Cluster level 65 (52.8)
Individual level 58 (47.2)
Unit of analysis, n (%)
Clusters 6 (4.9)
Individuals 117 (95.1)
Length of intervention, n (%)
One-off 5 (4.1)
Short term 35 (28.4)
Long term 83 (67.5)
Clusters randomised per arm, Median (1st-3rd quartiles) 12 (7-24)
Range 2-199
Cluster size, Median (1st-3rd quartiles)a 27 (10-65)
Rangea 2-14350
Primary analysis population, n (%)
Intention-to-treat 119 (96.8)
Per protocol/as treated 4 (3.2)
a Based on the average number of individuals per cluster reported in each trials.
ITT analysis was done as primary analysis in 119 trials (97%), with the remaining 4
trials (3.2%) using PP or AT analysis. Only 6 trials (5%) used cluster-level analysis
(primary outcome defined at the cluster level) while the remaining 117 trials use
individual-level analysis. Among these, clustering was not accounted for in 12 trials
(10%). See Table 2.2.
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Table 2.2: Analysis methods stratified by unit of analysis
Cluster-level Individual-level
analysis analysis
Methods of analysis 6 (100) 117 (100)
Generalized estimating equations - 27 (23.1)
Mixed effects models - 55 (47.0)
Repeated measures analysis of variance - 5 (4.3)
Generalized linear model with sandwich variance - 16 (13.7)
Chi square accounting for clustering - 1 (0.8)
Survival analysis accounting for clustering - 1 (0.8)
Other methods ignoring clustering a - 12 (10.3)
Weighted regression b 1 (16.7) -
Other methods without weighting a 5 (83.3) -
Methods of analysis when non-adherence
was addressed 1 (100) 18 (100)
Generalized estimating equations - 4 (22.2)
Mixed effects models - 9 (50.0)
Generalized linear model with sandwich variance - 4 (22.2)
t-test ignoring clustering c - 1 (5.6)
Unweighted t-test d 1 (100) -
The numbers in brackets are the column percentages. a Generalized linear model, analysis of vari-
ance, analysis of covariance, T-test, Mann-Whitney U test, Chi square test. b Number of events
(cluster size) used as weights (Buttha et al [47]). The use of weigths is applicable when cluster-
level summaries analysis is performed while accounting for clustering may be required for indivi-
dual-level analysis. c t-test with multiple testing adjustment but ignoring clustering was applied
to perform a per protocol analysis at individual-level (Neuzil et al. [48]). d Per protocol analysis
with unweighted t-test comparing rates at cluster level (Tagbor et al. [49]).
2.3.2 The reporting and handling of non-adherence
Sixty-one reports (50%) included information on adherence: full adherence was re-
ported in 5 trials while the remaining 56 trials reported some form of non-adherence
to the allocated treatment. Table 2.3 reports the adherence characteristics of these
trials. The reporting of adherence was more frequent in interventions of short du-
ration (57%) compared to those of long duration (47%). Forty-four trials (72%)
used a binary treatment adherence definition, with only one report justifying the
threshold used for this dichotomisation. Five trials (8%) recorded non-adherence as
a continuous variable, while the remaining 12 trials (20%) gave no details on the
definition of adherence used. Only 11 trials (9%) provided a flow chart with com-
plete information on how many clusters and/or individuals received the assigned
treatment. Nine trials reporting non-adherence performed adverse events analysis.
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Non-adherence at the cluster level was reported in 15 trials (24%), with a further
4 (6%) studies reporting full cluster adherence. Non-adherence at the individual
level was acknowledged in 41 trials (71%) out of 58 trials that provided information
on adherence (full adherence or presence of non-adherence), while one trial (2%)
reported full adherence. No study reported the use of an intra-cluster correlation
coefficient for adherence.
2.3.2.1 Adherence by allocated groups
Active group: Five studies provided the percentage of cluster-level non-adherence,
with a median (1st–3rd quartiles) of 44.8% (33%–50%), with a further 10 reporting
cluster non-adherence without further details. At the individual level, 30 (73%) out
of 41 studies reported this, with a corresponding median (1st–3rd quartiles) of 15%
(9%–24%).
Control group: Adherence to the control protocol was less frequently reported;
5 trials stated full adherence, while a further 15 studies reported some form of
non-adherence. Cluster-level non-adherence was reported in one trial, while full
adherence was reported in a further 4 trials. At the individual level, 19 trials reported
control-treatment non-adherence, with full adherence in one study.
2.3.2.2 Adherence-adjusted analyses
Fifteen trials performed PP analyses, with the remaining 4 studies carrying out
AT analyses either as primary or secondary analyses. No study reported LATE
estimates. Amongst the 9 studies with a safety outcome, 4 trials performed a PP
analysis [48, 50–52], with a further trial using an AT analysis [53]. Two studies
did not account for clustering in their adherence-adjusted analyses [48, 49]. No
study reported the assumptions necessary for their adherence-adjusted analyses to
be unbiased causal treatment estimates. In any case, none of these studies was
double-blinded. I summarise some of the characteristics of these adherence-adjusted
analyses in Table 2.4.
45
Table 2.3: Reporting of non-adherence by length of intervention, randomised arm and level of adherence.
One-off Short term Long term Total
Reporting of any non-adherence, n (%) 5 (100) 35 (100) 83 (100) 123 (100)
Non-adherence reported in both active and control groups - 4 (11.4) 16 (19.3) 20 (16.2)
Non-adherence reported in active group only 2 (40.0) 15 (42.9) 19 (22.9) 36 (29.3)
Non-adherence reported in control group only - - - -
Full adherence reported - 1 (2.9) 4 (4.8) 5 (4.1)
Not reported 3 (60.0) 11 (31.4) 36 (43.4) 50 (40.6)
Unclear - 4 (11.4) 8 (9.6) 12 (9.8)
Trials with adherence at cluster level 2 (100) 21 (100) 42 (100) 65 (100)
Non-adherence reported in both active and control groups - - 1 (2.4) 1 (1.5)
Non-adherence reported in active group only - 9 (42.9) 5 (11.9) 14 (21.5)
Non-adherence reported in control group only - - - -
Full adherence reported - 1 (4.7) 3 (7.1) 4 (6.2)
Not reported 2 (100) 9 (42.9) 29 (69.1) 40 (61.6)
Unclear - 2 (9.5) 4 (9.5) 6 (9.2)
Trials with adherence at individual level 3 (100) 14 (100) 41 (100) 58 (100)
Non-adherence reported in both active and control groups - 4 (28.6) 15 (36.6) 19 (32.8)
Non-adherence reported in active group only 2 (66.7) 6 (42.9) 14 (34.1) 22 (38.0)
Non-adherence reported in control group only - - - -
Full adherence reported - - 1 (2.4) 1 (1.7)
Not reported 1 (33.3) 2 (14.3) 7 (17.1) 10 (17.2)
Unclear - 2 (14.3) 4 (9.8) 6 (10.3)
Percentage of non-adherence at cluster levela
Total number of trials reporting non-adherence, n (%) - 9 (100) 6 (100) 15 (100)
Trials reporting % of non-adherence in active group, n (%) - 2 (22.2) 3 (50.0) 5 (33.3)
Median % of non-adherence in active groupb - 37.4 (30–44.8) 50 (33–80) 44.8 (33–50)
Continued on next page
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Table 2.3 Continued
One-off Short term Long term Total
Percentage of non-adherence at individual level
Total number of trials reporting non-adherence, n (%) 2 (100) 10 (100) 29 (100) 41 (100)
Trials reporting % of non-adherence in active group, n (%) 2 (100) 7 (70.0) 21 (72.4) 30 (73.2)
Median % of non-adherence in active groupb 16.5 (0.5–32.4) 13.7 (5.3–25) 15 (10–20) 15 (9–24)
Total number of trials reporting non-adherence, n (%) 2 (100) 10 (100) 29 (100) 41 (100)
Trials reporting % of non-adherence in control group, n (%) - 3 (30.0) 11 (37.9) 14 (34.1)
Median % of non-adherence in control groupb - 8.1 (1.7–32) 8.2 (3.4–20) 8.2 (3.4–20)
Total number of trials, n (%) 5 (100) 35 (100) 83 (100) 123 (100)
Flow chart with adherence information 1 (20.0) 4 (11.4) 6 (7.2) 11 (8.9)
Flow chart without adherence information 1 (20.0) 19 (54.3) 65 (78.3 ) 85 (69.1)
No flow char 3 (60.0) 12 (34.3) 12 (14.5) 27 (22.0)
Adherence type, n (%)c 2 (100) 20 (100) 39 (100) 61 (100)
Binary adherence 2 (100) 14 (70.0) 28 (71.8 ) 44 (72.1)
Continuous adherence - 2 (10.0) 3 (7.7) 5 (8.2)
Unclear - 4 (20.0) 8 (20.5) 12 (19.7)
Trials using adherence-adjusted methods, n (%) 1 (100) 4 (100) 14 (100) 19 (100)
Per protocol 1 (100) 4 (100) 10 (71.4) 15 (78.9)
As treated - - 4 (28.6) 4 (21.1)
a No report provided non-adherence % at cluster level in the control group. b Numbers in brackets are the 1st and 3rd quartiles. c Total number
of trials reporting non-adherence or full adherence.
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2.4 Summary of findings
This is the first systematic review of reporting practices of non-adherence with ran-
domised treatment in CRTs. Our findings show that about half of the studies include
information on treatment adherence, but details on numbers of clusters and indi-
viduals that adhered to the intended treatment are often incomplete. Schulz et al.
[67, 68] found that trials reporting exclusions after treatment initiation (i.e. devi-
ations from protocol) tend to be of higher methodological quality than those that
did not report it. This is known as the “exclusion paradox”. It is therefore possi-
ble that those studies that did not report on adherence also experienced protocol
deviations. On this basis, I estimate that in this study the proportion of trials with
non-adherence lies within the range 23% to 94% at the cluster level and 71% to 98%
at the individual level. In addition, I found that studies tended to report more often
adherence at the individual level. This potential under-reporting may be due to the
complexity of defining adherence in CRTs, and that as CRTs are often pragmatic in
nature, recording adherence to treatment protocol is not often a primary concern.
Amongst the studies reporting non-adherence, only one-third specified departures
from protocol in the control group. This has to be interpreted in light of the fact that
in our review, “usual care” was used as control in approximately three quarters of
studies, and that defining and measuring adherence to “usual care” may be difficult
or impractical. In general, the nature of the departures from protocol was very
poorly reported, and it was not possible to ascertain whether alternative treatments
to those in the trial, i.e. not originally included in the design of the study, were
taken. Knowledge of the alternative regimes followed by those individuals who
did not adhere to their allocated treatment is important if we want to judge the
impact of such non-adherence on the causal interpretation of an ITT analysis. If no
external treatments are available, then the ITT estimate will be diluted towards the
null, when compared with the true treatment effect. Moreover, the reported non-
adherence details (numbers initiating and completing the treatment protocol, period









































































































































































































































































































































































































































































































































































































































































































































































































































All of the studies reporting adherence-adjusted estimates performed PP or AT anal-
yses, without discussing the assumptions necessary to result in unbiased causal es-
timates and their plausibility [18, 19]. No study performed a LATE estimation or
any other statistical methods that are suitable under more plausible assumptions
in the context of a randomised trial (such as assuming random allocation is a valid
instrument) for unbiased causal estimation [24,34].
2.5 Comparison with previous studies
A previous systematic review by Eldridge et al. [12] assessed the quality of design
and reporting of CRTs published between 1997 and 2000 found that non-adherence
was reported in about 24% of 152 studies. However, they did not investigate how
non-adherence was addressed when estimating causal treatment effects. For indi-
vidual randomised trials, Dodd et al. [11], in a review of 100 trials published in
2008 in five leading medical journals, found this percentage to be 98%. In contrast,
the review performed by Zhang et al. [41], which considered individual randomised
drug trials published in 2010, found a prevalence of non-adherence reporting of 46%.
Both of these results are thus in line with the lower and upper bounds found in our
study. These two previous individually-randomised trials reviews noted a lack of
justification in the threshold used in defining a binary measure of non-adherence
[11,41]. In the present review, only one justified this choice.
The median percentage of individual-level non-adherence reported by the CRTs
included here was 13%. Similar median percentages of non-adherence were found
in previous reviews of adherence in individually randomised trials, 10–20% in Dodd
[11], and 11.6% in Zhang [41]. While the latter reported finding a monotonic trend
of adherence with regards to intervention duration [41], I did not find any such
trend. This could be because adherence was not clearly reported in over 40% of
both long and short-term interventions. In fact, in view of the “exclusion paradox”,
non-adherence with short-term interventions could be as high as the non-adherence
reported in long-term interventions.
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Only 3% of the studies included in the present review presented an adherence-
adjusted analysis as primary, with the great majority reporting an ITT approach.
Of those studies assessing treatment efficacy, PP analysis was the most used. Dodd
et al. [11] also found that the majority of studies attempting to adjust for non-
adherence in an analysis used PP.
Although the extended CONSORT statement for CRTs [14,39] recommends report-
ing the numbers of clusters and individuals randomised and receiving their assigned
treatment, I found that the reporting of these numbers was low (9%). This is in
contrast to the results reported by Dodd et al. [11], who found that 58% stated the
number of participants actually initiating their allocated treatment. A possible ex-
planation may be the lower adherence to CONSORT guidelines among CRT reports




Introduction to cluster-level summary ap-
proaches in CRTs
3.1 Introduction
CRT investigators are sometimes interested in evaluating the effect of their interven-
tion on the whole cluster, rather than the individual units. Such analyses may re-
quire a reduction of the hierarchical structure of clustered data to a single-level data.
This is achievable by first constructing summary statistics of variables (for exam-
ple, means or proportions where appropriate) for each cluster, and then performing
statistical analyses on those summaries. Estimates obtained from such approaches
are at the cluster level [8], with summaries taking values on a continuous scale.
Implementation of cluster-level (CL) summary analyses may require accounting for
the likely varying precision of CL summaries, which if substantial, would induce
heteroscedasticity (non-constant residual variance). Standard statistical methods
such as ordinary least squares (OLS) regression assume homoscedasticity (constant
residual variance). Failure to address heteroscedasticity, if present, results in wrong
inferences [70, 71]. Various re-weighting approaches such as cluster size (CS ) and
minimum-variance (MV ) weights [72–74], and the use of Huber-White (so-called
sandwich or robust) standard errors (SEs) are available to account for heteroscedas-
ticity, if present. CL-summary analyses are known to be inefficient [75], but adequate
weighting may improve efficiency [8, 76].
The current chapter introduces different approaches that have been proposed for CL-
summary analyses in the context of ITT analysis [8]. Although the chapter is about
CL-summary approaches, I present an overview of random effects linear modelling
which uses the hierarchical structure of the data in Section 3.2 before moving to
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CL-summary analyses. Then, section 3.3 introduces CL-summary approaches and
section 3.4 presents a summary of the chapter.
I consider a two-arm CRT, with n individual units indexed by i, in J clusters indexed
by j, each of size nj. Let Zj denote the binary treatment randomly allocated at
the cluster level with probability 0.50. Let Yij represent the continuous or binary
outcome, Xij a set of explanatory variables measured for individual i in cluster j,
and Wj a set of explanatory variables measured for cluster j.
3.2 Overview of random effects linear regression
Standard regressions assume that the observations are independent and identically
distributed. The independence assumption is violated when data are clustered i.e.
observations are on grouped individuals or are repeated measurements on the same
individuals. Ignoring the clustering leads to underestimating the SEs for cluster-level
covariates which include the treatment allocation variable, and therefore to incor-
rect inferences. Random effects modelling adequately handles clustered data (when
correctly specified) and is applicable to any type of dependent variables (continu-
ous, binary, counts, etc.). Here, we focus on linear regression models with random
intercepts. These models are not part of CL-summary approaches but are first in-
troduced in order to clarify notions such as the intracluster correlation coefficient
and the between-cluster variance used later for CL-summary analyses.
Random intercept linear models relax the standard assumption of independence
across individual units by allowing for cluster-specific intercepts. Here, Yij represents
only a continuous outcome. A random-intercept linear model for ITT analysis, with
covariate adjustment for generality, is as follows [8, 77, 78]
Yij = γ0 + γZZj + γWWj + γXXij + υj + εij (3.1)
where γ0 is the mean intercept shared by all clusters and individual units when Z,
W and X are equal to 0; γZ is the IL-ITT effect, conditional on W and X. γW and γX
are the change in mean outcome induced by a unit increase or a change in level of Wj
and Xij, but are of little interest in randomised trials. υj is the random intercept
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(or level-2 residual) for cluster j and εij the IL (level-1) residuals. It is assumed
that υj ∼ N(0, σ2υ), εij ∼ N(0, σ2ε ) and Cov(εij, υj|Xij,Wj, Zj) = 0. More explicitly,
E(εij|Xij,Wj, Zj, υj) = 0 and E(υj|Xij,Wj, Zj) = 0. This implies that the level-1
residual εij and random intercept υj are both uncorrelated with the explanatory
variables. It is also assumed that Cov(εij, εi′j′|Xij,Wj, Zj, υj, Xi′j′ ,Wj′ , Zj′ , υj′) = 0
for any i 6= i′ or j 6= j′ and Cov(υj, εij′|Xij,Wj, Zj, Xi′j′ ,Wj′ , Zj′) = 0 for any j 6= j′.
Note that it is not necessary to condition on Zj because randomisation ensures that
Zj is independent of υj and εij. Covariates adjustment in ITT analysis is not to
control for confounding, but rather for improving precision.
The regression coefficients are consistent if the mean structure is correctly specified
i.e. correct functional form and covariates, and Cov(εij, υj) = 0. The additional
assumption that the covariance structure (variances and covariances) of the total
residual (υj + εij) is correctly specified, is necessary to ensure the consistency of the
model-based SEs. When both mean and covariance structures are correctly speci-
fied, the coefficients estimation is efficient. The coefficients are unbiased if the mean
structure is correct and the total residuals have a symmetrical distribution [78]. Es-
timations are often done by maximum likelihood (ML) or restricted (or residual)
maximum likelihood (REML) [79]. ML estimation consists of maximizing the joint
likelihood function of the coefficients and variance component [77]. REML unlike
ML estimates the random-intercept variance accounting for the loss of degrees of
freedom resulting from the estimation of the coefficients. REML provides unbiased
estimates for the variance component whereas ML leads to a downward biased vari-
ance component when data are balanced, that is all clusters have the same size.
However for unbalanced data, both REML and ML are biased. It is unclear which
of REML and ML has the smaller mean square error, whether data are balanced or
unbalanced [77,78].
Note that the total residual variance (denoted σ2) is σ2 = σ2υ +σ
2
ε , where Var(Yij) =
σ2. The marginal intracluster correlation coefficient (ICC) for Yij, denoted ρy, is
obtained from fitting equation (3.1) without regressors (Zj included, i.e. an empty
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. Thus, the between-cluster variance of Yij can
be expressed as σ2υ = ρyσ
2 and the within-cluster variance of Yij as σ
2
ε = (1− ρy)σ2.
3.3 ITT analysis on CL summaries
Another strategy to handle CRT data is to first compute CL-summary statistics
and use these summaries as variables to analyse or include in a regression model
for the estimation of CL-ITT. This approach is suitable when the treatment effect
at the cluster level is of interest. I introduce two CL-summary approaches for
CRTs, the unadjusted and adjusted CL-summary outcomes. ITT analysis with
unadjusted or adjusted CL-summary outcome may require SEs that are robust to
heteroscedasticity to ensure valid inferences. This can be achieved via adequate
weighting strategy (CS or MV weights) or HW SEs. In this section, we formally
present the ITT analysis using the unadjusted and adjusted CL-summary outcomes,
combined with weighting and HW SEs.
I denote Y j and Xj be the sample means of Yij and Xij for cluster j respectively,










Xij. If Xij includes categorical variables, then
for each of these variables, dummy variables will be created for each category except
for one, and sample proportions generated for each of these dummies.
3.3.1 Unadjusted CL summaries
The unadjusted CL (unCL)-summary approach consists of generating CL-summary
statistics, such as means or proportions where appropriate, of the observed outcome.
These CL summaries are used in subsequent analyses. CL-summary statistics are
continuous regardless of whether the original variable was binary or not. For cate-
gorical regressors with q levels, (q− 1) dummy variables can be created and propor-
tions generated for each of these dummies. Thus, statistical methods such as t-test
or Wilcoxon-Mann-Whitney test can be used to assess the ITT effect by comparing
the CL summaries between the control and active treatment groups, if the trial in-
vestigators do not plan to adjust for covariates. A linear regression model can be
fitted to adjust for covariates, but only CL regressors should be directly included
i.e. Wj but not the mean of Xij. It has been shown that including CL summaries
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from IL variables as regressors is equivalent to using those regressors as instrumental
variables and is therefore inappropriate [76].
Here, we consider CL-sample means or proportions, Y j and Xj. Zj and Wj are
measured at the cluster level. In fact, equation 3.1 can be written as Yij = µj +
γXXij + εij where µj = γ0 + γZZj + γWWj + υj are the cluster means adjusted for
differences in the individual-level covariate Xij [76]. Likewise, Xij = φ0 + φXX̄j +
ψij = φ0 + Xj + ψij as φX is always equal to 1 (where ψij is a random error term
with mean 0, assumed to be independently and identically distributed). Therefore,
we have the following simultaneous equations to solve [76]:
Yij = γ0 + γZZj + γWWj + γXXij + υj + εij
Xij = φ0 +Xj + ψij
(3.2)
Equation 3.2 corresponds to an IV setting where Xj is an instrument for Xij. The
variability in Yij at the cluster level (adjusted for Xij) is captured by the µj’s.
Regressing the estimated cluster means µ̂j on the cluster-level covariates Zj and Wj
enables us to estimate the target treatment effect γZ [76]. If we substitute Xij by
Xj and express Yij as functions of Zj, Wj and Xj, then we have the cluster means
µ?j = γ0 + γZZj + γWWj + βXXj + υj that are different from µj. The µ
?
j ’s are not
adjusted for Xij and therefore using µ
?
j as cluster means to explain the variability
in Yij at the cluster level identifies a parameter that is different from the target
treatment effect γZ in equation 3.1 [76]. This is the rationale for using the adjusted
CL-summaries covered in section 3.3.2, if we want to adjust the cluster means for
adjusting individual-level covariates.
Since CL-summary outcomes are continuous, they can be assumed to be approx-
imately normally distributed, especially when nj is sufficiently large. The OLS
regression model for estimating the ITT effect with CL-summary outcome Y j as the
dependent variable and with covariate adjustment is as follows
Y j = α0 + αZZj + αWWj + ηj (3.3)
where j ∈ {1, . . . , J}, ηj is a random error term, assumed to be i.i.d., with mean 0
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and constant variance σ2η. Note that Xij is not included in equation (3.3). The ITT
effect is αZ . The OLS estimator α̂k of the parameter αk (here αk = α0, αZ or αW) is
consistent i.e. α̂k → αk as the number of clusters n goes to infinity. OLS estimator
is unbiased regardless the sample size if Cov(Zj , ηj) = 0 and Cov(Wj , ηj) = 0 [80].
Equation (3.3) is equivalent to equation (3.1) without IL regressor Xij as long as
the functional form is linear. In such a case, by using the expectation of Yij, we
can note that αZ and γZ are equivalent and therefore can be interpreted as either
CL-ITT or IL-ITT effects.
Let wj be the vector of all CL regressors in equation (3.3) for cluster j including a




and w′j its transpose, wj
has dimension 1 × p, where p is the number of parameters in equation (3.3). The





























where σ̂2ηj is the estimated variance of the residual ηj from equation (3.3). Under
independence and homoscedasticity assumptions, σ̂2ηj = σ̂
2
η for any cluster j. Thus,














If the ITT analysis is unadjusted i.e. Wj not included in equation (3.3), then
α̂Z =
Cov(Y j , Zj)
Var(Zj)
(3.7)
If Wj represents a single CL covariate in equation (3.3), then the expanded formula
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As noted, the formulae in equations (3.4) and (3.6), well known by econometricians,
are not that intuitive particularly in the presence of covariate adjustment. In fact,
in multivariable linear regression, OLS coefficient for the kth regressor is simply the
ratio of: (i) the covariance of the outcome variable and the residuals from regressing
that kth regressor on all remaining covariates, to (ii) the variance of those residuals
[76, 81, 82]. This is so-called “regression anatomy” [76, 83] and we can write the
covariate-adjusted ITT effect estimate α̂Z as
α̂Z =
Cov(Y j , εzj )
Var(εzj )
(3.8)
where εzj are the residuals from OLS regression of Zj on all other CL covariates Wj
included in equation (3.3) i.e. the residuals from the OLS model Zj = δ0+δWWj+εzj .
Intuitively, closely looking at equations (3.7) and (3.8), when the covariate-adjusted
ITT effect is of interest, we first obtain a “transformed” Zj (namely, the residuals
εzj) that is independent of all the CL covariates and then use this “transformed” Zj
as the single exposure or regressor for the ITT analysis. The proof of equation (3.8)
is provided in appendix A.6 [76,83].
As Zj and Wj are independent by randomisation, then δW = 0 and the predicted
value of Zj is Ẑj = E(Zj). Thus, εzj is the mean-centred Zj i.e. εzj = Zj −
E(Zj). Therefore, Cov(Yj, εzj) = Cov(Yj, Zj − E(Zj)) = Cov(Yj, Zj). Hence, the
covariate-adjusted and unadjusted ITT effect estimates are equivalent, supporting
the claim that covariate-adjustment in the presence of randomised treatment is not
to address confounding. Nevertheless, the covariate-adjusted and unadjusted ITT
effect estimates may differ due to possible covariates imbalance in finite samples.













Z|W is the coefficient of determination (often denoted R
2) of Zj regressed on
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all CL covariates Wj included in equation (3.3). From equation (3.9), it appears
clearly that – (i) the smaller the residual variance σ̂2η, the more efficient is the
covariate-adjusted ITT effect estimate α̂Z, – (ii) the lower R
2
Z|W, the more efficient
is α̂Z. By design, Zj ⊥⊥ Wj and thus, R2Z|W is expected to be equal to 0 (smallest





(Zj − Z)2 ≈
J
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Increasing the number of clusters would improve the efficiency of the CL-ITT effect
estimator α̂Z [85]. Adjusting for CL covariates that are associated with the unCL-
summary outcome Y j would substantially reduce the residual variance σ̂
2
η and sub-
sequently lead to efficiency gain. Otherwise, when CL covariates are not associated
with the outcome Y j, the loss of degrees of freedom coupled with the negligible re-
duction in the residual sum of squares undermines the efficiency, particularly when






∼ t(J−p) if ηj is normally or at least asymptoti-
cally distributed. The efficiency of OLS estimator relies on the homoscedasticity and
i.i.d. assumptions for the error term ηj. The lack of normality of the error term ηj
is neither a threat for consistency nor efficiency of OLS estimators. However, when
the normality assumption is satisfied, hypothesis testing and confidence intervals
are reliable.
3.3.2 Adjusted CL summaries
As mentioned in the previous section, a drawback of regression analyses on CL-
summary outcome is its inability to adequately adjust for IL regressors [76]. How-
ever, where there is interest in adjusting for covariates at the individual level when
analysing CL summaries, a two-step procedure so-called “residual index” [87] or
“covariate-adjusted residual” [8] can be applied. First, an IL regression analysis of
the outcome, while ignoring clustering, is performed incorporating all the relevant
covariates into the regression model except the treatment variable. Then, outcome
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residuals are predicted and used to compute CL-summary statistics which serve as
dependent variable in subsequent analyses. I refer to this as adjusted CL (adCL)-
summary outcome. The adCL-summary approach varies according to the type of
outcome variable. I present this for continuous (via OLS regression) and binary (via
logistic regression) outcomes.
3.3.2.1 Continuous outcome
The adCL-summary approach for continuous outcome Yij is as follows
 In the first step, OLS regression on Yij is performed as
Yij = γ10 + γ1WWj + γ1XXij + e1ij with e1ij ∼ N(0, σ
2
e1) (3.11)
and the outcome residuals are obtained as follows
ê1ij = Yij − Ŷij = Yij − (γ̂10 + γ̂1WWj + γ̂1XXij) (3.12)
where Ŷij = (γ̂10 + γ̂1WWj + γ̂1XXij) is the predicted outcome at the individual
level. The covariate-adjusted residuals ê1ij would be similar on average in the
control and active groups under the null hypothesis of no treatment effect [8].
 In the second step, CL-summary statistic of outcome residuals ê1ij , here means,




j=1 ê1ij . These CL summaries are then used as
dependent variables in a OLS regression for instance, as follows
êj = α0 + αZZj + ηj (3.13)
where ηj ∼ N(0, σ2η).
Caution is needed when drawing inference from equation (3.13). The degrees of
freedom is reduced by the number of CL regressors Wj included in equation (3.11)
and the t- statistic related to α̂Z must be adjusted accordingly [8]. In the absence of
CL covariates in equation (3.11), the degrees of freedom related to α̂Z are df = n−2.
However, when CL covariates are included in equation (3.11), then df = n− 2− k,
where k is the number of CL covariates in equation (3.11). Existing statistical
software do not automatically correct the degrees of freedom and therefore, it is the
analysts’ responsibility to do so. Alternatively, we can fit equation (3.11) without
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CL covariates Wj and later on, include Wj as regressor in equation (3.13) as follows
[8].
Yij = γ10 + γ1XXij + e1ij (3.14)
êj = α0 + αZZj + αWWj + ηj (3.15)
The adCL-summary ITT approach based on equations (3.14) and (3.15) do not
require the analyst to adjust the degrees of freedom. Results from standard software
can then directly be reported.
3.3.2.2 Binary outcome
Consider Yij to be binary. The two steps for adCL-summary approach are sum-
marised as follows [8].
 In the first step, a standard logistic regression is fitted as shown below
Yij ∼ Bern(πij) with πij = P (Yij = 1)
logit(πij) =γ0 + γWWj + γXXij
(3.16)
and then, the observed (Oj) and expected (Ej) number of events are obtained










exp(γ̂0 + γ̂WWj + γ̂XXij)
1 + exp(γ̂0 + γ̂WWj + γ̂XXij)
(3.17)
where π̂ij is the predicted probability that Yij = 1. γ̂0, γ̂W and γ̂X are the
estimated coefficients from equation (3.16).
 In the second step,











The ITT analysis can be carried out using the following OLS regression.
êj = α0 + αZZj + ηj (3.20)
Like in section 3.3.2.1, for convenience regarding the degrees of freedom adjustment
due to the inclusion of CL covariates, we can replace equation (3.16) with (3.21),
and equation (3.20) with (3.22) below.
Yij ∼ Bern(πij) with πij = P (Yij = 1)
logit(πij) =γ0 + γXXij
(3.21)
and,
êj = α0 + αZZj + αWWj + ηj (3.22)
αZ represents the adjusted CL-risk difference ITT effect if the adCL-summary out-
come is generated via equation (3.19) and the adjusted CL-risk ratio ITT effect if
the adCL-summary outcome is computed using equation (3.18).
Note that, irrespective of the CL-summary approach adopted, the OLS estimation
procedure of α̂Z as presented in section 3.3.1 remains applicable. OLS assump-
tions may not be met when CL summaries are analysed. I present various ways of
handling inferential flaws in the next section, when there are departures from key
OLS assumptions. These include the use of weighting and/or heteroscedastic-robust
standard errors.
3.3.3 Obtaining valid inferences
CL-summary analyses may lead to invalid inferences because of heteroscedasticity
due to the varying cluster size. Violation of the key assumption of homoscedasticity
also jeopardizes the efficiency of OLS estimator. CL-summary analyses, compared
to their IL counterparts, are known to be inefficient [75]. Estimation by weighted
least squares (WLS), where the weights are defined either by the CS or by the MV
weights can improve efficiency [76]. The use of weights and/or heteroscedasticity-
robust SEs helps in tackling heteroscedasticity. I present here different weighting
strategies and the popular HW SEs estimator [70].
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3.3.3.1 Heteroscedasticity-robust standard errors
The HW SE estimator is consistent even in the presence of substantial heteroscedas-
ticity and is recommended [70,80,88]. HW SEs are derived from equation (3.5) where



















However, HW SEs perform poorly in small samples of clusters; they are biased
downwards and provide a coverage substantially below the nominal rate [71].
3.3.3.2 Weighting strategies
Consider equation (3.1) without regressors as follows
Yij = γ0 + υj + εij (3.24)

















expression of σ2υ and σ
2
ε as functions of ρy and the total variance of Yij (i.e. σ
2)
presented in section 3.2, we can re-write Var(Y j) as follows.
Var(Y j) =
1 + ρy(nj − 1)
nj
σ2 (3.25)
Let ωj be the weight assigned to cluster j. CS weighting, sometimes referred to as
equal weights to individual units [73], consists of assigning the cluster size nj as the
weight to cluster j, i.e. ωj = nj. MV weights are proportional to the inverse of the
variance of CL-summary outcome and expressed as ωj =
nj
1 + ρy(nj − 1)
[73,74]. MV
weights minimize the variance of weighted estimators [90]. MV weights approximate
CS weights when ρy ≈ 0, whereas MV weights are approximately equivalent to no
weights i.e. “equal weights to clusters” if ρy ≈ 1 [89]. These equivalences can have
practical implications when the variance of υj cannot be consistently estimated,
for example when the number of clusters is small. In such setting, CS and no
weights are viable alternatives. When clusters are large, weighting by cluster size is
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inefficient [74]. When ρy is large, say 0.6 or greater [91], “equal weights to clusters”
are preferable over CS weights as there is little variability within clusters [92].
3.3.3.3 Weighted least squares estimation
WLS is a special case of generalised least squares (GLS) estimation [93] where the off-
diagonal elements of the residuals covariance matrix are 0, i.e. residuals are assumed
to be independent but are allowed to be heteroscedastic. The WLS estimation of
ITT effect is equivalent to using OLS estimation on the transformed equation below,









ωj + η̃j (3.26)
where η̃j = ηj
√
ωj is the error term. As noted in equation (3.26), WLS estimation
consists of fitting OLS where the outcome and covariates are rescaled by the square
root of the weight ωj, the intercept constrained to be 0 and the square root of the
weights also included as covariate.
Let us denote Y j
√
ωj by Ỹ j, Zj
√
ωj by Z̃j and Wj
√
ωj by W̃j. Let Ωj be a variable
whose values are
√









. Like the OLS setting (section 3.3.1),
the unadjusted (i.e. without CL covariates adjustment) WLS ITT effect estimate
can be obtained as
α̂Z =
Cov(Ỹ j , Z̃j)
Var(Z̃j)
(3.27)
Using the “regression anatomy” formula, we can write the adjusted WLS ITT effect
estimate α̂Z as
α̂Z =
Cov(Ỹ j , εz̃j )
Var(εz̃j )
(3.28)
where εz̃j are the residuals from OLS regression of Z̃j on all other rescaled CL
covariates W̃j and Ωj, but without intercept i.e. from the OLS model εz̃j = δωΩj +
δ
W̃
W̃j + εz̃j . Proof of equations (3.27) and (3.28) are shown in appendix A.7 [83].








































∼ t(J − p), where V̂ar(α̂Z) is the estimated WLS vari-
ance of α̂Z . If the homoscedasticity assumption conditional on the CL regressors
is satisfied, OLS estimation is generally more efficient than WLS in finite samples.
However, in the presence of substantial conditional heteroscedasticity, WLS is more
efficient than OLS [88]. Testing for conditional heteroscedasticity, using for example
the test of Breusch and Pagan [94] or White [70], may guide the choice between
OLS or WLS estimation. OLS estimation would be preferred if there is no evidence
of heteroscedasticity [88]. Regardless of the estimation method, OLS or WLS, it is
recommended to also use HW SEs [70,88].
3.4 Summary
The present chapter is an introduction of ITT analyses, based on individual-level
data (random intercept models) or CL-summary data. CL-summary ITT analyses
are known to perform well under various settings [8], but the performance of CL-
TSLS with alternative weighting while adjusting for cluster-level and/or individual
level covariates, has not been explored. Two CL-summary approaches based on
unadjusted and adjusted CL-summary outcome to estimate the ITT effect of a
randomised treatment are introduced. The former is simple whereas the latter offers
the possibility of adequately adjusting for both CL and IL covariates as often desired
by trial investigators to increase efficiency. It is possible to adjust for CL covariates
before generating the CL-summary outcome. However, this requires an adjustment
of the degrees of freedom when performing the TSLS estimation. An alternative way
to avoid correcting the degrees of freedom oneself is to only adjust for IL covariates
before computing the CL-summary outcome.
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Chapter 4.
Estimation of local average treatment ef-
fect at the cluster level in CRTs
4.1 Introduction
Chapter 3 introduced CL-summary approaches in the context of ITT analysis. How-
ever, analysis at the cluster level may extend to the causal treatment effect when
non-adherence is present [13, 36, 95]. In such a setting, two-stage least squares
(TSLS) can be used to estimate the local average treatment effect (LATE), that
is the causal effect of actually receiving the treatment [27]. While a CL method
based on the Wald estimator [31] has previously been proposed [13], the perfor-
mance of CL-TSLS to estimate LATE with alternative weighting while adjusting for
CL and/or IL covariates, has not been explored.
I present here TSLS estimation and the Wald estimator of CL-LATE using CL-
summary techniques introduced earlier in Chapter 3. The Wald estimator and TSLS
are originally developed in the econometric literature, but little is known about their
performance using CL summaries. This chapter is organized as follows. Section 4.2
outlines the required assumptions for the identification of CL-LATE. Section 4.3
presents TSLS estimation of CL-LATE. Section 4.4 introduces the Wald estimator
with the Schochet-Chiang approach for estimating CL-LATE and its standard error.
Section 4.5 presents a summary of the chapter. This chapter is part of the published
paper in Appendix A.4.
With a simplification of notation, I denote by Yj the unCL-summary outcome (la-
belled Y j in chapter 3) and ej the adCL-summary outcome (previously êj).
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4.2 Identification assumptions of CL-LATE
To define formally the causal effect of treatment received, I use the potential out-
comes (POs) framework [44]. I focus on a binary treatment assignment and a level
of treatment received at the cluster level, bounded by 0 and 1.
Let Dij ∈ {0, 1} be the treatment received by individual i in cluster j and Dj





Dij. In the CL adherence
settings, Dij is constant within clusters, and therefore Dj is binary. In contrast,
when non-adherence is at the individual level, Dj is a continuous measure that
varies from 0 to 1, representing the proportion of individuals receiving the active
treatment in cluster j, sometimes referred to as treatment intensity [28]. Let also
J0 and J1 be the number of clusters in the control and active groups, respectively
(thus, J = J0 + J1).
4.2.1 Notation and technical assumptions
I denote by Yij(dj) the PO that would manifest if, possibly contrary to fact, the j-th
cluster to which individual unit i belongs receives treatment dj, a vector of length nj
of 0s and 1s, where we are assuming no interference between clusters, i.e. the treat-
ment received by individuals in the j-th cluster are unrelated to the outcome status
of individuals in other clusters [13]. No interference between clusters is a special
case of partial interference, where individual units can be partitioned into groups
such that interference does not occur among individuals in different groups but may
occur between individuals in the same group [96]. This is commonly assumed in
CRTs [13, 30, 96, 97]. A major advantage of CRTs is to reduce interference across
clusters but not necessarily across individual units within clusters. The plausibil-
ity of this partial no interference assumption is enhanced by design (for example,
double blinding) or when clusters are well-defined and geographically far apart for
instance [8].
Assume counterfactual consistency, that is, for j = 1, . . . , J , if Zj = z then the
potential treatment received is Dij = Dij(z) and Yij = Yij(z,Dij(z)), for all i =
1, . . . , nj.
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4.2.2 Identification assumptions
Assuming no interference between clusters and consistency allows us to define LATE,
the estimand of interest [27].
In the setting considered here where both Zj and Dij are binary, the vector of poten-





tions the individual units in each cluster into four different compliance or adherence
classes [24]: Cij = n (never-takers) if Dij(0) = Dij(1) = 0; Cij = a (always-takers)
if Dij(0) = Dij(1) = 1; Cij = c (compliers) if Dij(z) = z for z ∈ {0, 1}; and Cij = d
(defiers) if Dij(z) = 1 − z for z ∈ {0, 1}. The non-numerical values n, a, c and d,
rather than being viewed as values taken by the adherence classes, are used to sim-
ply help to recognise the adherence classes. Any numerical values can be given to
n, a, c and d as long as they clearly refer to each adherence class. These adherence
classes are fixed but unknown for all units.



































Dij(1) = 1, Dij(0) = 0
) (4.1)
This is said to be a local causal effect as it is conditional on the stratum of complier
individuals. Following [13, 98], we write the cluster version of the corresponding
identification assumptions [24] as follows:
(A1) Cluster unconfoundedness : Zj ⊥⊥ Dij(z), Yij(z,Dij(z)), z ∈ {0, 1}. This
is also known as cluster or group independence or cluster randomisation assumption.
(A2) Exclusion restriction at the individual level : Conditional on the treat-
ment received Dij = d, the treatment assignment Zj had no effect on the outcome.
In terms of potential outcomes, we have Yij (1, d) = Yij (0, d) ∀d ∈ {0, 1}.
(A3) Instrument relevance: Also referred to as first stage assumption, that is,
Zj is causally associated with treatment received Dij, implying Zj 6⊥⊥ Dij.
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For point identification of LATE, (A4) monotonicity of the treatment mechanism
is assumed: Dij(1) ≥ Dij(0), often informally referred to as “there are no defiers”
[27]. Note that we need to assume this holds at the individual level [98]. For the
CL non-adherence setting, where Dij does not vary within clusters, this becomes
monotonicity at the cluster level Dj(1) = 1, Dj(0) = 0.
An extra assumption necessary when using adjusted CL-summary outcomes is that
the model used to derive the CL summaries is correctly specified.
In our setting, Zj is an IV if Zj fulfils assumptions (A1) to (A3). Figure 4.1 sum-
marizes the relationship between the random treatment allocation, the treatment





Figure 4.1: Diagram summarising the relationship between random treatment assign-
ment (Z), treatment received (D), measured CL covariate (W ), unmeasured covariate (U)
and outcome (Y ), assuming Z met assumptions (A1) to (A3)
In randomised trials, assumption (A1) holds. (A3) and (A4) are plausible, partic-
ularly in encouragement designs where individuals are encouraged to receive their
allocated treatment such as trials where units in the control group are not allowed
to have access to the active treatment. (A2) may be problematic in trials assessing
depression for instance, where patients randomised to the control group may get
more depressed for not being offered the active treatment.
4.2.3 Cluster and individual-level non-adherence
The population LATE estimand β can be thought of as a weighted average of the

































Dij(1) = 1, Dij(0) = 0
)}] (4.3)
where nc,j is the number of individual unit compliers in each cluster j, assumed




, that is the number of individual unit compliers in cluster j divided
by the total number of individual unit compliers across all clusters. This result is
useful when interpreting the estimates obtained using CL summaries. I first note
that the cluster-level LATE (CL-LATE) estimator applied to CL summaries, β̂CL,

















Dj |Zj = 0
] (4.4)
In the case where treatment received is at the cluster level (i.e. CL adherence), β̂CL
can be indeed interpreted as the population LATE. However, when non-adherence





where the CL-weights are ψCL,j =
nc,j/nj∑
j nc,j/nj
, i.e. the normalised proportion of
individual compliers in each cluster [98]. Thus, CL-LATE β̂CL identifies the popu-
lation LATE β in equation (4.2) only if – (i) the cluster sizes nj are identical for
all clusters, or – (ii) the cluster-specific LATE βj are homogeneous (i.e. constant)
across all clusters. If neither of these two conditions is satisfied, then CL-LATE β̂CL
cannot be interpreted as an estimator of the population LATE.
When CL covariate adjustment is done, then β̂CL is obtained after standardising
(i.e. marginalising) the CL-LATE estimator conditional on Wj, over the observed
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where Pr(Wj) is the empirical distribution of the observed Wj.
In the remainder, for IL non-adherence, we assume that the cluster-specific LATE
βj are constant across clusters, while allowing for the cluster sizes nj to vary. This
allows us to interpret β̂CL as an estimator for the population LATE β.
The next section introduces the TSLS method for estimating CL-LATE β̂CL.
4.3 TSLS estimation of CL-LATE
TSLS is an IV method that, in the presence of unmeasured confounding, can esti-
mate consistently the causal effect of an exposure under assumptions (A1) to (A3)
plus (A4) [24, 27].
TSLS estimation consists of a “first stage” which regresses treatment received on
randomised treatment, and a “second stage” which models the outcome on the
predicted treatment received [24,27].
4.3.1 TSLS on CL summaries
I present how to implement TSLS on CL summaries and address issues with het-
eroscedasticity and inefficiency via weighting and/or HW SEs. I also introduce the
small sample degrees of freedom adjustment to accommodate inference based on
small samples. In the sections below, I focus on unCL-summary outcome as the
principles are the same for both unCL and adCL summaries.
4.3.1.1 Unadjusted CL-LATE
The conditional expectations in equation (4.6) can be estimated via TSLS regression
of the CL summaries (referred to as CL-TSLS). CL-TSLS is most easily explained for
settings without weights and covariate adjustment. The first stage fits a regression
of CL treatment received (or cluster average treatment received) Dj on treatment
assigned Zj. Then, in the second stage, a regression of the CL-summary outcome
(either unCL or adCL) on the predicted treatment received is fitted. Crucially,
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both first and second stages must be linear models for the TSLS estimator to be
guaranteed consistent [99,100]. The first and second stage regressions of Dj and Yj
are respectively
Dj = γ0 + γZZj + ξ1j
Yj = β0 + βTSLSD̂j + ξ2j (4.7)
where ξ1j and ξ2j are assumed i.i.d. with mean zero and constant variance, ξ1j ⊥⊥ ξ2j
and D̂j are the predicted treatment received from the first stage regression. The








From equations (4.7) and (4.8), we can see that β̂TSLS is the ratio of the regression
coefficient of Yj on Zj to the regression coefficient of Dj on Zj, γZ. The estimated
asymptotic variance of β̂TSLS under the assumption of homoscedasticity of residuals























is the 2 × 1 vector of regressor and intercept indicator for










z′jDj and D̂j = zj γ̂Z from the first stage regression.
To account for the prediction error of D̂j when estimating σ̂
2
ξ2
, it is advised not to
implement TSLS by hand but rather to use common statistical software packages
like Stata and R.
β̂TSLS is asymptotically normal distributed i.e. β̂TSLS ∼ N(βTSLS, V̂ar(β̂TSLS)). This
asymptotic distribution is often assumed when implementing TSLS in common soft-
ware like Stata and R.
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Heteroscedasticity-robust standard errors





























where σ̂2ξ2j is the variance of the residual of cluster j in the second step regression.





























However, HW SEs are recommended but perform poorly in small samples. Testing
for conditional heteroscedasticity, using for example the test of Breusch and Pagan
[94] or White [70], may guide whether to use weights or not. Unweighted analyses
would be preferred if there is no evidence of heteroscedasticity.
Weighted TSLS
When weights are used, each TSLS regression stage is weighted. I refer to this as
weighted TSLS (WTSLS). The first and second stage regression equations like in



















where ξ̃1j = ξ1j
√
ωj and ξ̃2j = ξ2j
√
ωj are the error terms with mean zero and
constant variance, and ξ̃1j ⊥⊥ ξ̃2j.
Let denote Yj
√
ωj by Ỹj, Zj
√
ωj by Z̃j, Dj
√
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Small sample degrees of freedom
The asymptotic normal distribution used by default in standard statistical software
to test and construct the 95% confidence interval of β̂TSLS may not be adequate,
especially with small number of clusters. Rather than relying on asymptotic prop-
erties, the exact t−distribution of β̂TSLS can be used instead. This is so-called “small
sample degrees of freedom” (SSDF) adjustment. When SSDF correction is done,




























The SSDF correction consists of dividing the residual variance by the sample size
minus the number of parameters in the second stage regression, here J − 2.
4.3.1.2 Covariate-adjusted CL-LATE
Trial investigators often plan to adjust for baseline covariates when estimating the
ITT effect and also the causal effect, if of interest. It is possible to obtain covariate-
adjusted CL-LATE estimate from TSLS by including the covariates in both first
and second stage regressions as follows
Dj = γ0 + γZZj + γWWj + ξ1j
Yj = β0 + βIV,adjD̂j + βWWj + ξ2j (4.15)
where ξ1j and ξ2j are assumed i.i.d. with mean zero and constant variance, ξ1j and
ξ2j are uncorrelated, and D̂j are the predicted treatment received from first stage
regression. Analogously to the “regression anatomy” [76, 83], introduced in section
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3.7, the estimator β̂IV,adj of CL-LATE βCL can be expressed as [76]
β̂IV,adj =
Ĉov(Yj , εzj )
Ĉov(Dj , εzj )
=
Ĉov(Yj , εzj )/V̂ar(εzj )
Ĉov(Dj , εzj )/V̂ar(εzj )
(4.16)
where εzj are the residuals from regressing Zj on Wj. β̂IV,adj is the ratio of the
regression coefficient of Yj on εzj to the regression coefficient of Dj on εzj . Note that
equation (4.16) holds when there is a single IV (here, Zj) and a single exposure of
interest (here, Dj) like in randomised trials setting [76].
εzj can be viewed as an IV improved by eliminating any possible association between
Zj and measured covariates Wj. However, as mentioned in section 4.2.3, adjusting
for covariates in TSLS when the IV is a randomised treatment does not change the
specification of the LATE estimator. This is obvious in equation (4.16) as εzj = Zj−
E(Zj) because Zj ⊥⊥ Wj (i.e. Zj independent of Wj) by randomisation. Consider
the linear regression model Zj = δ0 + δWWj + εzj . Zj ⊥⊥ Wj implies that δW = 0
and the predicted value of Zj is Ẑj = E(Zj). Thus, εzj = Zj − E(Zj). It follows
that Cov(Yj, εzj) = Cov(Yj, Zj − E(Zj)) = Cov(Yj, Zj) and likewise Cov(Dj, εzj) =
Cov(Dj, Zj − E(Zj)) = Cov(Dj, Zj). Hence, β̂IV,adj = Ĉov(Yj ,Zj)
Ĉov(Dj ,Zj)
= β̂TSLS. This
supports the reason why it is not necessary to adjust for covariates in TSLS when
there is a valid IV as we do not expect to gain any bias reduction [101]. The
equivalence of β̂IV,adj and β̂TSLS may not be apparent in finite randomised trial samples
because of possible baseline covariates imbalance.
However, there will be gain in precision if Wj is associated with Yj and Dj. Though
not obvious in equation (4.16), adjusting for Wj when associated with Dj and Yj
reduces both first and second stage residual variances.























is the p × 1 vector of regressors and intercept indicator
(where Wj consists of (p− 2) covariates) for cluster j, σ̂2ξ2 is the residual variance in
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the second stage regression.
Heteroscedasticity-robust standard errors
The HW estimated asymptotic variance of V̂ar(βIV,adj) is of similar form to (4.10)












WTSLS with covariate adjustment is similar to the unadjusted WTSLS, except that











, where W̃j = Wj
√
ωj and Wj represents (p− 2)
covariates. The covariate-adjusted WTSLS CL-LATE estimator is
β̂IV,adj =
Ĉov(Yj , εz̃j )
Ĉov(Dj , εz̃j )
(4.18)
where εz̃j are the residuals from regressing Z̃j on W̃j without intercept. Similarly to





is the p× 1 vector of regressors and intercept indicator for
cluster j.
Small sample degrees of freedom
SSDF correction procedure is the same as in 4.3.1.1. When SSDF is done in the
presence of (p− 2) covariates (Zj not included), β̂IV,adj ∼ t(J − p).
4.4 Schochet-Chiang approach
The Schochet-Chiang’s estimation of CL-LATE is based on the Wald estimator [31],
which I denote here by β̂CL,Wald. I introduce the Wald estimator and its standard
error as suggested by Schochet and Chiang [13].
4.4.1 Wald estimator
The Wald estimator [31] is a ratio of the ITT effect on the outcome (effect of Z on Y )
to the ITT effect on treatment (effect of Z on D). The basis of the Wald estimator
[31] is equation (4.4) where Zj is binary and there is no covariate adjustment. β̂CL,Wald
is a simple and consistent estimator of βCL [102]. Schochet and Chiang [13] used OLS
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regressions to estimate the ITT effects on the unCL summaries Yj and on the unCL
summaries Dj when adherence is at the individual level or simply the treatment
received for CL adherence. Only CL covariate adjustment is valid [13,76].
When there is no covariate adjustment, the following equations are used to obtain
the Wald estimator:
Yj = β0 + βZZj + η1j (4.19)
Dj = γ0 + γZZj + η2j (4.20)
Covariate adjustment is done as shown in equations (4.21) and (4.22) as follows
Yj = β0 + βZZj + βWWj + η1j (4.21)
Dj = γ0 + γZZj + γWWj + η2j (4.22)
where η1j and η2j are i.i.d normal residuals with mean 0 and are independent of





β̂CL,Wald is a non-linear combination of two estimators and therefore obtaining an
analytic form of its variance may entail some approximations. I present two ways
of estimating the standard error of β̂CL,Wald. These include the traditional and the
Schochet-Chiang approaches.
A drawback of estimating the standard error of β̂CL,Wald using the unCL summaries
Yj and Dj is the inability to appropriately account for the influence of Xij on the
precision of β̂CL,Wald.
4.4.2 Traditional standard errors
An analytic form of the variance of a non-linear combination of estimators is com-
monly obtained using the first order approximation of Taylor series expansion, com-
monly known as the “Delta” method [103]. The first order approximation of Taylor












The variance of β̂CL,Wald is traditionally estimated assuming that the denominator γ̂Z
is estimated without error [13]. Thus, V̂ar(γ̂Z) = 0 and Ĉov(β̂Ẑ, γ̂Z) = 0 and equation












i=1(Yj − Ŷj)2 is the residual variance from equation (4.19), Ŷj is
the predicted value of unCL-summary outcome for cluster j and J−2 are the degrees
of freedom (here, number of clusters minus number of parameters in equation (4.19)).
Here, it is assumed that the residual variance is the same variance in the control and
active groups. This variance homogeneity assumption can be easily relaxed. In the
presence of CL covariates adjustment like in equation (4.21), the degrees of freedom
are equal to J − p where p is the number of CL regressors (Zj included) plus the
intercept. The standard error of β̂CL,Wald is then obtained by taking the square root
of equation (4.25).
The “Delta” method has been shown to perform poorly, particularly when propor-
tion of adherent units is low [98,104].
4.4.3 Schochet-Chiang standard errors
Schochet and Chiang [13] estimated the variance of β̂CL,Wald using equation (4.24).
This allows us to account for the estimation error in both numerator (β̂Z) and de-
nominator (γ̂Z) of the Wald estimator. The second term of equation (4.24) accounts
for the uncertainty of γ̂Z and the third term involves the covariance of β̂Z and γ̂Z. It
is possible to account for potential heteroscedasticity likely to occur from varying
precision of CL summaries, while estimating the variance of the Wald estimator as
in [13]. However, Schochet and Chiang found very similar results whether allowing
for weights or not when estimating the corrected variance [13].
Like in [13], I assume unequal variances of CL-summary treatment received Dj
across trial groups as this seems plausible in randomised experiments; for example,
in one-sided non-adherence where none of the units in the control group receives the
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i=1 Zj(Dj − D̂j)2, and
D̂j is the predicted value of Dj from equation (4.20) if no covariate adjustment and
(4.22) otherwise. A consistent estimator of the covariance of β̂Z and γ̂Z is [13]
Ĉov(β̂Z, γ̂Z) =
∑J0




i=1 Zj(Yj − Ŷj)(Dj − D̂j)
J1(J1 − p)
(4.27)
Thus, after inserting equations (4.25), (4.26) and (4.27) in equation (4.24), the































follows a standard normal distribution [98].
The Wald and TSLS estimators are equivalent in the absence of covariate adjustment
[80]. When applied to CL summaries without weighting, the point estimates from
the Schochet-Chiang method are equivalent to those from TSLS when there is no
covariate adjustment.
4.5 Summary
I presented CL-TSLS and the Wald estimator with Schochet-Chiang SEs for esti-
mating CL-LATE. In the presence of non-adherence, randomised treatment can be
used as an instrument to perform TSLS estimation of CL-LATE, that is the causal
effect of actually receiving the treatment on the CL-mean outcome. Covariates ad-
justment is not required because of randomisation being a valid instrument, but
rather aims to improve precision.
CL-summary analyses may lead to invalid inferences because of likely heteroscedas-
ticity due to the varying clusters size. Estimation by WLS, where the weights are
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defined either by the CS or by the MV weights can improve efficiency. The use
of weights and/or HW SEs help tackling heteroscedasticity, if present. However,
HW SEs perform poorly in small samples [71]. Testing for conditional heteroscedas-
ticity, using for example the test of Breusch and Pagan [94] or White [70], may
guide whether to use weights or not. Unweighted analyses would be preferred if
there is no evidence of heteroscedasticity. Inference in TSLS estimation often relies
on normality from large sample properties. Therefore, it may be necessary to use
the exact t−distribution in small samples by choosing the small sample degree of
freedom adjustment, available in standard software.
The Wald estimator for CL-LATE is a ratio where the numerator and denominator
are obtained via OLS estimations. The standard error of the ratio is estimated using
the first order approximation of Taylor series expansion as per Schochet-Chiang [13].
The point estimates from the Wald estimator are equivalent to those from TSLS in
the absence of covariate adjustment.
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Chapter 5.
Simulation study of cluster-level LATE es-
timation in CRTs
5.1 Introduction
This chapter investigates, via simulations, the finite sample performance of TSLS
and the Wald estimator with Schochet-Chiang SEs for CL-LATE introduced in
chapter 4. I evaluate their empirical bias and coverage. The simulation study
considers one-sided non-adherence CRTs of different sizes and where non-adherence
is either at the cluster or individual level. I allow for various effect sizes of cluster-
level and individual-level variables on the outcome and the treatment received.
The chapter is organized as follows. Section 5.2 introduces the data generating pro-
cess. Section 5.3 summarises the analysis and criteria used to assess the methods
performance. Section 5.4 presents the performance of CL-TSLS and the Wald es-
timator with Schochet-Chiang SEs. Some additional investigations are done and
presented in section 5.5. Finally, section 5.6 summarizes the chapter.
5.2 Data generating process
I simulate CRT with individual-level data where there is one-sided non-adherence
at either the cluster or individual level. With a fixed expected total sample size
n = 1000 individuals, I vary the number of clusters J and the average cluster size
nj. The marginal ICC of Y also takes two values. The effect of cluster-level and
individual-level variables on the outcome and the treatment received also varies, so
that the strength of the confounding (observed and unobserved) is either low or high,
while the value of the true LATE also has two levels i.e. low (0.1 standard deviation
of the outcome) or modest (0.4 standard deviation of the outcome). The cluster-
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level and individual-level covariates are confounders of the relationship between the
treatment received and the outcome. The unobserved confounding is introduced by
omitting either or both covariates from the analysis. In other words, there is no
unobserved confounding when both cluster-level and individual-level covariates are
included in the analysis. Table 5.1 summarises the factorial design and the values
taken by the different levels.
More specifically, I simulate cluster randomised treatment Zj ∼ Bern(0.5) and
two independent baseline covariates, a cluster-level covariate Wj ∼ N(0, σ2W) and
individual-level covariate Xij ∼ N(0, σ2X) with a moderate ICC ρX = 0.05, and
σ2W = σ
2
X = 0.08. I chose ρX = 0.05 as Kul et al. [105] reported a median ICC
value (1st-3rd quartiles) of 0.043 (0.026-0.052) for baseline characteristics in CRTs
in health care.
I generate a binary adherence class indicator variable Cij, which is considered as
latent. I present below how this indicator variable is generated for cluster-level and
individual-level adherence settings.
For settings where adherence is at the cluster level, the adherence class indicator
variable is constant within clusters, under the following model
Cij = Cj ∼ Bern(πj) with πj = P (Cj =1)
logit(πj) =λ0 + λWWj ,
with λW = 0.05 equivalent to an odds ratio OR ≈ 1.05 per unit increase in W
(denoted “small effect”) and λW =0.7 equivalent to OR ≈ 2 (“large effect”). I chose
πj = 0.6 on average, as the systematic review conducted in chapter 2 shows the
median proportion of non-adherent clusters in the active group to be 44.8%.
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Table 5.1: Factorial design of the data generating processes and values taken by the parameters in the simulations
Parameter Label Level Value
CRT size
n Total number of individuals Moderate ≈ 1000
J Number of clusters and Moderate clusters J = 50, nj ∼ Poi(20)
nj individuals per cluster Few large clusters J = 10, nj ∼ Poi(100)
Baseline variables
Wj Cluster-level variable - Wj ∼ N(0, 0.08)
ρX ICC for Xij Moderate 0.05
Xij Individual-level variable - Xij = Xj + eij , Xj ∼ N(0, 0.004), eij ∼ N(0, 0.076)
Adherence to treatment
π Expected probability of adherence Moderate 0.60 (cluster-level), 0.85 (individual-level)
λW, λX Wj and Xij effects on log odds of adherence Small, Large λW = λX = 0.05, λW = λX = 0.70
Cj Cluster-level adherence class - Bern[expit(λ0 + λWWj)]
Cij Individual-level adherence class - Bern[expit(λ0 + λWWj + λXXij + ζj)]
ζj Cluster-level random effects - ζj ∼ N(0, π2/3)
ρC ICC for Cij Moderate 0.50
Outcome
β0, βC β0=0, βC=0
βW, βX Wj and Xij effects on outcome Yij Small, Modest βW = βX=0.1 SD, βW = βX=0.4 SD
βCZ True LATE Small, Modest 0.1 SD, 0.4 SD
ρY ICC for Yij Small, Large 0.05, 0.20
a SD: standard deviation of the outcome Y , σ = 1.
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For individual-level adherence, the adherence class indicator variable is generated
using the model as follows
Cij ∼ Bern(πij) with πij = P (Cij = 1)





with σ2ζ = π






The treatment received at the individual level is derived as Dij = ZjCij, so that as
applied to one-sided non-adherence, those individuals in clusters randomly allocated
to control always have control treatment, but those in clusters randomised to the
active intervention can switch to the control treatment, depending on their adherence
class. I chose an expected value of πij of 0.8, as the systematic review conducted
in chapter 2 shows that the median proportion of non-adherent individuals at the
cluster level is 15% in the active group.
I finally generate continuous outcome Yij, under the ER assumption,
Yij = β0 + βCCij + βCZCijZj + βWWj + βXXij + υj + εij (5.1)
with υj ∼ N(0, σ2υ) and εij ∼ N(0, σ2ε ), where the values for σ2υ and σ2ε are chosen
such that the marginal ICC for Y has the corresponding value according to the
simulated scenario, given that Var(Yij) = σ
2 = 1. The choice of the parameters’
values is reported in Table 5.1. Note that the treatment effects are assumed to be
homogeneous within principal strata but heterogeneous across principal strata i.e.
the treatment effects for adherent units are different from those of non-adherent
units but are similar across units within each of those adherence classes.
Inclusion criteria for simulated datasets
I need the data generating process to result in randomised treatment Z that is
a valid IV i.e. fulfilling assumptions (A1) to (A3) introduced in section 4.2.2.
However, with the choices made, some simulated CRT datasets may result in weak
instruments, especially for cluster-level non-adherence settings, with only 5 clusters
per trial arm and an expected proportion of non-adherent clusters set at 40%.
84
Thus, after creating each dataset, I perform an unadjusted first stage regression of
Dj on Zj, and reject simulated datasets where the resulting F−statistic is < 10
as per Staiger & Stock’s rule of thumb for weak instruments [106]. I continue this
process until I get 2500 datasets with valid IV per scenario. For settings where non-
adherence is at the cluster level and only 5 clusters are assigned to each trial group,
about half of the generated CRTs result in weak instruments. This combination
of settings was included as an extreme scenario, and the rejection of simulated
CRTs where random treatment assignment is weakly or not associated with the
treatment received, was to ensure that we only simulated well conducted trials where
a well-argued case for a LATE analysis can be made. Random allocation not being
associated with treatment received is indicative of a failure of the study conduct
and/or the intervention being considered unacceptable by the participants. In such
extreme cases, a LATE analysis is not recommended. In practice, trials are expected
to be well conducted and therefore the simulation study is relevant for most CRT
settings.
The R code used to generate the datasets and the Stata code for CL summary-based
data analysis are shown in appendices A.8 and A.9, respectively.
5.3 Analysis and performance criteria
I consider the TSLS estimation using CL summaries and the Wald estimator with
Schochet-Chiang SEs introduced in chapter 4. Analyses are performed using Stata
15. Details of the CL summary-based analysis code can be found in appendix A.9.
A summary of the analysis scenario is given in Table 5.2.
5.3.1 TSLS and Wald estimator with Schochet-Chiang SEs
Recall that for TSLS, estimation in each scenario involves using unadjusted CL sum-
mary of treatment received in the first-stage, and either unadjusted or individual-
level variable adjusted CL summary outcomes, for the second stage. Each regression
in the TSLS was fitted via OLS or WLS, the latter with either CS or MV weights.
I also consider TSLS where each stage model is either unadjusted or adjusted for
a cluster-level variable. Finally, I obtain SEs assuming homoscedasticity or het-
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eroscedasticity, and SSDF-based or normal approximation-based CIs. As for the
Wald estimator with Schochet-Chiang SEs, only the unadjusted CL summaries of
the outcome and treatment received are analysed via OLS.
Table 5.2: Overview of TSLS and Wald estimator with Schochet-Chiang SEs of CL-LATE
and inference strategies used in the simulation study
Methods Analyses features
TSLS CL outcome Unadjusted Adjusted for Xij
Adjusted for Wj No Yes
Weights None (i.e. OLS) CS MV
SE estimation Normal theory HW
SSDF correction No Yes
Schochet-Chiang CL outcome and CL Unadjusted
treatment received
Adjusted for Wj No Yes
Adjusted for Xij No No
Weights None (i.e. OLS)
SE estimation First order approximation of Taylor
series expansion
CL: cluster level; HW: Huber-White; CS weights: cluster-size weights; MV weights: mini-
mum variance weights; SE: standard error; SSDF: Small sample degrees of freedom correction.
5.3.2 Performance criteria
The performance criteria used are empirical bias and coverage rates of the 95% CIs
over the 2, 500 replicate datasets per scenario. For the bias, I construct a 95% CI
using its Monte Carlo Error (MCE). The coverage rate sampling error given the size
of the simulation results in a valid range between 94.1% and 95.9%.
Let the mean of the estimated LATE across the replicate datasets in each scenario,







β̂IVl . The following criteria
were used to assess the performance of the methods investigated
(a) Empirical bias: estimated by
¯̂
βIV − βCZ.














|β̂IVl − βCZ| < 1.96si
)
,
where si denotes the model-based SE for β̂IVl . The MCE of coverage is given
by
√∑L
l=1(0.95)(0.05)/L, which means that the expected range of the nominal
95% CIs is between 94.1% and 95.9%.
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5.4 Results
I present the results for TSLS and the Wald estimator with Schochet-Chiang SEs
by plotting the empirical bias with the MCE-based CIs. The valid range for the
coverage rate at the 95% nominal confidence interval is represented by horizontal
dashed lines.
5.4.1 TSLS estimation
Figure 5.1 and Figure 5.2 report the empirical bias and 95% CI coverage resulting
from each of the different CL-TSLS estimators, when adherence is at cluster or
individual level respectively, and for scenarios where the true LATE is modest (0.4
SD). The corresponding figures for small true LATE are in Figures 5.3 and 5.4. The
scenarios considered here only include clusters with similar size.
Each figure reports results where J = 10 (Panel A, top) or J = 50 (Panel B), and
with the ICC for Y , ρY, is either small (first three columns) or large (last three
columns). In each cell, the results for alternative combinations of TSLS (unad-
justed/adjusted for Wj) applied to unCL or adCL outcomes are plotted along the
horizontal axis. The different data generation scenarios are identified by ∗,+,×,
and ◦, corresponding to varying strengths of the effects of X and W (considered as
either observed or unobserved confounding) on Y .
The CL–TSLS estimators show some finite sample bias in settings where the number
of clusters is small (J=10, Panel A), regardless of whether the non-adherence was
at the cluster or individual level and whether the CL summary for Y was adjusted
or unadjusted or Wj was included or not in the TSLS regressions. However, the
Monte-Carlo error CIs includes 0 in many settings. The bias is more severe when
the ICC for Y is larger (right hand side of each Figure), especially if the number
of clusters is small (Panel A). The bias is somewhat attenuated when we adjust
for Wj in the TSLS, and the non-adherence is at the cluster-level (Figures 5.1 and
5.3). In contrast, for settings with individual-level non-adherence, this adjustment
instead increases the bias, especially if W has only a small confounding effect. In
these scenarios, the estimates exhibit a small but statistically significant bias, which
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disappears when the number of clusters is larger (Figures 5.2 and 5.4). In general,
the bias is not affected by the choice of weighting strategy, nor by whether ρY is
small or large.
Comparing the results of the 2nd, 3rd, and 4th rows in each panel (Figures 5.1 and
5.2), we see that the coverage rate is affected by the choice of SE estimation and
also by whether SSDF correction is used. When the number of clusters is small, an
SSDF correction must be used as failing to do so results in under-coverage (Panel
A). The low coverage is more serious when TSLS adjusts for W (second and fourth
set of results in each panel).
Overall, the results in Panel A of each figure show that using HW SE or not has little
to no impact if there is no SSDF correction. However, when the SSDF correction is
used for settings with cluster-level non-adherence, large ρY, and large true LATE,
but where only X is strongly associated with Y , using “unCL” outcomes leads to
under-coverage, regardless of weighting or SE method (Figures 5.1 and 5.3, 3rd and
5th rows of Panel A, right hand side columns). The use of “adCL” outcomes (i.e.
where the CL outcome is the residual after adjusting for individual level variable
X) recovers coverage close to nominal. This is not the case when non-adherence is
at the individual level, and both W and X are confounders of the causal effect of
the treatment received D on the outcome Y in the data generating process.
In both cluster and individual-level non-adherence settings, it can be seen that using
MV weights increases the coverage by a small fraction, when compared with cluster
size weights, especially for scenarios with J = 50 and large ρY. However, since MV
weights require an estimate of the cluster-level variance, and this is badly estimated
when the number of clusters is small (J = 10), we can see that MV weights are less
efficient than using either no weights or cluster size weights. This is most clearly
seen when no HW SE correction has been used.
We can also see that when SSDF correction is used, then not using HW SE can result
in small over-coverage especially for cluster-level non-adherence settings, which is
improved when HW SE are used (Figures 5.1 and 5.3, 3rd and 5th rows of Panel A).
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When J = 50 (Panel B), the use of SSDF-based distributions is not expected to
make any material difference, and this is indeed the case. The impact of using HW
















































































































































































































































































































































































































































































































































































































































Wj and Xij effects on Yij: 0.4
Wj effect: 0.4; Xij effect: 0.1
Wj effect: 0.1; Xij effect: 0.4
Wj and Xij effects: 0.1
Figure 5.1: Bias (top row) and 95% CI coverage (rows 2–5) of CL-LATE with cluster-level
non-adherence and modest true LATE. Data generation scenarios represented by ∗,+,×,
and ◦. Estimates are obtained via unadjusted or W -adjusted TSLS with different weights
(none, cluster size (CS) and minimum-variance (MV)) (by column) using CL unadjusted
or adjusted for X outcomes (“unCL” or “adCL”). Small (J = 10) and large (J = 50)
















































































































































































































































































































































































































































































































































































































































Wj and Xij effects on Yij: 0.4
Wj effect: 0.4; Xij effect: 0.1
Wj effect: 0.1; Xij effect: 0.4
Wj and Xij effects: 0.1
Figure 5.2: Bias (top row) and 95% CI coverage (rows 2–5) of CL-LATE with individual-
level non-adherence and modest true LATE. Data generation scenarios represented by
∗,+,×, and ◦. Estimates are obtained via unadjusted or W -adjusted TSLS with different
weights (none, cluster size (CS) and minimum-variance (MV)) (by column) using CL
unadjusted or adjusted for X outcomes (“unCL” or “adCL”). Small (J = 10) and large
















































































































































































































































































































































































































































































































































































































































Wj and Xij effects on Yij: 0.4
Wj effect: 0.4; Xij effect: 0.1
Wj effect: 0.1; Xij effect: 0.4
Wj and Xij effects: 0.1
Figure 5.3: Bias (top row) and 95% CI coverage (rows 2–5) of CL-LATE with cluster-level
non-adherence and small true LATE. Data generation scenarios represented by ∗,+,×,
and ◦. Estimates are obtained via unadjusted or W -adjusted TSLS with different weights
(none, cluster size (CS) and minimum-variance (MV)) (by column) using CL unadjusted
or adjusted for X outcomes (“unCL” or “adCL”). Small (J = 10) and large (J = 50)
















































































































































































































































































































































































































































































































































































































































Wj and Xij effects on Yij: 0.4
Wj effect: 0.4; Xij effect: 0.1
Wj effect: 0.1; Xij effect: 0.4
Wj and Xij effects: 0.1
Figure 5.4: Bias (top row) and 95% CI coverage (rows 2–5) of CL-LATE with individual-
level non-adherence and small true LATE. Data generation scenarios represented by
∗,+,×, and ◦. Estimates are obtained via unadjusted or W -adjusted TSLS with dif-
ferent weights (none, cluster size (CS) and minimum-variance (MV)) (by column) using
CL unadjusted or adjusted for X outcomes (“unCL” or “adCL”). Small (J = 10) and
large (J = 50) number of clusters results are shown in Panel A and B.
5.4.2 Schochet-Chiang approach
Figures 5.5 and 5.6 display the empirical bias and 95% CI coverage resulting from the
Wald estimator with Schochet-Chiang SEs (all of which I refer to as the Schochet-
Chiang estimator), when non-adherence is at the cluster and the individual levels
respectively. Each Figure shows results for scenarios where the true LATE is small
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(0.1 SD) and modest (0.4 SD) with varying ICC for the outcome (low or high). As
above, each Figure also reports results where J = 10 (Panel A, top) or J = 50
(Panel B). The different data generation scenarios are identified by ∗,+,×, and ◦,
corresponding to varying strengths of the effects of X and W (considered as either
observed or unobserved confounding) on Y . The scenarios considered here only
include clusters with similar size.
The Schochet-Chiang estimator alike TSLS estimator shows finite sample bias irre-
spective of the level of adherence (whether at the cluster or at the individual level).
Recall that the Schochet-Chiang method uses the Wald estimator where the numera-
tor and denominator are estimated via OLS. In the absence of covariate adjustment,
the Wald and TSLS estimators are equivalent [80]. The Schochet-Chiang’s SEs are
severely underestimated when the number of clusters is small and irrespective of
the level of adherence (Panel A), leading to poor coverage. For settings with small
number of clusters in particular, I note that when the ICC for Y is low, LATE size
is large and CL covariate W is adjusted for while estimating LATE, the Schochet-
Chiang’s SEs result in values very close to 0 and sometimes are negative. Recall
that the Schochet-Chiang’s SEs are based on the between-variance which are small
here as ICC for Y is low. Moreover, the between-cluster variance gets smaller when
adjusting for W which, in my simulations, is associated with the outcome Y and the
treatment received D. In contrast, the subtracted term in the Schochet-Chiang’s
formula of SEs (equation (4.28)) gets larger with increasing LATE size, making the
variance of the Wald estimator to get close to 0 or negative. This is attenuated
when the ICC is high as the between-cluster variance gets larger even though LATE
size is large, leading to improved coverages.
The Schochet-Chiang estimator has good coverage when the number of clusters is
large irrespective of the settings or when no covariate adjustment is done except
for the settings with low ICC for Y and large LATE size. For those settings, the
performance of the Schochet-Chiang and TSLS methods are comparable. However,
the TSLS estimator with SSDF correction are preferable to the Schochet-Chiang














































































































































Wj and Xij effects on Yij: 0.4
Wj effect: 0.4; Xij effect: 0.1
Wj effect: 0.1; Xij effect: 0.4
Wj and Xij effects: 0.1
Figure 5.5: Bias (top row) and 95% CI coverage of CL-LATE with cluster-level non-
adherence. The true LATE size and the ICC for outcome vary by columns. Data gen-
eration scenarios represented by ∗,+,×, and ◦. Estimates are obtained using the Wald
estimator with Schochet-Chiang SEs without weighting and unadjusted or adjusted for
W . Small (J = 10) and large (J = 50) number of clusters results are shown in Panel A















































































































































Wj and Xij effects on Yij: 0.4
Wj effect: 0.4; Xij effect: 0.1
Wj effect: 0.1; Xij effect: 0.4
Wj and Xij effects: 0.1
Figure 5.6: Bias (top row) and 95% CI coverage of CL-LATE with individual-level
non-adherence. The true LATE size and the ICC for outcome vary by columns. Data
generation scenarios represented by ∗,+,×, and ◦. Estimates are obtained using the Wald
estimator with Schochet-Chiang SEs without weighting and unadjusted or adjusted for
W . Small (J = 10) and large (J = 50) number of clusters results are shown in Panel A




Two extra additional scenarios are now considered to investigate the sensitivity of
the performance of CL-TSLS and the Schochet-Chiang estimators’ to number of
clusters and cluster size imbalances, at both cluster and individual level adherence,
but focusing on settings where confounding is strong with a modest true LATE.
In the first additional simulation, I explore the impact that the outcome ICC and
the number of clusters have on bias, while leaving the expected total sample size
fixed (n = 1000). We consider two marginal ICC for Yij (ρY = 0.05 and ρY = 0.80)
and three average cluster size (nj = 20, 10 and 2.5, corresponding to whether the
number of clusters varied from J = 50, 100 or 400), which includes one of the
scenarios previously considered in the main simulations for comparison. Though
CRTs rarely have ICCs above 0.10 [107], the value of ρY = 0.80 is included to
evaluate the performance of the methods in extreme settings.
In the second additional set of simulations, I explore the effect of high cluster size
imbalances. While keeping the average sample size equal to 1000, and J = 10 or 50, I
create high cluster size imbalance using a Pareto distribution to generate the cluster
sizes [108]. The Pareto distribution parameters are chosen so that approximately
40% of the clusters have a size below 15, and 60% a size above 15, while the average
cluster size is 20 and the minimum cluster size is 10, resulting in approximately 1.8
for the shape and 9.1 for the scale.
5.5.1 Results from TSLS estimation
Figures 5.7 and 5.8, corresponding to cluster and individual level non-adherence
settings, show that for a fixed number of clusters (cells in the same row), the bias
increases with increasing ICC for Y , but that as the number of clusters increase
(moving down the column in the Figure), CL-TSLS results in negligible mean bias,
even for a very large ρY. It is well known that TSLS is only asymptotically unbiased,
and with CL analyses, we expect the asymptotics to depend on the number of
clusters, and not the number of individuals. Nevertheless, the CL-summaries treated
as outcomes for the two models involved in TSLS contain less “information” when
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the ICC is higher, which translates into a larger number of clusters being necessary
for the bias to be negligible.
The impact of high cluster size imbalance is reported in Figures 5.9 and 5.10, where
non-adherence is at the cluster and individual level respectively. We see that when
J = 10 (Panel A), even with SSDF correction, failure to use HW SE results in under-
coverage when using cluster size weights, which is especially pronounced when ρY
is large. This is because cluster size weights are known to perform well when the
cluster level residuals are homoscedastic, which is unlikely when cluster sizes are
very imbalanced [76]. This also explains why using HW SE brings the coverage














































































































Figure 5.7: Bias of the CL-LATE for the extra simulation where non-adherence is at the
cluster level and a modest true LATE, with high ICCs and varying numbers of clusters.
Estimates are obtained via unadjusted or adjusted TSLS with different weights (none,
















































































































Figure 5.8: Bias of the CL-LATE for the extra simulation where non-adherence is at
the individual level and a modest true LATE, with high ICCs and varying numbers of
clusters. Estimates are obtained via unadjusted or adjusted TSLS with different weights
(none, cluster size (CS) and minimum-variance (MV)). Number of clusters varies by rows
















































































































































































































































































































































































































































































































































































































































Wj and Xij effects on Yij: 0.4
Figure 5.9: Extra simulation for very imbalanced cluster size settings. Bias (top row)
and 95% CI coverage (Huber-White SEs (or not) and SSDF corrections (or not)) of the
CL-LATE where non-adherence is at the cluster level, and a modest true LATE. Estimates
are obtained via unadjusted or adjusted TSLS with different weights (none, cluster size
(CS) and minimum-variance (MV)). Small and large number of clusters results appear in
















































































































































































































































































































































































































































































































































































































































Wj and Xij effects on Yij: 0.4
Figure 5.10: Extra simulation for very imbalanced cluster size settings. Bias (top row)
and 95% CI coverage (Huber-White SEs (or not) and SSDF corrections (or not)) of the CL-
LATE where non-adherence is at the individual level, and a modest true LATE. Estimates
are obtained via unadjusted or adjusted TSLS with different weights (none, cluster size
(CS) and minimum-variance (MV)). Small and large number of clusters results appear in
Panels A and B respectively.
5.5.2 Results from Schochet-Chiang approach
Figures 5.11 displays the bias for cluster-level (panel A) and individual-level (panel
B) non-adherence settings for increasing number of clusters. Like TSLS, for a fixed
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number of clusters (cells in the same row), the bias exacerbates with increasing ICC
for the outcome. When the ICC for Y is large, the bias decreases as the number
of clusters increases. However, there is little impact of increasing the number of
clusters on the bias when the ICC or outcome is low. This is not surprising because
the Schochet-Chiang estimator uses information at the cluster level and thus with
high ICC or Y , the between-cluster variance is larger but increasing the sample size
(i.e. the number of clusters) is necessary to improve the efficiency of the Schochet-
Chiang estimator. The larger the ICC for Y is, the greater should the number of
clusters be to attenuate the bias.
The impact of high cluster size imbalance is shown in Figure 5.12, where non-
adherence is at the cluster level (Panels A and B) and at the individual level (Pan-
els C and D). Results from scenarios with small number of clusters are presented in
Panels A and C whereas those with large number of clusters are shown in Panel B
and D. Like TSLS, irrespective of the number of clusters, the cluster size imbalance
has little effect on the performance of the Schochet-Chiang estimator in terms of
empirical bias. Moreover, the Schochet-Chiang estimator shows good coverage irre-
spective of the scenarios. The Schochet-Chiang’s performance is similar to that of









































































































Figure 5.11: Bias of the CL-LATE for the extra simulation where non-adherence is at
the cluster level (Panel A) and at the individual level (Panel B). The true LATE size
is modest, with high ICCs and varying numbers of clusters. Estimates are obtained via
unadjusted or adjusted Schochet-Chiang method without weighting. Number of clusters








































































































































































































Wj and Xij effects on Yij: 0.4
Figure 5.12: Extra simulation for very imbalanced cluster size settings. Bias (top row)
and 95% CI coverage of the CL-LATE using Schochet-Chiang method without weighting,
where non-adherence is at the cluster level (Panels A and B) and at the individual level
(Panels C and D). Small number of clusters results appear in Panels A and C and large
number of clusters results in Panel B and D. The true LATE size is modest. The long-
dashed black parallel lines are the acceptable 95% coverage range in the second panel.
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5.6 Summary
I investigate the performance of Schochet-Chiang approach and TSLS to estimate
CL-LATE in terms of empirical bias and coverage through simulation study. For
TSLS estimation, different weighting strategies (none, cluster size, minimum vari-
ance) and methods for obtaining CIs (alternatively using or not HW SEs and/or
SSDF correction) have been explored. TSLS estimator is known in general to result
in finite sample bias but no simulation study has focused on TSLS performance
nor on the Schochet-Chiang approach as an alternative to TSLS in CRTs when
the causal treatment effect at the cluster level is of interest. I explore settings for
one-sided non-adherence CRTs of different sizes and where non-adherence is either
at the cluster or individual level, and I allow for various effect sizes of cluster-level
and individual-level variables on the outcome and the treatment received. I only
simulated CRTs where the random treatment assignment is a relevant instrument.
This inclusion criterion is to reflect well designed and conducted trials where there
are no major issues with the acceptability of the intervention. I demonstrate the
use of TSLS applied to CL summaries as a simple and valid method for obtaining
estimates of the LATE in CRTs where non-adherence occurs at the cluster or the
individual level.
Empirically via simulations, under the sufficient assumptions for identification, TSLS
regression of CL summaries provides consistent estimates of the causal treatment ef-
fect in the sub-population of compliers, where non-adherence is at the cluster level.
With individual-level non-adherence, the additional assumption that the cluster-
specific LATE is homogeneous across clusters is required for CL-TSLS to identify
the population LATE [98]. Moreover, provided that an appropriate distribution
with SSDF adjustment is used when the number of clusters is small and HW SEs
are used if there is high cluster size imbalance, valid 95% CIs can be constructed.
The simulations suggest that all weighting strategies perform similarly when the
number of clusters is not small. When the number of clusters is small, MV weights
tend to be badly estimated and are not recommended. Furthermore, when the
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cluster sizes are very variable, CS weights should not be used. Although in the
simulations the weights did not affect the point estimates, these were affected in the
illustrative example (see chapter 8). Overall the results show that unless there are
very few clusters, or the outcome ICC is large, MV weighting performs well [74].
The Schochet-Chiang estimator has good coverage when the number of clusters is
large irrespective of the settings or when no covariate adjustment is done except
for the settings with low ICC for Y and modest LATE size. For those settings, the
performance of the Schochet-Chiang and TSLS methods are comparable. However,
the TSLS estimator with at least SSDF correction is preferable to the Schochet-
Chiang estimator especially for settings where the number of clusters is small.
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Chapter 6.
Estimation of local average treatment ef-
fect at individual level in CRTs
6.1 Introduction
Data from CRTs are often analysed at the individual level. The systematic review
presented in chapter 2 shows that about 97% of the reviewed CRT reports used
IL analyses, of which 70% are performed via generalized estimating equations or
mixed effects modelling (Table 2.2). IL analysis has the advantage over CL sum-
mary approach (introduced chapter 3) to easily adjust for both baseline CL and IL
covariates.
The present chapter is structured as follows. In section 6.2, I introduce the assump-
tions required for the identification of IL-LATE. Section 6.3 presents some IL-LATE
estimation options such as the Wald estimator with bootstrapped SEs, TSLS with
cluster robust SEs and Moulton’s corrected SEs, multilevel mixture modelling using
a Bayesian approach. I also provide an overview of multilevel mixture modelling via
the expectation-maximization (EM) algorithm, which can be implemented in Mplus
[109]. Those methods are implemented in chapters 7 and 9, except the EM analysis
due to inaccessibility to Mplus. Though not covered in this thesis, note that TSLS
could also be used along with bootstrapped SEs. However, I focus on TSLS with
cluster robust SEs which is popular for causal inference using clustered data and
TSLS with Moulton’s corrected SEs which is attractive and simple but not often
used in practice.
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6.2 Identification of IL-LATE
I formally introduce the causal estimand LATE at the individual level, and the
assumptions for its identification within the POs framework as applied to CRTs in
the presence of binary treatment assignment and binary non-adherence.
6.2.1 Notation and technical assumptions
Like in chapter 4, I consider a two-arm CRT, with n individual units indexed by
i, and J clusters, labelled by j, each of size nj. Let Zj be the binary random
treatment assignment for cluster j, Yij be the continuous, and Dij ∈ {0, 1} be the
treatment received by individual i in cluster j. Let Wj and Xij be CL and IL
baseline covariates, respectively (which can be vectors of variables) and associated
with both Yij and Dij. Assume that there exists at least one unobserved confounder
of the Dij–Yij relationship, denoted by Uij .
The same notation and technical assumptions mentioned in section 4.2.1 are also
needed for IL-LATE settings i.e. assuming no interference between clusters and
counterfactual consistency.
6.2.2 IL-LATE estimand
Let Cij denote the adherence class [27, 34] for individual i in cluster j: Cij = n
(never-takers) if Dij(0) = Dij(1) = 0; Cij = a (always-takers) if Dij(0) = Dij(1) =
1; Cij = c (compliers) if Dij(z) = z for z ∈ {0, 1}; and Cij = de (defiers) if
Dij(z) = 1− z for z ∈ {0, 1}. Recall that the non-numerical values n, a, c and d are
used to simply help recognising the adherence classes. IL-LATE is the same as the
population LATE defined in equation (4.1) shown in section 4.2.2, that is,
β = E
[{























Dij(1) = 1, Dij(0) = 0
)
It is also necessary that assumptions (A1)-(A4) introduced in section 4.2.2 hold
to identify β. Under the relevant technical (no interference between clusters and
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counterfactual consistency) and identification (IV and monotonicity) assumptions,

















Dij |Zj = 0
]
βIL is the ratio of the ITT effect on Yij (causal effect of Zj on Yij) to the ITT effect on
Dij (causal effect of Zj on Dij). When IL-LATE is adjusted for a single covariate Wj























Dij |Zj = 0,Wj
])
Pr(Wj)
where Pr(Wj) is the empirical distribution of the observed Wj.
Note that the clustering does not affect the expected values. However, clustering
must be accounted for when estimating the variance of βIL’s estimates.
6.3 Estimation of IL-LATE
We introduce two popular approaches for estimating β, which are the Wald and
TSLS estimators and the mixture modelling. The former approach is the traditional
IV estimation and the latter explicitly models both the latent adherence class and
the outcome.
6.3.1 TSLS estimation
As introduced in chapter 4, TSLS provides a consistent estimate for β [76], which
I denote here β̂IL,TSLS. The first and second stages of TSLS estimation are OLS
regressions (ignoring clustering) as follows, considering that covariates are included:
first stage,
Dij = γ0 + γZZj + γWWij + γXXij + ε1ij (6.1)
and second stage,
Yij = β0 + βIL,TSLSD̂ij + βWWj + βXXij + ε2ij (6.2)
where D̂ij is the predicted value of Dij from the first stage, ε1ij ∼ N(0, σ2ε1) and
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ε2ij ∼ N(0, σ2ε2). D̂ij are afterwards used as a covariate as described in equation
6.2. I present below two approaches for estimating the standard error of β̂IL,TSLS,
acknowledging the clustering. These approaches are the Huber-White-Rogers (also
known as cluster-robust) and Moulton’s standard errors.
6.3.1.1 Huber-White-Rogers standard error
When data are clustered, ignoring the correlation between units within clusters may
bias the standard errors downward. However, a simple way of estimating β is to
implement TSLS estimation ignoring the clustering and subsequently correct the
standard error using Huber-White-Rogers method [70,110]. Huber-White standard
errors known also as robust or sandwich standard errors are consistent even in the
presence of heteroscedastic residuals provided that the residuals are independently
distributed. The Huber-White-Rogers method is an extension to the Huber-White
approach that relaxes the assumption of independent residuals and produces con-
sistent standard errors in the presence of clustering, provided that individual units
are correlated within clusters but independent across clusters. The point estimates
remain unchanged.
6.3.1.2 Moulton standard error correction
This estimation procedure is based on equations 6.1 and 6.2 as above, but the con-
ventional OLS standard error of β̂TSLS is inflated by a scalar referred to as Moulton
factor [76]. The Moulton factor for β̂TSLS is the ratio of β̂TSLS’s standard error ob-
tained from fitting linear random-intercept regressions (adding random intercepts in
equations 6.1 and 6.2 to account for the clustering) to its conventional standard error
from OLS regressions (as in equations 6.1 and 6.2). The Moulton factor is originally
applied to correct standard errors for valid inference posterior to the use of linear















where SEc is the conventional standard error from equation 6.2 and SE the valid
standard error accounting for clustering. Var(nj) is the variance of clusters size and
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n̂ the average cluster size. ρD̂ and ρε2 are the intra-cluster correlation coefficients
of D̂ij (predicted values of the first-stage) and ε2ij (residuals of the second stage),
respectively. From the following random-intercept models D̂ij = α0 + u1j +ψ1ij and
ε2ij = u2j + ψ2ij where u1j ∼ N(0, σ2u1), ψ1ij ∼ N(0, σ
2
ψ1












From equation 6.3, we note that the Moulton factor is not required when there is
no clustering i.e. ρD̂ = 0 and/or ρε2 = 0; for instance, when the treatment received
is at cluster level, ignoring clustering would give valid inferences. The higher the
cluster size imbalance, the greater the downward bias of the standard error when
clustering is present.
6.3.2 Wald estimator
The basis of the Wald estimator [31], denoted by β̂IL,Wald, in equation (6.1) where Zj
is a binary IV and there is no covariate adjustment. β̂IL,Wald is a simple and consistent
estimator of β [102]. Let us consider the following OLS regression models
Yij = β0 + βZZj + ε1ij (6.4)
Dij = γ0 + γZZj + ε2ij (6.5)






where β̂Z is the ITT effect on outcome (as the sample-means difference in Yij between
control and active groups) and γ̂Z the ITT effect on treatment received.
Although the Wald estimator refers to the setting with single binary IV and without
covariates, with a slight abuse of terminology, I label this ratio as the “adjusted”
Wald estimator when covariates Wj and/or Xij are included in equations (6.4) and
(6.5). Equation (6.6) is analogous to the so-called “indirect least squares” estimator,
where models (6.4) and (6.5) are fitted via OLS [76], i.e. ignoring clustering.
β̂IL,Wald is a non-linear combination of two estimators and therefore obtaining an
analytic form of its variance may entail some approximations. Moreover for valid
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inference, it is necessary to account for clustering in estimating the standard error
of β̂IL,Wald. The standard error of β̂IL,Wald can be estimated using the traditional Delta
method or a bootstrap approach. The former is commonly obtained using the first
order approximation of Taylor series expansion, known as the “Delta” method [103]
(see section 4.4.2). For the inference based on bootstrapping, both clusters and
individuals within clusters are re-sampled N times [80], and 95% CIs constructed
based on normal approximation. Bootstrap CIs are suitable for small and large
data sets and may avoid misleading inferences [112, 113]. As regards to how large
N should be, it has been suggested that N should be between 1000 and 2000 [113].
6.3.3 Multilevel mixture model
The LATE can also be estimated by fitting an appropriate mixture model, with the
LATE corresponding to a specific model parameter. Estimation of these models
can be achieved within a frequentist or a Bayesian framework. Here I focus on
Bayesian and the expectation-maximization (EM) estimations. These modelling
techniques are based on two main specifications: the outcome model and the model
for adherence. Clustering is accounted for by including a multilevel specification of
the error structure, leading to multilevel mixture models being fitted to estimate
the LATE.
In the setting of CRTs where there is one-sided non-adherence at the individual level,
that is where there are only compliers and never-takers by design, the multilevel
mixture model may be written as
Yijl ∼ f(Yij|θl, Cijl, Zj,Wj, Xij), l ∈ {1, 2}, Cijl ∼ Bern(πijl) (6.7)
where f(Yij|θl, Cijl, Zj,Wj, Xij) is the density probability of Y with parameter θl =
(βl,υl, σ
2
l ) where βl represents the vector of fixed effects (regression coefficients) to
be estimated, υl is the vector of random effects for adherence class l. Note that
each individual unit may have a non-zero probability πijl = p(Cij = l) to belong to
adherence class l. We label never-takers as l = 1 and compliers as l = 2. Thus, the
probability to be a complier is πij2 = p(Cij = 2) = πij and the probability of being
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a never-taker is πij1 = p(Cij = 1) = 1− πij.
When f is a normal distribution, equation 6.7 can explicitly be written as follows.
Yijl = β0l + βZlZj + βWlWj + βXlXij + υ0j l + εijl
Cijl ∼ Bern(πijl)
(6.8)
where υ0j l ∼ N(0, σ
2
υ0l
), εijl ∼ N(0, σ
2
ε0l
) and ζj ∼ N(0, σ2ζ ). The LATE is given by
βZ2 . Under exclusion restriction, βZ1 is constrained to be 0.
In the one-sided non-adherence setting, the true adherence class Cij is unknown
but it is assumed that the partially observed (i.e. observed in those assigned to
treatment) binary variable Rij is an indicator of Cij. We denote pij2 = P (Rij =
1) = pij the estimated probability of being a complier and pij1 = P (Rij = 0) = 1−pij
the estimated probability of being a never-taker.
I present in the next section how to estimate the parameters of equation 6.8. This
model can be fitted using either a Bayesian approach or a frequentist approach based
on the EM algorithm.
6.3.3.1 Bayesian multilevel mixture model
The Bayesian multilevel mixture (BMM) model without baseline covariates is spec-
ified as follows.
Yijl ∼ N(µijl , σ
2
υl
+ σ2εl) ; l ∈ {1, 2}
µij1 = β01 + βZ1Zj + υj1
µij2 = β02 + βZ2Zj + υj2
υjl ∼ N(0, σ2υl)
Rij ∼ Bern(pij) ; logit(pij) = λ0 + ζj ; ζj ∼ N(0, σ2ζ )
(6.9)
where σ2υ1 and σ
2
υ2
are the between-cluster variance in the never-takers and compliers
classes, respectively and ζj is the random effect included in the logistic regression
modelling the odds of being a complier. We assume, under exchangeability by design,
that the estimated probability of being a complier in the active group is equal to
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the true probability of being a complier i.e. πij = pij.
Adjustment for baseline covariates Covariates adjustment can easily be achieved
by simply including baseline covariates Wj and Xij in model 6.9, only if Wj and Xij
are fully observed. However, when there are some covariates with missing values,
equation (6.10) shows how covariate adjustment is achieved. Let V1ij and V2ij be two
baseline covariates with missing values such that V1ij has less missing values than
V2ij. We assume here that the baseline covariates Wj and Xij are fully observed.
The BMM model with adjustment for baseline covariates (with and without missing
values) is as follows.

Yijl ∼ N(µijl , σ
2
υl
+ σ2εl) ; l ∈ {1, 2}
µijl = β0l + βZlZj + βWlWj + βXlXij + υjl
υjl ∼ N(0, σ2υl)









θ1ij l = γ0,V1l + ω1jl + γZ,V1lZj + γW,V1lWj + γX,V1lXij
θ2ij l = γ0,V2l + ω2jl + γZ,V2lZj + γW,V2lWj + γX,V2lXij + γX,V2lV1ij
ω1jl ∼ N(0, σ
2
ω1l




Rij ∼ Bern(πij) ; logit(πij) = λ0 + γWWj + γXXij + ζj ; ζj ∼ N(0, σ2ζ )
(6.10)
Under exclusion restriction, βZ1 is set at 0, that is, the effect of treatment assignment
on Yij among never-takers. A vague prior distribution (normally distributed and
centered at 0) is often assumed for the coefficients. For level-2 variances in particular,
Gelman [114] recommended starting with a non-informative uniform prior density
on standard deviation parameters unless the number of clusters is low (below 5 for
instance); otherwise, the uniform prior density tends to lead to high estimates of
the standard deviation. He also suggested the use of a non-informative prior from
the Half-Cauchy distribution on the scale of the standard deviation when several
variance parameters are needed. The Half-Cauchy distribution is more flexible and
behaves better for standard deviations near 0. Jeffrey’s prior is often used for level-1
standard deviation.
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I fit the model using Markov Chain Monte Carlo (MCMC) simulation [115, 116] in
the “Just Another Gibbs Sampler” (JAGS) through R using the “Rjags” package
[117]. I mainly assess the convergence of Markov chain by looking at the trace plots
and formally using the Gelman-Rubin statistic, whose value is 1 for perfect mixing
of chains [118]. It is recommended that a Gelman-Rubin statistic greater than 1.10
indicates poor mixing of chains [119].
6.3.3.2 Multilevel mixture model via expectation-maximization
The expectation-maximization (EM) algorithm is an iterative computation of max-
imum likelihood estimates that can be used to address incomplete-data problems
[120]. By incomplete-data, it is meant that there exists some hidden variables or
parameters not measured in the observed data. Here, the data are incomplete be-
cause the adherence class indicator R is missing for the control group.
It mainly consists of two steps, the expectation step (E-step) and the maximization
step (M-step). In some settings like mixture modelling, the likelihood function of
the incomplete-data is difficult to maximize while the likelihood of the complete-
data is much simpler to work out [120]. To circumvent the maximization issue, it
is assumed that the true adherence class Cij for each individual unit and also the




are calculated after making an initial guess about the parameters βl, ε
2
l , and υjl . In
the M-step, the expected subsequent likelihood is maximized after substituting π
(pos)
ijl
with πijl . The EM algorithm goes on iteratively until convergence. The multilevel
mixture model via EM can be fitted in software such as Mplus [30,109] or in R using
the “lavaan” package [121] for instance.
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Chapter 7.
Simulation study of individual-level LATE
estimation in CRTs
7.1 Introduction
This chapter investigates, via simulations, the finite sample performance of TSLS,
Wald and Bayesian multilevel mixture estimations of IL-LATE introduced in chapter
6. I consider a setting of one-sided non-adherence CRTs with moderate number of
clusters (25 clusters per group) and a total size of 1, 000 units on average. The data
generating process is the same as in chapter 5. Note that the simulations assume
that the identification assumptions for LATE are met.
The current chapter is organized as follows. Section 7.2 summarises the analysis and
criteria used to assess the methods’ performance. Section 7.3 presents the simulation
results on the performance of the Wald or conditional Wald, TSLS with HWR SEs,
TSLS with Moulton-corrected SEs and Bayesian multilevel mixture modelling for
estimating IL-LATE. Finally, section 7.4 summarizes the chapter. I do not include
estimations via multilevel mixture EM because of inaccessibility to the specialized
software Mplus [109].
The objectives of the simulations are to assess the performance of the methods
mentioned above in terms of empirical bias and coverage, and to provide recom-
mendations as to when and how analysts should implement those methods when
interested in estimating IL-LATE.
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7.2 Inclusion criteria, analysis and performance
criteria
I implement the TSLS, Wald estimation and Bayesian multilevel mixture method
introduced earlier in chapter 6. The analyses are performed on the 2500 simulated
CRT data sets used in chapter 5, where the random treatment assignment is relevant
(i.e. first stage F−statistic from TSLS ≥ 10). I restrict the performance assessment
to the settings of moderate CRTs size (J = 50 i.e. 25 clusters per trial group) and
where LATE size is large (0.4SD). For every simulation, estimation via the Bayesian
method in particular is based on equation (6.9). A chain equal or longer than 50000
is run until convergence that is assessed using the Gelman-Rubin statistic which is
suggestive of good convergence if lower than 1.10 [118,119].
Standard errors for the frequentist-based methods, here TSLS and the Wald esti-
mator, are obtained via HWR approach and Moulton’s correction. I construct the
95% CIs for the Wald estimates using normal approximation bootstrapped-based
CIs with 1500 replications, where both clusters and individuals within clusters are
re-sampled. TSLS and Wald estimations are performed using Stata 15 and the
Bayesian analyses implemented in JAGS through R using the “Rjags” package. The
analysis codes are shown in appendix A.10. A summary of the analysis scenarios is
given in Table 7.1.
Table 7.1: Overview of TSLS, Wald and Bayesian multilevel mixture estimations of
IL-LATE in the simulation study
Methods Analyses features
TSLS Covariate adjustment None Wj Xij Wj and Xij
SE estimation HWR Moulton
Wald Covariate adjustment None Wj Xij Wj and Xij
SE estimation Bootstrap-based normal approximationa
Bayesian multi- Covariate adjustment None Wj Xij Wj and Xij
level mixture SE estimation Bayesian (2.5th-97.5th percentiles)
a Both clusters and individuals within clusters are re-sampled, with 1 500 replicates.
IL: individual level; HWR: Huber-White-Rogers; SE: standard error.
117
7.2.1 Estimation methods
I perform TSLS, the Wald estimator and the Bayesian multilevel mixture modelling
introduced earlier in Chapter 6. For TSLS, SEs are estimated using either HWR
method [70,110] or Moulton’s factor correction [76].
For the Wald estimation, the SE of the ratio is obtained via bootstrapping using 1500
replicates with both clusters and individuals within clusters re-sampled and 95%
CIs constructed based on normal approximation. I used 1500 bootstrap replicates
as most practitioners suggested a number of replicates between 1000 and 2000.
As regards to the Bayesian multilevel mixture modelling, I fit equations shown in
section 6.3.3.1. Uninformative normal priors are used for all coefficients and a vague
inverse gamma prior for level-1 variance. I used Uniform and half-Cauchy priors for
the level-2 standard deviation as recommended by Gelman [114].
7.2.2 Performance criteria
The performance criteria used are the same in chapter 5, that is, the empirical bias
and coverage rates of the 95% CIs over 2500 replicate data sets per scenario. The
bias uncertainty is presented using a 95% CI constructed based on the Monte Carlo
Error. The acceptable coverage rate due to the finite sampling error for this number
of replications is between 94.1% and 95.9%. For the Bayesian multilevel mixture,
the median value is used as the point estimate of IL-LATE. Details on the criteria
performance are presented in section 5.3.2.
7.3 Results
This section summarizes the performance of the Wald (conditional) estimator with
bootstrapped SEs, TSLS with HWR or Moulton-corrected SEs and Bayesian multi-
level mixture modelling with Uniform or half-Cauchy prior for the level-2 standard
deviation when estimating IL-LATE. I present below the results for CRTs where
adherence is at the cluster level and then when adherence is at the individual level.
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7.3.1 Adherence at cluster level
Figure 7.1 displays the results of the estimation of IL-LATE reported in terms of
empirical bias and coverage of the 95% nominal CI for the Wald estimator, TSLS
estimation with HWR or Moulton-corrected SEs and the Bayesian multilevel mixture
modelling with Uniform or Cauchy prior for the level-2 standard deviation when
adherence is at cluster level. Panels A and B present the performance of these
methods when the ICC for the outcome is 0.05 (low ICC) and 0.20 (high ICC),
respectively.
The Wald, TSLS with HWR SEs and TSLS with Moulton SEs provide unbiased IL-
LATE estimate with good coverage and outperform the Bayesian multilevel mixture
modelling whether the ICC for outcome is low or high. TSLS with HWR SEs and
TSLS with Moulton SEs have very similar performance, regardless of how covariate
adjustment is done. The Wald (or conditional Wald) estimation with bootstrapped
SEs is conservative i.e. has coverage above the 95% nominal CI when the ICC for
the outcome is low. For the higher ICC, the Wald estimation like TSLS with HWR
SEs and TSLS with Moulton-corrected SEs has a coverage at the 95% nominal level.
The Bayesian multilevel mixture modelling provides downward biased IL-LATE es-
timates, whether Uniform or half-Cauchy prior is used for the level-2 standard devi-
ation. Regardless of the level of ICC for the outcome (as low as 0.05% or as high as
0.20%), the empirical bias is attenuated (about 3% to 5%) when no covariate adjust-
ment is done whereas the bias increases (up to 15%−20%) with cluster-level and/or
individual-level covariate adjustment. The increase in parameters to be estimated
for the covariates while the number of clusters for predicting the adherence classes
is relatively small (as only 25 clusters in the active group provides information)
may reduce the model’s predictive accuracy of adherence classes, which in turn may
explain the bias of IL-LATE estimates after covariate adjustment. In the presence
of low ICC for the outcome, the coverage is above the 95% nominal level when no
covariate adjustment is done but falls below the 95% nominal level (between 89%
and 93%) with cluster-level and/or individual-level covariates adjustment. How-
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ever, in the presence of high ICC for the outcome, the Bayesian multilevel mixture
is conservative with and without covariate adjustment. Having only 25 clusters in
the active group seems too low to model the adherence classes. Thus, the Bayesian
multilevel mixture model may require larger number of clusters in the active group
to perform well.
7.3.2 Adherence at individual level
Figure 7.2 presents the results of the estimation of IL-LATE reported in terms
of the empirical bias and coverage of the 95% CI when the Wald (or conditional
Wald) estimator, TSLS with HWR SEs, TSLS with Moulton-corrected SEs and
Bayesian multilevel mixture modelling with uninformative Uniform or Cauchy prior
for the level-2 standard deviation are used when adherence is at the individual level.
Panels A and B show the performance of these estimation methods when the ICC
for outcome is 0.05 (low ICC) and 0.20 (high ICC), respectively.
When the ICC for outcome is low, the Wald estimator and TSLS with HWR or
Moulton’s SEs lead to unbiased IL-LATE estimates. This applies to the Bayesian
multilevel mixture modelling except when a half-Cauchy prior is used for the level-2
standard deviation and only the individual-level covariate is adjusted for. The Wald
estimator with bootstrapped SEs has good coverage except when only individual-
level covariate is adjusted for while there is a cluster-level covariate strongly affecting
both outcome and adherence to treatment. In the latter, the coverage is slightly
below the 95% nominal level (≈ 93.5%). TSLS with Moulton’s SEs correction shows
good coverage irrespective of how covariate adjustment is done. However, TSLS
with HWR SEs has a coverage slightly below the 95% nominal level (≈ 93.5%).
The coverage for the Bayesian multilevel mixture modelling is good but tends to
be conservative especially when a cluster-level covariate strongly associated with
outcome and adherence is adjusted for. The Bayesian multilevel mixture modelling
has a coverage close to the 95% nominal and is less conservative when no covariate
adjustment is done or when the cluster-level covariate has a small effect on outcome
and adherence to treatment.
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In the presence of higher ICC for the outcome, the Wald estimator and TSLS with
HWR or Moutlon’s SEs lead to unbiased IL-LATE unlike the Bayesian multilevel
mixture modelling that shows little downward bias (around 1%). The bias is attenu-
ated when both the cluster-level and individual-level covariates have strong effects on
outcome and adherence to treatment, and are adjusted for. The coverage for Wald
with bootstrapped SEs, TSLS with HWR SEs and TSLS with Moulton-corrected
SEs is below the 95% nominal (between 92.5% and 94%) and gets close to the 95%
nominal when the cluster-level covariate only has little effect on both outcome and
adherence. The Bayesian multilevel mixture model, however, shows good coverage
at the 95% nominal level.
7.4 Summary
The current chapter compares the performance of the Wald (or conditional Wald)
estimator, TSLS with HWR SEs, TSLS with Moulton SEs and the Bayesian multi-
level mixture modelling in terms of empirical bias and coverage at the 95% nominal
CI level when estimating IL-LATE under the required identification assumptions in
CRTs with moderate number of clusters (here 25 clusters per trial group) and where
there is one-sided non-adherence at the cluster level or at the individual level.
When adherence is at the cluster level, the Wald, TSLS with HWR SEs and TSLS
with Moulton SEs provide unbiased IL-LATE estimate with good coverage but the
Wald estimation is slightly conservative when the ICC for outcome is low. TSLS
with HWR SEs and TSLS with Moulton SEs show very similar performance, whether
covariates are adjusted for or not. The Wald, TSLS with HWR SEs and TSLS with
Moulton SEs outperform the Bayesian multilevel mixture modelling irrespective of
the level of ICC for outcome (low or high).
However, in the presence of individual-level adherence, the Bayesian multilevel mix-
ture modelling outperforms the Wald estimator and TSLS with HWR or Moulton’s
SEs in terms of coverage. TSLS with Moulton-corrected SEs performs well in terms
of empirical bias and coverage when the ICC for the outcome is low. Unlike the
Wald and TSLS, IL-LATE estimates from the Bayesian multilevel model show little
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but negligible bias (below 1%).
Irrespective of the level of ICC for the outcome or strength of association between
cluster-level or individual-level covariate and the outcome or adherence to treatment,
avoiding covariate adjustment appears as a good, simple and safer option when
estimating IL-LATE in the settings considered in these simulations i.e. in settings
where covariates are not used as design factors (in stratified randomisation, for
example). However, although not covered in our simulations, it is sensible to adjust
at least for covariates used as design factors. For the Bayesian multilevel mixture























































































































































































































































Wj and Xij effect on Yij: 0.4
Wj effect: 0.4; Xij effect: 0.1
Wj effect: 0.1; Xij effect: 0.4
Wj and Xij effect: 0.1
Figure 7.1: Performance of Wald, TSLS and Bayesian multilevel mixture methods to
estimate individual-level LATE in the presence of one-sided non-adherence at cluster level
for CRT with 25 clusters per group where ICC for outcome is 0.05 (A) and 0.20 (B). The
true LATE is 0.4 standard deviation. The long-dashed black parallel lines in the last panel








































































































































Wj and Xij effect on Yij: 0.4
Wj effect: 0.4; Xij effect: 0.1
Wj effect: 0.1; Xij effect: 0.4
Wj and Xij effect: 0.1
Figure 7.2: Performance of Wald, TSLS and Bayesian multilevel mixture methods to
estimate individual-level LATE in the presence of one-sided non-adherence at individual
level for CRT with 25 clusters per group where ICC for outcome is 0.05 (A) and 0.20 (B).
The true LATE is 0.4 standard deviation. The long-dashed black parallel lines in the last
panel are the acceptable 95% coverage range.
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Chapter 8.
Illustration of LATE estimation at the clus-
ter and individual level using the OPERA
and TXT4FLUJAB trial data
8.1 Introduction
The chapter presents the re-analysis of the TXT4FLUJAB and OPERA trials in-
troduced earlier in sections 1.5.1 and 1.5.2, respectively. Both cluster-level LATE
(chapter 4) and individual-level LATE (chapter 6) are the estimands of interest.
The TXT4FLUJAB trial investigators were interested in the causal treatment effects
at the cluster level (here GPs) expressed as a mean risk difference, where the outcome
is a binary variable indicating whether patients received the influenza vaccination or
not. Adherence to treatment was binary, two-sided and occurred at the individual
level (here patients). Patients whose GPs were allocated to the active group are
said to adhere if they received the reminder text message; whereas, those whose
GPs were allocated to the control group are said to adhere if they did not receive
any reminder text messages. Missing data were not an issue as everything was
automatically recorded.
Regarding the OPERA trial, investigators intended to assess causal treatment ef-
fects, but the trial protocol did not formally mention how this would be done. The
investigators anticipated and collected information on whether residents attended
any exercise sessions. There was no formal definition for adherence to treatment.
For illustrative purposes, I adopt a working definition of all-or-none adherence. Res-
idents in the active group are considered to have received their intended treatment
if they attended at least one group exercise session, whereas those in the control
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group received their intended treatment if they did not attend any group exercise
sessions. As little exposure (at least one) to the exercise sessions may improve res-
ident’s outcome than no exposure at all, the all-or-none definition of adherence is
less susceptible to violate the ER assumption than considering some residents with
a non-zero threshold of number of exercise sessions to not benefit at all from their
exposure to the active treatment. The control group did not have access to the
exercise sessions. The outcome of interest is the “short physical performance bat-
tery score (SPPB)” at 12 months, treated as a continuous variable as in the original
publication [37].
As missing data were present in the OPERA trial, I used multilevel joint modelling
multiple imputation [122,123] to handle missing data assuming missing at random,
that is, the distributions of the missing and observed data are the same, conditional
on covariates. The multilevel multiple imputation allows for clustering of the indi-
vidual records according to the residential home and is carried out using the “jomo”
package in R [124], separately in the control and active groups. The multilevel im-
putation model includes the actual treatment received as a covariate, enabling us
to allow non-adherence to predict missing values. The “jomo” package offers the
advantage of – (i) imputing with a common level-1 covariance matrix across level-2
units, – (ii) imputing with a cluster-specific level-1 covariance matrices, and – (iii)
imputing while allowing for the level-1 covariance matrix to be randomly distributed
across level-2 units [123–125].
The present chapter is organized as follows. Section 8.2 presents a descriptive analy-
sis, the cluster-level and individual-level ITT and LATE estimations for the OPERA
trial. Section 8.3 replicates similar analyses for the TXT4FLUJAB trial. Section 8.4
summarises the findings. The analyses presented here assume that all IV assump-
tions and monotonicity at the individual and cluster levels are met. Sensitivity
analyses to assess departures from these assumptions are presented in chapter 9.
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8.2 Re-analysis of the OPERA trial
I present here the descriptive analysis and the ITT and LATE estimates at the
cluster and individual levels.
8.2.1 Descriptive analysis
The OPERA trial was a non-blinded CRT carried out in 78 care-homes, of which
35 were allocated to the active group and 43 to the control group. Recall that
the intervention in the active group was a complex programme involving training
on depression awareness for care home staff, 45 minutes physiotherapist-led group
exercise sessions for residents (delivered twice a week) and a whole home component
designed to motivate residents to increased daily physical activity. Care homes staff
in the control group only received the training on depression awareness [37]. Care
homes represent the clusters and residents are the individuals.
The marginal ICC of the outcome was 0.09 overall, 0.02 in the control group and
0.11 in the active group, suggestive of a potential presence of level-1 and/or level-2
variance heterogeneity across trial groups. Table 8.1 shows the care-homes’ char-
acteristics and residents’ characteristics at baseline as well as the percentages of
adherence to treatment in each trial group. In total, 900 residents were enrolled
(498 in the control group and 402 in the active group). The distribution of the
clusters size (number of residents within clusters) was similar across trial groups;
the median (range) clusters size was 6 (2-11) and 6 (2-15) in the control and active
group, respectively. However, the distribution of cluster sizes was left-skewed with
a mean cluster size of 12 in each group, pointing out some imbalance in the cluster
sizes.
Care homes and residents characteristics were balanced across trial groups at base-
line. The percentages of missing values were similar across groups and less than
1% for baseline antidepressant uptake and age. However, the percentage of missing
values was higher in the control group compared to the active group for “moderate
to severe cognitive impairment score” (MMSE) (19% vs. 14%) and SPPB (17% vs.
13%) at baseline.
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Based on our working definition of adherence to treatment at individual level, all res-
idents (100%) assigned to the control group received the intended treatment whereas
89% of residents allocated to the active group received the intended treatment. The
median percentage (range) of active treatment uptake at the care home level was
92% (57%-100%) in the active group; the percentage of active treatment uptake at
the care home level was 0% for all care-homes in the control group.
Table 8.1: Baseline characteristics and percentages of treatment received by trial group
Characteristics Control Active
Number of care-homes, n (%) 43 35
Total number of residents 498 402
Number of resident per care home, median (range) 6 (2-11) 6 (2-15)
Location
London, n (%) 204 (41) 208 (52)
Warwick, n (%) 294 (59) 194 (48)
Type of care home provider
Private & care home, n (%) 280 (56) 172 (43)
Private & Nursing, n (%) 117 (23) 125 (31)
Voluntary, n (%) 101 (20) 105 (26)
Size of care home
< 32 residents, n (%) 250 (50) 204 (51)
≥ 32 residents, n (%) 248 (50) 198 (49)
Gender
Female, n (%) 388 (78) 298 (74)
Male, n (%) 110 (22) 104 (26)
Antidepressant treatment
Yes, n (%) 158 (31.7) 111 (27.6)
No, n (%) 337 (67.7) 290 (72.1)
Missing, n (%) 3 (0.6) 1 (0.3)
Residents’ age in years at baseline
median (range) 88 (65-107) 87 (65-107)
Missing, n (%) 4 (0.8) 3 (0.7)
Residents’ MMSE at baseline
median (range) 18 (0-30) 19 (0-30)
Missing, n (%) 94 (19) 56 (14)
Residents’ SPPB at baseline
median (range) 1 (0-10) 1 (0-10)
Missing, n (%) 84 (17) 54 (13)
Received intended treatment, n (%) 498 (100) 356 (89)




Percentage of active treatment uptake at the care
home level, median (range) 0 (0-0) 92 (57-100)
The variables dictionary is as follows: – the outcome is SPPB at 12 months since en-
rolment (SPPB2 ), continuous and measured at the individual level, – the individual-
level covariates are baseline SPPB (SPPB0, continuous), baseline “moderate to
severe cognitive impairment score” (MMSE0, continuous), age at baseline (AGE,
continuous), sex (SEX, binary) and baseline antidepressive treatment (ANTIDEP0,
binary), – the cluster-level covariates: care home location (PLACE, binary), size of
care home (SIZE, binary) and type of home (HOME, categorical with three levels),
and – the random treatment allocation of care-homes (ALLOC, binary). As often
done in practice, those covariates were pre-selected by the trial investigators at the
design stage as variables to be included in the model for estimating the treatment
effects. I therefore adjust the treatment effects for those covariates.
8.2.2 Cluster-level summary analyses
The covariates to be adjusted for are (i) individual-level covariates: AGE, SEX,
SPPB0 and ANTIDEP0, (ii) cluster-level covariates: PLACE, SIZE and HOME
and the proportions of residents with MMSE at baseline (MMSE0 ) < 20 within
care-homes [37]. The proportions of residents with MMSE0 < 20 within care-homes
as per [37] were computed ignoring the presence of missing values in MMSE0. This
may misrepresent the true proportions of residents with MMSE < 20 within care-
homes and subsequently introduced measurement error issues, unless the missingness
is completely at random or the missing values at the residents level are adequately
handled. For simplicity, I use the individual-level baseline MMSE instead of the
proportions of residents with MMSE < 20.
I re-analyse the OPERA trial using cluster-level (CL) summary approaches, with
and without covariate adjustment. I present both complete records analysis and
analysis from the multilevel multiple imputation. I gradually increased the number
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of imputations in order to choose an adequate number of simulations that leads to
a Monte Carlo error (MCE) below 1% for the point estimates, SEs and lower/upper
limits of 95% CI. I finally generated 250 imputed datasets and the estimates are
pooled using the Rubin’s rule [126,127]. Variables included in the imputation model
are those listed earlier. There was no variable used as an auxiliary in the imputation
model. Thus, the complete record and multiple imputation analysis model include
the same variables.
I applied the CL-summary approaches introduced in chapter 3, using the unad-
justed and adjusted CL-means SPPB2 as outcome, without/with weighting and
without/with covariate adjustment. Both complete records analysis and multilevel
multiple imputation are reported. These analyses are performed using Stata 15,
whereas data are imputed using the “jomo” package in R [124]. The multilevel
multiple imputation and the analysis codes are in Appendix A.11.
Prior to individual-level ITT analyses, I conducted an exploratory analysis to inves-
tigate the residual variance heterogeneity and understand to what extent covariate
adjustment and Huber-White (HW) SEs may affect the ITT inferences.
Exploratory assessment of residual variance
Chapter 3 introduced how the unadjusted and adjusted CL summaries are computed.
The unadjusted CL summaries here are the CL-means SPPB2 whereas the adjusted
CL summaries are the CL-means of the residuals from OLS regression of SPPB2 on
individual-level covariates SPPB0, MMSE0, SEX and ANTIDEP0. For individual-
level analyses, SPPB2 is analysed using a mixed effects linear regression. Table 8.2
shows the residual outcome variance for each trial group and the residual outcome
variance from the ITT analyses, with and without covariates using complete records
without weighting.
As expected, covariate adjustment reduces the residual variance. There is a notice-
able variance heterogeneity across trial groups. This is attenuated by the inclusion
of covariates associated with the outcome. For the adjusted CL-summary analy-
ses, there is no apparent suggestion of residual variance heterogeneity, likely due to
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the lack of evidence of association between the outcome and cluster-level covariates
(PLACE, p=0.25; SIZE, p=0.28; HOME, p=0.81). It is worth noting that the use of
adjusted CL-summary outcome greatly reduces the residual variance as opposed to
the unadjusted CL-summary analysis. This reduction of residual variance obtained
from adjusted CL-summary analysis would provide some efficiency gain.
Table 8.2: Residuals variance of SPPB at the individual level, unadjusted and adjusted
CL-summaries (means) SPPB at 12 months by trial group and overall, using complete
records analyses without weighting
Unadjusted analysis Adjusted analysisa
ITTb Control Active ITTb Control Active
Individual-level SPPB2
Level-1 variance 4.153 3.512 4.931 2.090c 1.986c 2.225c
Level-2 variance 0.384 0.091 0.671 0.226c 0.213c 0.263c
Unadjusted CL-means
SPPB2
Residuals variance 1.160 0.932 1.441 0.970 0.961e 0.845
Adjusted CL-means
SPPB2d
Residuals variance 0.631 0.640 0.619 0.631e 0.667e 0.614e
a Adjusted for cluster-level covariates PLACE, SIZE and HOME.
b Pooled residual variance obtained from the intention-to-treat (ITT) analysis.
c Also adjusted for individual-level covariates SPPB0, MMSE0, AGE, SEX and ANTIDEP0.
d Residuals obtained from OLS regression with individual-level covariates SPPB0, MMSE0,
AGE, SEX and ANTIDEP0.
e No evidence of association between outcome and any of the cluster-level covariates.
CL-ITT estimates
The cluster size imbalance previously observed may lead to varying precision of the
CL-means SPPB2, and may potentially cause heteroscedasticity. I used unweighted
and weighted linear regressions to estimate CL-ITT effect, expressed as the mean
difference in CL-means SPPB2. The weights are cluster size (CS ) and minimum
variance (MV ). HW SEs and/or the weighting are used to circumvent the suspected
heteroscedasticity. No small degrees of freedom adjustment is needed because OLS
inference is based on t-distribution.
Tables 8.3 and 8.4 show the CL-ITT effect estimates when the unadjusted and ad-
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justed CL-means SPPB2 are analysed, respectively. The CL-ITT effect estimates
vary considerably across analysis methods and increase after CL covariates adjust-
ment. Nevertheless, the conclusions from these results point towards no evidence of
ITT effect at the cluster level, except when adjusted CL-means SPPB2 are anal-
ysed without weighting and using complete records where there was weak evidence
of ITT effect at the cluster-level (unadjusted ITT effect: 0.30, 95% CI: -0.06,0.66,
p=0.098 and adjusted ITT effect: 0.32, 95% CI: -0.06,0.70, p=0.094 when HW SEs
are used). This efficiency gain from analysing the adjusted CL-means SPPB2 with
no weighting is due to the substantial reduction of the residual variance highlighted
in section 8.2.2, as opposed to the unadjusted CL-means SPPB2.
For all analysis methods, the CL-ITT point estimates using data from multilevel
multiple imputation are lower than those obtained from complete records analysis.
The multiple imputation leads to more conservative inferences, suggesting no evi-
dence of CL-ITT effect. As expected, there is some efficiency gain when covariates
are adjusted for, regardless the methods. This efficiency gain is, in fact, due to
the reduction in the residual variance induced by including a CL covariate that is
associated with the CL-means SPPB2 (HOME, p<0.001), and including individual-
level covariates associated with SPPB2 at the individual level (SPPB0, p<0.001;
MMSE0, p=0.04 and SEX, p=0.03).
The HW SEs have little impact when using adjusted CL-summary outcome and
not including any CL covariates in the regression model, regardless of the weighting
strategy and whether data are imputed or not. There was a similarity between the
residual variance across trial groups when analysing the adjusted CL-means SPPB2
without weighing (section 8.2.2). This is possibly but not necessarily an indication
of homoscedastic residuals, which is supported by the “absolute” no change of the
95% CIs when using HW SEs with no weighting (Table 8.4, 95% CI: -0.057 to 0.663
assuming homoscedasticity and 95% CI: -0.057 to 0.662 assuming heteroscedastic-
ity). The use of CS or MV weights influence the CL-ITT effect estimates. MV
weighting may be preferable as providing the optimal variance in principle. In ad-
dition, from our results, ITT effect estimates when using MV weights often fall
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within the estimates from not using any weights and CS weighting, offering then a
reasonable compromise.
Table 8.3: Care home-level ITT effect estimates (as mean difference) on SPPB at 12
months, using unadjusted CL-summaries on complete records and multiple imputed data
Unadjusted Adjusteda
ITT (95% CI) p ITT (95% CI) p
Complete records
No weighting None 0.292 (-0.196, 0.780) 0.237 0.369 (-0.082, 0.821) 0.107
HW (-0.207, 0.791) 0.247 (-0.088, 0.826) 0.112
Cluster size None 0.327 (-0.131, 0.785) 0.160 0.370 (-0.067, 0.806) 0.096
weights HW (-0.144, 0.797) 0.171 (-0.085, 0.825) 0.110
Minimum-variance None 0.305 (-0.170, 0.779) 0.205 0.366 (-0.079, 0.811) 0.106
weights HW (-0.176, 0.785) 0.211 (-0.086, 0.818) 0.111
Multilevel multiple imputation
No weighting None 0.286 (-0.184, 0.755) 0.233 0.355 (-0.082, 0.792) 0.112
HW (-0.200, 0.771) 0.249 (-0.096, 0.806) 0.123
Cluster size None 0.261 (-0.185, 0.708) 0.160 0.309 (-0.119, 0.736) 0.157
weights HW (-0.198, 0.721) 0.171 (-0.133, 0.750) 0.171
Minimum-variance None 0.273 (-0.187, 0.733) 0.244 0.333 (-0.100, 0.766) 0.131
weights HW (-0.198, 0.744) 0.256 (-0.110, 0.777) 0.141
HW: Huber-White. a Adjusted cluster-level covariates: PLACE, SIZE and HOME.
Table 8.4: Care home-level ITT effect estimates (as mean difference) on SPPB at 12
months, using adjusted CL-summaries on complete records and multiple imputed data
Unadjusted Adjusteda
ITT (95% CI) p ITT (95% CI) p
Complete records
No weighting None 0.303 (-0.057, 0.663) 0.098 0.320 (-0.044, 0.684) 0.084
HW (-0.057, 0.662) 0.098 (-0.056, 0.696) 0.094
Cluster size None 0.238 (-0.098, 0.573) 0.162 0.275 (-0.067, 0.616) 0.114
weights HW (-0.093, 0.568) 0.156 (-0.071, 0.620) 0.118
Minimum-variance None 0.266 (-0.083, 0.615) 0.133 0.292 (-0.063, 0.646) 0.105
weights HW (-0.075, 0.607) 0.125 (-0.067, 0.650) 0.109
Multilevel multiple imputation
No weighting None 0.236 (-0.127, 0.599) 0.203 0.251 (-0.114, 0.617) 0.178
HW (-0.130, 0.601) 0.206 (-0.122, 0.624) 0.187
Cluster size None 0.181 (-0.166, 0.527) 0.307 0.217 (-0.134, 0.568) 0.226
weights HW (-0.168, 0.530) 0.310 (-0.140, 0.573) 0.233
Minimum-variance None 0.209 (-0.147, 0.566) 0.250 0.232 (-0.127, 0.592) 0.205




ITT (95% CI) p ITT (95% CI) p
weights HW (-0.146, 0.564) 0.248 (-0.130, 0.595) 0.209
HW: Huber-White. a Adjusted cluster-level covariates: PLACE, SIZE and HOME.
8.2.3 Cluster-level LATE
In this section, I estimate LATE of attending at least one group exercise session on
SPBB2 at the cluster and individual levels. Analyses are performed on complete
records and after multilevel multiple imputation. Before LATE estimation, I discuss
the plausibility of LATE identification assumptions.
8.2.3.1 Plausibility of LATE identification assumptions
By design, the randomised treatment is unconfounded. The relevance of randomi-
sation as instrument (in the first stage) is assessed based on the rule of thumb
by Staiger and Stock [106] (F (1, 76) = 2505.17 > 10), suggesting that treatment
assignment is a relevant instrument.
Assuming exclusion restriction at the individual level implies that there is no other
path through which a resident’s SPBB2 can be affected except via the exercise ses-
sions. This assumption is disputable as residents whose care-homes are assigned to
the control group may feel discriminated and get demotivated during the assess-
ment of their physical function. Thus, despite not actually attending any exercise
sessions, such demotivated residents may have their SPBB2 affected by the home
care random treatment allocation.
The monotonicity assumption (that there are no defiers) is met as care-homes as-
signed to the control group did not implement any exercise sessions (see Table 8.9).
Although care-homes are recruited in such a way to minimise interference across
homes, it is not excluded that residents from different care-homes interact and in-
fluence each others’ potential outcome.
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8.2.3.2 CL-LATE estimates
As introduced in chapter 4, the Wald estimator with the Schochet-Chiang SEs (re-
ferred to as Schochet-Chiang method or estimator) is used and TSLS without and
with weighting (CS or MV weights) are fitted using unadjusted or adjusted CL
summary outcome. The treatment received is the unadjusted CL-proportions of
residents who received the treatment i.e. attended at least one group exercise ses-
sion within the cluster.
I include the same baseline covariates as in the ITT analyses and assume ho-
moscedasticity or heteroscedasticity for TSLS and Schochet-Chiang estimation. For
Schochet-Chiang method, I assume homoscedasticity and conduct analyses on com-
plete records only. For TSLS, in addition, small sample degrees of freedom (SSDF)
adjustment and normal approximation are considered. Analyses are performed in
Stata 15 and the codes can be found in Appendix A.11.
Table 8.5 reports the unadjusted CL summary analysis results, while Table 8.6 re-
ports the adjusted CL summary analysis results. Covariates adjustment provide
some efficiency gain regardless the methods, whether complete case analysis or mul-
tiple imputation is used. As for CL-ITT effect estimates, we note that adjusting for
covariates increases the CL-LATE point estimates. CL-LATE estimates from the
multilevel multiple imputation are more conservative.
As pointed out in chapter 4, the Schochet-Chiang Wald-based estimates are equiv-
alent to the unweighted CL-TSLS estimates when there is no covariate adjustment.
This translates in the results not only without covariate adjustment but also when
CL covariates are adjusted for. The 95% CIs slightly vary from one method to
another but the Shochet-Chiang method and unweighted TSLS result in similar
conclusions of no evidence of group exercise session effect on SPPB2, whether ad-
justed for CL covariates or not.
However, TSLS with CS and MV weighting in complete records analyses with CL
covariates adjustment are suggestive of weak evidence of a positive group exercise
sessions effect on SPPB2, except for TSLS with CS weights without any correction
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for the SEs where the results suggest some evidence of a positive group exercise
sessions effect on SPPB2.
Unsurprisingly, SSDF adjustment has in general a greater influence on the SEs than
does the HW method. This influence is more pronounced when CL covariates are
adjusted for, and is probably because of the loss of four degrees of freedom induced
by the two binary covariates and one covariate with three levels in the presence of
a moderate number of clusters (J = 78).
Considering the suspected presence of heteroscedasticity and the likely well esti-
mated between-cluster variance because of the moderate number of clusters, CL-
LATE obtained from TSLS with MV weights, SSDF adjustment and HW SEs when
the outcome is the adjusted CL-means SPPB2, may seem appropriate. Thus, the
CL-LATE estimate was 0.31 (95% CI: -0.08, 0.70; p=0.11) in complete records
analyses and 0.26 (95% CI: -0.14, 0.67; p=0.21) for two-level multiple imputation
analyses, both suggesting no evidence of causal treatment effect on SPPB2 among
care-homes whose residents were more likely to attend at least one group exercise
session if offered (p=0.11).
Table 8.5: CL-LATE estimates (as mean difference) at care home level, of residents’
attendance to at least one group exercise session on SPPB at 12 months, using unadjusted
CL-summaries on complete records and multiple imputed data
Unadjusted Adjusteda
LATE (95% CI) p LATE (95% CI) p
Complete records
Schochet None 0.314 (-0.218, 0.846) 0.248 0.394 (-0.106, 0.894) 0.122
TSLS
No weighting None 0.314 (-0.212, 0.839) 0.242 0.394 (-0.086, 0.874) 0.108
HW (-0.223, 0.851) 0.252 (-0.096, 0.884) 0.115
SSDF (-0.227, 0.855) 0.251 (-0.114, 0.903) 0.127
SSDF + HW (-0.239, 0.866) 0.262 (-0.125, 0.913) 0.134
CS weights None 0.401 (-0.089, 0.890) 0.108 0.470 (0.010, 0.929) 0.045
HW (-0.101, 0.902) 0.117 (-0.014, 0.953) 0.057
SSDF (-0.103, 0.904) 0.117 (-0.017, 0.956) 0.058
SSDF + HW (-0.116, 0.917) 0.126 (-0.043, 0.982) 0.072
MV weights None 0.368 (-0.134, 0.870) 0.150 0.447 (-0.019, 0.913) 0.060
HW (-0.143, 0.879) 0.158 (-0.031, 0.925) 0.067
SSDF (-0.148, 0.884) 0.160 (-0.047, 0.940) 0.075




LATE (95% CI) p LATE (95% CI) p
SSDF + HW (-0.158, 0.894) 0.168 (-0.059, 0.953) 0.083
Multilevel multiple imputation
Schochet None 0.320 (-0.201, 0.841) 0.229 0.396 (-0.088, 0.881) 0.108
TSLS
No weighting None 0.320 (-0.197, 0.836) 0.225 0.396 (-0.073, 0.866) 0.098
HW (-0.214, 0.854) 0.241 (-0.086, 0.879) 0.108
SSDF (-0.202, 0.841) 0.230 (-0.202, 0.841) 0.230
SSDF + HW (-0.220, 0.860) 0.246 (-0.102, 0.895) 0.119
CS weights None 0.295 (-0.201, 0.791) 0.295 0.347 (-0.115, 0.808) 0.141
HW (-0.214, 0.804) 0.256 (-0.129, 0.823) 0.154
SSDF (-0.206, 0.797) 0.249 (-0.130, 0.823) 0.154
SSDF + HW (-0.220, 0.810) 0.261 (-0.145, 0.838) 0.167
MV weights None 0.307 (-0.201, 0.815) 0.236 0.373 (-0.093, 0.840) 0.117
HW (-0.213, 0.826) 0.247 (-0.103, 0.850) 0.125
SSDF (-0.206, 0.820) 0.241 (-0.108, 0.855) 0.129
SSDF + HW (-0.218, 0.832) 0.252 (-0.119, 0.866) 0.137
a Adjusted for place, care home size and care home type.
HW: Huber-White; SSDF: small sample degrees of freedom; CS: cluster size; MV: minimum-variance.
Table 8.6: CL-LATE estimates (as mean difference) at care home level, of residents’
attendance to at least one group exercise session on SPPB at 12 months, using adjusted
CL-summaries on complete records and multiple imputed data
Unadjusted Adjusteda
LATE (95% CI) p LATE (95% CI) p
Complete records
TSLS
No weighting None 0.330 (-0.051, 0.711) 0.090 0.348 (-0.026, 0.723) 0.068
HW (-0.050, 0.710) 0.089 (-0.037, 0.734) 0.077
SSDF (-0.062, 0.722) 0.098 (-0.048, 0.745) 0.084
SSDF + HW (-0.061, 0.721) 0.097 (-0.060, 0.775) 0.093
Cluster size None 0.231 (-0.124, 0.587) 0.202 0.291 (-0.063, 0.644) 0.107
weights HW (-0.136, 0.598) 0.217 (-0.074, 0.656) 0.118
SSDF (-0.135, 0.597) 0.212 (-0.084, 0.665) 0.126
SSDF + HW (-0.146, 0.609) 0.226 (-0.096, 0.677) 0.138
Minimum- None 0.267 (-0.099, 0.631) 0.153 0.312 (-0.049, 0.673) 0.090
variance HW (-0.099, 0.631) 0.153 (-0.055, 0.679) 0.096
weights SSDF (-0.109, 0.641) 0.162 (-0.070, 0.694) 0.108
SSDF + HW (-0.110, 0.641) 0.162 (-0.077, 0.701) 0.114
Two-level multiple imputation
No weighting None 0.264 (-0.137, 0.665) 0.197 0.280 (-0.115, 0.676) 0.164
HW (-0.140, 0.667) 0.200 (-0.123, 0.683) 0.173




LATE (95% CI) p LATE (95% CI) p
SSDF (-0.141, 0.669) 0.202 (-0.141, 0.669) 0.202
SSDF + HW (-0.144, 0.671) 0.204 (-0.135, 0.696) 0.186
Cluster size None 0.204 (-0.182, 0.591) 0.300 0.244 (-0.138, 0.625) 0.211
weights HW (-0.184, 0.593) 0.303 (-0.143, 0.630) 0.217
SSDF (-0.186, 0.594) 0.305 (-0.149, 0.637) 0.224
SSDF + HW (-0.188, 0.597) 0.308 (-0.155, 0.642) 0.231
Minimum- None 0.235 (-0.160, 0.630) 0.244 0.260 (-0.129, 0.650) 0.190
variance HW (-0.158, 0.628) 0.241 (-0.133, 0.653) 0.194
weights SSDF (-0.164, 0.634) 0.248 (-0.141, 0.661) 0.204
SSDF + HW (-0.162, 0.632) 0.246 (-0.144, 0.665) 0.207
a Adjusted for PLACE, SIZE and HOME.
HW: Huber-White; SSDF: small sample degrees of freedom.
8.2.4 Individual-level analysis
Here, I report the results from ITT and LATE estimations. Since the assessment
of residual variance in section 8.2.2 suggested there is variance heterogeneity across
trial groups, I first assume homoscedasticity and then allow for level-1 or level-2
variance heterogeneity. The model did not converge when I allow simultaneously for
level-1 and level-2 variance heterogeneity.
8.2.4.1 ITT effect
ITT analyses were carried out using mixed effects linear regression on complete
records and multilevel multiple imputed datasets. Following the exploratory anal-
ysis in section 8.2.2, I tested the adequacy of variance homogeneity assumption,
using the likelihood ratio test performed only on the complete records. For the
unadjusted ITT analysis, there is strong evidence of level-1 variance heterogeneity
(p=0.006) and of level-2 variance heterogeneity (p=0.01) across trial groups. As to
the adjusted ITT analysis, no evidence of level-1 and level-2 variance heterogeneity
was found (p=0.39 and p=0.75, respectively). This suggests that the omission of
individual-level and/or cluster-level covariates is the source of variance heterogene-
ity. Therefore, the adjusted ITT analysis assuming variance homogeneity seems
appropriate.
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Table 8.7 shows ITT effect estimates at the individual level. The adjusted ITT ef-
fect estimates assuming variance homogeneity are 0.29 (95% CI: -0.06, 0.64; p=0.10)
for complete records analysis and 0.23 (95% CI: -0.13, 0.59; p=0.21) for analyses
based on multilevel multiple imputation, suggesting no evidence of ITT effect at
the individual level. Addressing the potential bias introduced by missing data via
multilevel multiple imputation leads to more conservative results. Adjusting for
covariates (both cluster and individual levels) provides some efficiency gain. How-
ever, unlike CL-ITT analyses, the point estimates of the ITT effect is reduced after
covariate adjustment.
Table 8.7: IL-ITT effect estimates (as mean difference) at resident level, on SPPB at 12
months, assuming and relaxing variance homogeneity assumption
Unadjusted Adjusted
ITT (95% CI) p ITT (95% CI)a p
Complete Case
Variance homogeneity 0.342 (-0.128, 0.812) 0.154 0.289 (-0.060, 0.639) 0.104
Level-1 heterogeneityb 0.345 (-0.113, 0.804) 0.140 0.290 (-0.060, 0.640) 0.105
Level-2 heterogeneityb 0.351 (-0.129, 0.832) 0.152 0.287 (-0.063, 0.637) 0.108
Multilevel multiple
imputation
Variance homogeneity 0.273 (-0.181, 0.727) 0.238 0.231 (-0.126, 0.588) 0.205
Level-1 heterogeneityb 0.269 (-0.178, 0.715) 0.238 0.231 (-0.128, 0.590) 0.207
Level-2 heterogeneityb 0.289 (-0.176, 0.753) 0.224 0.229 (-0.118, 0.575) 0.195
a Adjusted for cluster-level covariates PLACE, SIZE and HOME, and individual-level
covariates AGE, SEX, ANTIDEP0 MMSE and SPPB0.
b Variance heterogeneity across trial groups.
8.2.4.2 Individual-level LATE
Wald and TSLS estimation of LATE at the individual level were carried out in Stata
15. I did not perform the Wald estimation using multiple imputed data because of
the complexity of combining bootstrap techniques and multiple imputation. The
Bayesian multilevel mixture analysis was implemented in JAGS through R using
the “Rjags” package allowing for level-2 variance heterogeneity across either trial
groups or adherence classes.
Jeffrey’s prior was used for level-1 standard deviation while a Uniform or half-Cauchy
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prior for the level-2 standard deviation [114]. I chose a vague normal prior distribu-
tion for all model coefficients.
I used 900000 iterations and three chains. The first 100000 iterations were discarded
as burn-in. I used such a large number of iterations to ensure good convergence for all
model parameters (including variances), and particularly for settings where variance
homogeneity was relaxed. The analysis codes in Stata and R are shown in Appendix
A.10.
I compare the results allowing for level-2 heterogeneity across trial groups or adher-
ence classes, and level-1 heterogeneity across adherence class only. The results are
shown in Table 8.8.
Under variance homogeneity assumption, Wald estimation with bootstrapped SEs,
TSLS with Huber-White-Rogers SEs and TSLS with Moulton’s correction lead to
very similar LATE estimates and 95% CIs. The Wald estimation with bootstrapped
SEs appears to lead to slightly conservative results compared to TSLS after covariate
adjustment. The individual-level LATE estimates from the unadjusted Bayesian
multilevel mixture model are much lower compared to the Wald and TSLS ones for
multilevel multiple imputed data. However, after covariate adjustment, the Bayesian
multilevel mixture model approach provides LATE estimates close to those obtained
by other methods.
The LATE point estimate from the Bayesian model does not substantially change
when level-2 variance heterogeneity is assumed across trial groups or adherence
classes. However, there is a substantial gain in precision when allowing for level-2
variance heterogeneity across adherence classes instead of trial groups. This preci-
sion gain occurs when using a Uniform prior for the level-2 standard deviation, but
the LATE estimate reported for half-Cauchy prior did not converge. Results from
allowing for level-2 variance heterogeneity across adherence classes suggest weak
evidence of causal treatment effect among compliant residents, whereas there was
strong evidence of causal treatment effect when level-1 heterogeneity is allowed for.
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Except for the poor convergence noted when relaxing level-1 homogeneity across
adherence class, the use of a Uniform or half-Cauchy prior for the level-2 standard
deviation has little impact on the Bayesian estimation of LATE at the individual
level.
Substantive summary
I first conducted ITT analyses using various methods to address the question of
whether offering exercise sessions would affect the short physical performance bat-
tery neither at the care-home level or resident level. Overall, there was no evidence
of the effect of offering those exercise sessions.
Then, I investigated causal analyses by estimating LATE to assess whether actual
attendance to exercise sessions would affect the short physical performance battery
among the care-homes or residents that would comply to any intervention or condi-
tion they would be assigned to. I found no evidence of causal effect of attendance to
exercise sessions on the short physical performance battery neither at the care-home
level nor resident level in the OPERA trial.
141
Table 8.8: IL-LATE estimates (as mean difference) at resident level, of attending at least one group exercise session on SPPB at 12 months, assuming
ER
Unadjusted LATE (95% CI) Adjusted LATE (95% CI)a
Complete Case Multilevel MI Multilevel Mixture Complete Case Multilevel MI Multilevel Mixture
Variance homogeneity
Wald 0.401 (-0.102, 0.903) - - 0.294 (-0.086, 0.675) - -
TSLS HWR 0.401 (-0.101, 0.902) 0.295 (-0.214, 0.804) - 0.294 (-0.068, 0.656) 0.246 (-0.141, 0.634) -
TSLS Moulton 0.401 (-0.104, 0.905) 0.295 (-0.217, 0.807) - 0.294 (-0.071, 0.660) 0.246 (-0.147, 0.639) -
BMM Uniform - - 0.152 (-0.195, 0.499) - - 0.219 (-0.219, 0.648)
BMM Half-Cauchy - - 0.153 (-0.196, 0.500) - - 0.218 (-0.219, 0.648)
Level-2 variance heterogeneity across trial groups
BMM Uniform - - 0.437 (-0.116, 0.960) - - 0.205 (-0.161, 0.557)
BMM Half-Cauchy - - 0.437 (-0.114, 0.961) - - 0.205 (-0.162, 0.557)
Level-2 variance heterogeneity across adherence classes
BMM Uniform - - 0.151 (-0.175, 0.479) - - 0.206 (-0.047, 0.459)
BMM Half-Cauchy - - 0.151 (-0.175, 0.480) - - 0.206 (-0.047, 0.459)
Level-1 variance heterogeneity across adherence classes
BMM Uniform - - 0.428 (-0.191, 1.220) - - 0.373 (0.010, 0.737)
BMM Half-Cauchy - - 0.418 (-0.194, 1.216) - - 0.269 (-0.120, 0.801)b
a Adjusted for cluster-level covariates PLACE, SIZE, HOME, and individual-level covariates AGE, SEX, ANTIDEP0, MMSE0 and SPPB0.
b Gelman-Rubin statistics suggests poor mixing of chains.
MI: Multiple imputation. BMM: Bayesian Multilevel Mixture. HWR: Huber-White-Rogers.
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8.3 Re-analysis of the TX4FLUJAB trial
This was a CRT of general practices in England aiming at estimating the effect of
text messaging influenza vaccine reminders on increasing vaccine uptake in patients
with chronic conditions, carried during the 2013 influenza season [36]. General
practices (GPs) were stratified by the type of software used for text messaging and
randomised to either standard care (control group, 79 GPs and 51136 patients) or
a text messaging campaign (active group, 77 GPs and 51121 patients). Practices
were not blinded to their allocation. GPs were the unit of analysis and the outcome
of interest was the proportion of influenza vaccine uptake at the GP level. Influenza
vaccination within the GPs was automatically recorded in the clinical system from
which the data were extracted, so there are no missing data.
Since non-adherence was anticipated, the original statistical analysis plan specified
obtaining by IV regression an efficacy estimate at the GP level [36]. The origi-
nal publication reported an estimated increase in vaccine uptake from texting re-
minders of 14.3% (95% CI –0.59% to 29.2%) [36], after dichotomising adherence at
the cluster-level as either 100% of eligible patients, compared with texting < 100%.
Adherence to the intervention at the individual level could not be measured for
all practices because it was recorded in a usable form only for GPs using a specific
software. Therefore, for these re-analyses, I restrict the dataset to 116 GPs (58 in the
intervention and 58 in the standard care arm) for which individual-level adherence
data are available. I only show the results for CL-TSLS and the Schochet-Chiang
Wald-based estimations.
8.3.1 Descriptive analysis
Six of the 58 practices (10%) in the intervention arm, did not send any reminders.
Conversely, 21 of the 58 practices (36% in the standard care arm) actually sent a
reminder to at least one patient. Hence non-adherence is two-sided. It also varies at
the individual level. The median (range) of percentage of non-adherence at the GP
level was 0% (0%-78.4%) and 21.0% (0%-83.5%) in the control and active group,
respectively (Table 8.9).
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The characteristics of the GPs and of the patients included in these analyses are
comparable across trial groups (Table 8.9); further the marginal ICC for individual-
level outcome (vaccination) and treatment received (text message reminder) was
0.03 and 0.84 on the log-odds scale, respectively.




Number of practices, n (%) 58 (100.0) 58 (100.0)
Open on weekends, n (%) 39 (67.2) 37 (63.8)
Patients per practice, median (range) 660 (148-1678) 684 (79-3022)
Patient-level characteristics
Number of patients, n (%) 40633 (100) 41073 (100)
Male, n (%) 20752 (51.1) 21012 (51.2)
Has any disease, n (%) 39244 (96.6) 39672 (96.6)
Age, median (range) 50 (18-64) 50 (18-64)
Active treatment received
Patients receiving text message reminders, n (%) 2628 (6.5) 11113 (27.1)
Practices sending text message reminders, n (%) 21 (36.2) 52 (80.7)
% of patients in each GP receiving reminders, 0 (0-78.4) 21.0 (0-83.5)
median (range)
8.3.2 Cluster-level analyses
I first discuss the plausibility of the LATE identification assumptions. Then, I
present the analysis results.
8.3.2.1 Plausibility of LATE identification assumptions
The unconfoundedness assumption of the CL randomised treatment is satisfied by
design. To check whether cluster randomisation is a relevant instrument, I per-
formed a test on the first stage of the CL-TSLS. The corresponding F-statistic is
F (1, 114) = 28.7 > 10, thus passing Staiger and Stock’s rule suggesting that the
random treatment assignment is a relevant instrument [106].
The exclusion restriction at the individual level implies that there is no other mech-
anism by which the GP being randomised to sending text vaccination reminders
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can affect a patient’s actual vaccination uptake beside via the sending of the mes-
sage. This assumption needs further justification, as in principle, a GP randomised
to send reminders can be more conscious of the risks the patients face during the
influenza season and use other means to remind at-risk patients, either in person,
by post or by putting out flyers and posters in the clinic. So, it is possible that
there are patients who do not receive text reminders and yet are prompted to get
vaccinated by other means, by virtue of their practice being in the active group.
However, flyers, posters and postal letters already form part of regular care, so we
believe they do not really vary by whether the GP is randomised to the active group.
The monotonicity assumption also seems plausible as GPs randomised to the active
group were more likely to send a text message reminder than those in the control
group (see Table 8.9). Finally, there is a small risk of interference. The cluster
defined by GP practice should minimise this, as we only need to assume no interfer-
ence at the cluster level, but it could be plausible that patients interact with those
outside their GP, so that the exposure to a text message reminder of one patient
may indeed affect the potential outcome, in this case, influenza vaccination of an-
other patient from a different GP. The risk is small as usually close family members
belong to the same general practice.
8.3.2.2 CL-LATE estimation
CL-TSLS and the Schochet-Chiang’s method using the unadjusted CL outcome
summaries are implemented by adjusting and not adjusting for a baseline CL co-
variate, namely whether the clinic was open on the weekends (yes/no). Table 8.10
shows the CL-LATE estimates (expressed as mean risk differences), with 95% CIs
and p-values obtained via different weighting strategies, and corrections.
Using cluster size weights results in different point estimates from the rest. This
was expected as there is substantial cluster size imbalance (cluster size range: 148–
1678 in the control group and 79–3022 in the active group (Table 8.9). The results
obtained from TSLS using no weights or MV weights leads to point estimates that are
very close to those found in the original publication [36]. As expected, the Schochet-
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Chiang method and the unweighted TSLS produces the same point estimates. Like
in the OPERA trial, the two estimation methods lead to similar conclusions and
suggest weak evidence of a positive text messaging effect on the proportion of flu
vaccines uptake at the cluster level (p-value between 0.06 and 0.07).
In terms of inference, the use of SSDF correction in calculating CIs is not important,
as the number of clusters is large, but the HW SEs paired with MV weighting
provides efficiency gains, especially for the adjusted CL-TSLS analyses. Overall
however, the CIs are still very wide.
These results suggest that there is weak evidence that receiving a text reminder
increases the expected proportion of patients within a compliant practice that get
vaccinated against influenza by 14% (95% CI: −0.5 to 30%, p = 0.065, based on the
adjusted CL-TSLS using MV weights and normal-based CI with HW SEs estimate).
Contrast this with the unadjusted CL-summaries mean risk difference ITT estimate,
which indicates a 2.89% increase (95% CI −0.17 to 5.95, p = 0.064), highlighting
the dilution effects deriving from the non-adherence.
One of the disadvantages of TSLS is lack of efficiency. Adjusting for individual-
level baseline covariates may help obtaining narrower CIs. Since CL-TSLS cannot
adjust for individual level covariates, we now perform the analyses using “adCL”
summary outcomes, generated by adjusting for gender, age and the presence of
disease. Results are reported in Table 8.11. The results do not materially change
(weak evidence of a 13% increase uptake of vaccination), possibly because these
individual-level covariates are not strongly associated with the outcome.
Our illustrative example is limited by the availability of baseline cluster-level vari-
ables. Since there was only one CL-variable recorded, the impact of covariate ad-
justment on the CL-TSLS is negligible. Other limitations of these results include
the possibility of measurement error, for if patients received their influenza vaccine
outside the practice, this would not have been recorded in the system, unless the
patient informed their GP.
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Table 8.10: Schochet-Chiang and TSLS estimation of practice-level LATE of reminder
text messaging to receive flu vaccine on the percentage uptake of flu vaccine in the
TXT4FLUJAB trial using unadjusted CL outcomes, adjusting for individual-level covari-
ates gender, age and presence of disease
Unadjusted Adjusteda
LATE (95% CI) p LATE (95% CI) p
Schochet None 0.149 (-0.008, 0.306) 0.063 0.148 (-0.010, 0.306) 0.066
TSLS
No weighting None 0.149 (-0.006,0.305) 0.060 0.148 (-0.078,0.303) 0.063
HW 0.149 (-0.006,0.305) 0.060 0.148 (-0.005,0.301) 0.058
SSDF 0.149 (-0.009,0.308) 0.065 0.148 (-0.012,0.308) 0.069
SSDF + HW 0.149 (-0.009,0.308) 0.065 0.148 (-0.009,0.305) 0.064
Cluster size None 0.071 (-0.065,0.207) 0.307 0.074 (-0.061,0.209) 0.284
weights HW 0.071 (-0.088,0.230) 0.382 0.074 (-0.077,0.225) 0.338
SSDF 0.071 (-0.068,0.209) 0.313 0.074 (-0.064,0.212) 0.292
SSDF + HW 0.071 (-0.091,0.233) 0.388 0.074 (-0.081,0.228) 0.346
Minimum- None 0.143 (-0.008,0.293) 0.064 0.142 (-0.009,0.293) 0.065
variance HW 0.143 (-0.006,0.291) 0.060 0.142 (-0.005,0.289) 0.058
weights SSDF 0.143 (-0.011,0.296) 0.069 0.142 (-0.012,0.297) 0.071
SSDF + HW 0.143 (-0.009,0.294) 0.065 0.142 (-0.008,0.293) 0.064
a Adjusted for whether clinic is opened during weekends.
HW: Huber-White; SSDF: small sample degrees of freedom.
Table 8.11: TSLS estimation of practice-level LATE of reminder text messaging to
receive flu vaccine on the percentage uptake of flu vaccine in the TXT4FLUJAB trial
using adjusted CL outcomes, adjusting for individual-level covariates gender, age and
presence of disease
Unadjusted Adjusteda
LATE (95% CI) p LATE (95% CI) p
No weighting None 0.133 (-0.016,0.282) 0.081 0.133 (-0.017,0.282) 0.082
HW (-0.016,0.282) 0.081 (-0.014,0.280) 0.077
SSDF (-0.019,0.285) 0.086 (-0.021,0.286) 0.089
SSDF + HW (-0.019,0.285) 0.086 (-0.018,0.283) 0.083
Cluster None 0.068 (-0.063,0.198) 0.310 0.071 (-0.058,0.200) 0.280
size weighting Huber-White (-0.081,0.216) 0.372 (-0.069,0.212) 0.320
SSDF (-0.065,0.201) 0.316 (-0.061,0.203) 0.288
SSDF + HW (-0.084,0.219) 0.378 (-0.073,0.215) 0.328
Minimum- None 0.128 (-0.017,0.273) 0.084 0.128 (-0.017,0.273) 0.084
variance weighting HW (-0.015,0.271) 0.080 (-0.014,0.269) 0.077
SSDF (-0.020,0.275) 0.090 (-0.021,0.277) 0.091
SSDF + HW (-0.018,0.273) 0.086 (-0.017,0.273) 0.083
a TSLS estimation was adjusted for weekend clinics (yes/no).
HW: Huber-White; SSDF: small sample degrees of freedom.
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8.3.3 Individual-level analyses
Table 8.12 shows the results from the Wald estimation and TSLS with HWR or
Moulton correction, with and without covariate adjustment. For the Wald estima-
tion, I obtained the 95% CI for LATE via bootstrapping using 1500 replicates and
normal approximation. In order to get the risk difference from the Bayesian mul-
tilevel mixture modelling, I marginalize the individual-level probability of receiving
influenza vaccine over the space of random effects using the Monte Carlo integration,
for the control and active groups separately. Unfortunately, I encountered a con-
vergence issue potentially due to the large number of clusters and individuals and
therefore cannot present any results for this analysis. The Wald and TSLS (with
HWR and Moulton correction) estimations lead to very similar results and suggest
no evidence of text messaging on influenza vaccine uptake.
Substantive summary
I conducted causal analyses by estimating LATE using several methods to address
the question of whether actually receiving a text messaging reminder of influenza
vaccine would affect the uptake of influenza vaccine among GPs or patients that
would comply to any condition they would be randomised to. I found weak evidence
of positive causal effect of text messaging reminder of influenza vaccination on the
uptake of influenza vaccine at the GP level but no evidence of causal effect at the
patient level in the TXT4FLUJAB trial.
Table 8.12: IL-LATE estimates (as mean difference) at patient level, of text message
reminders to receive flu vaccination on the uptake of flu vaccine in the TXT4FLUJAB trial,
assuming and relaxing variance homogeneity assumption and adjusting/not adjusting for
gender, age, presence of disease and whether clinic is opened during weekends
Unadjusted Adjusted
LATE (95% CI) p LATE (95% CI)a p
TSLS HWR 0.071 (-0.088, 0.230) 0.382 0.071 (-0.069, 0.211) 0.320
TSLS Moulton 0.071 (-0.086, 0.228) 0.377 0.071 (-0.076, 0.218) 0.342
Wald ratio b 0.071 (-0.093, 0.235) 0.398 0.071 (-0.075, 0.217) 0.338
a Adjusted for cluster-level covariate “whether clinic is opened during weekends” and
individual-level gender, age and presence of disease.




Covariate adjustment offers some efficiency gain whether CL-summaries or individual-
level analyses are performed particularly when the covariates are associated with the
outcome, with or without weighting using either complete records or multiple im-
puted data.
As expected, the Schochet-Chiang method and unweighted CL-TSLS provide the
same CL-LATE point estimates. Moreover, estimates from the Schochet-Chiang
method and unweighted CL-TSLS result in similar conclusions. The relatively large
number of clusters makes the between-cluster variance likely reliable and therefore,
the CL-TSLS with MV weighting seems appropriate to report. As for IL-LATE,
the Wald estimation with bootstrapped SEs and TSLS (with HWR or Moulton
correction) estimation also lead to very similar results.
The Bayesian multilevel mixture is suitable when the assumption of variance ho-
mogeneity across trial groups is to be relaxed. Relaxing the variance homogeneity
assumption either at the cluster level or at the individual level may favour efficiency.
A larger number of iterations may be required when allowing for level-1 variance
heterogeneity and using a half-Cauchy prior for level-2 standard deviation. These
findings provide additional insights as I did not investigate via simulations the per-
formance of the Bayesian multilevel mixture under variance heterogeneity scenario.
In applying these methods to the analyses of two CRTs, I have investigated whether
the actual uptake of the randomised intervention among compliers had a causal effect
on the outcomes of interest. I found – (i) weak evidence of positive causal effect of
text messaging reminder of influenza vaccination on the uptake of influenza vaccine
at the care-home level but no evidence of causal effect at the resident level in the
TXT4FLUJAB trial and – (ii) no evidence of causal effect of attendance to exercise
sessions on the short physical performance battery neither at the care-home level nor
resident level in the OPERA trial. In interpreting the results, I have also considered
the plausibility of the relevant assumptions. Given the design and implementation of
these two trials, ER and monotonicity are justifiable assumptions. With regards to
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the other assumptions, I have examined their plausibility by relaxing some of them
(variance homogeneity at each level across trial groups or adherence classes) and
found that there is a substantial gain in efficiency when allowing for level-2 variance
heterogeneity across adherence classes instead of trial groups in the OPERA trial.
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Chapter 9.
Illustration of sensitivity analyses using the
OPERA trial data
9.1 Introduction
The present chapter is an extension to chapter 8 and explores some sensitivity
analyses to ascertain the robustness of the estimates of IL-LATE in the OPERA
trial. Among the IV assumptions (defined in chapter 4), those of unconfoundedness
at cluster level and instrument relevance are often met in one-sided non-adherence
trials. Furthermore, in one-sided non-adherence trials, the monotonicity assumption
is met by design. However, departures from the ER assumption may occur especially
in psychological interventions like the OPERA trial, where some participants in the
control group may get more depressed for not being offered the active treatment.
The purpose of the sensitivity analyses is to assess how robust the results are if there
are departures from key untestable assumptions or how severe violations of those
assumptions must be to reverse the results.
Therefore, I hypothesize that residents whose care-homes are randomised to the
control group in the OPERA trial would be demotivated during the assessment of
their functional mobility, resulting in lower SPBB scores at 12 months. In other
words, not being offered the active treatment would negatively affect their motiva-
tion to do the required exercises for SPPB assessment. I investigated the impact
of relaxing the ER assumption when implementing TSLS and Bayesian multilevel
mixture methods for estimating individual-level LATE.
The chapter is structured as follows. Section 9.2 introduces the Baiocchi and Conley
sensitivity analysis approaches. Section 9.3 presents the results of applying these
sensitivity analyses to both TSLS and Bayesian multilevel mixture estimation. Fi-
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nally, section 9.4 summarizes the chapter.
9.2 Sensitivity analysis approaches
I first introduce the sensitivity analysis approach for TSLS estimation as in Baiocchi
et al. [35] which is a special type of relaxing ER assumption only in the exposed.
Then, I present the Conley’s approach for the Bayesian mixture [33] to cope with
more general types of direct effects of treatment assignment. Using the same ideas as
in Baiocchi et al. [35], I elicited the sensitivity parameter, and used this within the
Conley’s method so the prior was centred around the sensitivity parameter. The
codes for sensitivity analyses in Stata (for TSLS) and R (for Bayesian multilevel
mixture) can be found in Appendix A.12.
9.2.1 TSLS estimation
Angrist et al. [24] pointed out that the ER assumption does not hold if the IV
has an effect on the outcome while holding the value of the treatment received
fixed. Recall that the ER assumption is violated when there is a direct effect of
treatment assignment (i.e. an association not mediated by the treatment received)
on outcome. Using data from an observational study, Baiocchi et al. [35] relaxed the
ER assumption by allowing for a pre-specified interaction effect between the IV and
treatment received on the outcome. They used TSLS method so that the original
outcome is replaced by a new variable, which I refer to as ER-“adjusted” outcome
(adjusted by the effect of the IV that is not mediated by treatment received). This
“adjusted” outcome is generated as the difference between the original outcome and
the fitted interaction between the IV and the treatment received.
The interaction effect used by Baiocchi [35] as a sensitivity parameter is a partic-
ular type of effect of the IV on Y , where there is an added effect on top of the
effect of the treatment received D alone among the exposed. This interaction effect
has to be posited from external knowledge in order to point-identify LATE when
relaxing the ER. Denote by λ the hypothetical added effect of treatment received
on the observed outcome Yij among the exposed and Y
adj
ij the “adjusted” outcome.
The outcome equation that allows for an IV-treatment received interaction and the
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adjusted outcome are formulated by Baiocchi et al. [35] as follows.
Yij = β0 + βDij + βWWj + βXXij + λ(1− Zj)Dij + ε2ij (9.1)
Y adjij = Yij − λ(1− Zj)Dij (9.2)




. The term λ(1 − Zj)Dij expresses the ER violation on
the exposed only. However, none of the residents in the control groups received
the treatment. Thus, equation 9.1 is modified to allow for direct Z effect on both
exposed and unexposed as shown in equation 9.3.
Yij = β0 + βDij + βWWj + βXXij + λ(1− Zj)(1−Dij) + ε2ij (9.3)
Then, the “adjusted” outcome is given by
Y adjij = Yij − λ(1− Zj)(1−Dij) (9.4)
I allow for two hypothetical direct effects of treatment assignment on the outcome
SPPB2 by postulating that residents whose care-homes are assigned to the control
group have their SPPB at 12 months reduced either by 5% (low effect) or by 30%
(high effect) of the ITT estimates. This enables us to ascertain how severe departures
from the ER must be to reverse the conclusions regarding the causal treatment effect.
9.2.2 Bayesian multilevel mixture model
Conley et al. [33] proposed a Bayesian estimation using non-clustered data from
an observational study where the IV is assumed to be “plausibly exogenous”, that
is, the ER assumption is weakly relaxed such that the direct effect of the IV on
the outcome is allowed to be local-to-zero (i.e. close to 0) rather than exactly zero.
As per Conley [33], I assume a local-to-zero prior for the direct effect of treatment
assignment on SPPB at 12 months but also make alternative assumptions. The
assumptions investigated to assess departures from the ER assumption are as follows.
I assume a normal distribution for the direct effect of treatment assignment either
– (i) with mean 0 and a large precision τ (here, I use τ = 1000) which is a local-to-0
prior, – (ii) with mean λ different from zero and a large precision τ (here, τ = 1000
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as well) and finally – (iii) an uninformative prior with mean 0 and a precision of
τ = 0.001. I consider both Uniform and half-Cauchy prior distributions for the
standard deviation of the random effects as recommended [114].
I extend Conley’s approach [33] to one-sided non-adherence CRTs using the following
model. 
Yij ∼ N(µijC , σ
2
υC
+ σ2εC) ; C ∈ {0, 1}
µij0 = β0,0 + βZ,0Zj + βW,0Wj + βX,0Xij + υj0
µij1 = β0,1 + βZ,1Zj + βW,1Wj + βX,1Xij + υj1
Cij ∼ Bern(pij)
logit(pij) = λ0 + λWWj + λXXij + ζj
(9.5)
where C is the latent adherence class such that Cij = Dij if Zj = 1 and Cij =
missing if Zj = 0. Here 1 = “complier” and 0 = “never-taker”. υ
0
j ∼ N(0, σ2υ0),
υ1j ∼ N(0, σ2υ1) and ζj ∼ N(0, σ2ζ ).
The ER assumption is relaxed by formulating priors for βZ,0 in equation (9.5) as
follows: – (i) βZ,0 ∼ N(λ, τ = 1000), – (ii) βZ,0 ∼ N(λ, τ = 1000) and – (iii)
βZ,0 ∼ N(0, τ = 0.001). Like in section 9.2.1, λ is either 5% or 30% of the ITT
effects.
9.3 Results
Table 9.1 shows the IL-LATE estimates obtained assuming and relaxing the ER
assumption. Estimations are performed using TSLS with Huber-White-Rogers or
Moulton SEs and the Bayesian multilevel mixture model. I assume level-1 and level-2
variance homogeneity. Table 9.2 shows the IL-LATE estimates obtained from fitting
the Bayesian multilevel mixture model only, assuming and relaxing ER assumption
but with level-2 variance heterogeneity across trial groups or adherence classes.
TSLS estimation of IL-LATE is sensitive to the size of the pre-specified direct effect
of treatment assignment on outcome, regardless of covariate adjustment and the
SEs estimation approach (HWR or Moulton correction). Although the IL-LATE
point estimates have substantially changed and the 95% CIs get narrower after
adjusting for covariates, there is no noticeable gain in efficiency. The p-values,
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whether adjusted for covariates or not, seem to increase with larger sizes of the direct
effect of treatment assignment on outcome. This may suggest that TSLS estimation
may be more inefficient when relaxing ER and this inefficiency gets worse as the
size of the direct effect of treatment assignment increases. As noted under the ER
assumption, estimating the SEs using HWR or Moulton’s correction leads to very
similar results.
Unlike TSLS, the IL-LATE estimates from the Bayesian multilevel mixture model
seem in general less affected by the assumption made on the direct effect of treatment
assignment on outcome. However, when allowing for level-2 variance heterogeneity
across trial groups, using an uninformative prior with a mean 0 for the direct effect
of treatment assignment without covariate adjustment results in IL-LATE estimates
with opposite signs compared to those obtained from other analysis scenarios. In
addition, the resulting 95% credible intervals do not overlap with the rest of the
estimates. This is corrected after adjusting for covariates, leading to conclusions
that are similar across all the assumptions made on the sensitivity parameter. For
the scenario where I allow for level-2 variance heterogeneity across trial groups and
no covariates are adjusted for, the posterior distribution of the treatment effect in
never-takers when using a vague prior (mean 0 with very small precision) results in
large values (median: 5.97; 2.5th to 97.5th : 4.95 to 7.02) in contrast with the small
values (median: −0.0002; 2.5th to 97.5th : −0.06 to 0.06) obtained when a local-
to-0 prior for the treatment effect in never-takers is used. Allowing for variance
heterogeneity across trial groups coupled with no covariate adjustment may result
in poor estimates of the variance in each trial group because of the reduced number of
clusters contributing to the estimation, as opposed to allowing for the heterogeneity
across adherence classes where all the clusters potentially contribute to estimating
the outcome variance. The fact that IL-LATE estimates are downward when using a
vague prior may be because the adherence classes are badly predicted as no covariates
are included in the model coupled with the weak identification of LATE subsequent
to a strong violation of the ER assumption, which translates via the vague prior on
the treatment effect in never-takers. The fact that IL-LATE estimates are similar
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across all the sensitivity assumptions after covariate adjustment supports the claim
of poor prediction of adherence classes in the absence of covariates, as the covariates
have information that helps predict the adherence classes.
The prior distribution used for the level-2 standard deviations, whether Uniform or
Half-Cauchy, has little impact on the results. IL-LATE estimation using Bayesian
multilevel mixture modelling appears to be more efficient than TSLS.
When estimation is done using Bayesian multilevel mixture model, efficiency is
gained by allowing for level-2 variance heterogeneity across adherence classes rather
than trial groups, regardless of the assumptions made on the size of the direct ef-
fect of treatment assignment on outcome and whether covariates are included in the
model or not.
As to the suitability of relaxing ER, the results from the Bayesian multilevel mixture
modelling support the plausibility of ER assumption in the OPERA trial as the
LATE estimates assuming or relaxing ER are very similar with or without covariate
adjustment and irrespective of the assumption made on the direct effect of treatment
assignment on outcome. The results validate our assumption of direct treatment
assignment effect and suggest that only attendance to at least one exercise session
may have an effect on SPPB at 12 months and there is no noticeable effect of
treatment allocation. The plausibility of the ER assumption may be due to the “all-
or-none” (attending at least one exercise session or not at all) working definition
of adherence to treatment adopted in this thesis. This definition of adherence is
less susceptible to violation of the ER assumption as even little exposure to exercise
sessions may induced a non-zero effect on the outcome than no exposure at all may
do.
Moreover, when allowing for level-2 variance heterogeneity across adherence classes,
the results are suggestive of weak evidence of causal effects of exercise sessions on
SPPB at 12 months. More precisely, attending at least one exercise session increases
SPPB at 12 months by approximately 0.21 on average and there is 95% probability
that this effect is roughly within -0.05 to 0.46 in residents who would attend at least
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one exercise session had they been assigned to the active group but would not attend
any exercise session at all if they were assigned to the control group.
Table 9.1: Individual-level LATE estimates expressed as a mean difference on SPPB
at 12 months with/without the exclusion-restriction assumption and assuming variance
homogeneity, adjusting and not adjusting for covariates and obtained on complete records
and multiple imputed data
Unadjusted Adjustedb
LATE (95% CI)a p LATE (95% CI) p
Complete records
TSLS Assumed ER 0.401 (-0.101, 0.902) 0.117 0.294 (-0.068, 0.656) 0.111
HWR λ = 5% ITT 0.382 (-0.120, 0.884) 0.135 0.279 (-0.084, 0.641) 0.132
λ = 30% ITT 0.290 (-0.213, 0.793) 0.258 0.201 (-0.163, 0.564) 0.279
TSLS Assumed ER 0.401 (-0.104, 0.905) 0.119 0.294 (-0.071, 0.905) 0.115
Moulton λ = 5% ITT 0.382 (-0.122, 0.887) 0.138 0.279 (-0.087, 0.644) 0.135
λ = 30% ITT 0.290 (-0.215, 0.795) 0.261 0.201 (-0.165, 0.567) 0.282
Bayesian Assumed ER 0.152 (-0.195, 0.499) - 0.219 (-0.219, 0.648) -
Multilevel Local-to-0 0.153 (-0.194, 0.499) - 0.211 (-0.230, 0.644) -
Mixture, λ = 0, vague prior 0.266 (-0.087, 0.619) - 0.195 (-0.181, 0.564) -
Uniform λ = 5% ITT 0.151 (-0.196, 0.498) - 0.212 (-0.232, 0.645) -
λ = 30% ITT 0.146 (-0.202, 0.492) - 0.213 (-0.232, 0.652) -
Bayesian Assumed ER 0.153 (-0.196, 0.500) - 0.218 (-0.219, 0.648) -
Multilevel Local-to-0 0.153 (-0.196, 0.500) - 0.211 (-0.230, 0.643) -
Mixture, λ = 0, vague prior 0.266 (-0.087, 0.620) - 0.195 (-0.184, 0.566) -
Half-Cauchy λ = 5% ITT 0.152 (-0.197, 0.500) - 0.211 (-0.230, 0.645) -
λ = 30% ITT 0.147 (-0.201, 0.494) - 0.214 (-0.228, 0.647) -
Multilevel multiple imputation
TSLS Assumed ER 0.295 (-0.214, 0.804) 0.256 0.246 (-0.141, 0.634) 0.213
HWR λ = 5% ITT 0.303 (-0.229, 0.836) 0.264 0.229 (-0.141, 0.598) 0.225
λ = 30% ITT 0.303 (-0.229, 0.836) 0.264 0.229 (-0.141, 0.598) 0.226
TSLS Assumed ER 0.295 (-0.217, 0.807) 0.258 0.246 (-0.147, 0.639) 0.219
Moulton λ = 5% ITT 0.272 (-0.248, 0.791) 0.306 0.220 (-0.177, 0.617) 0.276
λ = 30% ITT 0.272 (-0.248, 0.791) 0.306 0.220 (-0.177, 0.617) 0.276
a Confidence intervals for estimates from TSLS and credible intervals for the Bayesian models.
b Adjusted for cluster-level covariates PLACE, SIZE and HOME, and individual-level covariates
AGE, SEX, ANTIDEP0 MMSE and SPPB0.
HWR: Huber-White-Roger. ER: exclusion-restriction. Uniform or Half-Cauchy prior for the level-2
standard deviations.
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Table 9.2: Individual-level LATE estimates expressed as a mean difference on SPPB at 12
months with/without the exclusion-restriction assumption and assuming level-2 variance
heterogeneity across trial groups or adherence classes, adjusting and not adjusting for
covariates
Unadjusted LATE Adjustedb LATE
(95% CI)a (95% CI)
Level-2 variance heterogeneity across
trial groups
Bayesian Assumed ER 0.437 (-0.116, 0.960) 0.205 (-0.219, 0.557)
Multilevel Local-to-0 0.467 (-0.113, 0.960) 0.225 (-0.147, 0.584)
Mixture, λ = 0, vague prior -0.197 (-0.621, 0.222) 0.195 (-0.128, 0.519)
Uniform λ = 5% ITT 0.439 (-0.110, 0.960) 0.224 (-0.148, 0.584)
λ = 30% ITT 0.442 (-0.103, 0.960) 0.223 (-0.152, 0.582)
Bayesian Assumed ER 0.437 (-0.114, 0.961) 0.205 (-0.162, 0.557)
Multilevel Local-to-0 0.437 (-0.111, 0.961) 0.196 (-0.172, 0.547)
Mixture, λ = 0, vague prior -0.197 (-0.622, 0.224) 0.196 (-0.127, 0.519)
Half-Cauchy λ = 5% ITT 0.438 (-0.111, 0.960) 0.196 (-0.172, 0.547)
λ = 30% ITT 0.442 (-0.104, 0.961) 0.193 (-0.178, 0.546)
Level-2 variance heterogeneity across
adherence classes
Bayesian Assumed ER 0.151 (-0.175, 0.479) 0.206 (-0.047, 0.459)
Multilevel Local-to-0 0.151 (-0.175, 0.480) 0.204 (-0.050, 0.457)
Mixture, λ = 0, vague prior 0.188 (-0.144, 0.524) 0.200 (-0.054, 0.453)
Uniform λ = 5% ITT 0.151 (-0.174, 0.479) 0.223 (-0.052, 0.584)
λ = 30% ITT 0.149 (-0.178, 0.477) 0.204 (-0.049, 0.457)
Bayesian Assumed ER 0.151 (-0.175, 0.480) 0.206 (-0.047, 0.459)
Multilevel Local-to-0 0.151 (-0.174, 0.480) 0.204 (-0.050, 0.458)
Mixture, λ = 0, vague prior 0.188 (-0.145, 0.525) 0.200 (-0.054, 0.453)
Half-Cauchy λ = 5% ITT 0.150 (-0.175, 0.479) 0.204 (-0.050, 0.458)
λ = 30% ITT 0.150 (-0.176, 0.477) 0.225 (-0.052, 0.547)
a Confidence intervals for estimates from TSLS and credible intervals for the Bayesian models.
b Adjusted for cluster-level covariates PLACE, SIZE and HOME, and individual-level
covariates AGE, SEX, ANTIDEP0 MMSE and SPPB0.




TSLS estimation of LATE when applied to the OPERA trial is sensitive to the
pre-specified size of the direct effect of treatment assignment on outcome. For that
same trial, I note that TSLS estimation appears to be inefficient and the inefficiency
degenerates with increasing size of the direct effect of treatment assignment on
outcome. On the contrary, the LATE estimates from the Bayesian multilevel mixture
modelling are not sensitive to the assumptions made on the size of the direct effect
of treatment assignment on outcome. Estimation using the Bayesian multilevel
mixture modelling appears to be more efficient compared to TSLS. Efficiency is
gained in the OPERA trial after allowing for level-2 heterogeneity across adherence
class rather across trial groups. Based on the Bayesian multilevel mixture modelling
which offers a more elaborate approach for sensitivity analyses, assuming ER in the
OPERA trial is plausible. However, those contradictory findings between TSLS
and the Bayesian multilevel mixture modelling are specific to the OPERA trial and




This final chapter summarises and discusses key findings along with some recom-
mendations to guide trial investigators interested in estimating LATE at the cluster
or individual level in CRTs where there is non-adherence. The chapter is struc-
tured as follows. Section 10.1 highlights key findings from the systematic review on
the reporting of non-adherence and how it is addressed (chapter 2) and from the
estimation of cluster-level LATE (chapters 4, 5 and 8) and individual-level LATE
(chapters 6, 7, 8 and 9). Then, I point out the strengths and limitations in section
10.2, and I outline the practical implications of the thesis in section 10.3 and future
avenues of research on the estimation of causal treatment effects in section 10.4. I
end with a conclusion in section 10.5.
10.1 Summary of findings
This thesis contributes to the literature on the estimation of causal treatment effects
in CRTs where there is non-adherence to treatment and focuses on IV-based methods
which enable the estimation of causal effects even in the presence of unmeasured
confounders [27]. I first ascertained the current practice of reporting and addressing
non-adherence when causal treatment effects are of interest in CRTs via a systematic
review. Then, I introduced and assessed the performance of IV-based methods
for estimating cluster-level LATE and individual-level LATE through simulations
under the required identification assumptions for LATE. In addition, I performed
some sensitivity analyses for individual-level LATE estimation particularly. Two
motivating examples of CRTs, namely the OPERA [37] and TXT4FLUJAB [36]
trials, have been used to illustrate those methods.
From the systematic review which includes CRT reports published in 2011 and
may be outdated, I estimated the prevalence of non-adherence and reported the
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methods used to estimate causal treatment effects. This has to be interpreted in
light of the fact that there has been many recent methodological developments and
an increased awareness of the need for causal inference methods for clinical trials
with non-adherence. In particular, the 2017 addendum to the ICH E9 guidelines
[45] has focused attention on LATE estimands. Therefore, the conclusions drawn
in my review, which pre-dated this publication, may no longer apply to the current
reporting and analysis practice.
About half of the studies included information on treatment adherence. The non-
reporting on treatment adherence by the remaining half of the studies may be be-
cause of a poorer methodological quality than the other half of the studies that
provided information on adherence, so-called the “exclusion paradox” [67, 68] and
may have encountered non-adherence to treatment. Non-adherence to treatment
was common in CRTs but it was not sufficiently well reported. Cluster-level non-
adherence was less common than individual-level non-adherence. Moreover, after
taking into consideration possible under-reporting, the overall level of non-adherence
in CRTs may be comparable with that in RCTs reported in Dodd et al. [11], con-
tradicting the claim that a CRT design improves adherence to treatment. All of
the reviewed CRTs that reported adherence-adjusted estimates performed easy-to-
implement methods such as per-protocol and as-treated, without discussing the
plausibility of the very strong assumptions necessary for such analyses to result in
unbiased causal treatment estimates [18, 19]. No study estimated LATE or any
other appropriate statistical methods under more plausible assumptions for unbi-
ased causal estimation [24, 34]. More effort should be made to improve the quality
of reporting of non-adherence.
I proposed some recommendations for CRT investigators which are summarised in
Box 10.1 and published in Clinical Trials (see appendix A.3). Previous recommen-
dations for reporting adherence and conducting causal analyses for RCTs are still
relevant [11], and I encourage researchers to follow these as much as possible.
161
Box 10.1: Guidelines for analysing and reporting cluster randomised trials
with non-adherence to treatment
1. Report how adherence to treatment is defined and measured. Describe adher-
ence at the cluster and individual level. If dichotomised, justify the choice of
threshold made. These choices should be pre-specified in the protocol [11].
2. Where there is interest in the causal treatment effect, this should be stated
clearly in the trial protocol, prior to data collection.
3. Adherence measures should be collected alongside other trial data.
4. Report the number of clusters and individuals that received the intended treat-
ment in each trial arm [39].
5. Details of the planned causal analyses should be included in the statistical anal-
ysis plan, in advance of receiving the data.
6. Efforts should be made in the statistical analysis to reduce any bias introduced
by the fact that treatment received may be associated with other variables af-
fecting the outcome.
7. Choose a statistical method that relies on assumptions that are clarified for the
estimates to be valid and interpret non-adherence adjusted analyses as explana-
tory.
8. Discuss the assumptions necessary for the chosen analysis method to result in
unbiased causal treatment effect estimates and their plausibility in the context
of the CRT being analysed and reported.
9. In particular, the use of per protocol analysis must be supported by an explana-
tion of why it is reasonable to assume that the group of participants and clusters
who did and did not deviate from their allocated treatment are equivalent.
10. If clusters or individuals are excluded from analyses, describe if the fraction
excluded is similar between arms, and that the included groups were comparable
at baseline [18].
11. Use a method that accounts for clustering adequately. Principal stratification
can be used to estimate the LATE while accounting for clustering; alternatives
include multilevel mixture models [30] and Bayesian hierarchical models [34].
Alternatively, IV methods can use sandwich variance estimation, which is robust
to clustering [35].
12. Sensitivity analyses should be considered when the assumptions necessary for
the primary causal analysis are likely to be violated [34,35].
13. A discussion of potential bias introduced by assumptions’ violations in any of
the causal analyses should be included in the published report.
It is also important to remember that for CRTs, the validity of the results also
relies on obtaining an appropriate estimate for the standard errors, for which it
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is crucial to use a method that correctly models the dependence structure of the
data [78]. Causal methods that accommodate the clustering should be made more
widely available and easy to implement in commonly used software. To promote
their use in practical applications, there is need for more tutorial papers describ-
ing clearly the assumptions needed and detailing the challenges of performing such
adherence-adjusted analyses in the context of a good empirical example. To this end,
I investigated the performance of methods estimating LATE in CRTs, in terms of
empirical bias and coverage of the 95% CI. Information from the systematic review
such as the median proportion of non-adherence at the cluster or individual level,
the median ICC for the outcome and the median number of randomised clusters per
arm and of number of individuals guided in simulating CRTs.
I first conducted extensive simulations to assess how TSLS using cluster-level out-
come summaries and the Schochet-Chiang approach perform when estimating LATE
at the cluster level. The simulation study suggests that CL-TSLS outperforms the
Schochet-Chiang method in some settings. The Schochet-Chiang method has good
coverage when the number of clusters is large irrespective of the settings or when
no covariate adjustment is done except for the settings with low ICC for Y and
large LATE size. For those settings, the performance of the Schochet-Chiang and
TSLS methods are comparable. However, the TSLS estimator with at least SSDF
correction is preferable to the Schochet-Chiang method especially for settings where
the number of clusters is small. For CL-TSLS, all weighting strategies performed
similarly when the number of clusters is not small. When the number of clusters
is small, minimum-variance weights tend to be badly estimated and therefore are
not recommended. Furthermore, when the cluster sizes are very variable, cluster
size weights should not be used. Although in the simulations the choice of weights
did not affect the point estimates, these were affected in the illustrative example.
Overall the results show that, unless there are very few clusters, or the outcome ICC
is large, minimum-variance weighting performs well [74].
Based on the simulations study, Table 10.1 summarises when to adjust for con-
founders, to use weighted least square and to correct for degrees of freedom in small
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samples while performing CL-TSLS. This summary of findings has been published
in Statistical Methods in Medical Research (see Appendix A.4).
Table 10.1: Summary of how to perform CL-TSLS
Adherence Comments
At CL:
If the number of clusters J is small Use small sample DF correction
to improve inference
If J is small and the outcome ICC is large Adjust for CL variables in TSLS to
reduce bias and improve efficiency
If an IL variable is a strong confounder Use adjusted CL-outcomes in the
TSLS to improve efficiency
If CS are imbalanced Use small sample DF correction to
improve inference
At IL:
If the number of clusters J is small Use small sample DF correction
to improve inference
If J is small and the outcome ICC is large Avoid adjusting for CL
variables
If CS are imbalanced Use small sample DF correction to
improve inference and avoid using
CS weights
CS: cluster sizes; CL: cluster level; DF: degrees of freedom; IL: individual level
CL-TSLS is attractive and easy to implement, but it suffers from being inefficient.
Cluster-level summary analyses are in general inefficient unless the cluster sizes are
(almost) equal [128] and TSLS is also known to be inefficient. However, adjusting for
covariates can improve the efficiency [99]. In the context of cluster-level summary
analyses, it is only possible to include cluster-level covariates in the regressions [76].
However, I tested the performance of cluster-level outcome summaries which are
adjusted for individual-level covariates [8], and showed that this indeed has the
potential to improve efficiency in certain settings.
For CL-TSLS analyses, inference should be based on the number of clusters, with
CIs constructed by using t-distributions with degrees of freedom equal to J − p
[129], where J is the number of clusters and p the number of parameters in TSLS
regression. The outcome ICC value is important too, with higher ICCs requiring a
larger number of clusters for the asymptotical arguments to work, as well as whether
the cluster-level variances are homoscedastic [76].
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In view of existing literature and my findings, I conclude with some recommendations
for trial analysts when cluster-level LATE is of interest. Those recommendations
are summarised in Box 10.1 below.
Box 10.1: Recommendations for cluster-level LATE estimation in CRTs
where there is non-adherence to treatment
Which cluster-level summary approach to choose?
1. For simplicity, use unadjusted cluster-level outcome summaries if covariate ad-
justment is not planned for in the trial protocol.
2. If covariate adjustment is planned for, use adjusted (for individual-level covari-
ates only) cluster-level outcome summaries and include cluster-level covariates
only in TSLS regression. This prevents analysts from having to correct the
degrees of freedom themselves.
How to ensure valid inferences?
3. Firstly, use the planned cluster-level ITT analysis and check whether het-
eroscedasticity exists by comparing the residual variance across trial groups.
a. Obtain those residuals from a linear regression of the chosen cluster-level
outcome summaries approach.
b. Residuals plot across trial groups can be used, or formal heteroscedasticity
tests such as of Breusch-Pagan [94] or White [70].
c. If there is no evidence of heteroscedasticity across trial groups, no need for
weighting.
4. Always use Huber-White standard errors whether heteroscedasticity is present
or not, but not when the number of clusters is small [71].
5. Use t−distribution rather than normal approximation when the number of clus-
ters is small i.e. use small sample degrees of freedom adjustment.
Which weighting strategy to choose?
6. Use minimum-variance weights, except when the number of clusters is small.
7. If the marginal ICC for outcome is large (≥ 0.6 [91]) and number of clusters is
small, use “no weight”.
8. When clusters are of similar size, minimum-variance, cluster size and “no”
weights are equivalent. For simplicity, choose “no weight”.
How to interpret cluster-level LATE from TSLS?
9. If adherence is at the cluster level, cluster-level LATE can be interpreted as the
population LATE.
10. If non-adherence is at the individual level and clusters are of same size, cluster-
level LATE can be interpreted as the population LATE.
11. If non-adherence is at the individual level and clusters are not of same size but
LATE is constant across clusters, cluster-level LATE can be interpreted as the
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population LATE. To the best of our knowledge, there is no formal procedure to
assess the assumption of homogeneous LATE across clusters, which is a strong
assumption.
How plausible are LATE identification assumptions?
12. Discuss potential bias introduced by assumptions’ violations. Designs such as
double blinding enhance the plausibility of LATE identification assumptions
[23]. When a threshold of cluster-level proportion of treatment received is used
to define adherence to treatment at the cluster level as binary (rather than con-
tinuous), analysts should be cautious about departures from the ER assumption.
In addition, an incorrect dichotomization of treatment receipt leads to LATE
estimates that are too large compared to the average per-unit effect of the con-
tinuous treatment received [28].
13. Test the relevance of random treatment assignment as instrument using Staiger
& Stock’s rule of thumb [106]. The reporting of the instrument’s relevance has
been advocated [35].
a. If F−statistic≥ 10, random treatment assignment is a relevant instrument
and TSLS estimator is consistent.
b. If F−statistic< 10, random treatment assignment is a weak instrument.
TSLS estimator may be biased and not appropriate. This is likely to happen
when only few clusters are recruited per treatment and non-adherence is at
the cluster level. The bias is larger in small samples and very sensitive to
even small departures from the ER assumption [76, 104]. In addition, infer-
ences are wrong but robust procedures such as permutation-based inference
[130], Anderson-Rubin’s structural parameter test [131] and conditional like-
lihood ratio test [132] have been suggested. Alternatively, seek for estimands
other than LATE, for instance average total effects that can be estimated
using propensity scores approach (see [133] for binary treatment and [134]
for continuous treatment).
Sensitivity analyses to violation of LATE identification assumptions
14. Use for instance TSLS where the original outcome is replaced by a new variable
generated as the difference between the original outcome and the fitted interac-
tion between the random treatment assignment and the treatment received. The
fitted interaction is an interaction effect used as a sensitivity parameter elicited
from external knowledge to enable the point-identification of LATE when relax-
ing the ER assumption.
Handling of missing data
15. Diaz-Ordaz et al. [42] provided comprehensive guidelines on the assumptions
and common techniques that can be used to address missing data when data are
clustered. Ignoring clustering in the multiple imputation may inflate the Type I
error [135] whereas including cluster’s fixed effect in the imputation model may
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result in overestimated between-cluster variance in particular in the presence of
small cluster sizes and low intracluster correlation coefficient [136].
16. To estimate cluster-level LATE, an option is to first use a multilevel joint mod-
elling multiple imputation [122, 123] assuming a missing-at-random mechanism
and impute missing data separately in the control and active groups using the
“jomo” package in R [124]. Then, perform cluster-level analysis on each imputed
dataset and finally pool the estimates using Rubin’s rule [126,127].
17. The imputation model must include all variables in the analysis model and
adding auxiliary variables may enhance the plausibility of the missing-at-random
assumption more plausible [42].
18. Evaluate via sensitivity analyses the robustness of the results to departure
from the missing-at-random assumption by for instance modifying the multiply-
imputed data as follows
a. Multiply-impute the missing data assuming missing-at-random mechanism.
b. Modify the imputed data in a. to reflect various plausible scenarios under
missing-not-at-random mechanism by multiplying and/or shifting the im-
puted values by a scalar.
c. Estimate cluster-level LATE using each modified imputed data and pool the
estimates using Rubin’s rules [126, 127]. Leurent et al. [137] published a
tutorial illustrating the procedure.
After focusing on cluster-level LATE estimation, I compared the performance of the
Wald (or conditional Wald) estimator with bootstrapped SEs, TSLS with Huber-
White-Rogers SEs, TSLS with Moulton SEs and the Bayesian multilevel mixture
modelling, in terms of empirical bias and coverage at the 95% CI, for estimating
LATE at individual level. Further illustrations have explored TSLS and Bayesian
multilevel mixture model estimating LATE when relaxing the ER assumption.
The Wald estimator with bootstrapped SEs, TSLS with HWR SEs and TSLS with
Moulton SEs can be used but the bootstrapped SEs for the Wald estimator tend to
result in CIs which are conservative. In the presence of individual-level adherence,
when the ICC for outcome is low, TSLS with Moulton’s SE is appropriate. However,
when the ICC for outcome is large, the Bayesian multilevel model is preferable
though it leads to little but negligible bias (below 1%).
As per my findings, I propose some recommendations for trial analysts when individual-
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level LATE is of interest and missing data issues have been adequately addressed
in a preliminary step, with multiple imputation results obtained using the standard
Rubin’s rule [126,127]. Those recommendations are summarised in Table 10.2 below.
Table 10.2: Recommendations about the estimation of LATE at individual level
Adherence Comments
At CL If expected ICC Use either Wald estimator with bootstrapped
for outcome is SEs, TSLS with HWR SEs or TSLS with
large Moulton’s SEs.
Covariate adjustment has no effect.
Avoid using Bayesian multilevel mixture model
if number of clusters is not large.
If expected ICC Use either TSLS with HWR SEs, or TSLS with
for outcome is Moulton’s SEs.
low Adjust for CL confounders to improve inference.
Avoid using Bayesian multilevel mixture model
if number of clusters is not large.
At IL If expected ICC Use Bayesian multilevel mixture model.
for outcome is Adjust for CL and/or IL confounders.
large Use either Uniform or half-Cauchy priors for
level-2 standard deviation.
If expected ICC Use TSLS with Moulton’s SEs with/without
for outcome is covariate adjustment, or Bayesian multilevel
low mixture model without covariate adjustment.
Use either Uniform or half-Cauchy priors for
level-2 standard deviation.
CL: cluster level; IL: individual level; TSLS: Two-stage least square; HWR: Huber-White-Rogers;
SEs: Standard errors.
Note that when missing data are of concern, the recommendations pertaining to the
handling of missing data in Box 10.1 are also applicable to individual-level LATE
estimation.
10.2 Strengths and limitations
This research provided the first systematic review of reporting practices of non-
adherence with randomised treatment in CRTs and to what extent non-adherence is
handled when trial investigators are interested in addressing causal questions. The
findings pointed out the need for improving the quality of CRTs reports in terms
of causal analyses. The CRTs database used for this review was identified using a
rigorous electronic search procedure previously published [42]. This search strategy
was calibrated with a previously published one [138], which had been validated with
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an ideal set of cluster randomised trials identified from manual examination of a
large sample of health journals and was found to have high sensitivity (90.1%).
Nevertheless, I may have inherited limitations from the previous strategy search.
Some cluster randomised trials may have been missed, as reports may fail to clearly
identify the cluster randomisation design in either the title or abstract.
The inclusion criteria were broad, and thus our sample should be representative of
the quality of conducting and reporting of CRTs. The included reports were pub-
lished in 2011, but I do not expect a change in practice for adherence reporting,
as the updated CONSORT statement for CRTs [39] was available in pre-print form
since 2010 and did not contain any new guidelines with regards to adherence report-
ing or handling over and above those included in the 2004 version [14]. However,
more recent studies focusing on the estimation of causal treatment effects in CRTs
[35,98,139] as well as the 2017 addendum to the ICH E9 guidelines [45] encouraging
good causal analysis practice have been published and therefore, my review findings
may not reflect the current practice.
As with reviews of this nature, our assessments were based only on the information
included in the trial reports. It is possible that non-adherence is more common
but under-reported, the so-called exclusion paradox [67, 68]. I calculated ranges of
non-adherence to reflect this possibility. Another possible limitation is the use of
a single reviewer for data extraction. However, single-reviewer extraction was only
carried out after a validation phase, where a second reviewer conducted extraction.
Agreement between the two extractors was high during validation. Additionally,
during full-extraction, whenever there was ambiguity, the second reviewer’s opinion
was sought and disagreements were resolved by consensus.
I covered the two levels of unit of inference, that is at the cluster level and at the
individual level, when addressing non-adherence in CRTs. Cluster-level inference
may be preferable for CRTs with a small number of clusters whereas inference at
the individual level may be suitable when there is relatively large number of clus-
ters as the between-cluster variance may be adequately estimated [8]. Cluster-level
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summary ITT analyses are known to perform well under various settings [8], but the
performance of CL-TSLS with alternative weighting while adjusting for cluster-level
and/or individual level covariates as well as the Wald estimator with Schochet-
Chiang’s SEs has not been explored. This research filled this gap by conducting
an extensive simulation study where scenarios vary by cluster size and the outcome
intracluster correlation coefficient, whether adherence is at the cluster level or at the
individual level, and the strength of covariates’ effect sizes (small or large effect).
Most of the studies investigating cluster size imbalance have only focused on its
impact on the statistical power [140–142]. To my knowledge, this research is the
first to explore the impact of cluster size imbalance on the coverage of methods for
estimating cluster-level LATE.
Selection bias may potentially occur when individuals are recruited after the clus-
ters have been randomised to a treatment group. This does not violate the uncon-
foundedness assumption, which needs to hold only at the cluster level. It can be
argued that random allocation remains a strong instrument, as clusters are more
likely to recruit individual participants who find the known cluster allocation desir-
able/acceptable. However, the validity of the ER is questionable, as in principle,
knowledge of the allocation before accepting to participate may have a “direct”
effect on the outcome and this should be addressed via sensitivity analyses.
Only IV-based methods allowing for LATE estimation have been explored so far as
per the remit of this thesis. A common criticism pertains to the nature of the LATE
estimand. The LATE estimand is often criticised because the estimates obtained
apply to the “compliers” in the population, and these cannot be observed in prac-
tice, thus limiting applicability. However, LATE estimates may be used to provide
information about the average causal effect in the entire population [35]. Moreover,
the average treatment effect on the compliers is often of interest to patients and
medical decision makers, especially when they expect patients to comply with the
treatment [143].
The identification assumptions for LATE are often untestable. The assumption
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of random treatment assignment is met by design. I simulated that the ER and
monotonicity are met. The simulations only considered CRT settings where the
random treatment assignment is a strong instrument. In general, the random as-
signment of treatment is expected to be associated with treatment received in well
conducted trials and therefore the findings are relevant for most trial settings in
practice. Monotonicity holds in one-sided non-adherence CRT settings like in my
simulations. However, I performed sensitivity analyses on real CRT data by relaxing
the ER assumption using TSLS and Bayesian multilevel mixture estimation meth-
ods. The monotonicity assumption, without which LATE is not point-identifiable,
was either met or plausible in the motivating examples. The random treatment
assignment and IV relevance assumptions are met in the motivating trials and the
ER assumption is plausible. Double blinding design may enhance the plausibility of
the identification assumptions.
The simulation study conducted to assess the performance of the Wald (or condi-
tional Wald) estimator, TSLS with Huber-White-Rogers SEs, TSLS with Moulton’s
SEs and the Bayesian multilevel mixture modelling for estimating LATE at individ-
ual level only focused on CRT settings with moderate number of clusters (50 clusters
in total). Thus, I did not investigate the small sample properties of those methods.
Moreover, the apparent benefit of allowing for level-2 variance heterogeneity across
adherence classes rather than across trial groups was only observed from real CRT
but has not been explored through simulations. Therefore, my conclusions may
not be general but limited to the OPERA trial. The Bayesian multilevel mixture
modelling, though very attractive and flexible, may require long iterations to ensure
good convergence and therefore may be slow to run.
I did not investigate via simulations situations where the identification assumptions
are violated but I only conducted sensitivity analyses to departures from the ER
assumption using real CRTs. Missing data are common in trials but my simulations
focused on CRTs with complete records. However, missing data were present in one
of the motivating example. I used a multilevel joint modelling multiple imputation
[122, 123] to handle missing data assuming missing at random and I provided the
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code that can be implemented using the “jomo” package in R [124].
I was unable to obtain the results from the Bayesian multilevel mixture model for the
TXT4FLUJAB trial where the outcome of interest is binary with a large number of
clusters (116 clusters) and number of patients (about 100000) because of convergence
and computational issues. Further work is required to optimize the analysis code
for such CRT settings.
10.3 Practical implications
This research has compared different methods for estimating LATE at the cluster
or individual level in the presence of non-adherence at cluster or individual level. I
investigated a wide range of CRT settings combining various numbers of clusters,
cluster size levels of ICC for outcome, strengths of cluster-level and individual-level
covariates on outcome and adherence to treatment, and LATE effect sizes. The pro-
posed recommendations have covered those CRT settings. The methods explored
in this thesis for estimating cluster or individual-level LATE are relatively easy to
implement in available statistical software. The provision of analysis codes in Stata
and R will facilitate the implementation of these methods by trial investigators and
potentially contribute to improving the current suboptimal practice (as per the sys-
tematic review conducted as part of this thesis) towards the adequate handling of
non-adherence when the assessment of treatment efficacy is of interest. The statis-
tical methods covered in this thesis are applicable to two-level data structures more
generally i.e. to observational studies [33, 35]. However, a crucial challenge away
from randomised experimental settings is to identify a valid instrumental variable,
and thus, each application should carefully argue the validity of the proposed IV.
10.4 Further work
My simulations explored so far CRT settings with continuous outcome when individual-
level LATE is of interest whereas I illustrated the methods using trials where the
outcomes of interest are continuous and binary. As binary outcomes are often used in
CRTs, it would be useful to conduct extensive simulations to assess the performance
of TSLS, Wald estimator and Bayesian multilevel mixture model to estimate LATE
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at the individual level in the presence of binary outcome. Note that for cluster-level
LATE, cluster-level summaries are continuous whether the outcome of interest is bi-
nary or continuous. Further simulation study may be needed for assessing the small
sample properties of the Wald estimator, TSLS and Bayesian multilevel mixture
model when estimating LATE at individual level.
I found little impact of cluster size imbalance when estimating cluster-level LATE.
While it is well known that cluster size imbalance reduces the power [140–142],
no study to my knowledge has investigated how severe the cluster size imbalance
should be to affect the performance of methods in terms of coverage. This may be
important for improving the analysis practice as cluster size imbalance is likely in
real life.
Moreover, LATE has been the focus of this thesis. It may be relevant to investigate
the performance of different methods estimating other estimands such as ATE or
ATT when investigators are not interested in LATE. This will offer alternatives for
addressing causal questions in CRTs where there is presence of non-adherence.
The lack of simulations when relaxing the ER assumption weakens the in-depth and
critical assessment of the performance of sensitivity analyses using TSLS and the
Bayesian multilevel mixture modelling under various settings. Extensive simulations
assessing the performance of TSLS and the Bayesian multilevel mixture modelling
when the ER assumption is violated may be necessary to help understand how severe
violations of the ER assumption must be to reverse the results.
My simulation study suggests that when adherence is at cluster level, the Bayesian
multilevel mixture modelling performs poorly and slightly less poorly if covariates
are adjusted for. This may be because of the relatively small number of clusters in
the active group. Note that only clusters in the active group provides information for
the prediction of the adherence classes. Having relatively small number of clusters
in the active group while increasing the number of parameters to be estimated
after adding covariates in the model may reduce the model’s predictive accuracy
of adherence classes (i.e. having to determine to what latent class an individual
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belongs but there is little information to do so), which in turn may explain the
poor performance of the Bayesian multilevel mixture modelling. Future research
is needed to assess the performance of the Bayesian multilevel mixture modelling
across a range of number clusters along with different prior’s elicitation.
In some CRTs, investigators may be interested in comparing a new treatment to
an active comparator instead of a placebo or standard care. When non-adherence
occurs in such a setting and there are no other available treatments except the two
treatments under investigation, the methods covered in this thesis can be used to
estimate LATE. Otherwise, if participants had access to other treatments than those
under investigation, this introduces alternative treatments not accounted for at the
design stage and weakens the internal validity of the design even if only an intention-
to-treat approach is of interest. Methodological developments for addressing causal
questions in such CRT settings are needed to help to clarify the assumptions as well
as to provide analytical tools to answer such questions. This would be a fruitful
avenue for future research.
The data generating process assumes that the treatment effects are homogeneous
within principal strata. Note that although the treatment effect was set to a fixed
value for all adherent units, the data generating process will reflect settings where the
treatment effects moderately vary across units within principal strata as the average
treatment effect can be used as a valid measurement in such a population. However,
in settings where the treatment effects vary considerably across units within princi-
pal strata, future research may help to establish how to allow for treatment effect
heterogeneity within the potential outcomes and principal stratification framework
and what estimands are identifiable in such settings.
The performance of methods investigated in this thesis could be assessed under
various missing data patterns. I do recognise that simulating under the sufficient
assumptions must be considered when interpreting our results, and that when viola-
tions are suspected, sensitivity analyses must be performed. Simulations exploring
settings where the random treatment assignment is only a weak instrument may be
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valuable. It may also be worth extending the present research to CRTs’ settings
where treatment non-adherence may occur at both the cluster and individual levels.
10.5 Conclusion
In this thesis, I have investigated through extensive simulations various IV-based
methods for estimating cluster-level LATE and individual-level LATE. I illustrated
those methods using two real CRTs and conducted some sensitivity analyses to
assess the robustness of the findings to departures from the ER assumption. I
have proposed some recommendations pertaining to the estimation of cluster-level
LATE and individual-level LATE and for settings where non-adherence occurs at
the cluster level or at the individual level. Those recommendations may contribute
to improving the quality of analysis when estimating causal treatment effects in the
presence of non-adherence in CRTs.
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A.1 Systematic Review Protocol
Title: Reporting non-adherence in cluster randomised trials:
A systematic review
Lead author and data extractor: Schadrac C. Agbla
Supervisor (CRTs selection): Karla Diaz-Ordaz
Sifting and selection of studies: Karla Diaz-Ordaz, Claire Coleman, Abie
Cohen
Advisors (CRT non-adherence): Karla Diaz-Ordaz
Background
The aim of this project is to establish the prevalence of non-adherence in cluster randomised
trials (CRTs) (how many cluster randomised trials reported non-adherence and if reported, what
percentage of non-adherence), how many studies have addressed non-adherence as well as how non-
adherence is handled in CRTs reported in 2011 and to establish the occurrence of methods used
for adjusting for non-adherence, e.g. intention-to-treat analysis (ITT), per-protocol analysis (PP),
as treated (AT), instrument variable, propensity score, principal stratification, complier average
causal effect (CACE).
In addition, the frequency of the pattern of non-adherence will be provided (binary, categorical,
continuous, accurately measured or not, non-adherence at individual or cluster level).
To this end, we aim to collect information on primary outcome, method of analysis for primary
outcome, description of non-adherence. We will extract data on total sample size, number of
clusters/individuals randomly allocated in each trial arm and number of clusters/individuals that
received intended treatment. The questions addressed by this review are:
 To what extend are CRTs analysis accounting for non-adherence with trial protocol?
 How non-adherence is measured and reported?
 What methods are being used to handle non-adherence?
 Are these methods accounting for clustering appropriately?
Inclusion criteria
We are using a database of CRTs published in 2011, previously used by Diaz-Ordaz et al 2013.
Details of the inclusion criteria are given below.
 Studies will be included if they are full report of phase 3 randomised controlled trials where
the randomisation is by cluster, as long as there are some outcomes collected at a level below
randomisation unit.
 All trial designs will be included.
 English-language publications only.
 All published in peer-reviewed journals in 2011.
 Unpublished trials will be excluded. Pilot and feasibility studies will also be excluded.
 When the same study is reported in more than one paper this will be documented, and data
extraction on adjusting for non-adherence on secondary papers will be performed.
 No studies will be excluded on the basis of quality, since the aim is to provide a description
of current practice, which will include studies of poor quality.
 Studies using data from CRTs as secondary data source (sub-samples) will be excluded.
 Pilot and feasibility studies will be included.
 Crossover trials will be excluded because of the implications of treatment adherence. In
crossover trials, units are randomised to sequence of treatments and not to a single treat-
ment. Units may not adhere to their allocated sequence of treatments but may receive a
specific treatment as intended and therefore would correctly contribute to estimating the




Sifting was previously conducted by DiazOrdaz et al [42], from which 132 reports were identified.
For those 132 studies, the following data will be recorded if available from the full text of the
published paper(s):
 Name of the first author
 Year of publication
 Journal
 Study identification number for paper
 Identification numbers of other papers referring to the same study
 Primary outcome: defined as that specified by the authors or, if not specified, the outcome
used in sample size calculations. If no sample size calculation was reported, the first outcome
presented in the abstract was considered primary.
 Any harm outcomes?
 What is the type of control comparator (active control? usual practice? placebo?)
 Length of intervention?
 Analysis
– Method of statistical analysis.
– Intraclass correlation coefficients for adherence behaviour.
 Number of clusters and individuals randomised (total sample size) and analysed (the number
of complete cases).
 Number of individuals and clusters that received randomised treatment
 Numbers of clusters randomised per arm
 Reporting of how non-adherence was addressed and nature of non-adherence and whether
any statistical technique used to account for the non-adherence was adjusted for clustering
 Level of adherence (cluster-level adherence? Individual-level adherence? Both cluster and
individual-level adherence?)
 Nature of adherence measurement (binary? continuous?)
 ICC for adherence behaviour for individual-level adherence
 Reporting of any reason for addressing non-adherence
 Type of intervention: drug, lifestyle changes (e.g. exercise), educational, surgery, vaccina-
tion, etc...
 Proportion of non-adherence at cluster and/or individual level
Analysis
 Information will be produced to show the number and type of studies excluded at various
points in the project, and the reasons for exclusion (Prisma flow chart).
 Tables will be produced to show the relationship between various aspects pertaining to
statistical quality, i.e. correctly accounting for clustering in analysis and adjusting for for
non-adherence. Prevalence of non-adherence will be reported, as well as proportion of studies
that addressed non-adherence.
SA will record the trial publication characteristics relating to the quantitative items listed in Table
1 using a piloted, standardised form. In cases of any doubt or ambiguity, the paper will be reviewed
and extracted by KDO.
Pilot study
The study will be piloted on about 10% of 2011 identified papers, randomly selected (15 papers).
The data extraction form (excel) will be piloted. After piloting, we will refine the data extraction
definitions and terms if necessary.
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Reporting non-adherence in cluster
randomised trials: A systematic review
Schadrac C Agbla and Karla DiazOrdaz
Abstract
Background: Treatment non-adherence in randomised trials refers to situations where some participants do not
receive their allocated treatment as intended. For cluster randomised trials, where the unit of randomisation is a group
of participants, non-adherence may occur at the cluster or individual level. When non-adherence occurs, randomisation
no longer guarantees that the relationship between treatment receipt and outcome is unconfounded, and the power to
detect the treatment effects in intention-to-treat analysis may be reduced. Thus, recording adherence and estimating
the causal treatment effect adequately are of interest for clinical trials.
Objectives: To assess the extent of reporting of non-adherence issues in published cluster trials and to establish which
methods are currently being used for addressing non-adherence, if any, and whether clustering is accounted for in these.
Methods: We systematically reviewed 132 cluster trials published in English in 2011 previously identified through a
search in PubMed.
Results: One-hundred and twenty three cluster trials were included in this systematic review. Non-adherence was
reported in 56 cluster trials. Among these, 19 reported a treatment efficacy estimate: per protocol in 15 and as treated
in 4. No study discussed the assumptions made by these methods, their plausibility or the sensitivity of the results to
deviations from these assumptions.
Limitations: The year of publication of the cluster trials included in this review (2011) could be considered a limitation
of this study; however, no new guidelines regarding the reporting and the handling of non-adherence for cluster trials
have been published since. In addition, a single reviewer undertook the data extraction. To mitigate this, a second
reviewer conducted a validation of the extraction process on 15 randomly selected reports. Agreement was satisfactory
(93%).
Conclusion: Despite the recommendations of the Consolidated Standards of Reporting Trials statement extension to clus-
ter randomised trials, treatment adherence is under-reported. Among the trials providing adherence information, there was
substantial variation in how adherence was defined, handled and reported. Researchers should discuss the assumptions
required for the results to be interpreted causally and whether these are scientifically plausible in their studies. Sensitivity
analyses to study the robustness of the results to departures from these assumptions should be performed.
Keywords
Non-adherence, cluster randomised trials, trial reporting, causal treatment effect
Introduction
Cluster randomised trials, where pre-existing groups of
individuals are randomised, have become a common
design to test public health and primary care interven-
tions, as often the target of the intervention is a hospital
or general practice, or their staff. Increased administra-
tive convenience, reduction of contamination between
experimental arms and improved adherence with allo-
cated treatment are often cited among the advantages
of adopting this design.1–3 Nevertheless, treatment
adherence may be more challenging in cluster trials
because of the hierarchical nature of the design and the
delivery of the intervention, where at least two levels at
which deviations from protocol called non-adherence
can occur, for example, cluster or individual level.4 The
nature of the non-adherence patterns largely depends on
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the nature of the intervention. Some interventions are
aimed exclusively at the clusters and thus all individuals
within a cluster are exposed to the same treatment. Water
fluoridation in a village would be one such example.
In other cluster trials, participants within the same
cluster may individually stop adhering to the allocated
treatment. An example of this is the study conducted
by Sommer et al.,5 where villages were randomised to
‘vitamin A supplements’ or not, to be offered to all
infants. However, some children whose villages
were randomised to ‘vitamin A supplements’ did not
receive the supplements. Finally, non-adherence at both
levels is possible for interventions with components tar-
geted at both levels. For example, the OPERA study
(exercise for treating depression in care home residents)
aimed to evaluate the impact of a ‘whole home’ exercise
intervention on depressive symptoms in older adults
living in care homes in England.6 Clusters were ran-
domly allocated to provide either a depression aware-
ness training session for care home staff (control) or a
twice-weekly physiotherapist-led exercise class (active
intervention) for 12 months. Some of the exercise
classes did not occur due to a shortage of staff (cluster-
level non-adherence). In addition, even when the nur-
sing home ran the exercise classes, some individuals
recruited to attend these classes did not to do so (indi-
vidual-level non-adherence). Nursing homes and indi-
viduals complied with their assigned treatment during
some weeks, but then deviated at a later time, introdu-
cing a time-varying non-adherence pattern.
The standard analysis of a trial with departures
from allocated treatment is intention-to-treat, which
compares outcomes between the groups as randomised,
ignoring the actual treatments received. The intention-
to-treat estimates the effect of being offered (or allocated
to) the treatment and cannot necessarily be interpreted
as the causal effect of treatment received. An intention-
to-treat analysis with poor adherence may dilute a true
treatment effect; with negative outcomes such as side
effects, adverse events or mortality, an intention-to-treat
estimate which is closer to the null than the true causal
effect may make a more toxic or aggressive treatment
look less harmful. In addition, non-adherence leads to a
loss of power in intention-to-treat analysis.7
Where there is an interest in estimating treatment
efficacy, as the causal effect of receiving the treatment
according to the protocol is called, analytical
approaches such as ‘per protocol’ and ‘as treated’ are
often used.8 Per protocol restricts the analysis only to
participants who received their assigned treatment,
whereas as treated analysis compares participants
according to their treatment receipt, regardless of their
treatment assignment. Both per protocol and as treated
may be subject to selection bias, and their validity as
causal estimands depends on the assumption that the
groups being compared are exchangeable, that is, com-
parable in terms of their measured and unmeasured
covariates. This is a very strong assumption. Since the
original comparable groups achieved through randomi-
sation are not preserved, any observed differences in
outcomes are not necessarily due to the treatment
effect, but potentially also due to differences in covari-
ates.9 Per protocol also leads to a reduction of statisti-
cal power.7 However, some design features may
increase the likelihood of per protocol analysis to be
unbiased. One example is when the trial is double-
blinded and the treatments have low rates of adverse
events, because in this situation, both treatment switch-
ing and discontinuations are unlikely to be associated
to outcomes, as described by White.7
More recently, ‘modified’ per protocol analyses, that
adjust for potential confounders that may lead to selec-
tion bias, have been advocated.10,11 These modified per
protocol analyses allow the investigators to adjust for
baseline, and post-randomisation variables believed to
be sufficient to adjust for the confounding of the asso-
ciation between treatment received and outcome. The
assumption of ‘no unobserved confounding’, required
for their validity, is still strong.
There are statistical methods that do not assume ‘no
unobserved confounding’. Instead, they rely on rando-
mised treatment being an instrumental variable12–14 and
have been proposed in the context of individually rando-
mised trials.7,15 Extensions to cluster randomised trials
exist.4,16–18 A brief summary of these is given in Box 1.
However, methods which are applicable to cluster set-
tings tend to be limited in their usefulness, requiring
some programming or the use of specialised software.
Previous systematic reviews investigating the reporting
and statistical handling of non-adherence in individually
randomised controlled trials have been published.8,26
These have found that adherence to treatment is often
under-reported and when reported, sufficient detail on
how adherence was defined is often not included. They
also found that the majority of the studies used ‘unad-
justed’ per protocol analyses to obtain treatment effi-
cacy estimates.8 Cluster randomised trials are more
complex to run, analyse and report than individually
randomised trials, and previous systematic reviews of
cluster trials have found that despite the Consolidated
Standards of Reporting Trials (CONSORT) extension
mentioning explicitly the need to report numbers
assigned, on treatment and analysed at the cluster and
individual levels, this information is often lacking.3,27
However, no previous study has focused on the conduct
of statistical analyses aiming to estimate causal treat-
ment effects in the presence of treatment non-adherence.
Thus, the aim of this study is to assess the reporting
and handling of non-adherence in cluster randomised
trials, and in particular, to establish the prevalence of
non-adherence and describe the methods used to obtain
adherence-adjusted treatment effects. For this, we per-
form a secondary analysis of data originally extracted
for a systematic review investigating the reporting and
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adjustment of missing data in cluster trials.28 We also
propose some guidelines for reporting adherence and for
conducting adherence-adjusted analysis of cluster trials.
Methods
Search strategy and inclusion criteria
This review uses a database of 132 cluster trials previ-
ously identified using a published electronic search strat-
egy.28 The full electronic search strategy is reported in
Box A in the Supplemental File. Reports were eligible
for inclusion if they were full reports of cluster rando-
mised controlled trials, published in English in 2011.
They were excluded if they were quasi-experimental,
self-identified as pilot, feasibility, or preliminary studies;
only reported cost-effectiveness or where no data at the
individual level were collected. We also excluded cross-
over trials, where deviations from randomised treatment
may include failure to follow the randomised sequence
of treatments, and studies reporting only sub-samples of
previously published cluster trials data.
Piloting and validation
Two researchers independently piloted a data extrac-
tion form using five randomly selected reports. This
Box 1. Causal methods for obtaining adherence-adjusted treatment estimates.
There exists many statistical methods estimating causal treatment effects in randomised trials. They target different estimands, that
is, quantities of interest in a defined population, and they also differ in the assumptions required to guarantee identification and
unbiased estimation. Interested readers are directed to introductory materials by Bellamy et al.,15 Baiocchi et al.18 and Stuart et al.19
A key idea is that of potential outcomes, that is, the outcome that would have been observed had the randomised allocation been
different. Likewise, the potential treatment received is the treatment that individuals/clusters would have received had their
randomised allocation been different. Assuming all-or-nothing compliance, the most common assumptions are as follows:
1. Stable unit treatment value assumption: the potential outcomes of the ith individual are unrelated to the treatment status of all
other individuals (known as no interference). In addition, we assume consistency: for those who actually received treatment-level
z, the observed outcome is the potential outcome corresponding to that level of treatment. In cluster trials, stable unit
treatment value assumption as above is unlikely to hold. Instead, we may assume that no interference holds at the cluster level,
that is, the potential outcome of an individual is unrelated to the treatment status of individuals in different clusters, but may
depend on those within the same cluster.4,17
2. Ignorability of the treatment assignment: randomised allocation is independent of unmeasured confounders (conditional on
measured covariates) and the potential outcomes.
3. Instrument relevance: the random allocation predicts treatment received.
4. Exclusion restriction: the random allocation cannot affect the outcomes directly.
5. Monotonicity: there are no defiers, that is, individuals who receive treatment if and only if they are not randomised to it.
Generalisations of these assumptions to cluster trials settings can be found in Schochet.4
Here, we concentrate on methods that target the complier average causal effect.
 Principal stratification.14 Under assumptions (1)–(5), each individual may be grouped into a compliance principal stratum, which is a
latent class, and can be thought of as a baseline covariate:
1. Never-takers receive no active treatment, regardless of their randomised treatment;
2. Compliers receive the active treatment if and only if they are randomised to it;
3. Always-takers, who receive the active treatment, regardless of their randomised treatment.
The complier average causal effect can then be identified from the observed data. Estimation for the principal stratification is based
on a mixture of distributions across compliance strata. Extensions to cluster trials are possible, using multilevel mixture models, in
either a Bayesian16 or likelihood approaches.17
 Instrumental variables. Under assumptions (1)–(5), Angrist et al.20 showed that the instrumental variable estimand is the
intention-to-treat effect in compliers. This is then usually estimated using two-stage least squares. To account for the clustering,
it has been recommended to use two-stage least squares using Huber–White variance estimator.18
 Principal scores. While this method is based on principal stratification, it differs from the previous version, because it does not
assume exclusion restriction, but instead assumes principal ignorability:21 the observed covariates are sufficient for identifying
principal stratum membership.22,23 The compliance or principal score is a function solely of pre-randomisation covariates.
Similar to the use of propensity scores, this method uses baseline covariates to model principal stratum membership. Once
principal scores are obtained, the complier average causal effect is estimated using either matching or weighting, as it is usually
done in propensity scores literature. Because it does not assume exclusion restriction, this method is attractive when this
assumption is believed to not hold, but the principal ignorability assumption is more plausible.
The choice of causal estimation methods depends on the estimand that investigators are interested in and whether the trial setting
supports the plausibility of the underlying causal assumptions. Many of these assumptions are untestable, and often their plausibility
is questionable. There are several options to study the sensitivity to departures from these assumptions. For example, when
exclusion restriction does not hold, researchers could use the principal scores methods. Alternatively, a Bayesian parametric model
can use priors on the non-zero direct effect of randomisation on the outcome for identification on the mixture models used in the
principal stratification approach.24 In the frequentist instrumental variables framework, such modelling is also possible, see Baiocchi
et al.18 for a tutorial on how to perform sensitivity analyses to departures from exclusion restriction and monotonicity assumptions.
See also Stuart and Jo25 for a comparison of the sensitivity to departures from assumptions of principal stratification under
exclusion restriction and principal scores under principal ignorability.
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helped to identify extra relevant information to extract
and to improve the study protocol. After updating the
study protocol and the data extraction form, a random
sample of 15 reports was used for validation of the
extraction procedures. In case of discrepancy, a final
decision was made by consensus and the appropriate
information was recorded in the data extraction form.
Once the team was satisfied with the extraction proce-
dure, one researcher performed the data extraction in
the whole sample. When there was doubt or ambiguity,
this was reviewed by the second extractor and a consen-
sus was reached.
Data extraction
Data were extracted on one primary outcome per
report, defined as that specified by the authors or, if not
specified, the outcome used in sample size calculations.
If no primary outcome was specified and no sample size
calculation was reported, the first outcome presented in
the abstract or manuscript was considered as primary.
Information was collected on the type of cluster, the
type of primary outcome (binary, continuous and cate-
gorical), whether a harm outcome was investigated29
and the type of intervention given in the control arm
(placebo, standard care or active). Information on the
level of adherence (cluster level or individual level) was
also recorded. Non-adherence was considered to be at
the cluster level if the treatment received was different
from that assigned for all the participants within clus-
ters, and it was considered to be at the individual level
if the treatment received differed from the allocated
treatment on an individual basis within the same
cluster.
In addition, data on total number of clusters and
individuals randomised and analysed were extracted as
well as numbers of clusters and individuals receiving
the allocated treatment. We defined treatment non-
adherence as discrepancy between the allocated course
of treatment and the actual treatment received.8
Descriptions of treatment adherence, including intra-
cluster correlation coefficient for treatment adher-
ence,17 were also recorded, when reported. We also
recorded information on adherence-adjusted analyses
and whether clustering was accounted for.
We adapted the definitions by Dodd et al.8 and
extracted data about the duration of the intervention.
A ‘one-off’ intervention is defined as that which is
received at a single time point, for example, a surgery.
A ‘short-term’ intervention is defined as an intervention
implemented at different time points over a short
period; for example, five training sessions on the impor-
tance of breastfeeding over 1 week. Any other recurrent
intervention over an extended period of time was classi-
fied as a ‘long-term’ intervention.
Analysis
Simple analyses were performed to describe the fre-
quency of adherence-reporting and the reported meth-
ods used to adjust for non-adherence. The median (and
the first and third quartiles) of the number of clusters
and individuals randomised, on treatment and ana-
lysed, is provided.
For the percentage of non-adherence, we used the
author-reported non-adherence when this was reported
numerically. If not, we calculated the percentage of
non-adherence for each study, from the data provided
in the manuscript (the ratio between ‘off allocated treat-
ment’ participants to the total number randomised).
Results
After excluding seven reports that used only sub-
samples of cluster trials data and two crossover trials,
our final sample included 123 cluster trials. See the
flowchart (Figure 1). During the validation phase, the
two extractors had an initial agreement of 93%, ulti-
mately achieving consensus by discussion.
Trial characteristics
Trial characteristics are shown in Table 1. Interventions
were mainly concerned with changing healthcare prac-
tices (63 trials, 51%), educational practices (27 trials,
Figure 1. Flow diagram of the identification process for the
sample of 123 cluster trials included in this review.
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22%) or lifestyle (25 trials, 20%). In most trials, stan-
dard care was used as the control intervention (96 trials,
76%). The primary outcome was either continuous (65
trials, 53%) or binary (57 trials, 46%), with one excep-
tion (multi-category). Adverse events were investigated
in 12 trials (10%).
The intervention was implemented exclusively at the
cluster level in 65 trials (53%) and at the individual level
in 58 trials (47%). Long-term interventions were the
most common (83 trials, 68%), followed by short-term
interventions (35 trials, 28%). The majority of the stud-
ies were two-arm trials (106 trials, 86%). The median
(first–third quartiles) number of clusters randomised in
each trial arm was 12 (7–24), and the number of clusters
per trial arm ranged from 2 to 199. The number of indi-
viduals per cluster had a median (first–third quartiles)
of 27 (10–65) with a range of 2–14,350.
Intention-to-treat analysis was done as primary
analysis in 119 trials (97%), with the remaining 4 trials
(3.2%) using per protocol or as treated analysis. Only 6
trials (5%) used cluster-level analysis (primary outcome
defined at the cluster level) while the remaining 117
trials used individual-level analysis. Among these, clus-
tering was not accounted for in 12 trials (10%) (see
Table 2).
The reporting and handling of non-adherence
Sixty-one reports (50%) included information on
adherence: full adherence was reported in five trials
while the remaining 56 trials reported some form of
non-adherence to the allocated treatment. Table 3
reports the adherence characteristics of these trials. The
reporting of adherence was more frequent in interven-
tions of short duration (57%) compared to those of
long duration (47%). Forty-four trials (72%) used a
binary treatment adherence definition, with only one
report justifying the threshold used for this dichotomi-
sation. Only 5 trials (8%) recorded non-adherence as a
continuous variable, while the remaining 12 trials
(20%) gave no details on the definition of adherence
used. Only 11 trials (9%) provided a flowchart with
complete information on how many clusters and/or
individuals received the assigned treatment. Nine trials
reporting non-adherence performed adverse events
analysis. Non-adherence at the cluster level was
reported in 15 trials (24%), with a further 4 (6%) stud-
ies reporting full cluster adherence. Non-adherence at
the individual level was reported in 41 trials, represent-
ing 71% of the 58 trials reporting treatment non-
adherence at the individual level, while 1 trial (2%)
reported full adherence. No study reported the use of
an intra-cluster correlation coefficient for adherence.
Adherence by allocated groups. Active group: 5 studies pro-
vided the percentage of cluster-level non-adherence,
with a median (first–third quartiles) of 44.8% (33%–
50%), with a further 10 reporting cluster non-adherence
without further details. At the individual level, 30
(73%) out of 41 studies reported this, with a corre-
sponding median (first–third quartiles) of 15% (9%–
24%).
Control group: adherence to the control protocol was
less frequently reported; 5 trials stated full adherence,
while a further 15 studies reported some form of non-
adherence. Cluster-level non-adherence was reported in
one trial, while full adherence was reported in a further
four trials. At the individual level, 19 trials reported
control-treatment non-adherence, with full adherence
in 1 study.
Adherence-adjusted analyses. Fifteen trials performed per
protocol analyses, with the remaining four studies




Type of intervention, n (%)
Healthcare practice 63 (51.2)
Lifestyle changes 25 (20.3)
Educational 27 (22.0)
New drug 5 (4.1)
Vaccination/screening 3 (2.4)
Type of control intervention, n (%)
Standard practice 94 (76.4)
Active control 27 (22.0)
Placebo 2 (1.6)




Investigation of adverse events 12 (9.8)
Number of trial arms, n (%)
2 106 (86.2)
3–4 17 (13.8)
Level of intervention, n (%)
Cluster level 65 (52.8)
Individual level 58 (47.2)
Unit of analysis, n (%)
Clusters 6 (4.9)
Individuals 117 (95.1)
Length of intervention, n (%)
One-off 5 (4.1)
Short term 35 (28.4)
Long term 83 (67.5)




Cluster size, median (first–third quartiles)a 27 (10–65)
Rangea 2–14,350
Primary analysis population, n (%)
Intention-to-treat 119 (96.8)
Per protocol/as treated 4 (3.2)
aBased on the average number of individuals per cluster reported in
each trials.
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carrying out as treated analyses either as primary or
secondary analyses. No study reported the complier
average causal effect estimate. Among the nine studies
with a safety outcome, four trials performed a per pro-
tocol analysis,31,33–35 with a further trial using an as
treated analysis.36 Two studies did not account for clus-
tering in their adherence-adjusted analyses.31,32 No
study reported the assumptions necessary for their
adherence-adjusted analyses to be unbiased causal treat-
ment estimates. In any case, none of these studies was
double-blinded. We summarise some of the characteris-
tics of these adherence-adjusted analyses in Table 4.
Discussion
This is the first systematic review of reporting practices
of non-adherence with randomised treatment in cluster
randomised trials. Our findings show that about half of
the studies include information on treatment adherence,
but details on numbers of clusters and individuals that
adhered to the intended treatment are often incomplete.
Schulz and colleagues50,51 found that trials reporting
exclusions after treatment initiation (i.e. deviations
from protocol) tend to be of higher methodological
quality than those that did not report it. This is known
as the ‘exclusion paradox’. It is, therefore, possible that
those studies that did not report on adherence also
experienced protocol deviations. On this basis, we esti-
mate that in this study the proportion of trials with
non-adherence lies within the range 23%–94% at the
cluster level and 71%–98% at the individual level. In
addition, we found that studies tended to report more
often adherence at the individual level. This potential
under-reporting may be due to the complexity of defin-
ing adherence in cluster trials and that as cluster trials
are often pragmatic in nature, recording adherence to
treatment protocol is not often a primary concern.
Among the studies reporting non-adherence, only
one-third specified departures from protocol in the con-
trol group. This has to be interpreted in light of the fact
that in our review, ‘usual care’ was used as control in
approximately three quarters of studies and that defin-
ing and measuring adherence to ‘usual care’ may be dif-
ficult or impractical. In general, the nature of the
departures from protocol was very poorly reported,
and it was not possible to ascertain whether alternative
treatments to those in the trial, that is, not originally
included in the design of the study, were taken.
Knowledge of the alternative regimes followed by those
individuals who did not adhere to their allocated treat-
ment is important if we want to judge the impact of
such non-adherence on the causal interpretation of an
intention-to-treat analysis. If no external treatments are
available, then the intention-to-treat estimate will be
diluted towards the null, when compared with the true
treatment effect. Moreover, the reported non-adherence
details (numbers initiating and completing the treat-
ment protocol, period of discontinuation, etc.) were
often inadequate for a meaningful interpretation of the
study results.
All of the studies reporting adherence-adjusted esti-
mates performed per protocol or as treated analyses,
without discussing the plausibility of the necessary
assumptions for the results to be interpretable as
Table 2. Analysis methods stratified by unit of analysis.
Cluster-level analysis Individual-level analysis
Methods of analysis 6 (100) 117 (100)
Generalised estimating equations – 27 (23.1)
Mixed effects models – 55 (47.0)
Repeated measures analysis of variance – 5 (4.3)
Generalised linear model with sandwich variance – 16 (13.7)
Chi-square accounting for clustering – 1 (0.8)
Survival analysis accounting for clustering – 1 (0.8)
Other methods ignoring clusteringa – 12 (10.3)
Weighted regressionb 1 (16.7) –
Other methods without weightinga 5 (83.3) –
Methods of analysis when non-adherence was addressed 1 (100) 18 (100)
Generalised estimating equations – 4 (22.2)
Mixed effects models – 9 (50.0)
Generalised linear model with sandwich variance – 4 (22.2)
Poisson regression ignoring clusteringc – 1 (5.6)
Unweighted t-testd 1 (100) –
The numbers in brackets are the column percentages.
aGeneralised linear model, analysis of variance, analysis of covariance, t-test, Mann–Whitney U test and Chi-square test.
bNumber of events (cluster size) used as weights.30 The use of weights is applicable when cluster-level summaries analysis is performed while
accounting for clustering may be required for individual-level analysis.
ct-test with multiple testing adjustment but ignoring clustering was applied to perform a per protocol analysis at individual level.31
dPer protocol analysis with unweighted t-test comparing rates at cluster level.32
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unbiased causal estimates. These ‘unadjusted’ analyses
rely on the assumption that the association between
treatment received and outcome is completely uncon-
founded.7,9 Since this assumption is very strong, we
would advise adjusting for measured confounders in a
‘modified’ per protocol analysis (as suggested by
Hernán and Robins11), thus relying instead on the ‘no
unobserved confounding’ assumption. Moreover, in
the context of randomised trials, randomised treatment
is very plausibly a valid instrumental variable, and the
monotonicity assumption may sometimes hold by
design, for example, where the experimental interven-
tion is not available to the controls. These assumptions
are sufficient to identify the CACE, allowing the ana-
lyst to obtain causal effects in the presence of unob-
served confounding. In the absence of complex
interactions between compliance classes at the cluster
and individual level, statistical methods to estimate
CACEs accounting for the clustering in the data could
be used (See Box 1). However, no report included in
this review performed a complier average causal effect.
Comparison with previous studies
A previous systematic review including 152 cluster trials
published between 1997 and 2000 found that non-
Table 3. Reporting of non-adherence by length of intervention, randomised arm and level of adherence.
One-off Short term Long term Total
Reporting of any non-adherence, n (%) 5 (100) 35 (100) 83 (100) 123 (100)
Non-adherence reported in both active and control groups – 4 (11.4) 16 (19.3) 20 (16.2)
Non-adherence reported in active group only 2 (40.0) 15 (42.9) 19 (22.9) 36 (29.3)
Non-adherence reported in control group only – – – –
Full adherence reported - 1 (2.9) 4 (4.8) 5 (4.1)
Not reported 3 (60.0) 11 (31.4) 36 (43.4) 50 (40.6)
Unclear – 4 (11.4) 8 (9.6) 12 (9.8)
Trials with adherence at cluster level 2 (100) 21 (100) 42 (100) 65 (100)
Non-adherence reported in both active and control groups – – 1 (2.4) 1 (1.5)
Non-adherence reported in active group only – 9 (42.9) 5 (11.9) 14 (21.5)
Non-adherence reported in control group only – – – –
Full adherence reported – 1 (4.7) 3 (7.1) 4 (6.2)
Not reported 2 (100) 9 (42.9) 29 (69.1) 40 (61.6)
Unclear – 2 (9.5) 4 (9.5) 6 (9.2)
Trials with adherence at individual level 3 (100) 14 (100) 41 (100) 58 (100)
Non-adherence reported in both active and control groups – 4 (28.6) 15 (36.6) 19 (32.8)
Non-adherence reported in active group only 2 (66.7) 6 (42.9) 14 (34.1) 22 (38.0)
Non-adherence reported in control group only – – – –
Full adherence reported – – 1 (2.4) 1 (1.7)
Not reported 1 (33.3) 2 (14.3) 7 (17.1) 10 (17.2)
Unclear - 2 (14.3) 4 (9.8) 6 (10.3)
Percentage of non-adherence at cluster levela
Total number of trials reporting non-adherence, n (%) – 9 (100) 6 (100) 15 (100)
Trials reporting % of non-adherence in active group, n (%) – 2 (22.2) 3 (50.0) 5 (33.3)
Median % of non-adherence in active groupb – 37.4 (30–44.8) 50 (33–80) 44.8 (33–50)
Percentage of non-adherence at individual level
Total number of trials reporting non-adherence, n (%) 2 (100) 10 (100) 29 (100) 41 (100)
Trials reporting % of non-adherence in active group, n (%) 2 (100) 7 (70.0) 21 (72.4) 30 (73.2)
Median % of non-adherence in active groupb 16.5 (0.5–32.4) 13.7 (5.3–25) 15 (10–20) 15 (9–24)
Total number of trials reporting non-adherence, n (%) 2 (100) 10 (100) 29 (100) 41 (100)
Trials reporting % of non-adherence in control group, n (%) – 3 (30.0) 11 (37.9) 14 (34.1)
Median % of non-adherence in control groupb – 8.1 (1.7–32) 8.2 (3.4–20) 8.2 (3.4–20)
Total number of trials, n (%) 5 (100) 35 (100) 83 (100) 123 (100)
Flowchart with adherence information 1 (20.0) 4 (11.4) 6 (7.2) 11 (8.9)
Flowchart without adherence information 1 (20.0) 19 (54.3) 65 (78.3) 85 (69.1)
No flow char 3 (60.0) 12 (34.3) 12 (14.5) 27 (22.0)
Adherence type, n (%)c 2 (100) 20 (100) 39 (100) 61 (100)
Binary adherence 2 (100) 14 (70.0) 28 (71.8) 44 (72.1)
Continuous adherence – 2 (10.0) 3 (7.7) 5 (8.2)
Unclear – 4 (20.0) 8 (20.5) 12 (19.7)
Trials using adherence-adjusted methods, n (%) 1 (100) 4 (100) 14 (100) 19 (100)
Per protocol 1 (100) 4 (100) 10 (71.4) 15 (78.9)
As treated – – 4 (28.6) 4 (21.1)
aNo report provided non-adherence % at cluster level in the control group.
bNumbers in brackets are the first and third quartiles.
cTotal number of trials reporting non-adherence or full adherence.
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adherence was reported in about 24% of the studies.52
For individual randomised trials, Dodd et al.,8 in a
review of 100 trials published in 2008 in five leading
medical journals, found this to be 98%. In contrast, the
review performed by Zhang et al.,26 which considered
individual randomised drug trials published in 2010,
found a prevalence of non-adherence reporting of 46%.
Both of these results are thus in line with the lower and
upper bounds found in our study. These two previous
individually randomised trials reviews noted a lack of
justification in the threshold used in defining a binary
measure of non-adherence.8,26 In the present review,
only one justified this choice.
The median percentage of individual-level non-
adherence reported by the cluster trials included here
was 13%. Similar median percentages of non-adherence
were found in previous reviews of adherence in indivi-
dually randomised trials, 10%–20% in Dodd et al.8
and 11.6% in Zhang et al.26 While the latter reported
finding a monotonic trend of adherence with regard to
intervention duration,26 we did not find any such trend.
This could be because adherence was not clearly
reported in over 40% of both long- and short-term
interventions. In fact, in view of the ‘exclusion para-
dox’, non-adherence with short-term interventions
could be as high as the non-adherence reported in long-
term interventions.
Only 3% of the studies included in the present
review presented an adherence-adjusted analysis as
primary, with the great majority reporting an
intention-to-treat approach. Of those studies assessing
treatment efficacy, per protocol analysis was the most
used. Dodd et al.8 also found that the majority of stud-
ies attempting to adjust for non-adherence in an analy-
sis used per protocol.
Although the extended CONSORT statement for
cluster randomised trials53,54 recommends reporting the
numbers of clusters and individuals randomised and
receiving their assigned treatment, we found that the
reporting of these numbers in the flowchart was low
(9%). This is in contrast to the results reported by
Dodd et al.,8 who found that 58% stated the number
of participants actually initiating their allocated treat-
ment. A possible explanation may be the lower adher-
ence to CONSORT guidelines among cluster trial
reports,27 as well as the extra complexities of defining,
measuring and recording adherence at both levels.
Strengths and limitations
The cluster trials database used for this review was
identified using a rigorous electronic search procedure
previously published.28 This search strategy was cali-
brated with a previously published one,55 which had
been validated with an ideal set of cluster randomised
trials identified from manual examination of a large
sample of health journals and was found to have high
sensitivity (90.1%). Nevertheless, we may have missed
Table 4. Details of the adherence-adjusted analyses performed.
Study Reason Type Differences in inference
Per protocol
Acolet et al.37 Exploratory Binary PP not shown, stated similar to ITT
Auger et al.38 Unclear Binary ITT not done
Beer et al.39 Unclear Binary Evidence of effect with PP, but not with ITT
Bickman et al.40 Unclear Binary No change
Boorsma et al.33,a Unclear Binary Evidence of effect with PP, but not with ITT
Cooke et al.41 Unclear Binaryb ITT not done
Cutrer et al.42 Unclear Binary ITT not done
Dangour et al.34a Exploratory Binary No change
Estrada et al.43 Unclear Binary No change
Luoto et al.35,a Unclear Binary No change
Neuzil et al.31a,c Safety Binary No change
Smith et al.44 Additional analyses Binary No change
Tagbor et al.32,c Unclear Binaryc,d Evidence of effect with PP, but not with ITT
Taveras et al.45 Unclear Binary No change
Zurovac et al.46 Unclear Binary No change
As treated
Stiell et al.47 Additional analyses Binary No change
Zamorano et al.36,a Efficacy Binary ITT not done
LaBella et al.48 Unclear Continuous Evidence of effect with ITT, but not with AT
Levine et al.49 Unclear Continuous AT not shown
PP: per protocol analysis; ITT: intention to treat analysis.
aCarried out a safety outcome analysis.
bThe threshold chosen to define the binary non-adherence was based on a previous study.
cFailed to adjust for clustering in the analysis.
dAll possible definitions of binary adherence explored (. 1 dose, .2 doses and full exposure).
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some cluster randomised trials, as reports may fail to
clearly identify the cluster randomisation design in
either title or abstract.
Our inclusion criteria were broad, and thus our sam-
ple should be representative of the quality of conducting
and reporting of cluster trials. The included reports were
published in 2011, but we do not expect a change in prac-
tice for adherence reporting, as the updated CONSORT
statement for cluster trials54 was available in pre-print
form since 2010 and did not contain any new guidelines
with regards to adherence reporting or handling over and
above those included in the 2004 version.53
As with reviews of this nature, our assessments were
based only on the information included in the trial
reports. It is possible that non-adherence is more com-
mon but under-reported, the so-called exclusion para-
dox.50,51 We calculated ranges of non-adherence to
reflect this possibility.
Another possible limitation is the use of a single
reviewer for data extraction. However, single-reviewer
extraction was only carried out after a validation
phase, where a second reviewer conducted extraction.
Agreement between the two extractors was high during
validation. In addition, during full-extraction, whenever
there was ambiguity, the second reviewer’s opinion was
sought and disagreements were resolved by consensus.
Conclusion
Non-adherence with allocated treatment is common in
cluster randomised trials, but it is not sufficiently well
reported. Our study suggests that cluster-level non-
adherence is less common than individual-level non-
adherence. However, after taking into consideration
possible under-reporting, the overall level of non-
adherence in cluster randomised trials may well be com-
parable with that previously observed in individually
randomised trials,8 weakening the claim that a cluster
randomisation design improves treatment-adherence.1
A greater effort should be made to improve the quality
of reporting of adherence data and analyses. When under-
taking causal analyses as part of a cluster randomised trial
with non-adherence, researchers should consider carefully
the assumptions necessary for their analyses to result in
valid inferences and discuss their plausibility in the context
of their trial. Sensitivity analyses should be undertaken
when departures from these assumptions are suspected. It
is also important to remember that in cluster randomised
trials, the validity of the results also relies on obtaining an
appropriate estimate for the standard errors, for which it
is crucial to use a method that correctly models the depen-
dence structure of the data.
Methodologists should make existing causal methods
that accommodate the clustering more widely available
and easy to implement in commonly used software. To
promote their use in practical applications, methodolo-
gists should also publish more tutorial papers describing
clearly the assumptions needed and detailing the chal-
lenges of performing such adherence-adjusted analyses
in the context of a good empirical example.
We conclude by making some recommendations for
trialists conducting cluster randomised trials (see Box 2).
Box 2. Guidelines for analysing and reporting cluster randomised trials with non-adherence to treatment.
1. Report how adherence to treatment is defined and measured. Describe adherence at the cluster and individual level. If
dichotomised, justify the choice of threshold made. These choices should be pre-specified in the protocol.8
2. Where there is interest in the causal treatment effect, this should be stated clearly in the trial protocol, prior to data
collection.
3. Adherence measures should be collected alongside other trial data.
4. Report the number of clusters and individuals that received the intended treatment in each trial arm.54
5. Details of the planned causal analyses should be included in the statistical analysis plan, in advance of receiving the data.
6. Efforts should be made in the statistical analysis to reduce any bias introduced by the fact that treatment received may be
associated with other variables affecting the outcome.
7. Choose a statistical method that relies on a set of plausible assumptions for the trial at hand and interpret non-adherence
adjusted analyses as explanatory.
8. Discuss the assumptions necessary for the chosen analysis method to result in unbiased causal treatment effect estimates and
their plausibility in the context of the cluster trial being analysed and reported.
9. In particular, the use of per protocol analysis must be supported by an explanation of why it is reasonable to assume that the
group of participants and clusters who did and did not deviate from their allocated treatment are equivalent. If a set of
baseline or post-randomisation variables available is believed to be sufficient to adjust for the confounding, a ‘modified’ per
protocol analysis may be valid.10,11
10. If clusters or individuals are excluded from analyses, describe whether the fraction excluded is similar between arms and that
the included groups were comparable at baseline.7
11. Use a method that accounts for clustering adequately. Principal stratification can be used to estimate the complier average
causal effect while accounting for clustering; alternatives include multilevel mixture models17 and Bayesian hierarchical
models.14 Alternatively, instrumental variable methods can use sandwich variance estimation, which is robust to clustering.18
12. Sensitivity analyses should be considered when the assumptions necessary for the primary causal analysis are likely to be
violated.16,18
13. A discussion of potential bias introduced by assumptions’ violations in any of the causal analyses should be included in the
published report.
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Previous recommendations for conducting and report-
ing adherence analyses for individually randomised
trials are still relevant.8 A new framework for the con-
duct and interpretation of randomised trials in the pres-
ence of treatment non-adherence has been recently
published, and we encourage the readers to follow these
guidelines as much as possible.56
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Estimating cluster-level local average
treatment effects in cluster randomised
trials with non-adherence
Schadrac C Agbla,1 Bianca De Stavola2 and Karla DiazOrdaz1
Abstract
Non-adherence to assigned treatment is a common issue in cluster randomised trials. In these settings, the efficacy
estimand may also be of interest. Many methodological contributions in recent years have advocated using instrumental
variables to identify and estimate the local average treatment effect. However, the clustered nature of randomisation in
cluster randomised trials adds to the complexity of such analyses. In this paper, we show that the local average treatment
effect can be estimated via two-stage least squares regression using cluster-level summaries of the outcome and
treatment received under certain assumptions. We propose the use of baseline variables to adjust the cluster-level
summaries before performing two-stage least squares in order to improve efficiency. Implementation needs to account
for the reduced sample size, as well as the possible heteroscedasticity, to obtain valid inferences. Simulations are used to
assess the performance of two-stage least squares of cluster-level summaries under cluster-level or individual-level non-
adherence, with and without weighting and robust standard errors. The impact of adjusting for baseline covariates and of
appropriate degrees of freedom correction for inference is also explored. The methods are then illustrated by re-
analysing a cluster randomised trial carried out in a specific UK primary care setting. Two-stage least squares estimation
using cluster-level summaries provides estimates with small to negligible bias and coverage close to nominal level,
provided the appropriate small sample degrees of freedom correction and robust standard errors are used for inference.
Keywords
Cluster randomised trials, non-adherence, local average treatment effect, instrument variable, cluster-level analysis
Introduction
Cluster randomised trials (CRTs), which randomise groups of individuals, are common in public health and
primary care. The adoption of this design is often justified given the reduction of ‘cross-over contamination’
between the experimental arms and improved adherence with allocated treatment.1–3 Nevertheless, treatment
non-adherence is as common in CRTs as it is in individually randomised trials.4 Dealing with non-adherence is
more challenging because there are at least two levels at which deviations from protocol can occur, e.g. cluster or
individual level.5 We say that adherence is at the cluster level if all individuals within a cluster receive the treatment
the cluster was randomised to. In contrast, we say that adherence is at the individual level, if the treatment received
varies across individuals within the same cluster, so that some individuals received the treatment allocated to their
cluster, while others did not.
The standard analysis of randomised clinical trials is intention-to-treat (ITT), which compares average
outcomes across randomised groups. However, if the effect of treatment received is confounded, in the sense
that there are measured and unmeasured common causes of receiving treatment and experiencing the outcome, the
ITT provides the causal effect of being offered, rather than of receiving the treatment. An ITT analysis with poor
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adherence may dilute a true treatment effect.6 Recently, there has been an increased interest in estimating other
estimands alongside the ITT, as highlighted by the International Council for Harmonisation addendum to
guideline E9 (Statistical Principles for Clinical Trials). Amongst them, the causal effect in those adhering to
treatment has been singled out as being of interest for patients.7
In the presence of unmeasured confounding, instrumental variable (IV) methods can estimate consistently the
causal effect of an exposure under certain assumptions.8,9 An IV is a variable which is correlated with the exposure
but is not associated with any confounders of the exposure–outcome association, nor is there any pathway by
which the IV affects the outcome, other than through the exposure.
Since randomised treatment is usually a valid instrument, IV methods have been proposed to estimate the
treatment causal effect in the context of randomised clinical trials affected by non-adherence.10,11 The population
to which an IV estimate applies, however, depends on the assumed behaviour of the instrument.9 When, as it is
often the case, randomised treatment influences treatment received monotonically,9 in the sense that the level of
treatment received is greater when randomised to treatment, than when randomised to the control (the precise
technical definition will be given shortly), IV methods lead to estimating the causal effect among the adherers,
known as the local average treatment effect (LATE) or complier-average causal effect.
This estimand can be estimated via the ratio estimator or the two-stage least squares (TSLS) approach.12 The
latter consists of a ‘first stage’, which regresses treatment received on randomised treatment, and a ‘second stage’,
which models the outcome on the predicted treatment received. Additional covariates can be included in each stage
to control for measured confounding or increase precision. The regression coefficient for the predicted treatment
received in the second stage model is a consistent estimator of the LATE, provided that the first stage model is a
linear regression, containing all the variables appearing in the second stage.13,14
Extensions of this approach for the estimation of LATE in CRTs have been proposed, ranging from a TSLS of
individual-level data with variance inflation by the design effect factor15 to multilevel mixture models that include
the latent compliance class membership as a regressor and a random effect for cluster.16,17 An alternative approach
suggested by Schochet18 constructs Wald-type ratio estimators using cluster-level (CL) summaries for both
treatment received and outcome.
In this paper, we focus on TSLS estimation applied to CL outcome summaries. Similar to Schochet,18 this
approach exploits well-known methods from CL analysis, which consist of calculating for each cluster a relevant
summary measure of the individual-level outcomes, such as means or proportions, and then analysing these using
appropriate statistical methods, such as regression. Because each cluster provides only one data point, the units of
analysis can be considered to be independent, but the procedure is inefficient.19 Estimation by weighted least
squares, where the weights are defined either by the cluster size or by the so-called minimum variance weights, can
improve the efficiency.15 Comparing these alternative estimation strategies for the implementation of TSLS
estimation using CL data is the focus of this paper. We also demonstrate that using individual-level covariate-
adjusted cluster summaries in the (weighted) TSLS regression can increase efficiency.
The rest of the paper proceeds as follows: ‘Methodology’ section provides an overview of CL analysis methods,
defines the estimand of interest and the LATE and introduces the identification assumptions and the different CL
TSLS approaches. The finite-sample performance of the methods considered is evaluated using Monte Carlo
simulations, presented in ‘LATE for CL data’ section. In ‘Simulation study’ section, we illustrate the methods
by re-analysing the TXT4FLUJAB trial, a UK-based CRT evaluating the effectiveness and efficacy of text
messaging influenza vaccine reminders in increasing vaccine uptake amongst patients with chronic conditions.20
We conclude with a ‘Discussion’ section.
Methodology
Consider a two-arm CRT, with n participants, indexed by i, in J clusters, indexed by j, each of size nj. Let Zj
denotes the binary treatment randomly allocated at the CL with probability 0.50. Let Yij denotes the continuous or
binary outcome, and Dij 2 f0, 1g be the treatment received by individual i in cluster j. Let Wj and Xij be baseline
covariates at CL and individual level, respectively (which can be vectors of variables).





hereafter referred to as the unadjusted CL (unCL) outcome. Analogously, let Dj denotes the unCL





In the CL adherence settings, Dij is constant within clusters, and therefore Dj is binary. In contrast, when non-
adherence is at the individual level, Dj is a continuous measure that varies from 0 to 1, representing the proportion
of individuals receiving the active treatment in cluster j.
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CL analysis
The unCL analysis uses simple CL summary statistics as the outcomes in subsequent analyses. Let 2 denotes the
variance of Yij, which can be decomposed as 




 is the between-cluster variance and 
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variance of Yj is











2 þ 2ðnj  1Þ
nj
¼ 2
1þ yðnj  1Þ
nj
  ð1Þ
where we have used the fact that y ¼ 
2
=
2 in the last equality.21
Since CL outcomes are continuous regardless of whether the original variable was binary, they can be thought
to be approximately normally distributed provided nj is sufficiently large. Thus, a linear regression with CL
outcome Yj as dependent variable and Zj as the explanatory variable can be fitted to estimate the ITT effects.
In the simplest setting without adjustment for other covariates, we have
Yj ¼ 0 þ ZZj þ j ð2Þ
where j is a random error term, assumed to be independently and identically distributed (i.i.d.), with mean 0. The
ITT is estimated by Z.
Efficiency is gained by estimating this model using generalised least squares, with the weights being either the




1þ yðnj  1Þ
When y  0, minimum-variance weights are approximately equivalent to cluster size weights, while if y  1,
minimum-variance weights are approximately 1.21 These equivalences can have practical implications when the
variance of j cannot be consistently estimated, for example if the number of clusters is small, so weighting by the
cluster size or even no weights are viable alternatives. Where clusters are large, weighting by cluster size is
inefficient.23
Since the j can be heteroscedastic especially when cluster sizes are very imbalanced, the standard errors (SE)
should be obtained using a method that takes this into account, such as the Huber–White SE24 which are
consistent when there is heteroscedasticity.25
Finally, because each cluster now contributes only one observation, inference should be based on the number of
clusters J. Therefore, if p is the number of parameters being estimated, hypothesis tests and confidence intervals
(CIs) should be based on appropriate distributions, for example tJp and not on normal-based approximations.
We refer to this as small-sample degrees of freedom (SSDF) correction. Where J is sufficiently large (>40), normal
approximations are adequate.
Regression analyses of CL summary outcomes can only adjust for CL covariates directly, as using CL
summaries for individual-level regressors is not appropriate.15 However, where there is interest in adjusting for
baseline covariates at the individual level, whether for scientific reasons or to increase statistical efficiency, this can
be done through a two-step procedure.26 First, an individual-level regression analysis of the outcome is performed
incorporating all the relevant covariates into the regression model except for the treatment indicator and ignoring
clustering, e.g. with only one covariate Xij, we have
Yij ¼ 0 þ 1Xij þ e1ij ð3Þ







These are then used as CL outcomes in any subsequent analyses. See Appendix 1 for the formulation for binary
outcomes.
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We refer to these summaries as adCL outcomes. Regression models involving them can also be estimated by
generalised least squares, with inference based on normal approximations or Huber–White SEs and/or SSDF
corrections, as before. Of note, if CL covariates are used to compute adCL outcomes, the degrees of freedom must
be further reduced by the number of CL regressors used to obtain the CL outcome. No such adjustment is
necessary for individual-level variables.26 In this work, we only use adCL outcomes obtained by adjusting for
individual-level variables. In the remainder, we denote the CL summary outcomes by Yj, whether they are unCL or
adCL, will be clear from the context.
LATE for CL data
Notation and technical assumptions
Denote by Yijðdj Þ the potential outcome that would manifest if, possibly contrary to fact, the jth cluster
to which the individual belongs receives treatment dj, a vector of length nj of 0s and 1s, where we are
assuming no interference between clusters, i.e. the potential outcomes and potential treatment received of
individuals in the jth cluster are unrelated to the treatment status of individuals in other clusters.5
‘No interference between clusters’ is a special case of partial interference, where individuals can be partitioned
into groups such that interference does not occur between individuals in different groups but may occur between
individuals in the same group.27 This is commonly assumed in clustered randomised trials.16,17 We also assume
counterfactual consistency: for j ¼ 1, . . . , J, if Zj¼ z, then Dij ¼ DijðzÞ, Yij ¼ Yijðz,DijðzÞÞ and Yij ¼ Yijðd Þ for all
i ¼ 1, . . . , nj and z and d.
The consistency assumption implies that the outcome realised under observation of treatment at level d will
equal the potential outcome under a hypothetical intervention to set treatment to value d, regardless of the nature
of this hypothetical intervention, in what is called ‘treatment-variation irrelevance’.28,29 More precisely, if we index
the different ways of setting the treatment at level d by kd, the consistency assumption says that Yij ¼ Yijðd, kd Þ, if
Dij¼ dij, no matter the value of kd.
Estimand of interest and identification assumptions
Assuming no interference between clusters and consistency allows us to define the estimand of interest, the LATE.8
In the setting considered here, where both Zj and Dij are binary, the vector of potential treatment received under
alternative random allocation, ðDijð0Þ,Dijð1ÞÞ partitions the participants into four different compliance classes:
30
Cij ¼ n (never-takers) if Dijð0Þ ¼ Dijð1Þ ¼ 0; Cij ¼ a (always-takers) if Dijð0Þ ¼ Dijð1Þ ¼ 1; Cij ¼ c (compliers) if
DijðzÞ ¼ z for z 2 f0, 1g and Cij ¼ d (defiers) if DijðzÞ ¼ 1 z for z 2 f0, 1g.
The estimand of interest here is the so-called population LATE, defined as






i¼1 fYijð1,Dijð1ÞÞ  Yijð0,Dijð0ÞÞgfIðDijð1Þ ¼ 1,Dijð0Þ ¼ 0ÞgPJ
j¼1
Pnj
i¼1 IðDijð1Þ ¼ 1,Dijð0Þ ¼ 0Þ
ð4Þ
This is said to be a ‘local’ causal effect as it is conditional on the stratum of complier individuals.
Following Schochet and Chiang,5,31 we write the cluster version of the corresponding identification
assumptions9 as follows:
A1. CL unconfoundedness: Zj??DijðzÞ,Yijðz,DijðzÞÞ, z 2 f0, 1g:
This is also known as cluster randomisation assumption and is often stated in terms of the cluster
randomisation to treatment being independent of measured and unmeasured confounders of the relationship
between the treatment-received and the outcome. In the context of cluster randomised trials, we know this
holds by design.
A2. Exclusion restriction at the individual level: Conditional on the treatment received Dij ¼ d, the treatment
assignment Zj has no effect on the outcome. In terms of potential outcomes, we have
Yij 1, dð Þ ¼ Yij 0, dð Þ, 8d 2 f0, 1g
A3. Instrument relevance: Also referred to as first stage assumption:
Zj is causally associated with treatment received Dij, i.e. Zj 6??Dij.
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We remark that in the standard TSLS literature, a weaker version of the assumption A3 is made instead, namely
that the instrument Z and treatment received D are only associated, but not necessarily causally. Denote this
assumption by A3’. In the causal inference literature, an ‘associational’ instrument is known as proxy or surrogate
instrument. Now, if Z and D are associated but not causally associated, there exists a common cause V, which is
the causal instrument, and may be unobserved. In order to define, identify and interpret the LATE causally, under
A1, A2 and A3’, we further require that Z is conditionally independent from D and Y given V and that V is binary.
We refer the interested reader to Hernàn and Robins32 for further details.
For point identification of local treatment effects, A4 monotonicity of the treatment mechanism is often
assumed: Dijð1Þ  Dijð0Þ. In the case of a causal binary instrument, as randomised treatment, the monotonicity
asumption implies that there are no individuals who would have received the active treatment when randomised to
control (Z¼ 0) and not received it when randomised to it. This assumption is often referred informally to as ‘there
are no defiers’.8 We remark that the definition and interpretation of the monotonicity assumption is also more
complex in non-causal instrument settings.33 The monotonicity assumption is often justified by design, when the
active treatment is not available to those in the control group. Where this is not the case, the investigators have to
argue carefully why monotonicity is still plausible.
We also remark that in the case of CL randomisation, but with individual-level non-adherence, we need to
assume that monotonicity holds at the individual level.31 For the CL non-adherence setting, where Dij does not
vary within clusters, then this becomes monotonicity at the CL, i.e. Dj (1)¼ 1 and Dj (0)¼ 0.
An extra assumption necessary when using adCL is that the model used to derive them is correctly specified.
Cluster and individual-level non-adherence
The population-level LATE estimand 	 can be thought of as a weighted average of the cluster-specific LATE 	j for
















IðDijð1Þ ¼ 1,Dijð0Þ ¼ 0Þ
oh i ð6Þ
with nc,j is the number of individual-level compliers in each cluster j, assumed here to be >0 for all clusters. The




, i.e. the number of cluster-specific compliers divided by the total
number of compliers.
This result is useful when interpreting the estimates obtained using CL summaries. We first note that the Wald
ratio estimand applied to CL summaries, 	CL, does not always correspond to the population LATE 	. The former
can be expressed as5
	CL ¼
E½Yj jZj ¼ 1  E½Yj jZj ¼ 0
E½Dj jZj ¼ 1  E½Dj jZj ¼ 0
ð7Þ
In the case where treatment received is at the CL (i.e. CL adherence), this CL Wald estimand indeed can be
interpreted as the population LATE.
In the case where non-adherence varies at the individual level, it can be shown that 	CL ¼
PJ
j¼1  CL,j	j where




, i.e. the normalised proportion of individual compliers in each cluster.31 So,
CL–LATE 	CL identifies the population LATE, equation (5), only if (i) the cluster sizes nj are identical for all j or
(ii) the cluster-specific LATEs 	j are the same across all clusters, i.e. 	j ¼ 	, for all j 2 f1, . . . , Jg.
In the remainder, with individual-level non-adherence, we assume that every cluster has the same cluster-specific
LATE, but allow for the cluster sizes to vary. If this is not the case, the CL–LATE 	CL identifies a weighted
average of the heterogeneous cluster-specific LATE because of clusters with the same proportions of compliers are
weighted the same, without accounting for the cluster size.
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TSLS for CL data
The conditional expectations appearing in the Wald estimand (equation (7)) can be estimated via standard TSLS
regression of the CL summaries (referred to as CL–TSLS). CL–TSLS is most easily explained for settings without
weights or covariate adjustment. The first stage fits a regression to CL treatment received Dj on treatment assigned
Zj. Then, in a second stage, a regression for the CL outcome on the predicted treatment received is fitted. This can
use either unCL summaries or adCL summaries if there are baseline individual-level variables predictive of the
outcome, as this can help gain efficiency. Crucially, both first and second stages must be linear models for the




Yj ¼ 	0 þ 	IVbDj þ !2j ð8Þ
where !1j and !2j are assumed i.i.d. with mean zero and constant variance and such that !1j??!2j. The estimate of
CL–LATE is then given by 	̂IV.
The asymptotic variance of this estimator is given by
cCovðY,E½DjZÞcCovðD,E½DjZÞ, where we assume that CovðD,E½DjZÞ 6¼ 0.
Assuming that the residuals from the second stage  ¼ Y E½Y  	IVD E½DjZÞ are such that E½
2jZ ¼ z ¼ 2Y,
the asymptotic variance of the IV estimator simplifies to 2ðD>PZDÞ
1, where PZ is the projection matrix
PZ ¼ ZðZ
>ZÞ1Z>Z. See Imbens and Angrist8 for further details. These variance estimators are used in most
commonly used software implementations of TSLS.






Yj ¼ 	0 þ 	IVD̂j þ 	WWj þ 2j
ð9Þ
where the error terms are as before.
As with the CL estimation of ITT, where the number of clusters is small, the CIs are constructed using a t
distribution with degrees of freedom equal to J – p, where p is the number of parameters estimated by the second
stage (i.e. the SSDF correction). As before, minimum-variance or cluster size weights can be used to increase
efficiency. Finally, the error terms in the CL–TSLS are assumed to be homoscedastic. Where this is not a sensible
assumption, Huber–White SEs should be used.35
Simulation study
We now perform a simulation study comparing the finite sample performance of TSLS estimation applied to CL
data. We simulate CRT individual-level data assuming that the control group does not have access to the active
intervention, referred to as one-way non-compliance, at either CL or individual level. In this setting, there are only
two compliance classes: compliers and never takers. With a fixed expected total sample size equal to 1000, we vary
the number of clusters J and the average cluster size nj. The marginal ICC of Y also takes two values. The effect of
individual and CL variables on the outcome and the treatment received also varies, so that the strength of the
confounding is either low or high, while the value of the true LATE also has two levels. Table 1 summarises the
factorial design and the values taken by the different levels.
More specifically, we simulate cluster randomised treatment Zj  Bernð0:5Þ and two independent baseline
covariates, a CL covariate Wj  Nð0, 
2
WÞ and individual-level covariate Xij  Nð0, 
2
XÞ with a moderate ICC





We then generate a binary adherence class indicator variable Cij, which is considered as latent. Let Cij¼ 1 for
the compliers, 0 otherwise. For settings where adherence is at the CL, this is constant within clusters, under the
following model
Cij ¼ Cj  Bernðj Þ with j ¼ PðCj ¼ 1Þ
logitðj Þ ¼ 0 þ WWj,
with W ¼ 0:05 equivalent to an odds ratio (OR)  1:05 per unit increase in W (denoted ‘small effect’) and
W ¼ 0:7 equivalent to OR  2 (‘large effect’).
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For settings with individual-level adherence, the data generating model is
Cij  BernðijÞ with ij ¼  ¼ PðCij ¼ 1Þ
logitðijÞ ¼ 0 þ WWj þ XXij þ j
j  Nð0, 
2
 Þ
with 2 ¼ 






We derive treatment received at the individual level as
Dij ¼ CijZj
so that those individuals in clusters randomly allocated to control have always control treatment, but those in
clusters randomised to the active intervention can switch to the control treatment, depending on their adherence
class. We finally generate continuous outcome Yij, under the exclusion restriction assumption
Yij ¼ 	0 þ 	CCij þ 	CZCijZj þ 	WWj þ 	XXij þ j þ ij ð10Þ
with j  Nð0, 
2
Þ and ij  Nð0, 
2




 are chosen, such that the marginal ICC for Y
has the corresponding value according to the simulated scenario, given that VarðYijÞ ¼ 
2 ¼ 1.
For simplicity, but without loss of generality, we assume that there is no direct effect of complying on the
outcome, and thus 	C ¼ 0, so that the mean potential outcome in the control never-takers is equal to the mean
potential outcome of the control compliers and thus complying with the control treatment has no effect on the
outcome. Since 	CZ 6¼ 0, there is a non-zero effect of complying with the active arm (i.e. receiving active
treatment). The choice of 	C does not affect our estimation, as the effect of 	C (and the intercept 	0) cancels
out for the average treatment effect in the compliers and non-compliers, respectively.
The choice of the parameters’ values is reported in Table 1.
Table 1. Factorial design of the data generating processes and values taken by the parameters in the simulations.
Parameter Label Level Value
CRT size
N Total number of individuals Moderate  1000
J Number of clusters and Moderate clusters J ¼ 50, nj  Poið20Þ
nj individuals per cluster Few large clusters J ¼ 10, nj  Poið100Þ
Baseline variables
Wj CL variable – Wj  Nð0, 0:08Þ
X ICC for Xij Moderate 0.05
Xij Individual-level variable – Xij ¼ Xj þ eij,Xj  Nð0, 0:004Þ,
eij  Nð0, 0:076Þ
Adherence to treatment
Expected probability of adherence Moderate 0.60 (CL adherence)
0.85 (individual-level adherence)
W, X Wj and Xij effects on log odds of adherence Small W ¼ 0:05, X ¼ 0:05
Large W ¼ 0:70, X ¼ 0:70
Cj CL adherence class – Bern [expitð0 þ WWj Þ
Cij Individual-level adherence class – Bern [expitð0 þ WWjþ XXij þ j)]
j CL random effects – j  Nð0,
2=3Þ
C ICC for Cij Moderate 0.50
Outcome
	0 Intercept 	0¼ 0
	C Effect of complying amongst controls 	C¼ 0
	W, 	X Wj and Xij effects on outcome Yij Small 	W¼ 0.1 , 	X¼ 0.1 
Large 	W¼ 0.4 , 	X¼ 0.4 
	CZ True LATE Small, Large 0.1 , 0.4 
Y ICC for Yij Small, Large 0.05, 0.20
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We need the data generating process to result in randomised treatment Z being a valid IV, but with this choice of
parameters, some combinations may result in weak instruments, for example, CL non-adherence settings, with only
five clusters per arm, and the proportion of non-adherent clusters set at 40% (the median proportion of non-adherent
clusters reported in Agbla and DiazOrdaz4 being 44.8%). Thus, after creating each dataset, we perform an unadjusted
first stage regression of Dj on Zj and reject simulated datasets where the resulting Fstatistic is <10 (Staiger and
Stock’s rule of thumb for weak instruments36). We continue this process until we have 2500 datasets per scenario.
Estimation in each scenario involves using unCL summary of treatment received in the first stage, and either
unadjusted or individual-level variable adCL summary outcomes, for the second stage. Each regression in the
TSLS was fitted via ordinary least squares or generalised least squares, the latter with either cluster size or
minimum-variance weights. We also consider TSLS where each stage model is either unadjusted or adjusted for
a CL variable. Finally, we obtain SEs assuming homoscedasticity or Huber–White SEs and SSDF-based or
normal approximation CIs. A summary is given in Table 2. Details of the Stata code used for analysis are
found in the online Appendix.
The performance criteria used are empirical bias and coverage rates of the 95% CIs over the 2500 replicate
datasets per scenario. For the bias, we construct a 95% CI using the Monte Carlo errors. The coverage rate
sampling error, given the size of the simulation, results in a valid range between 94.1 and 95.9%. See Appendix 2
for the formal definitions.
Results
We present the results by plotting the empirical bias with the Monte Carlo error-based CIs. The coverage rate valid
range is represented by horizontal-dashed lines.
Figures 1 and 2 report the empirical bias and 95% CI coverage resulting from each of the different CL–TSLS
estimators, when adherence is at CL or individual level, respectively, and for scenarios where the true LATE is
large. The corresponding figures for small true LATE are shown in Appendix 4 (Figures 7 and 8).
Each figure reports results where J¼ 10 (Panel A, top) or J¼ 50 (Panel B), and with the ICC for Y, Y is either
small (first three columns) or large (last three columns). In each cell, the results for alternative combinations of
TSLS (unadjusted/adjusted for Wj) applied to unCL or adCL outcomes are plotted along the horizontal axis. The
different data generation scenarios are identified by , þ , and 	, corresponding to varying strengths of the
effects of X and W on Y.
We see that all CL–TSLS estimators show some finite sample bias in settings where the number of clusters is
small (J¼ 10, Panel A), regardless of whether the non-adherence was at the cluster or individual level and whether
the CL summary for Y was adjusted or unadjusted or Wj was included or not in the TSLS regressions. However,
the Monte-Carlo error CIs includes 0 in many settings. The bias is more severe when the ICC for Y is larger (right
hand side of each figure). The bias is somewhat attenuated when we adjust for Wj in the TSLS, and the non-
adherence is at the CL (Figures 1 and 7). In contrast, for settings with individual-level non-adherence, this
adjustment instead increases the bias, especially if W has only a small confounding effect. In these scenarios,
the estimates exhibit a small but statistically significant bias, which disappears when the number of clusters is
larger (Figures 2 and 8). In general, the bias is not affected by the choice of weighting strategy nor by whether Y is
small or large. The bias is negligible for settings where the number of clusters is moderate or large (J¼ 50).
Comparing the results of the second, third and fourth rows in each panel (Figures 1 and 2), we see that the
coverage rate is affected by the choice of SE estimation and also by whether SSDF correction is used. When the
Table 2. Overview of TSLS estimation and inference strategies used in the simulation study.
Analyses strategy Levels
CL outcome Unadjusted Adjusted for Xij
TSLS adjusted for Wj No Yes
Least square method Ordinary Weighted
Weights (if using) CS MV
SE estimation Normal theory HW SE
SSDF correction No Yes
CL: cluster level; HW: Huber–White; CS weights: cluster-size weights; MV: minimum variance; SE: standard error; SSDF: small sample degrees of
freedom correction.
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(a)
(b)
Figure 1. Bias (top row) and 95% CI coverage (rows 2–5) of CL-LATE with CL non-adherence and large true LATE. Data generation
scenarios represented by , þ ,, and 	. Estimates are obtained via unadjusted or W-adjusted TSLS with different weights (none,
cluster size (CS), and minimum-variance (MV)) (by column) using CL unadjusted or adjusted for X outcomes (‘‘unCL’’ or ‘‘adCL’’).
Small (J¼ 10) and large (J¼ 50) number of clusters results are shown in Panels A and B.
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(a)
(b)
Figure 2. Bias (top row) and 95% CI coverage (rows 2–5) of CL-LATE with individual-level non-adherence and large true LATE. Data
generation scenarios represented by , þ ,, and 	. Estimates are obtained via unadjusted or W-adjusted TSLS with different weights
(none, cluster size (CS) and minimum-variance (MV)) (by column) using CL unadjusted or adjusted for X outcomes (‘‘unCL’’ or
‘‘adCL’’). Small (J¼ 10) and large (J¼ 50) number of clusters results are shown in Panels A and B.
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number of clusters is small, an SSDF correction must be used as failing to do so results in under-coverage (Panel
A). The low coverage is more serious when TSLS adjusts for W (second and fourth set of results in each panel).
Overall, the results in Panel A of each figure show that coverage is closer to the nominal levels when using SSDF
correction when constructing CIs (third and fifth rows). Using Huber–White SE or not has little to no impact if
there is no SSDF correction. However, the SSDF correction for the CIs resulting from a TSLS using unCL
outcomes can lead to under-coverage, as shown in the specific case with CL non-adherence, large Y and large
true LATE, but where only X is strongly associated with Y (Figures 1 and 7, third and fifth rows of Panel A, right-
hand side columns, scenario represented by in the plots). The use of adCL outcomes (i.e. where the CL outcome
is the residual after adjusting for individual-level variable X) recovers coverage to values close to nominal. This is
not the case when the non-adherence is at the individual level, and both W and X are confounders in the data
generating process.
In both cluster and individual-level non-adherence settings, it can be seen that using minimum-variance weights
increases the coverage by a small fraction, when compared with cluster size weights, especially for scenarios with
J¼ 50 and large Y. However, since minimum-variance weights require an estimate of the CL variance, and this is
badly estimated when the number of clusters is small (J¼ 10), we can see that the minimum-variance weights are
less efficient than using either no weights or cluster-size weights. This is most clearly seen when no Huber–White
SE correction has been used.
We can also see that when SSDF correction is used, then not using Huber–White SE can result in small over-
coverage especially for CL non-adherence settings, which is improved when Huber–White SE are used (Figures 1
and 7, third and fifth rows of Panel A). When J¼ 50 (Panel B), the use of SSDF-based distributions is not expected
to make any material difference, and this is indeed the case. The impact of using Huber–White SE or the different
weighting strategies is also minimal.
Additional simulations
Two extra additional scenarios are now considered to investigate the sensitivity of the CL–TSLS performance to
number of clusters and cluster-size imbalances, at both CL and individual-level adherence, but focusing on settings
where confounding is strong with a large true LATE.
In the first additional simulation, we explore the impact that the outcome ICC and the number of clusters have
on bias, while leaving the expected total sample size fixed (¼ 1000).
We consider two marginal ICC for Yij (Y ¼ 0:05 and Y ¼ 0:80) and three average cluster sizes (nj¼ 20,
10 and 2.5, corresponding to whether the number of clusters varied from J¼ 50, 100 or 400), which includes
one of the scenarios previously considered in the main simulations for comparison. Although CRTs rarely
have ICCs above 0.10,37 the value of Y ¼ 0:80 is included to evaluate the performance of the methods in
extreme settings.
In the second additional set of simulations, we explore the effect of high cluster-size imbalances. While keeping
the average sample size equal to 1000, and J¼ 10 or 50, we create high cluster size imbalance using a Pareto
distribution to generate the cluster sizes.38 The Pareto distribution parameters are chosen so that approximately
40% of the clusters have a size below 15, and 60% a size above 15, while the average cluster size is 20 and the
minimum cluster size is 10, resulting in approximately 1.8 for the shape and 9.1 for the scale.
Results
Figures 3 and 4, corresponding to CL and individual-level non-adherence settings, show that for a fixed number of
clusters (cells in the same row), the bias increases with increasing ICC for Y, but that as the number of clusters
increases (moving down the column in the figure), CL–TSLS results in negligible mean bias, even a very large Y. It
is well known that TSLS is only asymptotically unbiased, and with CL analyses, we expect the asymptotics to
depend on the number of clusters and not the number of individuals. Nevertheless, the CL-summaries treated as
outcomes for the two models involved in TSLS contain less ‘information’ when the ICC is higher, which translates
into a larger number of clusters being necessary for the bias to be negligible.
The impact of high cluster size imbalance is reported in Figures 5 and 6, where non-adherence is at the CL and
individual level, respectively. We see that even with the use of Huber–White SE, failure to do SSDF correction
results in under-coverage, especially when Y is large. Looking at Panel B in Figure 6, we can see that using cluster-
size weights results in even lower coverage. This is because cluster-size weights are known to perform well when the
CL residuals are homoscedastic, which is unlikely when cluster sizes are very imbalanced.15 The use of SSDF
correction brings the coverage close to nominal levels.
Agbla et al. 11
Illustrative example
We now illustrate the methods in practice by applying each in turn to the analysis of the TXT4FLUJAB trial. This
was a CRT of general practices (GP) in England aiming at estimating the effect of text messaging influenza vaccine
reminders on increasing vaccine uptake in patients with chronic conditions, carried during the 2013 influenza
season.20 GPs were stratified by the type of software used for text messaging and randomised to either standard
care (control group, 79 GPs and 51,136 patients) or a text messaging campaign (active group, 77 GPs and 51,121
patients). Practices were not blinded to their allocation. GPs were the unit of analysis, and the outcome of interest
was the proportion of influenza vaccine uptake at the GP level.
Influenza vaccination within the GPs was automatically recorded in the clinical system from which the data
were extracted, so there are no missing data.
Since non-adherence was anticipated, the original statistical analysis plan specified obtaining by IV regression
an efficacy estimate at the GP level.20 The original publication reported an estimated increase in vaccine uptake
from texting reminders of 14.3% (95% CI: –0.59%–29.2%),20 after dichotomising adherence at the CL as either
100% of eligible patients, compared with texting 5100%.
Adherence to the intervention at the individual level could not be measured for all practices because it was
recorded in a usable form only for GPs using a specific software. Therefore, for these re-analyses, we restrict the
dataset to 116 GPs (58 in the intervention and 58 in the standard care arm) for which individual-level adherence
data are available. Six of the 58 practices (10%) in the intervention arm did not send any reminders. Conversely, 21
of the 58 practices (36%) in the standard care arm actually sent a reminder to at least one patient. Hence non-
adherence is two-sided. It also varies at the individual level. The median (range) of percentage of non-adherence at
the GP level was 0 (0–78.4%) and 21.0% (0–83.5%) in the control and active group, respectively (Table 3).
Figure 3. Bias of the CL-LATE for the extra simulation where non-adherence is at the CL and a large true LATE, with high ICCs and
varying numbers of clusters. Estimates are obtained via unadjusted or adjusted TSLS with different weights (none, cluster size (CS) and
minimum-variance (MV)). Number of clusters varies by rows and ICC by column.
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The characteristics of the GPs and of the patients included in these analyses are comparable across trial groups
(Table 3); further, the marginal ICC for individual-level outcome (vaccination) and treatment received (text
message reminder) was 0.03 and 0.84 on the log-odds scale, respectively.
For our re-analysis, we begin by discussing the plausibility of the necessary assumptions.
First, the consistency assumption in this setting implies that the means of sending and receiving the text
message, as well as the timings are irrelevant, in the sense that all of these would lead to the same observed
outcome. So whether the text was pre-programmed, or sent by a doctor or a nurse, or received in the morning or at
night or weekend, it would have the same effect of either getting the patient to be vaccinated, or not, irrespective of
any of these factors. This seems a reasonable assumption for this intervention.
In contrast, there is a small risk of interference. The cluster defined by GP practice should minimise this, as we
only need to assume no interference at the CL, but it could be plausible that patients interact with those outside
their GP, so that the exposure to a text message reminder of one patient may indeed affect the potential outcome,
in this case, influenza vaccination of another patient from a different GP. The risk is small as usually close family
members belong to the same GP.
Now, regarding the identification assumptions, we note that the unconfoundedness of the CL randomised
treatment assumption is satisfied by design. To check whether cluster randomisation is a relevant instrument,
we perform a test on the first stage of the CL–TSLS. The corresponding F-statistic is Fð1, 114Þ ¼ 28:74 10, thus
passing Staiger and Stock’s rule of no null first-stage.36
The exclusion restriction at the individual level implies that there is no other mechanism by which the GP being
randomised to sending text vaccination reminders can affect a patient’s actual vaccination uptake beside via the
sending of the message. This assumption needs further justification, as in principle, a GP randomised to send
reminders can be more conscious of the risks the patients face during the influenza season and use other means to
Figure 4. Bias of the CL-LATE for the extra simulation where non-adherence is at the individual-level and a large true LATE, with
high ICCs and varying numbers of clusters. Estimates are obtained via unadjusted or adjusted TSLS with different weights (none,
cluster size (CS) and minimum-variance (MV)). Number of clusters varies by rows and ICC by column.
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(a)
(b)
Figure 5. Extra simulation for very imbalanced cluster size settings. Bias (top row) and 95% CI coverage (Huber–White SEs (or not)
and SSDF corrections (or not)) of the CL-LATE where non-adherence is at the CL, and a large true LATE. Estimates are obtained via
unadjusted or adjusted TSLS with different weights (none, cluster size (CS), and minimum-variance (MV)). Small and large number of
clusters results appears in Panels A and B, respectively.
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(a)
(b)
Figure 6. Extra simulation for very imbalanced cluster size settings. Bias (top row) and 95% CI coverage (Huber–White SEs (or not)
and SSDF corrections (or not)) of the CL-LATE where non-adherence is at the individual-level, and a large true LATE. Estimates are
obtained via unadjusted or adjusted TSLS with different weights (none, cluster size (CS), and minimum-variance (MV)). Small and large
number of clusters results appears in Panels A and B, respectively.
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remind at-risk patients, either in person, by post or by putting out flyers and posters in the clinic. So,
it is possible that there are patients who do not receive text reminders and yet are prompted to get vaccinated
by other means, by virtue of their practice being in the active group. However, flyers, posters and postal letters
already form part of regular care, so we believe they do not really vary by whether the GP is randomised to the
active group.
Finally, the monotonicity assumption (that there are no defiers) also seems plausible as GPs randomised to the
active group were more likely to send a text message reminder than those in the control group (see Table 3).
CL–TSLS on unCL outcomes was implemented adjusting and not adjusting for a baseline CL covariate, namely
whether the clinic was open on the weekends (yes/no). Table 4 shows the CL–LATE estimates (expressed as mean
risk differences), with 95% CIs and p-values obtained via different weighting strategies and corrections.
Using cluster-size weights results in different point estimates from the rest. This was expected as there is
substantial cluster-size imbalance (cluster size range: 148–1678 in the control group and 79–3022 in the active
group (Table 3)). The results obtained using no weights or minimum-variance weights lead to point estimates that
are very close to those found in the original publication.20





pLATE (95% CI) LATE (95% CI)
No weighting None 0.149 (0.006, 0.305) 0.060 0.148 (0.078, 0.303) 0.063
HW 0.149 (0.006, 0.305) 0.060 0.148 (0.005, 0.301) 0.058
SSDF 0.149 (0.009, 0.308) 0.065 0.148 (0.012, 0.308) 0.069
SSDF þ HW 0.149 (0.009, 0.308) 0.065 0.148 (0.009, 0.305) 0.064
Cluster size weights None 0.071 (0.065, 0.207) 0.307 0.074 (0.061, 0.209) 0.284
HW 0.071 (0.088, 0.230) 0.382 0.074 (0.077, 0.225) 0.338
SSDF 0.071 (0.068, 0.209) 0.313 0.074 (0.064, 0.212) 0.292
SSDF þ HW 0.071 (0.091, 0.233) 0.388 0.074 (0.081, 0.228) 0.346
Minimum-variance weights None 0.143 (0.008, 0.293) 0.064 0.142 (0.009, 0.293) 0.065
HW 0.143 (0.006, 0.291) 0.060 0.142 (0.005, 0.289) 0.058
SSDF 0.143 (0.011, 0.296) 0.069 0.142 (0.012, 0.297) 0.071
SSDF þ HW 0.143 (0.009, 0.294) 0.065 0.142 (0.008, 0.293) 0.064
Weighting strategy SE and correction Unadjusted p Adjusteda p
LATE (95% CI) LATE (95% CI)
aAdjusted for whether clinic is opened during weekends.
HW: Huber-White; SSDF: small sample degrees of freedom.
Table 3. Baseline characteristics and percentages of non-adherence for the TXT4FLUJAB trial.
Characteristics Control Active
Practice-level characteristics
Number of practices, n (%) 58 (100.0) 58 (100.0)
Open on weekends, n (%) 39 (67.2) 37 (63.8)
Patients per practice, median (range) 660 (148–1678) 684 (79–3022)
Patient-level characteristics
Number of patients, n (%) 40633 (100) 41073 (100)
Male, n (%) 20 752 (51.1) 21 012 (51.2)
Has any disease, n (%) 39244 (96.6) 39672 (96.6)
Age, median (range) 50 (18–64) 50 (18–64)
Active treatment received
Patients receiving text message reminders, n (%) 2628 (6.5) 11113 (27.1)
Practices sending text message reminders, n (%) 21 (36.2) 52 (80.7)
% of patients in each GP receiving reminders, median (range) 0 (0–78.4) 21.0 (0–83.5)
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In terms of inference, the use of SSDF correction in calculating CIs is not important, as the number of clusters
is large, but the Huber–White SEs paired with minimum-variance weighting provides efficiency gains, especially
for the adCL–TSLS analyses. Overall, however, the CIs are still very wide.
These results suggest that there is some evidence that receiving a text reminder increases the expected
proportion of patients within a compliant practice that get vaccinated against influenza by 14% (95% CI: –0.5
to 29.3%, p¼ 0.058, based on the adCL–TSLS using minimum-variance weights and normal-based CI with
Huber–White SEs estimate).
Contrast this with the unCL-summaries mean risk difference ITT estimate, which indicates a 2.89% increase
(95% CI: –0.17–5.95, p ¼ 0:064Þ, highlighting the dilution effects deriving from the non-adherence.
One of the disadvantages of TSLS is lack of efficiency. Adjusting for individual-level baseline covariates may help
obtaining narrower CIs. Since CL–TSLS cannot adjust for individual-level covariates, we now perform the analyses
using adCL summary outcomes, generated by adjusting for gender, age and the presence of disease. Results are
reported in Table 6 in Appendix 3. The results do not materially change (weak evidence of a 13% increase
vaccination uptake), possibly because these individual-level covariates are not strongly associated with the outcome.
The illustrative example shows the importance of choosing and pre-specifying the TSLS analysis according to
the trial characteristics. In the example, the choice of weights changed the point estimate to such an extent that the
small evidence in support of treatment benefit disappeared completely. So, if the trial has very imbalanced cluster
sizes, Huber–White corrections can help for the SEs, but the point estimates may be biased, if large clusters are
somewhat atypical.
Our application is limited by the availability of baseline CL variables. Since there was only one CL variable
recorded, the impact of covariate adjustment on the CL–TSLS is negligible. Other limitations of these results
include the possibility of measurement error, for if patients received their influenza vaccine outside the practice,
this would not have been recorded in the system, unless the patient informed their GP.
Discussion
This paper demonstrates the use of TSLS regression applied to CL summaries (CL–TSLS) as a simple and valid
method for obtaining estimates of the LATE in CRTs where non-adherence occurs at either the CL or the
individual level. To improve the efficiency of CL–TSLS estimates, we proposed adjusting for baseline variables;
if these are CL, in the TSLS regression, while if these are individual level, by adjusting the CL-summary outcomes
before performing TSLS. The performance of CL–TSLS regression of either adjusted or unCL-outcomes and
adjusting or not for CL-baseline variables was evaluated with different weighting strategies (none, cluster size,
minimum variance) as well as the use of different methods for constructing CIs (alternatively using or not Huber–
White SEs and/or SSDF correction) in a factorial simulation study.
We have demonstrated empirically through simulations that under the stated sufficient assumptions for
identification, TSLS regression of CL summaries provides consistent estimates of the causal treatment effect in
the sub-population of compliers, where non-adherence is at the CL. With individual-level non-adherence, the
additional assumption that the cluster-specific LATE is the same across clusters is required for CL–TSLS to
identify the population LATE.31 Moreover, provided that an appropriate distribution with SSDF adjustment is
used when the number of clusters is small and Huber–White SEs are used if there is high cluster size imbalance,
valid 95% CIs can be constructed.
Our simulation study suggests that all weighting strategies perform similarly when the number of clusters is not
small. When the number of clusters is small, minimum-variance weights tend to be badly estimated and are not
recommended; furthermore when the cluster sizes are very variable, cluster-size weights should not be used.
Although in the simulations, the choice of weights did not affect the point estimates, and these were affected in
the illustrative example. Overall, our results show that, unless there are very few clusters, or the outcome ICC is
large, minimum-variance weighting performs well.23 An overall summary of these findings in the format of
recommendations is given in Table 5.
Although CL–TSLS is easy to implement, it suffers from being very inefficient. We can see this in the illustrative
example where all CIs for the CL–TSLS LATE estimates are much wider than those for the estimated ITT. There
are two reasons for this: CL analyses are inefficient, unless the cluster sizes are (almost) equal,39 and TSLS is
known to be inefficient, although adjusting for baseline covariates can ameliorate this.14 In the context of CL
analysis, it is only possible to include CL baseline covariates in the regressions.15 However, we tested the
performance of CL outcomes which are adjusted for individual-level covariates26 and showed that this indeed
has the potential to improve efficiency in certain settings.
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For CL–TSLS analyses, inference should be based on the number of clusters, with CIs constructed by using
tdistributions with degrees of freedom equal to J – p.40 The outcome ICC value is important too, with higher
ICCs requiring a larger number of clusters for the asymptotical arguments to work as well as whether the CL
variances are homoscedastic.15
Other methods for estimating causal treatment effects in CRTs with non-adherence at the individual level exist,
in particular, Kang and Keele31 have recently proposed a finite-sample estimator that identifies the population
LATE and obtains valid inferences even when compliance is low.
We do not consider here situations where the identification assumptions are violated. There are several options
to study the sensitivity to departures from these assumptions. For example, if the exclusion restriction does not
hold, a Bayesian parametric model can use priors on the non-zero direct effect of randomisation on the outcome
for identification.41 Since the models are only weakly identified, the results depend strongly on prior distributions.
Alternatively, violations of the exclusion restriction can also be handled by using baseline covariates to model the
probability of compliance directly, within structural equation modelling via expectation-maximisation.42,43
We have only focused on LATE estimands. These are often criticised because the estimates obtained apply to
the ‘compliers’ in the population, and these cannot be observed in practice, thus limiting applicability. However,
LATE estimates may be used to provide information about the average causal effect in the entire population.44
Moreover, the average treatment effect on the compliers is often of interest to patients and medical decision
makers, especially when they expect patients to comply with the treatment.45
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If the number of clusters J is small Use small sample DF correction to improve inference
If J is small and the outcome ICC is large Adjust for CL variables in TSLS to reduce bias and improve efficiency
If an IL variable is a strong confounder Use adjusted CL-outcomes in the TSLS to improve efficiency
If CS is imbalanced Use small sample DF correction to improve inference and avoid using CS weights
At IL:
If the number of clusters J is small Use small sample DF correction to improve inference
If J is small and the outcome ICC is large avoid adjusting for CL variables
If CS are imbalanced Use small sample DF correction to improve inference and avoid using CS weights
CS: cluster sizes; CL: cluster level; DF: degrees of freedom; IL: individual level.
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Appendix 1. Adjusted CL summaries for binary data







¼ 1 þ 2Xij ð11Þ
Let Mj and M̂j be the observed and predicted number of successes in the jth cluster, respectively. After fitting







expit ̂1 þ ̂2Xij

 
Then the observed and predicted numbers of success are compared by computing a residual for each cluster. If we
want to estimate the adjusted RD, the residual, known as difference-residual, for each cluster is calculated as
ej ¼ ðMj  M̂j Þ=nj
and treated as a continuous outcome in any subsequent analyses.
Appendix 2. Performance criteria







l¼1 	̂IVl . The following criteria were used to assess the performance of the methods
investigated.
(a) Empirical bias: estimated by
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	IV  	CZ.










(c) Coverage rate of the nominal of 95% CIs 1L
PL
l¼1 Iðj	̂IVl  	CZj5 1:96siÞ, where si denotes the model-based SE
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Appendix 3. Results for adjusted CL summaries CL–TSLS for TEXT4FLUJAB
Table 6. TSLS estimation of practice-level LATE of reminder text messaging to receive flu vaccine on the percentage uptake of flu





pLATE (95% CI) LATE (95% CI)
No weighting None 0.133 (0.016, 0.282) 0.081 0.133 (0.017, 0.282) 0.082
HW (0.016, 0.282) 0.081 (0.014, 0.280) 0.077
SSDF (0.019, 0.285) 0.086 (0.021, 0.286) 0.089
SSDF þ HW (0.019, 0.285) 0.086 (0.018, 0.283) 0.083
Cluster size weighting None 0.068 (0.063, 0.198) 0.310 0.071 (0.058, 0.200) 0.280
HuberWhite (0.081, 0.216) 0.372 (0.069, 0.212) 0.320
SSDF (0.065, 0.201) 0.316 (0.061, 0.203) 0.288
SSDF þ HW (0.084, 0.219) 0.378 (0.073, 0.215) 0.328
Minimum-variance weighting None 0.128 (0.017, 0.273) 0.084 0.128 (0.017, 0.273) 0.084
HW (0.015, 0.271) 0.080 (0.014, 0.269) 0.077
SSDF (0.020, 0.275) 0.090 (0.021, 0.277) 0.091
SSDF þ HW (0.018, 0.273) 0.086 (0.017, 0.273) 0.083
aTSLS estimation was adjusted for weekend clinics (yes/no).
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Large Wj and Xij effects on Yij
Large Wj effect; small Xij effect
Small Wj effect; large Xij effect
Small Wj and Xij effects
(a)
(b)
Figure 7. Bias (top row) and 95% CI coverage (rows 2–5) of CL-LATE with CL non-adherence and small true LATE. Data generation
scenarios represented by , þ ,, and 	. Estimates are obtained via unadjusted or W-adjusted TSLS with different weights (none,
cluster size (CS), and minimum-variance (MV)) (by column) using CL unadjusted or adjusted for X outcomes (‘‘unCL’’ or ‘‘adCL’’).
Small (J¼ 10) and large (J¼ 50) number of clusters results are shown in Panels A and B.



















































































































































































































































































Large Wj and Xij effects on Yij
Large Wj effect; small Xij effect
Small Wj effect; large Xij effect
Small Wj and Xij effects
(a)
(b)
Figure 8. Bias (top row) and 95% CI coverage (rows 2–5) of CL-LATE with individual-level non-adherence and small true LATE. Data
generation scenarios represented by , þ ,, and 	. Estimates are obtained via unadjusted or W-adjusted TSLS with different weights
(none, cluster size (CS) and minimum-variance (MV)) (by column) using CL unadjusted or adjusted for X outcomes (‘‘unCL’’ or
‘‘adCL’’). Small (J¼ 10) and large (J¼ 50) number of clusters results are shown in Panels A and B.
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A.5 Choice of parameters value
To maintain the consistency of the structural model equations used in our simulations, it is nec-
essary to choose a combination or set of parameters values that are suitable. We explain here the
approximation strategy used to select the parameters value in our simulations.
1. Adherence at cluster level
Note that R and Z are independent and E(R) = π = 0.6, Var(R) = π(1 − π) = 0.24, E(Z) = 0.5
and Var(Z) = 0.25. For simplicity, we chose β0 = 0 and βR = 0.
The expectation of Vij using the structural model equation is as follows:
E(V ) = βRZE(RZ) + βWE(W ) + βBE(B) + E(υ) + E(ε)
= βRZE(R)E(Z) + βW 0 + βB0 + 0 + 0
= βRZE(R)E(Z)
(1)






ε ), ρYcon and ρYmar the conditional and






εmar ), where σ
2
υmar is the unconditional
cluster-level variance, σ2εmar the unconditional individual-level variance.
The variance of Vij , σ
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= β2RZVar(RZ) + β
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Var(R)Var(Z) + Var(R)[E(Z)]2 + Var(Z)[E(R)]2
)
+ β2WVar(W )
+ β2BρBVar(B) + β
2
B(1− ρB)Var(B) + ρVconσ2res + (1− ρVcon)σ2res
(2)





Var(R)Var(Z) + Var(R)[E(Z)]2 + Var(Z)[E(R)]2
)
+






When σ2V = 1 and βRZ = βW = βB = β, then σ
2
υmar = ρVmar and equation (2) becomes the
equation of an ellipse:
β2
(
Var(R)Var(Z) + Var(R)[E(Z)]2 + Var(Z)[E(R)]2 + Var(W ) + Var(B)
)
+ σ2res = 1 (4)
where the major radius a and minor radius b: b = 1 and
a =
[
Var(R)Var(Z) + Var(R)[E(Z)]2 + Var(Z)[E(R)]2 + Var(W ) + Var(B)
]−1/2
.
To ensure that σ2res > 0 and ρVcon > 0 across all scenarios investigated in our simulations, we chose
β = 0.1SD as small effect and β = 0.4SD as large effect, Var(W ) = Var(B) = 0.08 and Var(V ) = 1.
2. Adherence at individual level
Here, E(R) = πR = 0.85, Var(R) = πR(1 − πR) = 0.1275. Like in cluster-level adherence setting,
E(Z) = 0.5, Var(Z) = 0.25, β0 = 0 and βR = 0. Equations 1 to 2 remain the same. Because
adherence is at individual level, Var(R) = Var(Rij) = πR(1− πR) and the variance of the cluster-
specific true proportions are given by Var(πj) = ρ
Bin
R Var(R) as described in Hayes and Moulton
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ρBinR Var(R)Var(Z) + ρ
Bin
R Var(R)[E(Z)]2 + Var(Z)[E(R)]2
)
+






However, we generated Rij using random-intercept logistic regression and set an ICC for adherence
in the log-odds scale that we denoted by ρR = 0.50, implying a level-2 variance of π
2/3. Then,
we approximate the value of ρBinR using the delta method to obtain a between-cluster variance in















Therefore, we get Var(πij) =
π2
3 [πR(1− πR)]
2 ≈ 0.053 (lower than Var(R)). Using Var(πij) as the
variance of cluster-specific true proportions leads to ρBinR ≈ 0.42. Equation 4 remains applicable
to adherence at individual level setting. Choosing β = 0.1SD as small effect and β = 0.4SD as
large effect, Var(W ) = Var(B) = 0.08 and Var(V ) = 1, also ensure that σ2res > 0 and ρVcon > 0 for
across all scenarios investigated in our simulations.





















































































































A.6 Proof of “regression anatomy” formula for
OLS estimation
We re-write equation (3.3) referring to Y j simply as Yj and recall the regression model of Zj on
Wj . We consider Wj to be a single covariate here, for notation simplicity. However, the proof is
easily expendable to many covariates. Yj = α0 + αZZj + αWWj + ηj and Zj = δ0 + δWWj + εzj .
Then, εzj = Zj − δ0 − δWWj . We have by construction, Cov(Wj , ηj) = 0, Cov(Zj , ηj) = 0 and
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Cov(Wj , εzj ) = 0.
Cov(Yj , εzj )
Var(εzj )
=
Cov(α0 + αZZj + αWWj + ηj , εzj )
Var(εzj )
=
αZCov(Zj , εzj ) + αWCov(Wj , εzj ) + Cov(ηj , εzj )
Var(εzj )
=
αZCov(Zj , εzj ) + Cov(ηj , εzj )
Var(εzj )
We have Cov(ηj , εzj ) = Cov(ηj , Zj − δ0 − δWWj) = Cov(ηj , Zj)− δWCov(ηj ,Wj) = 0. Then,
Cov(Yj , εzj )
Var(εzj )
=
αZCov(Zj , εzj )
Var(εzj )
We can write Cov(Zj , εzj ) = Cov(δ0 + δWWj + εzj , εzj ) = δWCov(Wj , εzj ) + Cov(εzj , εzj ) =
Var(εzj ).
Hence,






A.7 Proof of “regression anatomy” formula for
WLS estimation
The proof is similar to A.6, but with the rescaled variables. We use here equation (3.26) where Ỹ j
is referred to as Ỹj and also the regression model of Z̃j on W̃j . Let Ωj be a variable whose values
are the square root of the weight variable ωj .
Ỹj = α0Ωj + αZZ̃j + αWW̃j + η̃j and Z̃j = δ0Ωj + δWW̃j + ε̃zj . Then, ε̃zj = Zj − δ0Ωj −
δWW̃j . By construction, Cov(Ωj , η̃j) = 0, Cov(W̃j , η̃j) = 0, Cov(Z̃j , η̃j) = 0, Cov(Ωj , ε̃zj ) = 0 and
Cov(W̃j , ε̃zj ) = 0.
Cov(Ỹj , ε̃zj )
Var(ε̃zj )
=
Cov(α0Ωj + αZZ̃j + αWW̃j + η̃j , ε̃zj )
Var(ε̃zj )
=
α0Cov(Ω̃j , ε̃zj ) + αZCov(Z̃j , ε̃zj ) + αWCov(W̃j , ε̃zj ) + Cov(η̃j , ε̃zj )
Var(ε̃zj )
=
αZCov(Z̃j , ε̃zj ) + Cov(η̃j , ε̃zj )
Var(ε̃zj )
We have Cov(η̃j , ε̃zj ) = Cov(η̃j , Z̃j−δ0Ωj−δWW̃j) = Cov(η̃j , Z̃j)−δ0Cov(η̃j ,Ωj)−δWCov(η̃j , W̃j) =
0. Then,
Cov(Ỹj , ε̃zj )
Var(ε̃zj )
=
αZCov(Z̃j , ε̃zj )
Var(ε̃zj )
We have Cov(Z̃j , ε̃zj ) = Cov(δ0Ωj + δWW̃j + ε̃zj , ε̃zj ) = δ0Cov(Ωj , ε̃zj ) + δWCov(W̃j , ε̃zj ) +
Cov(ε̃zj , ε̃zj ) = Var(ε̃zj ).
Hence,







A.8 R code for simulated CRT datasets
A.8.1 Generating CRTs with cluster-level adherence
### Upload necessary packages
library(foreign) ; library(lme4) ; library(data.table)
library(DataCombine) ; library(foreach)
### SET VALUES FOR MEANS, VARIANCES, ICC AND EFFECTS SIZE
mean.Z<- 0.5; var.W<- 0.08; var.X<- var.W; var.Y<- 1; beta.small<- 0.1
beta.large <- 0.4 ; rho.Ymar.min <- 0.05 ; rho.Ymar.max <- 0.20
### CREATE FUNCTION TO GENERATE CRT
# CRT SIZE PARAMATERS
Nsim <- NA # Number of simulations
N.mu <- NA # Total number of individual
k <- NA # Number of clusters per arm
var.Zj <- 0.25 # variance of Zj
mean.Zj <- 0.5 ; k.min <- 5 ; k.max <- 25
# BASELINE COVARIATES PARAMETERS
mu.Wj <- 0 # mean of level-2 covariate Wj
var.Wj <- NA # variance of Wj
mu.Xij <- 0 # mean of level-1 covariate Xij
rho.Xij <- 0.05 # ICC of Xij (moderate: 0.05)
var.Xij <- NA # Marginal variance of Xij
# ADHERENCE PARAMETERS
pi <- mean.C # adherence probability for cluster j (0.60)
mean.C <- 0.6
var.C <- 0.24 # variance of Cj (0.24)
lambda0 <- log(pi/(1-pi)) # intercept
lambda.W <- NA # effect of Wj (small: 0.05 ; large: 0.7)
lambda.W.min <- 0.05 ; lambda.W.max <- 0.70
# OUTCOME PARAMETERS (complier=c and never-taker=nt)
beta.0 <- 0 # never-taker clusters mean outcome in control group
beta.C <- 0 # mean difference c vs. nt in control
beta.Z <- 0 # randomisation effect in nt (ER assumption)
beta.CZ <- NA # randomisation effect in c
beta.W <- NA # change in outcome per unit increase in Wj in nt
beta.CW <- NA # change in outcome per unit increase in Wj in c
beta.X <- NA # change in outcome per unit increase in Xij in nt
beta.CX <- NA # change in outcome per unit increase in Xij in c
rho.Ycon <- NA # marginal ICC (low: 0.05 ; high: 0.20)
var.Yij <- NA # Marginal variance of Yij
var.res <- NA # Residuals variance
# DIRECTORY PATH PARAMATER
mainDir <- "H:/"
set <- "" # Scenario ID






sim <- 1 # simulation order
include <- 0 # Count number of eligible CRT (Dj != Zj)
repeat {
# Set clusters and size
set.seed(sim)
mj <- rpois(n=1:(2*k), lambda=N.mu/(2*k))
j <- rep(1:(2*k), times=mj[1:(2*k)])
Zj <- as.numeric(j>k)
N <- length(j) # Total number of individuals in CRT
# Generate level-2 and level-1 explanatory variables
Wj <- rep(rnorm(2*k, mean=mu.Wj, sd=sqrt(var.Wj))[1:(2*k)], times=mj[1:(2*k)])
Xij <- rep(rnorm(2*k, mean=mu.Xij, sd=sqrt(rho.Xij*var.Xij))[1:(2*k)],
times=mj[1:(2*k)]) + rnorm(N, mean=mu.Xij, sd=sqrt((1-rho.Xij)*var.Xij))↪→
# Generate true compliance class (compliers and noncompliers)
logit.pi.j <- lambda0 + lambda.W*Wj
pi.j <- 1/(1+exp(-logit.pi.j))
Cj <- rep(rbinom(2*k, 1, pi.j)[1:(2*k)], times=mj[1:(2*k)])
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# Generate treatment receipt Dj
Dj <- rep(NA,N)
Dj[Cj==0 & Zj==0] <- Zj[Cj==0 & Zj==0]
Dj[Cj==0 & Zj==1] <- 1-Zj[Cj==0 & Zj==1]
Dj[Cj==1 & Zj==0] <- Zj[Cj==1 & Zj==0]
Dj[Cj==1 & Zj==1] <- Zj[Cj==1 & Zj==1]
# Calculate residuals variance and conditional ICC for Y
var.res <- var.Yij - ((var.C*var.Z + var.C*mean.Zˆ2 + var.Z*mean.Cˆ2)*beta.CZˆ2 +
var.W*beta.CWˆ2 + var.X*beta.CXˆ2)↪→
rho.Ycon <- (rho.Ymar - ((var.C*var.Z + var.C*mean.Zˆ2 + var.Z*mean.Cˆ2)*beta.CZˆ2 +
var.W*beta.CWˆ2 + var.X*beta.CXˆ2*rho.Xij))/var.res↪→
# Generate Yij and Dj, ensure Zj different from Dj, replace CRT otherwise
data.Cj0 <- subset(data.frame(j,k,Cj,Zj,Dj,Wj,Xij), Cj==0)
data.Cj1 <- subset(data.frame(j,k,Cj,Zj,Dj,Wj,Xij), Cj==1)
attach(data.Cj0) ; attach(data.Cj1)
V0 <- rep(1,N)
if (all(Dj==Zj) == "FALSE" & all(Dj==0) == "FALSE" & all(Dj==1) == "FALSE" & all(Cj==V0)
== "FALSE") {↪→












data <- rbind.data.frame(data.Cj0, data.Cj1)
attach(data)
data <- MoveFront(data, c("j","k","Cj","Zj","Dj","Wj","Xij","Yij"))
subDir1 <- paste0("Scenario", " ", set)
subDir2 <- paste0("Raw")
dir.create(file.path(mainDir, subDir1, subDir2))
include <- include + 1
mydata <- file.path(mainDir, subDir1, subDir2, paste0("onesided_", set, "_", include,
".dta"))↪→
write.dta(data, file=mydata) }
sim <- sim + 1




A.8.2 Generating CRTs with individual-level adherence
# SET VALUES FOR MEANS, VARIANCES, ICC AND EFFECTS SIZE
mean.C <- 0.85 ; mean.Z <- 0.5 ; rho.C <- 0.5
var.C <- mean.C*(1-mean.C) # instead of (piˆ2/3)/(1-rho.C)
var.Z <- 0.25 ; var.W <- 0.08 ; var.X <- var.W
var.Y <- 1; beta.small<- 0.1; beta.large<- 0.4
rho.Ymar.min <- 0.05 ; rho.Ymar.max <- 0.20
### CREATE FUNCTION TO GENERATE CRT
# CRT SIZE PARAMATERS
Nsim <- NA # Number of simulations
N.mu <- NA # Total number of individual on average
k <- NA # Number of clusters per arm
k.min <- 5 ; k.max <- 25 ; mean.Zj<- mean.Z
var.Zj<- var.Z # variance of Zj
# BASELINE COVARIATES PARAMETERS
mu.Wj <- 0 # mean of level-2 covariate Wj
var.Wj <- NA # variance of Wj
mu.Xij <- 0 # mean of level-1 covariate Xij
rho.Xij <- 0.05 # ICC of Xij (moderate: 0.05)
var.Xij <- NA # Marginal variance of Xij
# ADHERENCE BEHAVIOUR PARAMETERS
pij <- mean.C # adherence probability
rho.Cij <- rho.C # ICC for adherence
var.Cij <- var.C # variance of Cj
lambda0 <- log(pij/(1-pij)) # intercept
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lambda.W <- NA # effect of Wj (small: 0.05; large: 0.7)
lambda.W.min <- 0.05 ; lambda.W.max <- 0.70
lambda.X <- NA # effect of Xij (small: 0.05; large: 0.7)
lambda.X.min <- 0.05 ; lambda.X.max <- 0.70
# OUTCOME PARAMETERS (complier=c; never-taker=nt)
beta.0 <- 0 # nt's mean outcome in control group
beta.C <- 0 # mean difference c vs. nt outcome in control
beta.Z <- 0 # randomisation effect in nt (ER assumption)
beta.CZ <- NA # randomisation effect in c
beta.W <- NA # change in outcome per unit increase in Wj in nt
beta.CW <- NA # change in outcome per unit increase in Wj in c
beta.X <- NA # change in outcome per unit increase in Xij in nt
beta.CX <- NA # change in outcome per unit increase in Xij in c
rho.Ycon <- NA # marginal ICC (low: 0.05 ; high: 0.20)
var.Yij <- NA # Marginal variance of Yij
var.res <- NA # Residuals variance
# DIRECTORY PATH PARAMATER
mainDir <- "H:/"
set <- "" # Scenario ID
# CREATE FUNCTION TO SIMULATE CRTs
CRT.1SidIndAdh <- function(set,N.mu,k,Nsim,lambda.W,lambda.X,beta.CZ,beta.W,beta.CW,
beta.X,beta.CX,rho.Ymar,var.Yij,var.Wj,var.Xij,var.Cij,rho.Xij,rho.Cij) {↪→
sim <- 1 # simulation order
include <- 0 # Count number of eligible simulated data (Dij different from Zj)
repeat {
# Set clusters and size
set.seed(sim)
mj <- rpois(n=1:(2*k), lambda=N.mu/(2*k))
j <- rep(1:(2*k), times=mj[1:(2*k)])
Zj <- as.numeric(j>k)
N <- length(j) # Total number of individuals in CRT
# Generate level-2 and level-1 explanatory variables
Wj <- rep(rnorm(2*k,mean=mu.Wj,sd=sqrt(var.Wj))[1:(2*k)],times=mj[1:(2*k)])
Xij <- rep(rnorm(2*k, mean=mu.Xij, sd=sqrt(rho.Xij*var.Xij))[1:(2*k)],
times=mj[1:(2*k)])+rnorm(N,mean=mu.Xij,sd=sqrt((1-rho.Xij)*var.Xij))↪→
# Generate true compliance class (compliers and noncompliers)
zeta.j <- rep(rnorm(2*k,mean=0,sd=sqrt((rho.Cij*var.Cij))),times=mj[1:(2*k)])
logit.pi.ij <- lambda0 + lambda.W*Wj + lambda.X*Xij + zeta.j
pi.ij <- 1/(1+exp(-logit.pi.ij))
Cij <- rbinom(N, 1, pi.ij)
# Generate treatment receipt Dij (one-sided non-adherence)
Dij <- rep(NA,N)
Dij[Cij==0 & Zj==0] <- Zj[Cij==0 & Zj==0]
Dij[Cij==0 & Zj==1] <- 1-Zj[Cij==0 & Zj==1]
Dij[Cij==1 & Zj==0] <- Zj[Cij==1 & Zj==0]
Dij[Cij==1 & Zj==1] <- Zj[Cij==1 & Zj==1]
# Calculate residuals variance and conditional ICC for Y
var.res <- var.Yij - ((var.Cij*var.Z + var.Cij*mean.Zˆ2 + var.Z*mean.Cˆ2)*beta.CZˆ2 +
var.Wj*beta.CWˆ2 + var.Xij*beta.CXˆ2)↪→
rho.Ycon <- (rho.Ymar - ((rho.Cij*var.Cij*var.Z + rho.Cij*var.Cij*mean.Zˆ2 +
var.Z*mean.Cˆ2)*beta.CZˆ2 + var.Wj*beta.CWˆ2 + var.Xij*beta.CXˆ2*rho.Xij))/var.res↪→
# Generate outcome Yij and treatment receipt and ensure Zj different from Dij, replace
datat set otherwise↪→
data.Cij0 <- subset(data.frame(j,k,Cij,Zj,Dij,Wj,Xij), Cij==0)
data.Cij1 <- subset(data.frame(j,k,Cij,Zj,Dij,Wj,Xij), Cij==1)
attach(data.Cij0) ; attach(data.Cij1)
V0 <- rep(1,N)
if (all(Dij==Zj) == "FALSE" & all(Dij==0) == "FALSE" & all(Dij==1) == "FALSE" &
all(Cij==V0) == "FALSE") {↪→














data <- rbind.data.frame(data.Cij0, data.Cij1)
attach(data)
data <- MoveFront(data, c("j","k","Cij","Zj","Dij","Wj","Xij","Yij"))
subDir1 <- paste0("Scenario", " ", set)
subDir2 <- paste0("Raw")
dir.create(file.path(mainDir, subDir1, subDir2))
include <- include + 1
mydata <- file.path(mainDir, subDir1, subDir2, paste0("onesided_", set, "_", include,
".dta"))↪→
write.dta(data, file=mydata) }
sim <- sim + 1




A.9 Stata code for CL-TSLS and Schochet-Chiang
method
Variables definition
i: Individual unit ID ; j: Cluster unit ID ; Yij : Outcome ; Dij : Treatment received ;
Wj : Baseline cluster-level covariate and Xij : Baseline individual-level covariate
A.9.1 CL-TSLS with covariate adjustment, using unadjusted
CL summaries
* Estimate marginal ICC for Yij
qui mixed Yij || j:, reml
scalar rhoY_noEs = exp(2*[lns1_1_1]_cons)/(exp(2*[lns1_1_1]_cons) +
exp(2*[lnsig_e]_cons))↪→
* Generate cluster summaries
gen clusterid = j
collapse (count) nobs=j (mean) Zj=Zj (mean) propDij=Dij (mean) meanWj=Wj (mean)
meanYij=Yij, by(clusterid)↪→
* Create minimum variance weights
gen mvw_noE = nobs/(1+rhoY_noEs*(nobs-1))
* No weighting, with Huber-White SEs and SSDF adjustment
ivregress 2sls meanYij meanWj (propDij = Zj), robust small
* Cluster size weighting, with Huber-White SEs and SSDF adjustment
ivregress 2sls meanYij meanWj (propDij = Zj) [aw=nobs], robust small
* Minimum-variance weighting, with Huber-White SEs and SSDF adjustment
ivregress 2sls meanYij meanWj (propDij = Zj) [aw=mvw_noE], robust small
A.9.2 CL-TSLS with covariate adjustment, using adjusted
CL summaries
* Generate predicted level-1 residuals adjusted for Xij, using OLS
qui regress Yij Xij
predict Ehatij, r
* Estimate marginal ICC for Ehatij
qui mixed Ehatij || j:, reml
scalar rhoEhat_noEs = exp(2*[lns1_1_1]_cons)/(exp(2*[lns1_1_1]_cons) +
exp(2*[lnsig_e]_cons))↪→
* Generate CL summaries
gen clusterid = j
collapse (count) nobs=j (mean) Zj=Zj (mean) propDij=Dij (mean) meanWj=Wj (mean)
meanEhatij=Ehatij, by(clusterid)↪→
* Create minimum variance weights
gen mvw_noE = nobs/(1+rhoEhat_noEs*(nobs-1))
* No weighting, with Huber-White SEs and SSDF adjustment
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ivregress 2sls meanEhatij meanWj (propDij = propZj), robust small
* Cluster size weighting, with Huber-White SEs and SSDF adjustment
ivregress 2sls meanEhatij meanWj (propDij = propZj) [aw=nobs], robust small
* Minimum-variance weighting, with Huber-White SEs and SSDF adjustment
ivregress 2sls meanEhatij meanWj (propDij = propZj) [aw=mvw_noE], robust small
A.9.3 Schochet-Chiang method
*** Macro for estimating CL-LATE without covariate adjustment
preserve
collapse (mean) Yij (mean) Dij, by(j Zj)
regress Yij i.Zj
matrix B_ITTy_noE = e(b)
matrix V_ITTy_noE = e(V)
regress Dij i.Zj
matrix B_ITTd_noE = e(b)
matrix V_ITTd_noE = e(V)
scalar cace = el(B_ITTy_noE,1,2)/el(B_ITTd_noE,1,2)
* Estimate variance of CACE
/* Predict cluster-level outcome and treatment receipt */
qui regress Yij i.Zj
scalar k = e(rank)
predict Yij_hat if e(sample), xb
qui regress Dij i.Zj if Yij<.
predict Dij_hat if e(sample), xb
/* Store number of clusters in control and in active group (only account for clusters
included in analysis) */↪→
qui regress Yij i.Zj if Zj==0
scalar K_control = e(N)
qui regress Yij i.Zj if Zj==1
scalar K_active = e(N)
/* Calculate variance of ITTd */
gen rsq = (Dij-Dij_hat)ˆ2
total rsq if Zj==0
scalar var_ITTd_control= el(r(table),1,1)/((K_control-k)*K_control)
total rsq if Zj==1
scalar var_ITTd_active = el(r(table),1,1)/((K_active -k)*K_active )
scalar var_ITTd = var_ITTd_control + var_ITTd_active
drop rsq
/* Calculate covariance of ITTy and ITTd */
gen ydsq = (Yij-Yij_hat)*(Dij-Dij_hat)
total ydsq if Zj==0
scalar covar_ITTyd_control= el(r(table),1,1)/((K_control-k)*K_control)
total ydsq if Zj==1
scalar covar_ITTyd_active = el(r(table),1,1)/((K_active -k)*K_active )
scalar covar_ITTyd = covar_ITTyd_control + covar_ITTyd_active
drop ydsq
/* Calculate variance of CACE */
scalar var_cace = el(B_ITTd_noE,1,2)ˆ(-2) * (el(V_ITTy_noE,2,2) + caceˆ2*var_ITTd -
2*cace*covar_ITTyd)↪→
/* Store results */
scalar se = sqrt(var_cace)
scalar ll95ci = cace - invnormal(0.975)*se
scalar ul95ci = cace + invnormal(0.975)*se
*** Macro for estimating CL-LATE with covariate adjustment
preserve
collapse (mean) Yij (mean) Dij (mean) Wj, by(j Zj)
regress Yij i.Zj Wj
matrix B_ITTy = e(b)
matrix V_ITTy = e(V)
regress Dij i.Zj Wj
matrix B_ITTd = e(b)
matrix V_ITTd = e(V)
scalar cace = el(B_ITTy,1,2)/el(B_ITTd,1,2)
* Estimate variance of CACE
/* Predict cluster-level outcome and treatment receipt */
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qui regress Yij i.Zj Wj
scalar k = e(rank)
predict Yij_hat if e(sample), xb
qui regress Dij i.Zj Wj if Yij<.
predict Dij_hat if e(sample), xb
/* Store number of clusters in control and active groups */
qui regress Yij i.Zj Wj if Zj==0
scalar K_control = e(N)
qui regress Yij i.Zj Wj if Zj==1
scalar K_active = e(N)
/* Calculate variance of ITTd */
gen rsq = (Dij-Dij_hat)ˆ2
total rsq if Zj==0
scalar var_ITTd_control= el(r(table),1,1)/((K_control-k)*K_control)
total rsq if Zj==1
scalar var_ITTd_active = el(r(table),1,1)/((K_active -k)*K_active )
scalar var_ITTd = var_ITTd_control + var_ITTd_active
drop rsq
/* Calculate covariance of ITTy and ITTd */
gen ydsq = (Yij-Yij_hat)*(Dij-Dij_hat)
total ydsq if Zj==0
scalar covar_ITTyd_control= el(r(table),1,1)/((K_control-k)*K_control)
total ydsq if Zj==1
scalar covar_ITTyd_active = el(r(table),1,1)/((K_active -k)*K_active )
scalar covar_ITTyd = covar_ITTyd_control + covar_ITTyd_active
drop ydsq
/* Calculate variance of CACE */
scalar var_cace = el(B_ITTd,1,2)ˆ(-2) * (el(V_ITTy,2,2) + caceˆ2*var_ITTd -
2*cace*covar_ITTyd)↪→
/* Store results */
scalar se = sqrt(var_cace)
scalar ll95ci = cace - invnormal(0.975)*se
scalar ul95ci = cace + invnormal(0.975)*se
A.10 Code for TSLS, Wald and Bayesian estima-
tions
A.10.1 Wald estimation with covariate adjustment for cluster-
level adherence
*** Macro for estimating IL-LATE
cap program drop illateest
program def illateest, eclass
marksample touse
/* Estimate of ITT effect on outcome as risk difference */
qui reg Yij i.Zj Wj Xij
scalar ITTy = _b[1.Zj]
/* Estimate of ITT effect on treatment received as risk difference */
preserve
egen pickonecluster = tag(j)
qui reg Dj i.Zj Wj if pickonecluster==1
scalar ITTd = _b[1.Zj]
restore
/* IL-LATE point estimate */
mat late = ITTy/ITTd
mat colnames late = "late"
eret post late, e(`touse')
eret local cmd illateest
eret display
end
*** Run Macro for estimating IL-LATE with bootstrap
use "...\dataset.dta", clear
gen id = _n
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bootstrap _b[late], cluster(j) idcluster(j_newid) group(id) strata(Z) reps(1500)
seed(123456789): illateest↪→
mat CI = e(ci_normal)
mat B = e(b)
/* Store results */
scalar LATE = B[1,1]
scalar ll95ci = CI[1,1]
scalar ul95ci = CI[2,1]
A.10.2 Wald estimation with covariate adjustment for individual-
level adherence
*** Macro for estimating IL-LATE
cap program drop illateest
program def illateest, rclass
/* Estimate of ITT effect on outcome as risk difference */
qui reg Yij i.Zj Wj Xij
matrix B_ITTy = e(b)
local ITTy = el(B_ITTy,1,2)
/* Estimate of ITT effect on treatment received as risk difference */
qui reg Dij i.Zj Wj Xij
matrix B_ITTd = e(b)
local ITTd = el(B_ITTd,1,2)
/* IL-LATE point estimate */
return scalar late = `ITTy'/`ITTd'
end
*** Run Macro for estimating IL-LATE with bootstrap
use "...\dataset.dta", clear
gen id = _n
bootstrap r(late), cluster(j) idcluster(j_newid) group(id) strata(Z) reps(1500)
seed(123456789): illateest↪→
mat CI = e(ci_normal)
mat B = e(b)
/* Store results */
scalar LATE = B[1,1]
scalar ll95ci = CI[1,1]
scalar ul95ci = CI[2,1]
A.10.3 TSLS with HWR SEs and covariate adjustment
*** Estimate IL-LATE
use "...\dataset.dta", clear
ivregress 2sls Yij Wj Xij (Dij = i.Zj), vce(cluster j)
matrix B_HWR = e(b)
matrix V_HWR = e(V)
/* Store results */
scalar LATE = B_HWR[1,1]
scalar ll95ci = B_HWR[1,1] - invnorm(0.975)*sqrt(V_HWR[1,1])
scalar ul95ci = B_HWR[1,1] + invnorm(0.975)*sqrt(V_HWR[1,1])
A.10.4 TSLS with Moulton’s SEs and covariate adjustment
*** Estimate IL-LATE
use ".../dataset.dta", clear
/* predict Y residuals and estimate its ICC */
ivregress 2sls Yij Wj Xij (Dij = i.Zj), first
predict Yres, resid
loneway Yres j
scalar rho_Yres = r(rho)
/* Fit 1st stage regression, predict Dhat and estimate ICC for Dhat */
regress Dij i.Zj Wj Xij
predict Dhat2, xb
loneway Dhat j
scalar rho_Dhat = r(rho)
/* Estimate Var(cluster size) and Mean(cluster size) */
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bysort j: egen n_j = count(Zj)
egen pickonecluster = tag(j)
sum n_j if pickonecluster, d
scalar Var_n_j = r(Var)
scalar Mean_n_j = r(mean)
/* Calculate Moulton factor */
scalar Moulton_factor = sqrt(1 + (((Var_n_j/Mean_n_j) + Mean_n_j -
1)*rho_Dhat*rho_Yres))↪→
/* Obtain SEs from conventional TSLS i.e. ignoring clustering */
ivregress 2sls Yij Wj Xij (Dij = i.Zj)
matrix B_Moulton = e(b)
matrix V = e(V)
/* Store results */
scalar LATE = B_Moulton[1,1]
scalar ll95ci = B_Moulton[1,1] - invnorm(0.975)*sqrt(V[1,1] * Moulton_factorˆ2)
scalar ul95ci = B_Moulton[1,1] + invnorm(0.975)*sqrt(V[1,1] * Moulton_factorˆ2)
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A.10.5 Bayesian multilevel mixture model with covariate
adjustment







# Set burn-in and iterations
n.chains<- 2; n.iter<- 50000; n.burnin<- 5000; n.thin <- 1
write("model {for (i in 1:Nlevel1) {
# Level-1 outcome model specification
Yij[i] ˜ dnorm(mu_Yij[i,Cij[i]],tau_Yij)
mu_Yij[i,1] <- B0[1] + b1[j[i]] + B.x[1]*Xij[i] + B.w[1]*Wj[i]
mu_Yij[i,2] <- B0[2] + b2[j[i]] + B2[2]*Zj[i] + B.x[2]*Xij[i] + B.w[2]*Wj[i]
# Level-1 compliance class model specification
Rij[i] ˜ dbern(pi[i])
pi[i] <- ilogit(A[i])





for (j in 1:Nlevel2) {










# Priors specification for outcome distribution
sigma_Yij <- 1/sqrt(tau_Yij)
tau_Yij ˜ dgamma(0.001,0.001)
# Priors specification for outcome model
A0 ˜ dnorm(0,0.001; B0[1] ˜ dnorm(0,0.001)
B0[2] ˜ dnorm(0,0.001); B2[2] ˜ dnorm(0,0.001)
A.x ˜ dnorm(0,0.001); B.x[1] ˜ dnorm(0,0.001)
B.x[2] ˜ dnorm(0,0.001); A.w ˜ dnorm(0,0.001)
B.w[1] ˜ dnorm(0,0.001); B.w[2] ˜ dnorm(0,0.001)
}", "simModel.jags")
rjags.model <- jags.model(simModel.jags", data=list(Nlevel1=Nlevel1, Nlevel2=Nlevel2, j=data$j, Zj=data$Zj, Wj=data$Wj, Xij=data$Xij, Rij=data$Rij, Yij=data$Yij), n.chains=n.chains)
rjags.par <- c("A0","B0[1]","B0[2]","B2[2]", "sigma_a", "sigma_b", "sigma_Yij")










A.11 Two-level multiple imputation codes using
the “jomo” package in R
Multilevel joint modelling multiple imputation [122,123] was used to handle missing data, assum-
ing missingness at random i.e. the probability of observing data is the same for all participants
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conditional on observed covariates and outcome variable. The multilevel multiple imputation was
carried out using “jomo” package in R [124] and done separately for the control and the active
groups. We generated a large number of imputations (250 imputed data sets) to minimise the
Monte Carlo error. We discarded the 700 000 first cycles and chose 1 000 iterations between two
successive imputations. Imputed data were exported to Stata 15 for analyses. Estimates were




data$HOME1 <− as.numeric(data$HOME=="Private & Nursing")
data$HOME2 <− as.numeric(data$HOME=="Voluntary/LA")
data.control <− subset(data, ALLOC=="Control")
data.active <− subset(data, ALLOC=="Intervention")
Nburnin <− 700000 ; Niterbtwn <− 1000 ; M <− 250
A. Convergence and imputation in control group only
Y1 <− data.frame(data.control$SPPB2, data.control$AGE,
data.control$SPPB0, data.control$MMSE0, data.control$ANTIDEP0)
X1 <− data.frame(data.control$RECEIVED, data.control$SEX,
data.control$PLACE, data.control$SIZE, data.control$HOME1,
data.control$HOME2)
clusterid <− data.control$ HOME ID
A.1. Convergence check in control group




A.2. Run imputation model in control group
imp.model.control <− jomo(Y=Y1, X=X1, clus=clusterid, nburn=Nburnin,
nbetween=Niterbtwn, nimp=M, meth="common")
imp.model.control$Z <− 0
names(imp.model.control) <− gsub("data.control.", "",
names(imp.model.control))
B. Convergence and imputation in active group only
Y1 <− data.frame(data.active$SPPB2, data.active$AGE,
data.active$SPPB0, data.active$MMSE0, data.active$ANTIDEP0)
X1 <− data.frame(data.active$RECEIVED, data.active$SEX,
data.active$PLACE, data.active$SIZE, data.active$HOME1,
data.active$HOME2)
clusterid <− data.active$ HOME ID
B.1. Convergence check in active group




B.2. Run imputation model in active group
imp.model.active <− jomo(Y=Y1, X=X1, clus=clusterid, nburn=Nburnin,
nbetween=Niterbtwn, nimp=M, meth="common")
imp.model.active$Z <− 1
names(imp.model.active) <− gsub("data.active.", "",
names(imp.model.active))




A.12 Sensitivity analyses code for the OPERA
trial
A.12.1 TSLS with Huber-White-Rogers and Moulton’s SEs
use ".../Opera.dta", clear
*** Estimate ITT effect
mixed sppb2 i.Z i.place i.size i.hometype mmse0 agebaseline i.sex sppb0 i.antidep0 ||
pat_hmeid:, reml↪→
matrix B_ITTy_E = e(b)
*** Set lambda to be 5% of ITT effect estimate
scalar lambda = 0.05*el(B_ITTy_noE,1,2)
*** Generate adjusted outcome (sppb2_adj)
gen sppb2_adj = sppb2
replace sppb2_adj = sppb2 + `lambda' *D1
*** TSLS with Huber-White-Rogers SEs
ivregress 2sls sppb2_adj i.place i.size i.hometype mmse0 agebaseline i.sex sppb0
i.antidep0 (D1 = i.Z), vce(cluster pat_hmeid)↪→
*** TSLS with Moulton' SEs
/* predict Y residuals and estimate its ICC */
ivregress 2sls sppb2_adj i.place i.size i.hometype mmse0 agebaseline i.sex sppb0
i.antidep0 (D1 = i.Z), first↪→
predict Yres, resid
loneway Yres pat_hmeid
scalar rho_Yres = r(rho)
/* Fit 1st stage regression, predict Dhat and estimate ICC for Dhat */
regress D1 i.Z i.place i.size i.hometype mmse0 agebaseline i.sex sppb0 i.antidep0
predict Dhat, xb
loneway Dhat pat_hmeid
scalar rho_Dhat = r(rho)
/* Estimate Var(cluster size) nd Mean(cluster size) */
bysort pat_hmeid: egen n_j = count(pat_id)
egen pickonecluster = tag(pat_hmeid)
sum n_j if pickonecluster, d
scalar Var_n_j = r(Var)
scalar Mean_n_j = r(mean)
/* Calculate Moulton factor */
scalar Moulton_factor = sqrt(1 + (((Var_n_j/Mean_n_j) + Mean_n_j -
1)*rho_Dhat*rho_Yres))↪→
/* Obtain SEs from conventional TSLS i.e. ignoring clustering */
ivregress 2sls sppb2_adj i.place i.size i.hometype mmse0 agebaseline i.sex sppb0
i.antidep0 (D1 = i.Z)↪→
matrix B = e(b)
matrix V = e(V)
/* Store results */
scalar LATE = B[1,1]
scalar ll95ci = B[1,1] - invnorm(0.975)*sqrt(V[1,1] * Moulton_factorˆ2)
scalar ul95ci = B[1,1] + invnorm(0.975)*sqrt(V[1,1] * Moulton_factorˆ2)
A.12.2 Bayesian multilevel mixture with local-to-0 prior














data$size <- as.numeric(data$size==">=32 beds")
data$hometype1<- as.numeric(data$hometype=="Private & Nursing")
data$hometype2<- as.numeric(data$hometype=="Voluntary/LA")
data$sex <- as.numeric(data$sex=="M")
### Set burn-in and iterations
n.chains<- 3; n.iter<- 900000; n.burnin<- 100000; n.thin<- 1
### 1. Assuming no ER and variance homogeneity across latent classes




for (i in 1:Nlevel1) {
# Level-1 missing covariates model specification in increasing order of missingness
antidep0[i]˜ dbern(pi_antidep0[i,C[i]])
pi_antidep0[i,1] <- ilogit(m1[1] + m1_b1[home_id[i]] + m1_2[1]*Z[i] + m1_3[1]*sex[i]
+ m1_4[1]*place[i] + m1_5[1]*size[i] + m1_6[1]*hometype1[i] + m1_7[1]*hometype2[i])↪→
pi_antidep0[i,2] <- ilogit(m1[2] + m1_b2[home_id[i]] + m1_2[2]*Z[i] + m1_3[2]*sex[i]
+ m1_4[2]*place[i] + m1_5[2]*size[i] + m1_6[2]*hometype1[i] + m1_7[2]*hometype2[i])↪→
age[i] ˜ dnorm(mu_age[i,C[i]],tau_age)
mu_age[i,1]<- m2[1] + m2_b1[home_id[i]] + m2_2[1]*Z[i] + m2_3[1]*sex[i] +




mu_age[i,2]<- m2[2] + m2_b2[home_id[i]] + m2_2[2]*Z[i] + m2_3[2]*sex[i] +





mu_sppb0[i,1] <- m3[1] + m3_b1[home_id[i]] + m3_2[1]*Z[i] + m3_3[1]*sex[i] +




mu_sppb0[i,2] <- m3[2] + m3_b2[home_id[i]] + m3_2[2]*Z[i] + m3_3[2]*sex[i] +





mu_mmse0[i,1] <- m4[1] + m4_b1[home_id[i]] + m4_2[1]*Z[i] + m4_3[1]*sex[i] +
m4_4[1]*place[i] + m4_5[1]*size[i] + m4_6[1]*hometype1[i] + m4_7[1]*hometype2[i] +
m4_8[1]*antidep0[i] + m4_9[1]*age[i] + m4_10[2]*sppb0[i]
↪→
↪→
mu_mmse0[i,2] <- m4[2] + m4_b2[home_id[i]] + m4_2[2]*Z[i] + m4_3[2]*sex[i] +
m4_4[2]*place[i] + m4_5[2]*size[i] + m4_6[2]*hometype1[i] + m4_7[2]*hometype2[i] +
m4_8[2]*antidep0[i] + m4_9[2]*age[i] + m4_10[2]*sppb0[i]
↪→
↪→
# Level-1 outcome model specification
sppb2[i] ˜ dnorm(mu_sppb2[i,C[i]],tau_sppb2)
mu_sppb2[i,1] <- B0[1] + b1[home_id[i]] + B2[1]*Z[i] + B3[1]*sex[i] + B4[1]*place[i] +
B5[1]*size[i] + B6[1]*hometype1[i] + B7[1]*hometype2[i] + B8[1]*antidep0[i] +
B9[1]*age[i] + B10[1]*sppb0[i] + B11[1]*mmse0[i]
↪→
↪→
mu_sppb2[i,2] <- B0[2] + b2[home_id[i]] + B2[2]*Z[i] + B3[2]*sex[i] + B4[2]*place[i] +
B5[2]*size[i] + B6[2]*hometype1[i] + B7[2]*hometype2[i] + B8[2]*antidep0[i] +
B9[2]*age[i] + B10[2]*sppb0[i] + B11[2]*mmse0[i]
↪→
↪→
# Level-1 compliance class model specification
R[i] ˜ dbern(pi[i])
pi[i] <- ilogit(A[i] + A3*sex[i] + A4*place[i] + A5*size[i] + A6*hometype1[i] +
A7*hometype2[i])↪→
A[i] <- A0 + a[home_id[i]]
C[i] ˜ dcat(p[i,]); p[i,2]<- pi[i]; p[i,1]<- 1-pi[i]
}
for (j in 1:Nlevel2) {
# Level-2 random-effects distribution
b1[j] ˜ dnorm(0,tau_b); b2[j] ˜ dnorm(0,tau_b)
a[j] ˜ dnorm(0,tau_a); m1_b1[j] ˜ dnorm(0,tau_m1_b)
m1_b2[j] ˜ dnorm(0,tau_m1_b); m2_b1[j] ˜ dnorm(0,tau_m2_b)
m2_b2[j] ˜ dnorm(0,tau_m2_b); m3_b1[j] ˜ dnorm(0,tau_m3_b)
m3_b2[j] ˜ dnorm(0,tau_m3_b); m4_b1[j] ˜ dnorm(0,tau_m4_b)
m4_b2[j] ˜ dnorm(0,tau_m4_b)
}
# Priors specification for random effects
tau_b <- 1/pow(sigma_b,2); sigma_b ˜ dt(0,pow(100,-2),1)T(0,)
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tau_a <- 1/pow(sigma_a,2); sigma_a ˜ dt(0,pow(100,-2),1)T(0,)
tau_m1_b <- 1/pow(sigma_m1_b,2); sigma_m1_b ˜ dt(0,pow(100,-2),1)T(0,)
tau_m2_b <- 1/pow(sigma_m2_b,2); sigma_m2_b ˜ dt(0,pow(100,-2),1)T(0,)
tau_m3_b <- 1/pow(sigma_m3_b,2); sigma_m3_b ˜ dt(0,pow(100,-2),1)T(0,)
tau_m4_b <- 1/pow(sigma_m4_b,2); sigma_m4_b ˜ dt(0,pow(100,-2),1)T(0,)
# Priors specification for outcome distribution
sigma_sppb2 <- 1/sqrt(tau_sppb2); tau_sppb2 ˜ dgamma(0.001,0.001)
sigma_age <- 1/sqrt(tau_age); tau_age ˜ dgamma(0.001,0.001)
sigma_sppb0 <- 1/sqrt(tau_sppb0); tau_sppb0 ˜ dgamma(0.001,0.001)
sigma_mmse0 <- 1/sqrt(tau_mmse0); tau_mmse0 ˜ dgamma(0.001,0.001)
# Priors specification for outcome model
A0 ˜ dnorm(0,0.001); A3 ˜ dnorm(0,0.001); A4 ˜ dnorm(0,0.001)
A5 ˜ dnorm(0,0.001); A6 ˜ dnorm(0,0.001); A7 ˜ dnorm(0,0.001)
B0[1] ˜ dnorm(0,0.001); B0[2] ˜ dnorm(0,0.001)
B2[1] ˜ dnorm(0,1000) # Plausibly exogeneous (informative prior)
B2[2] ˜ dnorm(0,0.001); B3[1] ˜ dnorm(0,0.001)
...
...
m4_8[2] ˜ dnorm(0,0.001); m4_9[2] ˜ dnorm(0,0.001)
m4_10[2] ˜ dnorm(0,0.001)
}", OperaModel.jags")
rjags.model.opera <- jags.model(OperaModel.jags", data=list(Nlevel1=Nlevel1,
Nlevel2=Nlevel2, home_id=data$home_id, =data$Z, R=data$R1, sppb2=data$sppb2,
sex=data$sex, place=data$place, size=data$size, hometype1=data$hometype1,






rjags.par.opera <- c("A0","B0[1]","B0[2]","B2[1]","B2[2]", "sigma_a", "sigma_b",
"sigma_sppb2")↪→
rjags.sim.opera <- coda.samples(rjags.model.opera, rjags.par.opera, n.burn=n.burnin,
n.iter=n.iter, thin=n.thin)↪→
summary(rjags.sim.opera)
# 2. Assuming no ER and level-2 variance heterogeneity across trial groups and use of
level-2 Sigma half-Cauchy prior↪→
write("model {for (i in 1:Nlevel1) {
# Level-1 missing covariates model specification in increasing order of missingness
antidep0[i]˜ dbern(pi_antidep0[i,C[i]])
pi_antidep0[i,1] <- ilogit(m1[1] + m1_b1[home_id[i]] + m1_2[1]*Z[i] + m1_3[1]*sex[i]
+ m1_4[1]*place[i] + m1_5[1]*size[i] + m1_6[1]*hometype1[i] + m1_7[1]*hometype2[i])↪→
pi_antidep0[i,2] <- ilogit(m1[2] + m1_b2[home_id[i]] + m1_2[2]*Z[i] + m1_3[2]*sex[i]
+ m1_4[2]*place[i] + m1_5[2]*size[i] + m1_6[2]*hometype1[i] + m1_7[2]*hometype2[i])↪→
age[i] ˜ dnorm(mu_age[i,C[i]],tau_age)
mu_age[i,1]<- m2[1] + m2_b1[home_id[i]] + m2_2[1]*Z[i] + m2_3[1]*sex[i] +




mu_age[i,2]<- m2[2] + m2_b2[home_id[i]] + m2_2[2]*Z[i] + m2_3[2]*sex[i] +





mu_sppb0[i,1] <- m3[1] + m3_b1[home_id[i]] + m3_2[1]*Z[i] + m3_3[1]*sex[i] +




mu_sppb0[i,2] <- m3[2] + m3_b2[home_id[i]] + m3_2[2]*Z[i] + m3_3[2]*sex[i] +





mu_mmse0[i,1] <- m4[1] + m4_b1[home_id[i]] + m4_2[1]*Z[i] + m4_3[1]*sex[i] +
m4_4[1]*place[i] + m4_5[1]*size[i] + m4_6[1]*hometype1[i] + m4_7[1]*hometype2[i] +
m4_8[1]*antidep0[i] + m4_9[1]*age[i] + m4_10[2]*sppb0[i]
↪→
↪→
mu_mmse0[i,2] <- m4[2] + m4_b2[home_id[i]] + m4_2[2]*Z[i] + m4_3[2]*sex[i] +
m4_4[2]*place[i] + m4_5[2]*size[i] + m4_6[2]*hometype1[i] + m4_7[2]*hometype2[i] +
m4_8[2]*antidep0[i] + m4_9[2]*age[i] + m4_10[2]*sppb0[i]
↪→
↪→
# Level-1 outcome model specification
sppb2[i] ˜ dnorm(mu_sppb2[i,C[i]],tau_sppb2)
mu_sppb2[i,1] <- B0 + b_Z0[home_id[i]]*(1-Z[i]) + b_Z1[home_id[i]]*Z[i] +
B2[1]*Z[i] + B3[1]*sex[i] + B4[1]*place[i] + B5[1]*size[i] + B6[1]*hometype1[i] +






mu_sppb2[i,2] <- B0 + b_Z0[home_id[i]]*(1-Z[i]) + b_Z1[home_id[i]]*Z[i] +
B2[2]*Z[i] + B3[2]*sex[i] + B4[2]*place[i] + B5[2]*size[i] + B6[2]*hometype1[i] +





# Level-1 compliance class model specification
R[i] ˜ dbern(pi[i])
pi[i] <- ilogit(A[i] + A3*sex[i] + A4*place[i] + A5*size[i] + A6*hometype1[i] +
A7*hometype2[i])↪→
A[i] <- A0 + a[home_id[i]]
C[i] ˜ dcat(p[i,]); p[i,2] <- pi[i]; p[i,1] <- 1-pi[i]
}
for (j in 1:Nlevel2) {
# Level-2 random-effects distribution
b_Z0[j] ˜ dnorm(0,tau_b_Z0); b_Z1[j] ˜ dnorm(0,tau_b_Z1)
a[j] ˜ dnorm(0,tau_a)
m1_b1[j] ˜ dnorm(0,tau_m1_b); m1_b2[j] ˜ dnorm(0,tau_m1_b)
m2_b1[j] ˜ dnorm(0,tau_m2_b); m2_b2[j] ˜ dnorm(0,tau_m2_b)
m3_b1[j] ˜ dnorm(0,tau_m3_b); m3_b2[j] ˜ dnorm(0,tau_m3_b)
m4_b1[j] ˜ dnorm(0,tau_m4_b); m4_b2[j] ˜ dnorm(0,tau_m4_b)
}
























# Priors specification for outcome model
A0 ˜ dnorm(0,0.001); A3 ˜ dnorm(0,0.001); A4 ˜ dnorm(0,0.001)
A5 ˜ dnorm(0,0.001); A6 ˜ dnorm(0,0.001); A7 ˜ dnorm(0,0.001)
B0 ˜ dnorm(0,0.001)
B2[1] ˜ dnorm(0,1000) # Plausibly exogeneous (informative prior)
B2[2] ˜ dnorm(0,0.001); B3[1] ˜ dnorm(0,0.001)
...
...
m4_8[2] ˜ dnorm(0,0.001); m4_9[2] ˜ dnorm(0,0.001)
m4_10[2] ˜ dnorm(0,0.001)
}", "OperaModel.jags")
rjags.model.opera <- jags.model(OperaModel.jags", data=list(Nlevel1=Nlevel1,
Nlevel2=Nlevel2, home_id=data$home_id, Z=data$Z, R=data$R1, sppb2=data$sppb2,
sex=data$sex, place=data$place, size=data$size, hometype1=data$hometype1,






rjags.par.opera <- c("A0","B0","B2[1]","B2[2]","sigma_a","sigma_b_Z0", "sigma_b_Z1",
"sigma_sppb2")↪→
rjags.sim.opera <- coda.samples(rjags.model.opera, rjags.par.opera, n.burn=n.burnin,
n.iter=n.iter, thin=n.thin)↪→
summary(rjags.sim.opera)
### 3. Assuming no ER and level-2 variance heterogeneity across adherence classes
# 3.1. Adjustment for baseline covariates with missing values and use of level-2 Sigma
half-Cauchy prior↪→
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write("model {for (i in 1:Nlevel1) {
# Level-1 missing covariates model specification in increasing order of missingness
antidep0[i] ˜ dbern(pi_antidep0[i,C[i]])
pi_antidep0[i,1] <- ilogit(m1[1] + m1_b1[home_id[i]] + m1_2[1]*Z[i] + m1_3[1]*sex[i]
+ m1_4[1]*place[i] + m1_5[1]*size[i] + m1_6[1]*hometype1[i] + m1_7[1]*hometype2[i])↪→
pi_antidep0[i,2] <- ilogit(m1[2] + m1_b2[home_id[i]] + m1_2[2]*Z[i] + m1_3[2]*sex[i]
+ m1_4[2]*place[i] + m1_5[2]*size[i] + m1_6[2]*hometype1[i] + m1_7[2]*hometype2[i])↪→
age[i] ˜ dnorm(mu_age[i,C[i]],tau_age)
mu_age[i,1] <- m2[1] + m2_b1[home_id[i]] + m2_2[1]*Z[i] + m2_3[1]*sex[i] +




mu_age[i,2] <- m2[2] + m2_b2[home_id[i]] + m2_2[2]*Z[i] + m2_3[2]*sex[i] +





mu_sppb0[i,1] <- m3[1] + m3_b1[home_id[i]] + m3_2[1]*Z[i] + m3_3[1]*sex[i] +




mu_sppb0[i,2] <- m3[2] + m3_b2[home_id[i]] + m3_2[2]*Z[i] + m3_3[2]*sex[i] +





mu_mmse0[i,1] <- m4[1] + m4_b1[home_id[i]] + m4_2[1]*Z[i] + m4_3[1]*sex[i] +
m4_4[1]*place[i] + m4_5[1]*size[i] + m4_6[1]*hometype1[i] + m4_7[1]*hometype2[i] +
m4_8[1]*antidep0[i] + m4_9[1]*age[i] + m4_10[2]*sppb0[i]
↪→
↪→
mu_mmse0[i,2] <- m4[2] + m4_b2[home_id[i]] + m4_2[2]*Z[i] + m4_3[2]*sex[i] +
m4_4[2]*place[i] + m4_5[2]*size[i] + m4_6[2]*hometype1[i] + m4_7[2]*hometype2[i] +
m4_8[2]*antidep0[i] + m4_9[2]*age[i] + m4_10[2]*sppb0[i]
↪→
↪→
# Level-1 outcome model specification
sppb2[i] ˜ dnorm(mu_sppb2[i,C[i]],tau_sppb2)
mu_sppb2[i,1] <- B0[1] + b1_C[home_id[i]] + B2[1]*Z[i] + B3[1]*sex[i] +
B4[1]*place[i] + B5[1]*size[i] + B6[1]*hometype1[i] + B7[1]*hometype2[i] +
B8[1]*antidep0[i] + B9[1]*age[i] + B10[1]*sppb0[i] + B11[1]*mmse0[i]
↪→
↪→
mu_sppb2[i,2] <- B0[2] + b2_C[home_id[i]] + B2[2]*Z[i] + B3[2]*sex[i] +
B4[2]*place[i] + B5[2]*size[i] + B6[2]*hometype1[i] + B7[2]*hometype2[i] +
B8[2]*antidep0[i] + B9[2]*age[i] + B10[2]*sppb0[i] + B11[2]*mmse0[i]
↪→
↪→
# Level-1 compliance class model specification
R[i] ˜ dbern(pi[i])
pi[i] <- ilogit(A[i] + A3*sex[i] + A4*place[i] + A5*size[i] + A6*hometype1[i] +
A7*hometype2[i])↪→
A[i] <- A0 + a[home_id[i]]
C[i] ˜ dcat(p[i,]); p[i,2] <- pi[i]; p[i,1] <- 1-pi[i]
}
for (j in 1:Nlevel2) {
# Level-2 random-effects distribution
b1_C[j] ˜ dnorm(0,tau_b1_C); b2_C[j] ˜ dnorm(0,tau_b2_C)
a[j] ˜ dnorm(0,tau_a)
m1_b1[j] ˜ dnorm(0,tau_m1_b); m1_b2[j] ˜ dnorm(0,tau_m1_b)
m2_b1[j] ˜ dnorm(0,tau_m2_b); m2_b2[j] ˜ dnorm(0,tau_m2_b)
m3_b1[j] ˜ dnorm(0,tau_m3_b); m3_b2[j] ˜ dnorm(0,tau_m3_b)
m4_b1[j] ˜ dnorm(0,tau_m4_b); m4_b2[j] ˜ dnorm(0,tau_m4_b)
}
















# Priors specification for outcome distribution
sigma_sppb2 <- 1/sqrt(tau_sppb2); tau_sppb 2˜ dgamma(0.001,0.001)
sigma_age<- 1/sqrt(tau_age); tau_age ˜ dgamma(0.001,0.001)
sigma_sppb0<- 1/sqrt(tau_sppb0); tau_sppb0˜ dgamma(0.001,0.001)
sigma_mmse0<- 1/sqrt(tau_mmse0); tau_mmse0˜ dgamma(0.001,0.001)
# Priors specification for outcome model
A0 ˜ dnorm(0,0.001); A3 ˜ dnorm(0,0.001)
A4 ˜ dnorm(0,0.001); A5 ˜ dnorm(0,0.001)
A6 ˜ dnorm(0,0.001); A7 ˜ dnorm(0,0.001)
B0[1] ˜ dnorm(0,0.001); B0[2] ˜ dnorm(0,0.001)
B2[1] ˜ dnorm(0,1000) # Plausibly exogeneous
B2[2] ˜ dnorm(0,0.001); B3[1] ˜ dnorm(0,0.001)
...
...
m4_8[2] ˜ dnorm(0,0.001); m4_9[2] ˜ dnorm(0,0.001)
m4_10[2] ˜ dnorm(0,0.001)
}", "OperaModel.jags")
rjags.model.opera <- jags.model("OperaModel.jags", data=list(Nlevel1=Nlevel1,
Nlevel2=Nlevel2, home_id=data$home_id, Z=data$Z, R=data$R1, sppb2=data$sppb2,
sex=data$sex, place=data$place, size=data$size, hometype1=data$hometype1,






rjags.par.opera <- c("A0","B0[1]","B0[2]","B2[1]", "B2[2]", "sigma_a", "sigma_b1_C",
"sigma_b2_C", "sigma_sppb2")↪→
rjags.sim.opera <- coda.samples(rjags.model.opera, rjags.par.opera, n.burn=n.burnin,
n.iter=n.iter, thin=n.thin, na.rm=FALSE)↪→
summary(rjags.sim.opera)
### 4. Assuming no ER and level-1 variance heterogeneity across adherence classes
# 4.1. Adjustment for baseline covariates with missing values and use of level-2 Sigma
half-Cauchy prior↪→
write("model {for (i in 1:Nlevel1) {
# Level-1 missing covariates model specification in increasing order of missingness
antidep0[i] ˜ dbern(pi_antidep0[i,C[i]])
pi_antidep0[i,1] <- ilogit(m1[1] + m1_b1[home_id[i]] + m1_2[1]*Z[i] + m1_3[1]*sex[i]
+ m1_4[1]*place[i] + m1_5[1]*size[i] + m1_6[1]*hometype1[i] + m1_7[1]*hometype2[i])↪→
pi_antidep0[i,2] <- ilogit(m1[2] + m1_b2[home_id[i]] + m1_2[2]*Z[i] + m1_3[2]*sex[i]
+ m1_4[2]*place[i] + m1_5[2]*size[i] + m1_6[2]*hometype1[i] + m1_7[2]*hometype2[i])↪→
age[i] ˜ dnorm(mu_age[i,C[i]],tau_age)
mu_age[i,1] <- m2[1] + m2_b1[home_id[i]] + m2_2[1]*Z[i] + m2_3[1]*sex[i] +




mu_age[i,2] <- m2[2] + m2_b2[home_id[i]] + m2_2[2]*Z[i] + m2_3[2]*sex[i] +





mu_sppb0[i,1] <- m3[1] + m3_b1[home_id[i]] + m3_2[1]*Z[i] + m3_3[1]*sex[i] +




mu_sppb0[i,2] <- m3[2] + m3_b2[home_id[i]] + m3_2[2]*Z[i] + m3_3[2]*sex[i] +





mu_mmse0[i,1] <- m4[1] + m4_b1[home_id[i]] + m4_2[1]*Z[i] + m4_3[1]*sex[i] +
m4_4[1]*place[i] + m4_5[1]*size[i] + m4_6[1]*hometype1[i] + m4_7[1]*hometype2[i] +
m4_8[1]*antidep0[i] + m4_9[1]*age[i] + m4_10[2]*sppb0[i]
↪→
↪→
mu_mmse0[i,2] <- m4[2] + m4_b2[home_id[i]] + m4_2[2]*Z[i] + m4_3[2]*sex[i] +
m4_4[2]*place[i] + m4_5[2]*size[i] + m4_6[2]*hometype1[i] + m4_7[2]*hometype2[i] +
m4_8[2]*antidep0[i] + m4_9[2]*age[i] + m4_10[2]*sppb0[i]
↪→
↪→
# Level-1 outcome model specification
sppb2[i] ˜ dnorm(mu_sppb2[i,C[i]],tau_sppb2[C[i]])
mu_sppb2[i,1] <- B0[1] + b1_C[home_id[i]] + B2[1]*Z[i] + B3[1]*sex[i] + B4[1]*place[i] +
B5[1]*size[i] + B6[1]*hometype1[i] + B7[1]*hometype2[i] + B8[1]*antidep0[i] +
B9[1]*age[i] + B10[1]*sppb0[i] + B11[1]*mmse0[i]
↪→
↪→
mu_sppb2[i,2] <- B0[2] + b2_C[home_id[i]] + B2[2]*Z[i] + B3[2]*sex[i] + B4[2]*place[i] +
B5[2]*size[i] + B6[2]*hometype1[i] + B7[2]*hometype2[i] + B8[2]*antidep0[i] +
B9[2]*age[i] + B10[2]*sppb0[i] + B11[2]*mmse0[i]
↪→
↪→
# Level-1 compliance class model specification
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R[i] ˜ dbern(pi[i])
pi[i] <- ilogit(A[i] + A3*sex[i] + A4*place[i] + A5*size[i] + A6*hometype1[i] +
A7*hometype2[i])↪→
A[i] <- A0 + a[home_id[i]]
C[i] ˜ dcat(p[i,]); p[i,2]<- pi[i]; p[i,1]<- 1-pi[i]
}
for (j in 1:Nlevel2) {
# Level-2 random-effects distribution
b1_C[j] ˜ dnorm(0,tau_b_C); b2_C[j] ˜ dnorm(0,tau_b_C)
a[j] ˜ dnorm(0,tau_a)
m1_b1[j] ˜ dnorm(0,tau_m1_b); m1_b2[j] ˜ dnorm(0,tau_m1_b)
m2_b1[j] ˜ dnorm(0,tau_m2_b); m2_b2[j] ˜ dnorm(0,tau_m2_b)
m3_b1[j] ˜ dnorm(0,tau_m3_b); m3_b2[j] ˜ dnorm(0,tau_m3_b)
m4_b1[j] ˜ dnorm(0,tau_m4_b); m4_b2[j] ˜ dnorm(0,tau_m4_b)
}
























# Priors specification for outcome model
A0 ˜ dnorm(0,0.001); A3 ˜ dnorm(0,0.001)
A4 ˜ dnorm(0,0.001); A5 ˜ dnorm(0,0.001)
A6 ˜ dnorm(0,0.001); A7 ˜ dnorm(0,0.001)
B0[1] ˜ dnorm(0,0.001); B0[2] ˜ dnorm(0,0.001)
B2[1] ˜ dnorm(0,1000) # Plausibly exogeneous
B2[2] ˜ dnorm(0,0.001); B3[1] ˜ dnorm(0,0.001)
...
...
m4_8[2] ˜ dnorm(0,0.001); m4_9[2] ˜ dnorm(0,0.001)
m4_10[2] ˜ dnorm(0,0.001)
}", "OperaModel.jags")
rjags.model.opera <- jags.model(OperaModel.jags", data=list(Nlevel1=Nlevel1,
Nlevel2=Nlevel2, home_id=data$home_id, Z=data$Z, R=data$R1, sppb2=data$sppb2,
sex=data$sex, place=data$place, size=data$size, hometype1=data$hometype1,






rjags.par.opera <- c("A0","B0[1]","B0[2]","B2[1]", "B2[2]", "sigma_a", "sigma_b_C",
"sigma_sppb2[1]", "sigma_sppb2[2]")↪→
rjags.sim.opera <- coda.samples(rjags.model.opera, rjags.par.opera, n.burn=n.burnin,
n.iter=n.iter, thin=n.thin, na.rm=FALSE)↪→
summary(rjags.sim.opera)
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